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The	  development	  of	   functional	   lymphocytes	   fending	  off	  pathogenic	   intruders	  
yet	   tolerating	   self	   is	   dependent	   on	   the	   instructive	   or	   permissive	   action	   of	   soluble	  
and/or	  membrane-­‐bound	  factors.	  This	   is	  best	  exemplified	  by	  the	  loss,	  reduction,	  or	  
functional	   impairment	   of	   some	   lymphocyte	   populations	   in	   mouse	   or	   man	   lacking	  
designated	  cytokines,	  their	  receptors	  or	  important	  signal	  mediators.	  
The	  Early	  Progenitor	  with	  Lymphoid	  and	  Myeloid	  potential	  (or	  EPLM)	  has	  been	  
identified	  in	  our	  laboratory	  several	  years	  ago	  [1].	  This	  cell	  population	  combines	  two	  
different	  fate	  options,	  namely	  lymphoid	  and	  myeloid,	  which	  were	  long	  thought	  being	  
mutually	   exclusive.	   However,	   now	   we	   were	   able	   to	   show	   that	   the	   total	   EPLM	  
population	  can	  be	  further	  subdivided	  into	  subpopulations	  with	  differentiation	  biases.	  
This	   finding	   follows	   the	   trend	   that	   multipotentiality	   of	   a	   given	   progenitor	   cell	  
population	   is	   often	   based	   on	   heterogeneity	   amongst	   the	   population,	   rather	   than	  
single	  cells	  having	  all	  the	  fate	  options	  still	  utilizable.	  EPLM	  co-­‐express	  the	  receptors	  
for	   Fms-­‐like	   tyrosine	   kinase	   3	   ligand	   (Flt3L)	   and	   interleukin-­‐7	   (IL-­‐7)	   and	   the	   Ly6D+	  
subpopulation	   of	   EPLM	   includes	   the	   direct	   progenitor	   of	   committed	   B-­‐cell	  
precursors.	  By	  generating	  an	  almost	  complete	  set	  of	  Flt3L	  and	  IL-­‐7	  deficient	  as	  well	  
as	  transgenic	  mice	  and	  the	  respective	  combinations,	  we	  analyzed	  the	  involvement	  of	  
Flt3L	   and	   IL-­‐7	   in	   the	   B-­‐cell	   commitment	   process.	   Strikingly,	   excess	   Flt3L,	   which	  
provides	  the	  system	  with	  tremendous	  numbers	  of	  functional	  precursors,	  rescued	  the	  
B-­‐cell	   defect	   in	   the	   absence	   of	   IL-­‐7.	   Even	   if	   the	   anti-­‐apoptotic	   factor	   Bcl2	   was	  
ectopically	  expressed,	  B-­‐cell	   commitment	  as	  well	   as	  development	  were	  possible	   in	  
IL-­‐7-­‐/-­‐Bcl2tg	  mice.	  These	  results	  contradict	  previous	  reports	  describing	  IL-­‐7	  as	  a	  non-­‐
redundant	   cytokine	   [2].	   We	   provide	   evidence	   that	   IL-­‐7	   acts	   in	   a	   permissive	   way	  
mediating	  survival	  of	  Ly6D+CD19-­‐	  EPLM	  precursors	  and	  proliferation	  of	  committed	  B-­‐
cell	   progenitors.	   The	   commitment	   event	   itself	   appears	   to	   be	   independent	   of	   the	  
action	  of	  IL-­‐7.	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Under	   physiological	   conditions,	   hematopoiesis	   occurs	   in	   the	   specialized	  
microenvironment	  of	  the	  bone	  marrow.	  Now	  we	  show	  the	  successful	  circumvention	  
of	  stromal	  cell	  dependency	  in	  in	  vitro	  culture	  systems	  for	  the	  long-­‐term	  propagation	  
of	   mouse	   progenitor	   lymphocytes.	   B-­‐lymphocyte	   precursors	   grew	   in	   suspension	  
cultures	   supplemented	   with	   Flt3L,	   IL-­‐7,	   and	   stem	   cell	   factor	   (SCF).	   This	   result	  
suggests	   that	   signals	   mediated	   by	   SCF	   and	   Flt3L	   substitute	   those	   delivered	   by	  
stromal	   cells,	   since	   up	   to	   now	   pro-­‐B	   cell	   propagation	   was	   only	   possible	   in	   the	  
presence	  of	  OP9	   stromal	   cells	   and	   IL-­‐7.	   T-­‐lymphocyte	  precursors	  depend	  on	  plate-­‐
bound	  Notch1	   ligand	  Delta-­‐like	  4	   as	  well	   as	   soluble	   IL-­‐7	   and	  SCF.	   Such	   feeder-­‐free	  
proliferation	  and	  also	  differentiation	  systems	  have	  several	  advantages.	  Firstly,	   they	  
provide	  control	  over	  the	  dose,	  strength,	  as	  well	  as	  duration	  of	  cytokines	  and	  other	  
ligand	   signaling	   for	   instance.	   Thereby	   the	  molecular	   requirements	   for	   lymphocyte	  
development	   can	   be	   further	   addressed.	   Subsequently,	   one	   could	   study	   the	  
molecular	   and	   epigenetic	   changes	   accompanying	   the	   development	   and	  
differentiation	   of	   mouse	   lymphocytes	   in	   vitro.	   Contaminations	   originating	   from	  
stromal	  cell	  nucleic	  acids	  or	  proteins	  can	  now	  be	  completely	  ruled	  out.	  Secondly,	  in	  
these	   cultures	   the	   progenitor	   cells	   remain	   accessible	   to	   manipulations,	   such	   as	  
overexpression	   or	   shRNA-­‐mediated	   knock-­‐down	   of	   gene	   transcripts	   encoding	  
proteins	   of	   interest.	   Since	   these	   progenitor	   lymphocytes	   maintain	   in	   vivo	  
reconstitution	   capacity	   and	   build	   a	   functional	   immune	   system	   upon	   injection	   into	  
sublethally	   irradiated	  recombination	  deficient	  hosts,	  the	  effect	  of	  mutations	  can	  be	  
immediately	  observed	  in	  vitro	  but	  also	  in	  vivo.	  Thirdly,	  an	  efficient	  in	  vitro	  system	  for	  
the	   expansion	   of	   functional	   progenitor	   cells	   is	   only	   likely	   to	   become	   approved	   for	  
potential	   therapeutic	   applications	   in	   humans	   if	   no	   co-­‐culture	   settings	   have	   been	  
applied.	  The	  next	  step	  would	  be	  to	  extend	  the	  applicability	  of	  this	  system	  to	  human	  
progenitor	   lymphocytes.	   This	   would	   be	   an	   ideal	   tool	   to	   address	   the	   still	   poorly	  
defined	  requirements	  for	  human	  hematopoiesis	  and	  one	  could	  potentially	  use	  these	  
cells	  in	  a	  therapeutic	  setting.	  
The	  fourth	  project	  that	   is	  discussed	  within	  this	  thesis	  addresses	  the	  B-­‐cell	  co-­‐
receptor	  molecule	   CD19.	   As	   a	   positive	   regulator	   of	   B-­‐cell	   receptor	   (BCR)	   signaling	  
divergent	   expression	   of	   CD19	   affects	   B-­‐cell	   development.	   In	   order	   to	   address	   this	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subject	   in	   further	   detail	   we	   employed	   the	   highly	   effective	   Nup98-­‐HoxB4	   (NH)	  
hematopoietic	  stem	  cell	  (HSC)	  immortalization	  system	  developed	  by	  Ruedl	  et	  al.	  [3].	  
We	   ectopically	   expressed	   CD19	   or	   a	   CD19	   mRNA	   directed	   shRNA	   in	   these	  
immortalized	   HSCs	   and	   reconstituted	   sublethally	   irradiated	   recipient	   mice.	   We	  
observed	  diminished	  developmental	  progression	  from	  pre/proB	  cells	  to	  immature	  B	  
cells	  due	  to	  transgene	  over-­‐expression	  of	  CD19.	  Also	  reduction	  of	  CD19	  expression	  
resulted	   in	   reduced	  numbers	   of	  mature	  B	   cells	  with	   a	   developmental	   block	   at	   the	  
immature	   to	   mature	   B	   cell	   transition.	   These	   results	   indicate	   that	   aberrant	   CD19	  
levels	   interfere	  with	  selection	  of	  B	  cells	   into	  the	  mature	  B-­‐cell	  compartment.	  Tonic	  
signals	   mediated	   by	   the	   BCR	   are	   indispensable	   for	   positive	   selection	   of	   B	   cells	  
whereas	   a	   strong	   signal	   causes	   negative	   selection	   [4-­‐10].	   CD19	   acts	   as	   a	   positive	  
regulator	  of	   BCR	   signaling	   [11].	   Therefore,	   high	  expression	  of	   CD19	  might	  mimic	   a	  
strong	  BCR	  signal,	  in	  this	  way	  mediating	  the	  developmental	  block.	  Low	  levels	  of	  CD19	  
might	   interfere	  with	  or	  dampen	  the	  tonic	  BCR	  signal	  required	  for	  positive	  selection	  
of	   non-­‐autoreactive	   immature	   B	   cells.	   Our	   results	   clearly	   indicate	   that	   a	   certain	  
minimal	   threshold	   level	   of	   CD19	   expression	   has	   to	   be	   reached	   but	   must	   not	   be	  
widely	   exceeded,	   to	   mediate	   normal	   B-­‐cell	   development.	   This	   highlights	   the	  
important	  regulatory	  role	  of	  CD19	  in	  fine-­‐tuning	  the	  BCR	  signal	  response.	  
	  
The	  projects	   described	   in	   this	   thesis	   address	   the	  molecular	   requirements	   for	  
mouse	   lymphocyte	   development.	   Using	   several	   mutant	   and	   transgenic	   mice,	   we	  
could	   clearly	   show	   that	   commitment	   to	   the	   B-­‐cell	   lineage	   is	   possible	   without	   the	  
action	  of	  IL-­‐7.	  Moreover,	  we	  successfully	  developed	  stromal	  cell	  free	  in	  vitro	  culture	  
systems	  to	  obtain	  large	  numbers	  of	  functional	  lymphocyte	  progenitors	  capable	  of	  in	  
vivo	  reconstitution.	  A	  second	  in	  vitro	  culture	  system	  we	  successfully	  implemented	  is	  
the	  Nup98-­‐HoxB4	  system.	  Multipotent	  HSCs	  can	  be	  expanded,	  manipulated,	  and	  the	  
effect	   of	   a	   manipulation	   can	   be	   monitored	   upon	   in	   vivo	   reconstitution	   of	   a	   fully	  
functional	  immune	  system.	  We	  found	  that	  the	  selection	  of	  mature	  B	  cells	  is	  critically	  
dependent	  on	  the	  amount	  of	  CD19	  expressed	  by	  B-­‐cell	  progenitors.	  
	  





4.1 Early	  Hematopoiesis	  and	  a	  changing	  dogma	  
Hematopoiesis	   is	   the	   term	   used	   to	   describe	   the	   process	   of	   blood	   cell	  
formation.	  There	  are	  many	  different	  kinds	  of	  blood	  cells	  but	  historically,	   these	  are	  
broadly	   classified	   as	   “erythrocytes”,	   meaning	   they	   are	   red	   cells,	   “thrombocytes”	  
meaning	  they	  are	  involved	  in	  thrombus	  formation,	  “myeloid	  cells”,	  meaning	  they	  are	  
found	  in	  and	  are	  derived	  from	  the	  bone	  marrow,	  and	  “lymphoid	  cells”	  meaning	  they	  
are	   found	   in	   lymphoid	   organs	   and	   circulate	   in	   lymphoid	   vessels.	   That	   the	   bone	  
marrow	   was	   also	   a	   producer	   of	   some	   lymphoid	   cells	   was	   only	   discovered	   in	   the	  
1950s.	  Myeloid	   and	   lymphoid	   cells	   constitute	   respectively	   the	   innate	  and	  adaptive	  
arms	  of	   the	   immune	  system	  fending	  off	   invading	  pathogens	  and	  transformed	  cells.	  
Erythrocytes	   and	   thrombocytes	   are	   essential	   mediators	   of	   oxygen	   transport	   and	  
blood	  coagulation,	  maintaining	  the	   integrity	  and	   functionality	  of	   the	  organism.	  The	  
short	   lifespan	   of	   most	   hematopoietic	   cells	   implicates	   the	   necessity	   for	   their	  
continuous	   replenishment	   from	  multipotent	  HSCs	   that	   reside	   in	  specialized	  cellular	  
niches	  in	  the	  bone	  marrow.	  James	  Till	  and	  Ernest	  McCulloch	  originally	  demonstrated	  
the	  existence	  of	  multipotent	  stem	  cells	   in	  the	  early	  sixties	  and	  thereby	  became	  the	  
fathers	  of	  stem	  cell	  science	  [12,	  13].	  They	  studied	  the	  effect	  of	  radiation	  on	  the	  bone	  
marrow	  of	  mice	  and	  found	  multipotent	  cells	  in	  hematopoietic	  tissue	  that	  proliferate	  
and	   form	  numerable	   colonies	   upon	   injection	   into	   heavily	   irradiated	  mice	   suffering	  
from	   bone	   marrow	   failure	   [14].	   Ultimately,	   research	   on	   HSCs	   has	   led	   to	   their	  
purification	  and	  characterization	  using	  phenotypic	  markers	  by	  Spangrude,	  Heimfeld,	  
and	  Weissman	  in	  1988	  [15].	  
Hematopoiesis,	  meaning	  the	  formation	  of	  all	  cellular	  blood	  components,	  is	  one	  
of	  the	  best-­‐understood	  developmental	  processes.	  By	  definition,	  HSCs	  are	  capable	  of	  
self-­‐renewal	  as	  well	  as	  directed	  differentiation	  via	  distinct	  lineage	  precursors	  to	  form	  
all	  cell	  types	  of	  the	  hematopoietic	  system.	  Subdivisions	  have	  been	  made	  in	  order	  to	  
discriminate	   between	   long-­‐term	   and	   short-­‐term	   reconstitution	   capabilities	   upon	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transplantation.	   Three	  models	   use	   differential	   cell-­‐surface	  markers	   to	   best	   classify	  
these	  HSC	  populations	  [16].	  Already	   in	  1996,	  Osawa	  et	  al.	  demonstrated	   long-­‐term	  
reconstitution	   of	   the	   lymphohematopoietic	   system	   from	   a	   single	   HSC	   highlighting	  
the	  power	  of	   this	   cell	   type	   [17].	   The	  balance	  between	   controlled	   self-­‐renewal	   and	  
differentiation	   needs	   to	   be	   tightly	   regulated,	   emphasized	   by	   the	   high	   incidence	   of	  
hematologic	  diseases	  caused	  by	  interference	  in	  this	  process.	  	  
The	   characterization	   of	   oligopotent	   hematopoietic	   precursors	   supported	   the	  
assumption	   of	   a	   stepwise	   differentiation	   process,	   in	   the	   course	   of	   which	   the	  
hematopoietic	   cells	   gradually	   loose	   differentiation	   capabilities	   and	   become	  
committed	  to	  a	  certain	   lineage.	  Downstream	  of	   the	  HSC	  compartment,	  where	  self-­‐
renewal	  capacity	  has	  been	  lost	  but	  multipotentiality	  retained,	  cells	  are	  described	  as	  
multipotent	   progenitors	   (MPPs).	   Loss	   of	   megakaryocyte	   and	   erythroid	   potential	  
characterizes	   the	   so-­‐called	   lymphoid	   primed	  multipotent	   progenitor	   compartment	  
(LMPP),	  where	   cells	   retain	   the	   capacity	   to	   give	   rise	   to	  myeloid	   and	   lymphoid	   cells	  
[18].	  At	   this	   early	   stage	  of	  differentiation,	   expression	  of	   lymphoid	   restricted	  genes	  
such	   as	   Rag1	   or	   Rag2,	   Dntt	   or	   CD127	   can	   already	   be	   correlated	   with	   lymphoid	  
priming	  [19,	  20].	  Further	  downstream	  of	  LMPPs,	   in	  most	  models	  of	  hematopoiesis,	  
progenitors	   become	   restricted	   to	   give	   rise	   to	   only	   lymphoid	   or	   myeloid	   cells,	  
respectively.	   According	   to	   their	   initial	   lineage-­‐restricted	   differentiation	   capability,	  
these	  progenitor	  populations	  were	  termed	  common	  lymphoid	  progenitor	  (CLP)	  and	  
common	   myeloid	   progenitor	   (CMP)	   [21,	   22].	   This	   classification	   into	   myeloid	   and	  
lymphoid	   development	   was	   believed	   to	   be	   irrevocable	   and	   the	   two	   emerging	  
lineages	   were	   thought	   to	   evolve	   in	   parallel	   proscribing	   any	   further	   bi-­‐potential	  
progenitors.	  This	  stepwise	  differentiation	  model	  of	  hematopoiesis	  was	  summarized	  
as	  a	  hierarchical	  scheme	  with	  HSCs	  at	   the	  apex,	  generating	   intermediate	  precursor	  
cell	   populations	   downstream	   and	   with	   the	   mature	   (end-­‐stage)	   hematopoietic	   cell	  
types	   at	   its	   end	   (Figure	   1).	   In	   this	   branched	  model	   of	   hematopoiesis,	   progenitors	  
with	  both	  lymphoid	  and	  myeloid	  capacity	  would	  seem	  to	  be	  excluded.	  




Figure	   1:	   Classical	   hematopoietic	   scheme.	   Classical	   schematic	   representation	   of	   hematopoietic	  
development	   with	   the	   HSC	   compartments	   at	   the	   apex	   and	   mature	   cell	   types	   resembling	   the	   end	   of	   the	  
differentiation	   process.	   Arrows	   indicate	   differentiation	   into	   a	   more	   restricted	   population.	   In	   this	   model	   the	  
lymphoid	  and	  myeloid	  branch	  of	  hematopoiesis	  are	  separated	  with	   the	  exception	  of	  dendritic	  cells.	  Moreover,	  
the	  differentiation	  process	  is	  unidirectional	  with	  clear-­‐cut	  developmental	  potentials	  assigned	  to	  the	  well-­‐defined	  
progenitor-­‐cell	   populations.	   LT-­‐HSC:	   long-­‐term	   hematopoietic	   stem	   cell,	   ST-­‐HSC:	   short-­‐term	   HSC,	   MPP:	  
multipotent	   progenitor,	   LMPP:	   lymphoid	   primed	   MPP,	   MEP:	   megakaryocyte/erythroid	   progenitor,	   ErP:	  
erythrocyte	  progenitor,	  GMP:	  granulocyte/macrophage	  progenitor,	  MkP:	  megakaryocyte-­‐committed	  progenitor,	  
CLP:	  common	  lymphoid	  progenitor,	  Pre-­‐B/NK/T:	  precursor	  B/NK/T	  cell.	  
The	   hematopoietic	   precursor	   populations	   placed	   in	   these	   schemes	   were	  
initially	   described	   as	   homogenous	   and	   strictly	   compartmentalized	   pools	   of	   cells.	  
Hematopoietic	   development	   was	   viewed	   as	   a	   unidirectional	   process	   and	   end-­‐cell	  
types	  were	  supposed	  to	  be	  generated	  via	  a	  series	  of	  precisely	  defined	  differentiation	  
steps	   ultimately	   resulting	   in	   commitment.	   However,	   emerging	   evidence	   is	  
challenging	   this	   constrained	  description	  of	   hematopoiesis	  with	   restricted	   routes	  of	  
differentiation	  that	  anticipates	  specification	  as	  an	  irrevocable	  decision.	  New	  models	  
of	  hematopoiesis	   favor	  a	  progressive,	  asymmetric	   loss	  of	   lineage	  potential,	  moving	  
away	  from	  the	  strict	  compartmentalization	  and	  allowing	  for	  more	  plasticity	  [23].	  
4.1.1 Plasticity	  during	  hematopoietic	  development	  
Initial	   and	   strong	   indication	   for	   more	   plasticity	   within	   hematopoiesis	   came	  
from	   studying	   pro-­‐B	   cells	   generated	   in	   mice	   in	   which	   the	   Pax5	   gene	   had	   been	  
deleted	   [24].	  The	  Pax5	  gene	  encodes	  a	  master-­‐transcription	   factor	   implicated	   in	  B-­‐
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lineage	   commitment	   and	  mice	   deficient	   in	   expression	   of	   this	   gene	   display	   a	   strict	  
block	   in	   B-­‐cell	   development	   [25].	   Interestingly,	   in	   vitro	   propagated	   Pax5-­‐deficient	  
pro-­‐B	   cells	   maintained	   plasticity	   with	   regards	   to	   lymphoid	   as	   well	   as	   myeloid	  
differentiation	  capabilities	  both	   in	  vitro	  and	   in	  vivo	   [26].	  Later	  on,	  a	  cell	  population	  
matching	  these	  differentiation	  characteristics	  was	  described	  in	  the	  bone	  marrow	  of	  
wild	   type	  mice.	   This	   cell	   population	  was	   called	   the	  early	  progenitor	  with	   lymphoid	  
and	  myeloid	  potential	  –	  or	  shortly	  EPLM	  [1].	  Even	  committed	  precursor	  B	  cells	  from	  
normal,	  wild-­‐type	  mice	   regain	  multipotentiality	   upon	   conditional	   loss	   of	   Pax5	   [27]	  
and	   a	   similar	   regain	   of	   multipotentiality	   has	   also	   been	   shown	   upon	   loss	   of	   Ebf1,	  
resulting	   in	   plasticity	   among	   CD19+	   progenitors	   [28].	   Interestingly,	   coincident	  
heterozygous	   deletions	   of	   both	   Ebf1	   and	   Pax5	   caused	   T-­‐lineage	   conversion	  within	  
committed	  B-­‐lymphoid	  progenitors	  [29].	  In	  summary,	  these	  discoveries	  showed	  that	  
the	   inactivation	   of	   a	   lineage	   commitment	   factor	   is	   able	   to	   activate	   the	   intrinsic	  
multilineage	   potential	   of	   cells.	   Lineage	   plasticity	   has	   also	   been	   shown	   for	   the	  
megakaryocyte/erythroid	   and	   granulocytic/macrophage	   lineages.	   Myelomonocytic	  
differentiation	  depends	  on	  the	  transcription	  factor	  PU.1	  [30]	  and	  the	  importance	  of	  
the	  transcription	  factor	  GATA-­‐1	  for	  erythroid	  and	  megakaryocytic	  differentiation	  has	  
been	   revealed	   by	   GATA-­‐1	   deficient	   mice	   [31-­‐33].	   These	   two	   proteins	   antagonize	  
each	  other	  and	  enforced	  expression	  of	  GATA-­‐1	  in	  myeloblasts	  transforms	  them	  into	  
megakaryocyte-­‐erythroid	   progenitors	   (MEP),	   and	   enforced	   expression	   of	   PU.1	  
reprograms	  MEP	  cells	  into	  myeloblasts	  (see	  also	  Figure	  2)	  [34,	  35].	  
	  
Figure	  2:	   changing	   the	  balance	  of	   two	   lineage	  hematopoietic	   transcription	   factors	   induces	   reversible	  
reprogramming	  of	  committed	  myeloid	  cells.	  Excess	  GATA-­‐1	  specifies	  MegE	  cell	  fate,	  and	  PU.1	  in	  excess	  specifies	  
GM	  cell	  fate.	  MegE:	  Megakaryocyte/erythroid.	  GM:	  Granulocyte/Macrophage.	  Figure	  taken	  from	  Laiosa,	  C.V.,	  M.	  
Stadtfeld,	  and	  T.	  Graf,	  Determinants	  of	  lymphoid-­‐myeloid	  lineage	  diversification.	  Annu	  Rev	  Immunol,	  2006.	  24:	  p.	  
705-­‐38.	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This	   shows	   that	   just	   by	   changing	   the	   balance	   of	   two	   lineage	   transcription	  
factors	  one	  can	  reprogram	  committed	  myeloid	  cells	  [36].	  
The	   identification	   of	   other	   progenitors	   with	   combined	   developmental	  
potentials	  besides	  the	  EPLM	  provides	  further	  evidence	  for	  a	  less	  hierarchical	  model	  
of	   hematopoiesis	   without	   the	   restricted	   lympho-­‐myeloid	   diversification.	   In	  
particular,	   cells	   sharing	   B/macrophage,	   T/macrophage,	   or	   natural	   killer	   (NK)/T	  
differentiation	   capability	   have	   been	   described	   [37-­‐40].	   For	   the	   earliest	   thymocyte	  
population	  a	  substantial	  B,	  macrophage,	  DC,	  and	  NK	  cell	  potential	  besides	  the	  T	  cell	  
potential	  was	  demonstrated	  [41,	  42].	  Moreover,	  using	  transplantation,	  a	  dual	  origin	  
from	   lymphoid	   and	   myeloid	   progenitor	   cells	   has	   been	   shown	   for	   plasmacytoid	  
dendritic	   cells	   (pDCs),	   which	   revokes	   the	   strict	   compartmentalization	   of	   mature	  
hematopoietic	   cells	   [43,	   44].	   Also	   transcriptionally	   identical	   human	   DCs	   were	  
successfully	  derived	  from	  CLPs	  and	  CMPs	  [45].	  These	  examples	  of	  lymphoid-­‐myeloid	  
bi-­‐potential	   clearly	   contradict	   the	   obligatory	   bifurcation	   of	   hematopoiesis	   in	  
lymphoid	   and	   myelo-­‐erythroid	   lineages	   [46]	   and	   reveal	   a	   substantial	   plasticity	  
amongst	  progenitor	  cells.	  	  
4.1.2 Heterogeneity	  
There	   is	   accumulating	   evidence	   that	  multipotent	   progenitor	   cell	   populations	  
identified	  over	  the	  years	  are	  more	  heterogeneous	  than	  previously	  thought.	  For	  the	  
CMPs	  differential	   cell-­‐surface	  expression	  of	  Slamf1	   (CD150),	  Endoglin	   (CD105),	  and	  
Itga2b	  (CD41)	  was	  shown	  to	  be	  correlated	  with	  individual	  developmentally	  restricted	  
lineage	   potentials	   for	   the	   granulocyte/macrophage,	   erythroid,	   and	  megakaryocytic	  
lineages	   respectively	   [47].	   Using	   single-­‐cell	   RNA	   sequencing	   the	   groups	   of	   Amos	  
Tanay	  and	  Ido	  Amit	  elegantly	  showed	  that	  myeloid	  progenitors	  consist	  of	  a	  mixture	  
of	   transcriptionally	   primed	   cells	   [48],	   thereby	   supporting	   the	   initial	   sub-­‐grouping	  
based	  on	  cell-­‐surface	  marker	  expression.	  In	  vivo	  lineage	  tracing	  experiments	  likewise	  
illustrated	   heterogeneity	   within	   CMPs	   [49].	   CLPs,	   characterized	   phenotypically	   by	  
high	  surface	  expression	  of	  CD127,	  low-­‐level	  expression	  of	  cKit	  (CD117)	  and	  Sca1	  and	  
absent	   expression	   of	   lineage	   markers	   were	   further	   sub-­‐grouped	   after	   their	   initial	  
description	   [21].	   Already	   by	   2000,	   expression	   of	   terminal	   deoxynucleotide	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transferase	  (TdT)	  within	  the	  lineage	  negative	  fraction	  of	  bone	  marrow	  cells	  indicated	  
CLP	   heterogeneity	   [50].	   When	   Flt3	   (CD135)	   was	   found	   to	   be	   expressed	   on	  
multipotent	   progenitors	   downstream	   of	   the	   HSC	   [51],	   re-­‐analysis	   of	   the	   CLP	  
compartment	   revealed	   absolute	   lymphoid	   multipotentiality	   only	   within	   the	   Flt3+	  
proportion.	   CLPs	   that	   have	   lost	   Flt3	   expression	   mostly	   contained	   B-­‐restricted	  
progenitors	   [52].	   Later	  on,	   Ly6D	  was	   identified	  and	  used	   to	  assign	  B-­‐cell	   restricted	  
progenitors	  within	  the	  Flt3+	  CLP	  population.	  Therefore,	  Ly6D+	  CLPs	  were	  termed	  BLPs	  
(B-­‐cell	   biased	   lymphoid	   progenitor),	   whereas	   Ly6D-­‐	   CLPs	   were	   named	   ALPs	   –	   all	  
lymphoid	  progenitors,	  since	  they	  retain	  T-­‐	  as	  well	  as	  NK-­‐cell	  potential	  [53].	  Different	  
combinations	  of	  expression	   levels	  of	   the	  surrogate	   light	  chain	  component	   lambda5	  
(λ5)	  and	  the	  Rag1	  protein	  within	  the	  Flt3+	  CLP	  compartment	  were	  also	  shown	  to	  be	  
useful	   in	  demonstrating	   restricted	   lineage	  potentials	   [54,	   55].	   Thus,	   a	  multitude	  of	  
indications	   suggests	   that	   classic	   multipotent	   progenitors	   identified	   in	   the	   bone	  
marrow	  of	  both	  mice	  and	   to	  a	   lesser	  extent	   in	  man	  are	  composed	  of	  a	  mixture	  of	  
cells	  with	  more	  constrained	   lineage	  potentials.	  This	  again	  emphasizes	  the	  plasticity	  
within	   the	   hematopoietic	   system	   and	   implicates	   a	   developmental	   continuum	  with	  
fluent	   passages	   linking	   the	   so-­‐far	   strict	   progenitor	   cell	   populations	   along	   the	  
hematopoietic	  scheme.	  This	  raises	  the	  question	  of	  whether	  it	  will	  ever	  be	  possible	  to	  
unambiguously	   identify	   a	   stage	   of	   hematopoiesis	   at	   which	   lineage	   commitment	  
becomes	   irrevocable.	   Taken	   together,	   the	   above	   results	   would	   seem	   to	   force	   a	  
rethink	  of	  current	  and	  propose	  alternative	  models	  of	  hematopoiesis.	  
4.1.3 The	  pairwise	  model	  of	  hematopoiesis	  
The	   identification	   of	   progenitor	   cells	   challenging	   the	   lymphoid/myeloid	  
dichotomy	  and	  the	  increasing	  evidence	  for	  plasticity	  resulted	  in	  a	  pairwise	  model	  of	  
hematopoiesis	   being	   proposed	   (Figure	   3)	   [16,	   56].	   The	   multipotent	   HSC	   remains	  
centered,	   whereas	   the	   developmental	   potentials	   of	   the	   hematopoietic	   progenitor	  
populations	   are	   now	   illustrated	   as	   colored	   arches	   arranged	   in	   a	   circle	   around	   the	  
HSC.	   With	   advancing	   development	   these	   arches	   become	   shorter	   indicating	  
restriction	  of	  potentials	  and	  ultimately	  commitment.	  The	  waiver	  of	  lineage	  branching	  
points	  and	  arrows	  allows	  for	  multiple	  alternative	  routes	  resulting	   in	  particular	  end-­‐
cell	  types,	  reflecting,	  for	  example,	  the	  development	  of	  identical	  DCs	  with	  dual	  origin	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[45].	   The	   placement	   of	   lineages	   in	   near-­‐neighbor	   relationships	   illustrates	   the	  
description	  of	  most	  bi-­‐potent	  hematopoietic	  cell	  populations	  that	  can	  also	  cross	  the	  
lymphoid-­‐myeloid	  divide.	  
	  
Figure	   3:	   The	   pairwise	   model	   of	   hematopoiesis.	   This	   revised	   model	   of	   hematopoiesis	   places	   closely	  
related	  lineages	  next	  to	  each	  other,	  without	  strictly	  compartmentalizing	  the	  scheme	  into	  different	  sub-­‐lineages	  
as	  the	  classical	  model	   is	  doing.	  The	  colored	  arches	  represent	  the	  known	  developmental	  potentials	  of	   individual	  
progenitor	  cell	  populations,	  which	  allows	  for	  more	  than	  one	  route	  ultimately	   leading	  to	  the	  very	  same	  end-­‐cell	  
type.	   CLP,	   common	   lymphoid	   progenitor;	   CMP,	   common	   myeloid	   progenitor;	   DC/Pro-­‐B,	   dendritic	   cell	   and	   B	  
lymphocyte	  progenitor;	  Eo/B-­‐CFU,	  eosinophil	  and	  basophil	  progenitor;	  EPLM,	  early	  progenitor	  with	  lymphoid	  and	  
myeloid	   potential;	   GMP,	   granulocyte	   and	   macrophage	   progenitor;	   LMPP,	   lymphoid-­‐primed	   multi-­‐potent	  
progenitor;	   MEP,	   megakaryocyte	   and	   erythrocyte	   progenitor;	   Mon/B/DC?,	   monocyte,	   B	   lymphocyte	   and	  
dendritic	   cell?	   progenitor;	   Mon/DC,	   monocyte	   and	   dendritic	   cell	   progenitor;	   NK/T,	   natural	   killer	   cell	   and	   T	  
lymphocyte	  progenitor;	  HSC,	  hematopoietic	  stem	  cell;	  Ly,	  lymphoid	  bias;	  Meg,	  megakaryocyte	  bias;	  My,	  myeloid	  
bias.	  Figure	   taken	   from	  Brown,	  G.,	  et	  al.,	  Versatility	  of	  stem	  and	  progenitor	  cells	  and	  the	   instructive	  actions	  of	  
cytokines	  on	  hematopoiesis.	  Crit	  Rev	  Clin	  Lab	  Sci,	  2015.	  52(4):	  p.	  168-­‐79.	  
One	   advantage	   of	   the	   pairwise	   model	   is	   that	   it	   enables	   flexibility	   and	   the	  
return	   to	   multipotentiality,	   as	   was	   shown	   for	   Pax5-­‐/-­‐	   pro-­‐B	   cells	   [26].	   The	  
contingencies	   of	   hematopoietic	   development	   are	   all	   represented	   and	   are	   now	  
illustrated	  as	  a	  continuum.	  Despite	  the	  multitude	  of	  evidence	  pointing	  towards	  a	  less	  
restricted	   lineage	   dichotomy,	   compartmentalization	   and	   unidirectionality	   within	  
hematopoietic	   development,	   so	   far	   no	   one	   has	   shown	   the	   extent	   to	   which	  
alternative	  routes	  are	  used	  in	  vivo.	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4.1.4 Stem	  cell	  transplantation	  as	  model	  for	  steady-­‐state	  hematopoiesis	  
Recent	  advances	  question	  our	  approaches	  of	  measuring	  stem	  cell	  activity	  and	  
the	   way	   we	   believe	   hematopoiesis	   is	   working.	   Because	   the	   mainstay	   of	   research	  
used	   to	   ascertain	   the	   functional	   properties	   of	   a	   given	   bone	   marrow	   progenitor	  
population	  were	  transplantation	  experiments,	  the	  deduced	  models	  of	  hematopoiesis	  
mostly	   describe	   blood	   cell	   formation	   under	   stress	   conditions.	  Myeloablated	   hosts	  
with	  purified	  cell	  populations	   injected	   into	   the	  blood	  circulation	  are	   far	  apart	   from	  
steady-­‐state	  hematopoiesis.	  Nevertheless,	  these	  models	  suggested	  that	  only	  a	  small	  
number	  of	  HSCs	  contribute	  to	  blood	  cell	  homeostasis	  [57].	  Now,	  Sun	  et	  al.	  as	  well	  as	  
Busch	  et	  al.	  provided	  strong	  evidence	  that	  in	  an	  unperturbed	  system,	  classical	  long-­‐
term	  HSCs	  have	  only	  limited	  contribution	  to	  blood	  cell	  formation.	  Instead	  thousands	  
of	   lineage-­‐restricted	   as	   well	   as	   multipotent	   clones	   are	   successively	   recruited	   into	  
hematopoiesis,	   each	   of	   them	  with	   only	  minimal	   contribution,	   as	   it	   is	   illustrated	   in	  
Figure	  4	  [58,	  59].	  
	  
Figure	  4:	  Schematic	  representation	  of	  HSC	  contribution	  to	  hematopoiesis	  tested	  in	  transplantation	  or	  
by	  fate	  mapping.	  (a)	  Transplantation	  of	  HSCs	  results	  in	  transient	  multiclonal	  contribution	  by	  many	  different	  HSCs	  
during	  the	  first	  weeks.	  However,	  multiclonality	   fades,	  as	  most	  of	  HSC	  clones	  are	   lost	  within	  the	  first	  4	  months.	  
Long-­‐term	   engraftment	   is	   achieved	   by	   few	   dominating	   HSC	   clones.	   (b)	   A	   fate	   map	   mouse	   model	   based	   on	  
Tamoxifen	   induced	  Cre/loxP-­‐mediated	   recombination	  of	   the	  Rosa26	   reporter	   locus	  marks	  Tie2+	  HSCs	  and	   their	  
progeny	  with	  YFP.	  Using	  this	  system,	  Busch	  et	  al.	  showed	  polyclonal	  contribution	  of	  many	  HSCs	   in	  steady-­‐state	  
hematopoiesis	   [59].	   Individual	   HSC	   clones	   participate	   only	   rarely.	   (a)	   and	   (b)	   Each	   colored	   line	   represents	   an	  
individual	  HSC	  clone	  and	  waves	  indicate	  periods	  of	  activity.	  HSC:	  hematopoietic	  stem	  cell,	  Mer:	  mutated	  estrogen	  
receptor	  site,	  MerCreMer:	  Cre	  recombinase	  fused	  to	  two	  Mer	  sites.	  Figure	  and	  part	  of	  the	  text	  taken	  from	  Busch,	  
K.	  and	  H.R.	  Rodewald,	  Unperturbed	  vs.	  post-­‐transplantation	  hematopoiesis:	  both	  in	  vivo	  but	  different.	  Curr	  Opin	  
Hematol,	  2016.	  23(4):	  p.	  295-­‐303.	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Sun	  et	  al.	  used	  an	  elegant	  clonal	  marking	  system	  based	  on	  a	  DNA	  transposon,	  
which	  is	  randomly	  integrated	  into	  the	  genome,	  thereby	  generating	  a	  specific	  genetic	  
tag	   for	   the	   corresponding	   cell	   and	   its	   progeny,	   whereas	   Busch	   et	   al.	   approached	  
steady-­‐state	  hematopoiesis	  by	  YFP	  labeling	  of	  Tie2+	  HSC	  and	  mathematical	  modeling.	  
These	   studies	   revealed	   that	   many	   transient	   clones	   initially	   drive	   hematopoiesis	  
following	  transplantation.	  However,	  the	  majority	  of	  them	  do	  not	  engraft.	  Instead,	  in	  
the	  long	  run	  hematopoiesis	  following	  transplantation	  is	  maintained	  by	  only	  few	  HSC	  
and	  hence	   is	  oligoclonal.	   Steady-­‐state	  hematopoiesis	  has	  polyclonal	   character	  with	  
stem	   and	   progenitor	   cells	   downstream	   from	   HSC	   as	   the	   main	   driver	   [59].	   Such	  
distinct	   results	   make	   it	   reasonable	   not	   only	   to	   re-­‐think	   our	   current	   model	   of	  
hematopoiesis,	   but	   also	   our	   experimental	   approaches	   of	   addressing	   the	   lineage-­‐
potentials	   as	   well	   as	   contributions	   of	   progenitor	   cell	   populations.	   Post-­‐
transplantation	   hematopoiesis	   seems	   to	   reflect	   the	   physiology	   of	   steady-­‐state	  
hematopoiesis	  only	  to	  a	  limited	  extent	  [60].	  
	  
4.2 Lymphocyte	  development	  
In	  adult	  mammals,	  B-­‐lymphocyte	  development	  takes	  place	  in	  the	  bone	  marrow	  
and	   to	   a	   lesser	   extent	   also	   in	   the	   spleen,	   whereas	   T-­‐cell	   development	   is	   largely	  
restricted	  to	  the	  thymus.	  The	  thymus	  does	  not	  contain	  self-­‐renewing	  stem	  cells	  and	  
in	   order	   to	   maintain	   thymopoiesis	   is	   absolutely	   dependent	   on	   the	   continuous	  
replenishment	  with	  precursors	  migrating	  from	  the	  bone	  marrow	  [61].	  T-­‐	  as	  well	  as	  B-­‐
lymphocytes	  express	  clonally-­‐distributed	  antigen	  receptors,	  which	  have	  been	  tested	  
for	   autoreactivity	   during	   their	   development.	   The	   enormous	   variety	   of	   potential	  
antigen-­‐recognition	   specificities	   amongst	   receptor	   molecules	   is	   generated	   by	   the	  
random	   recombination	   of	   gene	   segments	   orchestrated	   by	   the	   recombination-­‐
activating	  gene	  products,	  the	  Rag1	  and	  Rag2	  enzymes	  [62,	  63].	  Individual	  stages	  of	  B-­‐	  
and	   T-­‐lymphocyte	   development	   can	   be	   characterized	   by	   cell-­‐surface	   and	   intra-­‐
cellular	   markers,	   cell	   cycle	   profile,	   and	   rearrangement	   status	   of	   immunoglobulin	  
heavy	  and	   light	   chain	  genes	   for	  B	   cells	  or	   the	  α	  and	  β	   chain	  genes	   for	  T	   cells	   (See	  
Figure	  5	  and	  6)	  [64-­‐67].	  In	  mice,	  two	  different	  nomenclatures	  using	  slightly	  different	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markers	   were	   proposed	   to	   describe	   B-­‐cell	   developmental	   stages:	   the	   so-­‐called	  
Philadelphia	   nomenclature	   [68]	   and	   the	   Basel	   nomenclature	   [69].	   In	   this	  
introduction,	   the	   Basel	   nomenclature	   will	   be	   used.	   Through	   the	   coordinated	  
expression	   or	   down-­‐regulation	   of	   lineage-­‐related	   proteins,	   the	   B-­‐	   or	   T-­‐cell	   fate	   of	  
hematopoietic	   progenitors	   becomes	   specified	   and	   ultimately	   committed.	  
Specification	   means	   the	   establishment	   of	   lineage-­‐specific	   gene	   expression	  
signatures,	   and	   commitment	   implies	   the	   loss	  of	   the	   capability	   to	  differentiate	   into	  
alternative	  lineages	  [70].	  
4.2.1 B-­‐cell	  development	  
From	  very	   early	   on	   in	   their	   development,	   expression	  of	   several	   transcription	  
factors,	   including	   Ikaros,	  E2A,	  FoxO1,	  and	  Ebf1	  establishes	  an	  epigenetic	   landscape	  
permitting	  B-­‐cell	  specification	  [71,	  72].	  Consequently,	  Ebf1	  and	   in	  turn	  mainly	  Pax5	  
can	   activate	   the	   B-­‐cell	   specific	   transcriptional	   program	   and	   repress	   alternative	  
lineage	   opportunities,	   thereby	   accomplishing	   B-­‐cell	   commitment	   [73-­‐76].	   The	   first	  
cell	   that	  under	  physiological	   conditions	   is	   committed	   to	   the	  B-­‐lineage	   is	   the	  pre-­‐BI	  
cell	   (see	  Figure	  5).	   It	   is	  phenotypically	  characterized	  by	  the	  expression	  of	  CD19	  and	  
CD117	  (cKit)	  and	  genotypically	  by	  their	  immunoglobulin	  heavy	  (IgH)	  chain	  loci	  being	  
both	  DH-­‐JH	  rearranged	  [66].	  
	  
Figure	   5:	   Schematic	   representation	   of	   early	   stages	   of	   B-­‐cell	   development	   in	   analogy	   to	   T-­‐cell	  
development	  as	  depicted	  in	  Figure	  6.	  B	  cells	  develop	  in	  sequential	  stages	  identified	  by	  differential	  expression	  of	  
cell	  surface	  and	  intra-­‐cellular	  markers,	  the	  rearrangement	  status	  of	  the	  IgH	  and	  IgL	  chain	  gene	  segments,	  and	  the	  
cell-­‐cycle	  profile.	  Cell-­‐surface	  expression	  of	  CD19,	  CD117,	  CD25,	  CD127,	   IgM,	  and	   IgD	   is	   indicated	  for	  all	   stages	  
from	  pro-­‐B	  to	  mature	  B	  cells.	  Moreover	  the	  rearrangement	  events	  are	  indicated	  and	  expression	  of	  pre-­‐BCR	  and	  
BCR.	   In	   RAG1	   or	   RAG2	   deficiency	   or	   in	   SCID	   mutants	   B-­‐cell	   development	   is	   blocked	   at	   the	   pre-­‐BI	   to	   pre-­‐BII	  
transition.	  DH:	  heavy	  chain	  diversity	  gene	  segment,	  JH:	  heavy	  chain	  joining	  gene	  segment,	  VH:	  heavy	  chain	  variable	  
gene	  segment,	  IgM/IgD:	  immunoglobulin	  M/D,	  RAG1/2:	  recombination-­‐activating	  gene	  1/2,	  BCR:	  B-­‐cell	  receptor,	  
Vκ/λ:	  κ/λ	  light	  chain	  variable	  gene	  segment,	  Jκ/λ:	  κ/λ	  light	  chain	  joining	  gene	  segment.	  Figure	  taken	  from	  Ceredig,	  
R.	  and	  T.	  Rolink,	  A	  positive	  look	  at	  double-­‐negative	  thymocytes.	  Nat	  Rev	  Immunol,	  2002.	  2(11):	  p.	  888-­‐97.	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A	  successful	  VH	  to	  DJH	  rearrangement	  results	   in	   initially	  cytoplasmic	  and	   later	  
(see	   below)	   surface	   expression	   of	   a	   µ-­‐heavy	   (µH)	   chain,	   which	   together	   with	   the	  
surrogate	   light	  chain	  proteins	  VpreB	  and	  λ5	  builds	  the	  pre	  B-­‐cell	   receptor	   (preBCR)	  
[77-­‐80].	   These	   preBCR+	   cells	   are	   classified	   as	   large	   pre-­‐BII	   cells.	   They	   have	   lost	  
expression	   of	   cKit	   and	   gained	   expression	   of	   CD25	   [65].	   Only	   cells	   expressing	   a	   µ	  
heavy	   (µH)	   chain	   protein	   capable	   of	   pairing	   with	   the	   surrogate	   light	   chain	  
components	  build	  a	  functional	  surface-­‐expressing	  preBCR.	  The	  preBCR	  is	  responsible	  
for	  the	  proliferative	  expansion	  of	  large	  pre-­‐BII	  cells	  and	  also	  for	  the	  positive	  selection	  
of	   these	   progenitors	   [66,	   81,	   82].	   Further	   rearrangements	   at	   IgH	   chain	   loci	   are	  
suppressed	   by	   means	   of	   transient	   down-­‐modulation	   of	   the	   recombination	  
machinery,	   reduced	   germline	   transcription	   and	   histone	   acetylation	   [83-­‐86].	   These	  
mechanisms	  contribute	  to	  ensure	  allelic	  exclusion	  of	  antigen-­‐receptor	  genes,	  which	  
mediates	   mono-­‐specificity	   of	   mature	   lymphocytes	   [87].	   PreBCR	   signaling	  
extinguishes	   its	  own	  expression	  by	  directly	  silencing	  transcription	  of	  the	  VpreB	  and	  
Igll1	  genes	  [88].	  Subsequently,	  the	  cells	  stop	  proliferation	  and	  enter	  the	  small	  pre-­‐BII	  
stage.	   Here,	   the	   rearrangement	  machinery	   becomes	   re-­‐expressed	   and	   targets	   the	  
immunoglobulin	  light	  (IgL)	  chain	  gene	  loci	  κ	  and	  λ.	  Once	  a	  functional	  gene	  product	  is	  
generated	   it	  builds	   the	  BCR	  on	  the	  cell	   surface,	  again	  subject	   to	   the	  condition	  that	  
pairing	  of	  IgL	  chains	  with	  the	  µH	  chain	  is	  possible.	  At	  this	  stage	  the	  B	  cell	  is	  called	  an	  
IgM+	   immature	  B	  cell.	   If	  a	  correctly	   rearranged	   light	  chain	  cannot	  pair	  with	   the	  µH	  
chain	   or	   happens	   to	   forms	   a	   BCR	   with	   autoreactive	   specificity,	   secondary	  
rearrangements	   are	   initiated	   in	   order	   to	   resolve	   this	   issue.	   This	   process	   was	  
identified	   independently	   by	   Rolink,	   Weigert,	   and	   Nemazee	   and	   has	   been	   termed	  
receptor	  editing	  [89-­‐91].	  
IgM+	   immature	  B	  cells	   leave	   the	  bone	  marrow	  and	  migrate	   to	   the	   spleen	   for	  
their	   final	   maturation	   steps.	   In	   order	   to	   proceed	   in	   their	   development,	   the	   right	  
dosage	  of	  BCR	  signaling	   is	   required.	  This	   so-­‐called	   tonic	  or	  basal	  BCR	  signal	   is	  only	  
generated	  by	   a	  non-­‐autoreactive	  BCR	   composed	  of	   functionally	   paired	   IgH	  and	   IgL	  
chains.	  An	  autoreactive	  BCR	  would	  generate	  a	  much	   stronger	   signal,	  whereas	   cells	  
expressing	  only	  non-­‐pairing	  immunoglobulin	  chains	  lack	  a	  signal	  [92].	  If	  signaling	  via	  
the	  BCR	   is	  manipulated,	   this	  positive	  selection	  fails	  as	   is	   the	  case	   in	  CD19-­‐deficient	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mice	  [93].	  The	  developmental	  disturbances	  shown	  by	  many	  mice	  with	  mutations	  in	  
BCR	   signal	   strength	   regulators	   further	   underline	   the	   importance	   of	   appropriate	  
signaling	  [6,	  8,	  94-­‐96].	  In	  the	  spleen	  IgM+	  immature	  B	  cells	  recently	  arrived	  from	  the	  
bone	  marrow	  are	  termed	  transitional	  B	  cells	  and	  can	  be	  discriminated	  from	  mature	  B	  
cells	   by	   expression	   of	   CD93,	   their	   short	   half-­‐life	   as	   well	   as	   their	   sustained	  
susceptibility	  to	  anti-­‐IgM	  induced	  apoptosis	  [97-­‐100].	  The	  final	  developmental	  step	  is	  
the	  differentiation	  of	   transitional	  B	  cells	   into	  one	  of	   the	  mature	  B-­‐cell	  populations:	  
marginal	  zone	  B	  cells,	  follicular	  B	  cells,	  or	  B-­‐1	  B	  cells.	  
4.2.2 T-­‐cell	  development	  
T-­‐cell	   specification	   and	   commitment	   strongly	   depend	   on	   the	   thymic	  
microenvironment,	  or	  more	  specifically	  on	  the	  Notch1	  ligand	  Delta-­‐like	  4	  expressed	  
by	   thymus	   stromal	   cells	   [101].	   The	   importance	   of	   Notch	   signaling	   for	   T-­‐cell	  
commitment	  has	  been	  shown	  by	  conditional	  inactivation	  of	  Notch1	  in	  hematopoietic	  
precursors	  [102]	  or	  one	  of	  its	  ligands,	  Delta-­‐like	  4	  [101,	  103]	  in	  the	  thymus;	  this	  led	  
to	  ectopic	  B-­‐cell	  development.	  Moreover,	  expression	  of	  Notch1	  in	  the	  bone	  marrow	  
environment	   resulted	   in	   ectopic	   T-­‐cell	   development	   [104].	   Downstream	   of	   Notch	  
signaling,	   key	  T-­‐cell	   specification	   transcription	   factors	   such	  as	  Bcl11b,	  GATA-­‐3,	   and	  
Tcf1	  are	  induced	  [105-­‐108].	  The	  earliest	  thymic	  progenitors	  (ETPs)	  are	  characterized	  
phenotypically	   as	   Lin-­‐cKit+Flt3+CD44+CD25-­‐.	   Based	   on	   the	   controlled	   sequence	   of	  
expression	  of	  the	  T-­‐cell	  co-­‐receptor	  genes	  CD4	  and	  CD8,	  T-­‐cell	  development	  can	  be	  
roughly	  categorized	  (see	  Figure	  6).	  
	  
Figure	   6:	   Schematic	   representation	   of	   early	   stages	   of	   T-­‐cell	   development	   in	   analogy	   to	   B-­‐cell	  
development	  as	  depicted	  in	  Figure	  5.	  T	  cells	  develop	  in	  sequential	  stages	  identified	  by	  differential	  expression	  of	  
cell	  surface	  and	  intra-­‐cellular	  markers,	  the	  rearrangement	  status	  of	  the	  TCRβ	  and	  TCRα	  chain	  gene	  segments,	  and	  
the	  cell-­‐cycle	  profile.	  Cell-­‐surface	  expression	  of	  CD117,	  CD44,	  CD25,	  CD127,	  and	  CD3	   is	   indicated	   for	  all	   stages	  
from	  pro-­‐T1/DN1	  to	  mature	  CD4	  or	  CD8	  SP	  T	  cells.	  Moreover	  the	  rearrangement	  events	  are	  indicated	  as	  well	  as	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expression	  of	  pre-­‐TCR	  and	  TCR.	  In	  RAG1	  or	  RAG2	  deficiency	  or	  in	  SCID	  mutants	  T-­‐cell	  development	  is	  blocked	  at	  
the	   pre-­‐T1	   to	   pre-­‐T2	   transition.	   Two	   corresponding	   nomenclatures	   are	   used,	   describing	   equal	   developmental	  
stages.	  Dβ:	  β-­‐chain	  diversity	  gene	  segment,	  Jβ:	  β-­‐chain	  joining	  gene	  segment,	  Vβ:	  β-­‐chain	  variable	  gene	  segment,	  
RAG1/2:	  recombination-­‐activating	  gene	  1/2,	  TCR:	  T-­‐cell	  receptor,	  Vα:	  α-­‐chain	  variable	  gene	  segment,	  Jα:	  α-­‐chain	  
joining	   gene	   segment,	   DN:	   double-­‐negative	   with	   regards	   to	   CD4	   and	   CD8	   expression,	   ISP:	   immature	   single	  
positive	  with	  regards	  to	  CD8	  expression,	  DP:	  double-­‐positive	  with	  regards	  to	  CD4	  and	  CD8	  expression,	  SP:	  single	  
positive	   with	   regards	   to	   CD4	   or	   CD8	   expression,	   respectively.	   Figure	   taken	   from	   Ceredig,	   R.	   and	   T.	   Rolink,	   A	  
positive	  look	  at	  double-­‐negative	  thymocytes.	  Nat	  Rev	  Immunol,	  2002.	  2(11):	  p.	  888-­‐97.	  
In	   the	   thymus	   Flt3	   (CD135)	   expression	   can	   be	   used	   to	   subdivide	   the	   earliest	  
thymocyte	  subpopulation	  with	  any	   remaining	  B-­‐lineage	  potential	  being	  particularly	  
associated	   with	   CD135	   expression	   [42,	   109,	   110].	   ETPs	   and	   the	   earliest	  
developmental	   stages	   lack	   expression	   of	   both	   CD4	   and	   CD8	   markers	   and	   are	  
therefore	   termed	   double-­‐negative	   (DN)	   thymocytes.	   This	   episode	   can	   be	   further	  
subdivided	   using	   the	   cell	   surface	   markers	   CD44,	   CD25,	   and	   CD117	   into	   four	  
consecutive	  stages.	  The	  CD44+CD25-­‐CD117hi	  DN1	  stage,	  the	  CD44+CD25+CD117hi	  DN2	  
stage,	   the	   CD44-­‐CD25+CD117low	   DN3	   stage,	   and	   the	   CD44-­‐CD25-­‐CD117-­‐	   DN4	   stage	  
[67,	   111-­‐113].	   Thymocytes	   proceed	   along	   these	   stages	   and	   recombine	   the	   Vβ,	   Dβ,	  
and	   Jβ	   segments	   of	   the	   TCRβ-­‐chain.	   Expression	   of	   the	   pre	   T-­‐cell	   receptor	   (preTCR)	  
together	  with	  the	  surrogate	  α-­‐chain	  protein	  PreTα	  characterizes	  the	  DN3	  stage	  [114,	  
115].	   Following	   proliferative	   expansion,	  mouse	   thymocytes	   pass	   a	   CD8+	   immature	  
single	   positive	   (ISP)	   stage	   and	   then	   up-­‐regulate	   both,	   CD4	   and	   CD8	   to	   become	  
CD4/CD8	   double	   positive	   cells.	   At	   that	   double-­‐positive	   stage	   the	   Vα	   and	   Jα	   gene	  
segments	  of	  the	  TCRα	  chain	  are	  rearranged.	  Once	  a	  TCRαβ	  complex	  is	  expressed	  on	  
the	  surface,	  positive	  and	  negative	  selection	  generates	  mature	  CD4	  single-­‐positive	  or	  
CD8	  single-­‐positive	  T	  cells	  [116].	  
	  
4.3 IL-­‐7	  and	  Flt3L	  –	  Cytokines	  guiding	  lymphocyte	  development	  
Hematopoiesis	   depends	   on	   external	   signals	   provided	   by	   the	   combined	  
presence	  of	  soluble	  factors	  and	  stromal	  cells,	  which	  guide	  the	  maintenance,	  survival,	  
proliferation,	   and	   differentiation	   of	   progenitors.	   The	   bone	   marrow	   contains	  
specialized	   stromal	   cells,	   which	  make	   direct	   cell-­‐cell	   contact	   with	   progenitors	   and	  
secrete	  cytokines	  [117].	  Many	  of	  these	  cytokines	  are	  extremely	  potent	  and	  generally	  
act	  over	   short	   ranges.	   They	  are	   frequently	  made	  available	   to	  progenitors	  by	  being	  
incorporated	   into	  the	  extra-­‐cellular	  matrix	  that	  stromal	  cells	  produce.	  The	  mode	  of	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action	   of	   these	   cytokines	   can	   be	   either	   1)	   instructive,	   directly	   inducing	   a	   certain	  
lineage	   differentiation	   by	   actively	   switching	   lineage-­‐specific	   genes	   on	   or	   off,	   or	   2)	  
permissive,	  by	  selectively	  allowing	  proliferation	  or	  survival	  of	  progenitors	  destined	  to	  
become	  cells	  of	  a	  particular	  lineage	  [118,	  119].	  Whether	  cytokines	  play	  an	  instructive	  
or	  permissive	  role	  in	  hematopoiesis	  is	  extremely	  controversial.	  Two	  cytokines,	  which	  
have	  been	  of	  particular	  interest	  for	  T-­‐	  and	  B-­‐lymphocyte	  development,	  are	  IL-­‐7	  and	  
Flt3L.	  Their	  respective	  receptors	  are	  co-­‐expressed	  immediately	  before	  commitment	  
and	  mutant	  mice	  show	  disturbances	  of	  lymphoid	  development	  (see	  Figure	  7)	  [2,	  120-­‐
122].	  
	  
Figure	  7:	  Cytokine	  receptor	  expression	  on	  hematopoietic	  cell	  populations.	  Simplified	  representation	  of	  
hematopoietic	  development	   in	  analogy	  to	  the	  classical	  hematopoietic	  scheme	   in	  Figure	  1.	  Coloration	  of	  cells	   is	  
used	   to	   represent	   functional	   expression	   of	   the	   cytokine	   receptor	   Flt3	   (red),	   CD127/IL-­‐7Rα	   (blue),	   or	   both	  
(purple).	  Thereby	  it	  becomes	  clear	  that	  the	  closely	  related	  CLP/EPLM	  progenitors	  are	  the	  only	  population	  sharing	  
Flt3L	   and	   IL-­‐7	   responsiveness.	   LT-­‐HSC:	   long-­‐term	   hematopoietic	   stem	   cell,	   ST-­‐HSC:	   short-­‐term	   HSC,	   MPP:	  
multipotent	   progenitor,	   LMPP:	   lymphoid-­‐biased	   MPP,	   MEP:	   megakaryocyte-­‐erythrocyte	   progenitor,	   ErP:	  
erythrocyte	  progenitor,	  MkP:	  megakaryocyte-­‐committed	  progenitor,	  GMP:	  granulocyte-­‐macrophage	  progenitor,	  
CLP:	   common	   lymphoid	   progenitor,	   EPLM:	   early	   progenitor	  with	   lymphoid	   and	  myeloid	   potential,	   Pre-­‐B/NK/T:	  
precursor	  B/NK/T	  cell.	  
	  




IL-­‐7	  was	  originally	   identified	  as	   a	   cytokine	   secreted	  by	  bone	  marrow	   stromal	  
cells	   that	   supported	   progenitor	   B-­‐cell	   survival	   [123].	   Later,	   it	   was	   shown	   that	   IL-­‐7	  
also	   had	   activity	   on	   thymocytes	   and	   T-­‐cell	   survival	   [124].	   After	   that,	   a	   specific	  
receptor	   for	   IL-­‐7,	   comprising	  a	   ligand-­‐specific	   IL-­‐7	   receptor	   (IL-­‐7R)	  α	   chain	   (CD127)	  
and	   the	   “common”	   IL-­‐2Rγ	   (cγ)	   chain,	   was	   identified	   [125].	   Binding	   of	   the	   IL-­‐7	  
cytokine	  to	  the	  IL-­‐7	  receptor	  induces	  signaling	  via	  Jak1	  and	  Jak3,	  which	  consequently	  
activate	   the	   signal	   transducer	   and	   activator	   of	   transcription	   (Stat)	   5	   protein	   [126,	  
127].	  Deletion	  of	   the	   gene	   encoding	   the	   IL7r	   or	   the	   IL7	   cytokine	   results	   in	   a	   leaky	  
arrest	  of	  T-­‐cell	  development	  at	  the	  DN2	  stage	  and	  absence	  of	  γδ	  T	  cells	  [2,	  120,	  128],	  
whereas	   B-­‐cell	   development	   is	   blocked	   at	   the	   pro-­‐B	   cell	   stage.	   Cumulatively	   this	  
results	  in	  severely	  reduced	  numbers	  of	  T	  and	  B	  lymphocytes	  in	  the	  periphery,	  which	  
is	   indicative	   of	   a	   non-­‐redundant	   role	   of	   IL-­‐7,	   at	   least	   in	   mice.	   Since	   humans	   with	  
mutations	   in	   the	   IL7R	   gene	   display	   a	   normal	   B-­‐cell	   phenotype	   the	   role	   of	   IL-­‐7	   in	  
human	  B-­‐cell	  development	  remains	  unclear.	  This	  is	  discussed	  in	  chapter	  4.4.2.	  
Published	   reports	   showing	   the	   rescue	   of	   the	   T-­‐cell	   defect	   by	   transgenic	  
expression	  of	  the	  pro-­‐survival	  protein	  Bcl2	  in	  IL7r-­‐/-­‐	  mice	  suggested	  that	  IL-­‐7	  acts	  in	  a	  
permissive	  way	  during	  early	  T-­‐cell	  development	  [129,	  130].	  Further	  evidence	  for	  this	  
conclusion	   was	   provided	   by	   deletion	   of	   the	   pro-­‐apoptotic	   proteins	   Bax	   or	   Bim,	  
leading	   to	   a	   similar	   restoration	   of	   T-­‐cell	   development	   in	   the	   absence	   of	   IL-­‐7R	  
signaling	   [131,	  132].	   In	  contrast	   to	  this	  clear	  rescue	   initial	   reports	   indicated	  that	  B-­‐
cell	  development	  is	  not	  re-­‐established	  by	  transgenic	  expression	  of	  Bcl2	  in	  IL7r-­‐/-­‐	  mice	  
[133,	  134].	  Therefore	  it	  was	  assumed	  that	  IL-­‐7	  might	  work	  instructively,	  committing	  
cells	   to	   the	   B-­‐cell	   lineage.	   The	   identification	   of	   Stat5	   binding	   sites	   within	   the	  
promoter	   regions	   of	   Ebf1	   and	   Pax5,	   transcription	   factors	   indispensable	   for	   B-­‐
lymphoid	   commitment,	   supported	   this	   hypothesis	   [2,	   135,	   136].	   However,	   recent	  
advances	   have	   provided	   clear	   evidence	   for	   IL-­‐7	   operating	   permissively	   for	   B-­‐cell	  
development.	  The	  proof	  for	  binding	  of	  Stat5	  to	  regulatory	  elements	  of	  the	  Pax5	  gene	  
under	   physiological	   in	   vivo	   conditions	   is	   still	   pending	   [137].	   Even	   the	   regulation	  of	  
Ebf1	  by	  Stat5	  was	  shown	  to	  be	  only	   indirect	   [138].	  Also	  ectopic	  expression	  of	  Bcl2	  
could	   partially	   rescue	   the	   B-­‐cell	   developmental	   arrest	   that	   is	   observed	   in	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conditionally	  Stat5	  deficient	  mice	  [139].	  The	  same	  restoration	  has	  been	  shown	  now	  
also	   for	  Vav-­‐Bcl2	   IL7r-­‐/-­‐	  mice,	  where	  there	   is	   recovery	  of	  pre-­‐BI	  cell	  numbers	   [139].	  
Moreover,	  these	  recovered	  B	  cells	  expressed	  normal	  levels	  of	  E2A,	  Ebf1	  and	  Pax5.	  In	  
an	   in	   vitro	   system,	   stimulation	   with	   IL-­‐7	   failed	   to	   induce	   expression	   of	   the	  
endogenous	  Ebf1	  gene,	   indicating	  that	   IL-­‐7R	  signaling	  or	  active	  Stat5	  alone	  are	  not	  
sufficient	   to	   induce	   transcription	   [140].	   In	   summary,	   these	   data	   provide	   enough	  
evidence	  to	  state	  that	   IL-­‐7R	  mediated	  activation	  of	  Stat5	  might	  be	  sufficient,	  but	   is	  
not	  necessary	  for	  the	  induction	  of	  Ebf1	  and	  Pax5	  transcription	  factors.	  Also	  in	  B-­‐cell	  
development	   IL-­‐7	  seems	  to	  act	   in	  a	  permissive	  way	  through	  regulating	  cell	   survival	  
and	  proliferation	  rather	  than	  as	  an	  instructive	  cytokine	  [141].	  
4.3.2 Flt3L	  
Fms-­‐like	  tyrosine	  kinase	  3	  (Flt3),	  or	  CD135,	  is	  a	  receptor	  tyrosine	  kinase	  cloned	  
by	   homology	   with	   other	   receptor	   tyrosine	   kinases	   described	   simultaneously	   by	  
Matthews	   et	   al.	   in	   Cell	   [142]	   and	  Rosnet	   et	   al.	   in	  Oncogene	   [143].	   The	   Flt3	   ligand	  
(Flt3L)	   was	   cloned	   by	   Lyman	   et	   al.	   [144].	   Several	   hematopoietic	   cell	   populations	  
express	   Flt3	   that	   is	   first	   detectable	   within	   the	   LSK	   compartment	   [145].	   Later	   in	  
hematopoietic	   development,	   expression	   is	   sustained	   by	   progenitors	   with	   myeloid	  
and/or	   lymphoid	   potential,	   but	   not	   by	   progenitors	   of	   the	  
megakaryocyte/erythrocyte	   lineage	   (see	   Figure	   7)	   [18,	   146-­‐150].	   Recently,	   using	   a	  
Flt3L	   over-­‐expressing	   transgenic	   mouse	   line	   (Flt3Ltg),	   our	   laboratory	   revealed	   the	  
instructive	   action	   of	   Flt3L	   in	   hematopoietic	   development,	   inducing	   myeloid	   and	  
lymphoid	   lineages	   at	   the	  MPP	   stage	  at	   the	  expense	  of	  megakaryocyte/erythrocyte	  
development	  [151].	  With	  one	  known	  exception,	  namely	  DCs	  [150],	  expression	  of	  Flt3	  
is	  extinguished	  upon	  lineage	  commitment.	  During	  B-­‐cell	  development,	  expression	  of	  
Pax5	  directly	  antagonizes	  expression	  of	  Flt3	  [152].	  So	  far,	  the	  only	  ligand	  binding	  Flt3	  
and	   inducing	  downstream	  signaling	  seems	  to	  be	  Flt3L	  [144].	  The	  membrane-­‐bound	  
form	  of	  Flt3L	  can	  also	  be	  released	  as	  a	  soluble	  homodimeric	  protein	  and	  both	  forms	  
have	  been	  shown	  to	  activate	  the	  receptor	  [153,	  154].	  	  
Due	   to	   its	   high	   expression	   in	   a	   variety	   of	   hematologic	   malignancies	   and	  
especially	  its	  prominent	  involvement	  in	  acute	  myeloid	  leukemia	  (AML),	  Flt3	  and	  also	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its	  ligand	  have	  been	  extensively	  studied.	  In	  1996	  the	  group	  of	  Misawa	  first	  detected	  
an	   internal	   tandem	   duplication	   of	   exon	   14	   of	   the	   FLT3	   gene	   (FLT3-­‐ITD)	   amongst	  
patients	  suffering	  from	  AML,	  thereby	  suggesting	  an	  involvement	  of	  these	  mutations	  
in	   the	   pathogenesis	   of	   the	   disease	   [155].	   Subsequently,	   many	   groups	   confirmed	  
these	  data	  and	  additional	  types	  of	  mutations	  were	  identified	  [156,	  157].	  In	  a	  mouse	  
model	  expressing	  FLT3-­‐ITD	  in	  the	  hematopoietic	  system	  exclusively,	  the	  majority	  of	  
mice	  developed	  a	  myeloproliferative	  syndrome	  reminiscent	  of	  human	  AML	  [158].	  
Mice	  with	  a	  targeted	  disruption	  of	  the	  Flt3	  gene	  were	  described	  having	  normal	  
mature	   hematopoietic	   cell	   populations	   [121].	   More	   interestingly,	   they	   show	  
deficiencies	   in	   early	   B-­‐lymphoid	   progenitor	   cell	   populations,	   suggesting	   a	  
compensatory	   effect	   mediated	   by	   other	   cytokines	   neutralizing	   the	   loss	   of	   B-­‐cell	  
precursors	   after	   the	   Flt3L	   responsive	   stage.	   In	   bone	   marrow	   transplantation	  
experiments,	  the	  intrinsic	  Flt3	  deficiency	  revealed	  a	  further	  impairment	  in	  T-­‐cell	  and	  
myeloid	  reconstitution	  [121,	  159].	  Loss	  of	  Flt3L	  in	  mice	  resulted	  in	  reduced	  numbers	  
of	   leukocytes	   in	   the	   bone	  marrow,	   peripheral	   blood,	   lymph	   nodes,	   and	   spleen	   of	  
adult	  mice.	   In	  particular,	   in	   the	  bone	  marrow	   there	  was	  a	   reduction	   in	  myeloid	  as	  
well	  as	  B-­‐cell	  progenitor	  cell	  populations	  and	  reductions	   in	  NK	  cells	  and	  DCs	   in	   the	  
periphery.	   In	   contrast,	   thymic	   cellularity,	   blood	   hematocrit,	   as	   well	   as	   platelet	  
numbers	   were	   not	   affected	   [122].	   Since	   neither	   the	   ablation	   of	   Flt3	   nor	   Flt3L	  
resulted	  in	  a	  complete	  loss	  of	  any	  hematopoietic	  cell	  population,	  it	  is	  likely	  that	  Flt3	  
mediated	  signaling	  exerts	  its	  function	  in	  concert	  with	  signaling	  from	  other	  cytokines	  
such	   as	   SCF,	   or	   IL-­‐7	   and	   compensatory	   mechanisms	   presumably	   cause	   these	  
relatively	  mild	  phenotypes	  [140,	  147,	  157,	  160].	  Evidence	  for	  such	  complementarity	  
comes	  from	  analysis	  of	  Flt3L	  IL7r	  double-­‐deficient	  mice,	  which	  show	  loss	  of	  all	  stages	  
of	  fetal	  and	  adult	  B-­‐cell	  development	  [160].	  Moreover,	  in	  these	  mice	  both	  fetal	  and	  
adult	  thymopoiesis	  was	  abrogated	  thereby	  demonstrating	  an	  indispensable	  role	  for	  
Flt3L	  in	  IL-­‐7R-­‐independent	  lymphopoiesis	  [161].	  
Flt3L	   is	   best	   known	   for	   its	   ability	   to	   stimulate	   the	   expansion	   of	   CD34+	  
hematopoietic	   progenitors	   and	   DCs	   in	   vivo	   and	   in	   vitro	   [146,	   162-­‐167].	   Daily	  
injections	  of	   Flt3L	   result	   in	   a	  dramatic	   increase	   in	  peripheral	  DCs	  and	  an	   indirectly	  
mediated	  increase	  of	  functional	  peripheral	  regulatory	  T	  cells	  [168].	  Moreover	  NK-­‐cell	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numbers	  are	  elevated	  following	  Flt3L	  administration	  and	  Flt3L	  has	  been	  shown	  to	  act	  
as	   regulator	   of	   DC-­‐mediated	   NK-­‐cell	   activation,	   thereby	   rendering	   the	   cytokine	  
interesting	   as	   a	   potential	   broad-­‐spectrum	   anti-­‐tumor	   agent	   [169,	   170].	   Our	  
laboratory	   also	   showed	   expansion	   of	   the	   bone	   marrow	   EPLM	   progenitor	   cell	  
population	  upon	  Flt3L	   injection	   [171].	  Back	   then	   these	  promising	   results	  prompted	  
us	   to	   generate	   a	   transgenic	   mouse	   continuously	   over-­‐expressing	   human	   Flt3L	  
(Flt3Ltg)	  under	  the	  control	  of	  the	  β-­‐actin	  promoter	  [151].	  Flt3Ltg	  mice	  confirmed	  the	  
importance	   of	   Flt3L	   for	   dendritic	   cell	   homeostasis.	   They	   display	   large	   numbers	   of	  
dendritic	  cells	  and	  other	  cells	  of	  the	  myeloid	  lineage,	  resulting	  in	  splenomegaly	  and	  
blood	   leukocytosis.	   Due	   to	   a	   rapid	   reduction	   of	   erythroid	   progenitors,	   these	  mice	  
quickly	   develop	   anemia	   and	   a	   reduction	   in	   platelet	   numbers	   called	  
thrombocytopenia.	   In	  summary	  these	  data	  strongly	  suggested	  an	   instructive	  action	  
of	   Flt3L	   on	   multipotent	   progenitors,	   inducing	   their	   development	   into	  
myeloid/lymphoid	  lineages	  and	  suppressing	  the	  megakaryocyte/erythrocyte	  fate.	  
	  
4.4 Fetal	  and	  adult	  hematopoiesis	  
Cells	   of	   the	  hematopoietic	   system	  have	   to	  be	   continuously	   replenished	   from	  
hematopoietic	  stem	  and	  progenitor	  cells.	  For	  example,	  in	  man,	  throughout	  adult	  life,	  
the	  bone	  marrow	  produces	  approximately	  106	  red	  blood	  cells	  per	  second.	  However,	  
the	  intrinsic	  properties	  of	  stem	  cells	  change	  with	  development	  and	  relatively	  little	  is	  
known	  about	   the	   regulatory	  mechanisms	  guiding	   these	  modifications.	  For	  example	  
fetal	   HSCs	   vary	   significantly	   from	   adult	   HSCs	   in	   terms	   of	   gene	   expression,	  
developmental	   potential,	   self-­‐renewal,	   and	   regulation	   [172,	   173].	   The	   striking	  
difference	   between	   fetal	   and	   adult	   HSC	   is	   best	   exemplified	   by	   competitive	  
reconstitution	   experiments	   revealing	   the	   advantage	   of	   fetal	   liver	   derived	  
hematopoietic	  progenitors	  over	  adult	  bone	  marrow	  derived	  ones	  [110,	  174].	  In	  mice,	  
hematopoiesis	  from	  adult	  HSC	  begins	  at	  about	  3-­‐4	  weeks	  of	  age.	  One	  example	  of	  the	  
factors	   differentially	   expressed	   by	   fetal	   and	   adult	   HSC	   is	   the	   transcription	   factor	  
Sox17,	  which	  has	  been	  shown	  by	  Kim	  et	  al.	  to	  distinguish	  fetal	  liver	  from	  adult	  HSCs	  
[173].	  More	   recently	   Damnernsawad	   et	   al.	   highlighted	   the	   importance	   of	   Kras	   for	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adult	   hematopoiesis,	   while	   its	   role	   in	   fetal	   hematopoiesis	   remains	   questionable	  
[175].	   Since	   fetal	   HSCs	   retain	   their	   fetal-­‐like	   differentiation	   capability	   even	   in	   an	  
adult	  microenvironment,	  these	  features	  would	  seem	  to	  be	  cell	  intrinsic	  [176].	  
In	  vertebrates	  the	  sites	  of	  hematopoiesis	  change	  during	  ontogeny.	  This	  starts	  
in	   the	   yolk	   sac,	   later	   moving	   to	   the	   aorta-­‐gonad-­‐mesonephros	   (AGM)	   region,	   the	  
placenta,	  the	  fetal	  liver,	  and	  finally	  the	  bone	  marrow	  [177].	  From	  embryonic	  day	  7.5,	  
a	   first	  wave	  of	  hematopoiesis	  originates	   in	   the	  yolk	   sac.	  However,	  only	   from	  E10.5	  
onwards,	  when	  HSCs	  have	  been	  autonomously	  generated	   in	   the	  AGM	  region	   [178]	  
does	  definitive	  hematopoiesis,	  defined	  as	  the	  capability	  of	  complete	  and	  long-­‐term	  
hematopoietic	  repopulation	  of	  irradiated	  adult	  recipient	  mice,	  occur.	  From	  there	  the	  
fetal	   liver	   and	   later	   the	   bone	   marrow	   is	   seeded.	   The	   bone	   marrow	   is	   where	   all	  
hematopoietic	   stem	   cell	   and	  progenitor	   populations	   reside	  during	   adulthood	   [177,	  
179,	   180].	   Once	   the	   thymus	   anlage	   is	   formed	   from	   the	   third	   pharyngeal	   pouch	   it	  
attracts	   thymocyte	   progenitors	   via	   chemokine	   gradients	   [181,	   182].	   Recently,	  
Ramond	  et	  al.	  have	   shown	   that	   the	  colonization	  of	   the	   fetal	   thymus	  occurs	   in	   two	  
waves.	  Between	  E12	  and	  E15	   these	  early	   thymus-­‐settling	  progenitors	   (TSPs)	  are	  T-­‐
cell	  restricted	  with	  a	  clear	  preference	  for	  fast	  differentiation	  into	  mature	  T	  cells	  over	  
population	   expansion.	   From	   E16	   onward,	   TSPs	   resemble	   LMPPs	   in	   their	   possible	  
differentiation	  spectrum,	  proliferate	  extensively,	  and	  have	  lost	  the	  potential	  to	  give	  
rise	  to	  embryonic	  γδ	  T	  cells	  [183].	  
4.4.1 Lymphocytes	  with	  innate	  features	  
Fetal	  lymphopoiesis	  is	  known	  to	  give	  rise	  to	  some	  of	  the	  specialized	  subsets	  of	  
so-­‐called	  “innate-­‐like”	  B	  and	  T	  lymphocytes	  [184-­‐188].	  One	  of	  the	  characteristics	  of	  
innate-­‐like	   cells	   is	   their	   expression	   of	   a	   restricted	   set	   of	   semi-­‐invariant,	   germ-­‐line-­‐
encoded,	   mostly	   autoreactive,	   antigen	   receptors	   with	   limited	   diversity.	   This	  
restricted	   repertoire	   is	   achieved	   by	   preferential	   usage	   of	   a	   limited	   number	   of	  
variable	  gene	  segments	  during	  Rag1/2	  mediated	  gene	  rearrangements	  [189].	  These	  
features	  place	  them	  developmentally	  at	  the	  interface	  between	  innate	  and	  adaptive	  
immunity	  and	  also	  anatomically	  since	  they	  occupy	  specialized	  locations.	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Innate-­‐like	  B	  cells	  include	  marginal	  zone	  and	  B-­‐1	  B	  cells,	  whereas	  innate-­‐like	  T	  
cells	   are	   γδ	   T	   cells,	   CD1d-­‐restricted	   natural	   killer	   T	   (NKT)	   cells,	   and	   mucosal-­‐
associated	   invariant	   T	   (MAIT)	   cells.	   Amongst	   these,	   B-­‐1	   B	   cells	   and	   γδ	   T	   cells	   are	  
known	   to	   arise	   preferentially	   during	   embryogenesis.	   Nevertheless	   what	   all	   these	  
innate	  lymphocytes	  have	  in	  common	  is	  their	  ability	  to	  recognize	  conserved	  antigenic	  
structures	  on	  the	  surface	  of	  micro-­‐organisms,	  setting	  them	  apart	  from	  conventional	  
T	  and	  B	  cells,	  whose	  randomly	  recombined	  and	  clonally	  distributed	  antigen	  receptors	  
are	   evolutionary	   perfected	   to	   detect	   the	   multitude	   of	   potential	   pathogenic	  
structures.	  Many	  of	   these	   conserved	  antigenic	   structures	   seem	   to	  be	  of	   self-­‐origin	  
and	   are	   exposed	   upon	   stress	   or	   tissue	   damage.	   Innate-­‐like	   B	   cells	   spontaneously	  
secrete	   antibodies	   of	   the	   IgM	   isotype	   class.	   These	   “natural”	   antibodies	   recognize	  
antigen	  in	  a	  promiscuous	  manner	  and	  show	  a	  considerable	  degree	  of	  autoreactivity	  
[190-­‐193].	   Because	   of	   their	   broad	   range	   of	   reactivity,	   natural	   antibodies	   are	   an	  
effective	  first	   line	  of	  defense	  against	   invading	  pathogens	  or	  neoself	  antigens	   linked	  
with	  aging	  or	  cellular	  stress	  until	  the	  more	  specific	  adaptive	  immune	  response	  comes	  
into	  effect	  [192].	  
Marginal	   zone	   B	   cells	   are	   the	   only	   B-­‐cell	   subpopulation	   dependent	   upon	  
Notch2	   for	   their	   development.	   Conditional	   deletion	   of	   Notch2	   results	   in	   a	   strong	  
decrease	   in	   marginal	   zone	   B	   cells	   [194]	   rendering	   mice	   susceptible	   to	   bacterial	  
infections	  [195].	  This	  emphasizes	  the	  importance	  of	  these	  specialized	  B-­‐cell	  subsets	  
in	   the	   immune	   system.	   The	   BCR	   genes	   and	   corresponding	   antibody	   molecules	  
secreted	  by	  B-­‐1	  B	  cells	  lack	  non-­‐templated	  nucleotide	  (N)	  sequence	  insertions	  in	  the	  
heavy	   chain.	   This	   can	  be	   traced	  back	   to	   the	   lack	  of	   TdT	  enzyme	  expression	  during	  
embryogenesis	   [196,	   197].	   Only	   in	   2006	  Montecino-­‐Rodriguez	   et	   al.	   succeeded	   in	  
identifying	   within	   the	   fetal	   bone	   marrow	   a	   Lin-­‐B220lowCD19+	   B-­‐1	   B	   cell	   specified	  
progenitor	   cell	   population.	   Thereby	   B-­‐1	   B	   cells	   could	   be	   shown	   to	   represent	   a	  
separate	   lineage	   of	   B	   cells,	   which	   is	   mostly	   fetally	   derived	   [198].	   In	   adult	   bone	  
marrow	  these	  precursors	  are	  much	   less	  abundant,	   resulting	   in	  an	  almost	  complete	  
lack	   of	   ability	   by	   adult	   bone	   marrow	   to	   replenish	   B-­‐1	   B	   lymphocytes.	   Therefore	  
mature	  B-­‐1	  B	  cells	  show	  a	  robust	  self-­‐renewal	  capacity	  ensuring	  their	  maintenance	  
throughout	   life	   [199].	  The	  “natural	  memory”	  phenotype	  of	   innate-­‐like	   lymphocytes	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suggests	   an	   earlier	   exposure	   to	   antigen	   that	   might	   have	   occurred	   during	   their	  
development.	  The	  borderline	  self-­‐reactivity	  of	  their	  antigen	  receptors	  might	  indicate	  
that	   innate	   lymphocytes	   only	   just	   escape	   negative	   selection	   during	   their	  
development,	  indicating	  also	  that	  they	  may	  have	  arisen	  by	  a	  process	  called	  “agonist	  
selection”.	  Strong	  signals	  mediated	  by	   the	  antigen	   receptors	  would	  be	  a	  necessary	  
prerequisite	  for	  agonist	  selection.	  In	  accordance	  with	  that	  negative	  regulators	  of	  BCR	  
signaling	  inhibit	  the	  generation	  of	  B-­‐1	  B	  cells	  [200,	  201].	  It	  is	  the	  expression	  of	  these	  
special	  receptor	  specificities	  that	  drives	  differentiation	  into	  their	  particular	  lineage	  as	  
well	   as	   their	   preferential	   anatomical	   localization	   [202-­‐205].	   In	   the	   periphery,	  
unrestricted	   activation	   is	   potentially	   regulated	   by	   the	   expression	   of	   inhibitory	  
receptors	   reminiscent	   of	   NK	   cells	   [189].	   Since	   some	   of	   the	   innate-­‐like	   B	   and	   T	  
lymphocytes	   are	   generated	   during	   embryogenesis	   or	   shortly	   after	   birth,	   their	  
specialized	   differentiation	   requirements	   might	   be	   provided	   only	   within	   the	   fetal	  
primary	  lymphoid	  organ	  microenvironment.	  
In	  transplantation	  experiments,	  the	  generation	  of	  some	  innate-­‐like	  lymphocyte	  
subsets	  is	  an	  easy,	  yet	  powerful,	  readout	  to	  determine	  adult	  or	  fetal	  features	  of	  the	  
transplanted	   progenitor	   cells	   [184,	   185].	   Pro-­‐B	   cells	   isolated	   from	   fetal	   livers	   and	  
transplanted	  into	  severe	  combined	  immunodeficiency	  (SCID)	  mice	  generated	  mature	  
B	  cells	  expressing	  high	  levels	  of	  CD5	  and	  only	  low	  levels	  of	  IgD,	  phenotypic	  features	  
resembling	   B-­‐1	   B	   cells.	   These	   experiments	   indicated	   that	   the	   B-­‐1	   B-­‐cell	  
differentiation	   capacity	   is	   intrinsic	   to	   fetal	   derived	   hematopoietic	   precursors.	   In	  
contrast,	  transplantation	  of	  pro-­‐B	  cells	   isolated	  from	  adult	  bone	  marrow	  generated	  
CD5-­‐IgDhighIgM+	   B-­‐2	   B	   cells.	   These	   mutually	   exclusive	   developmental	   potentials	  
suggest	   a	   developmental	   switch	   occurring	   in	   B-­‐lymphopoiesis	   [206].	   This	  
developmental	   switch	   could	   be	   in	   part	  mediated	   by	   differential	   expression	   of	   the	  
microRNA	  (miRNA)-­‐binding	  protein	  Lin28b,	  which	  in	  turn	  regulates	  the	  transcription	  
factor	  Arid3a	  [188,	  207].	  Lin28b	  mRNA	  is	  targeted	  for	  degradation	  by	  Let-­‐7	  miRNA,	  
whose	   biogenesis	   is	   in	   turn	   blocked	   by	   Lin28b,	   resulting	   in	   a	   mutually	   exclusive	  
expression	  pattern	  illustrated	  in	  Figure	  8	  [208].	  




Figure	  8:	  Model	  for	  cross-­‐regulation	  of	  Lin28b,	  Let-­‐7	  miRNA,	  and	  the	  transcription	  factor	  Arid3a.	  Lin28b	  
induces	   expression	   of	   Arid3a,	  whose	  mRNA	   is	   targeted	   for	   degradation	   by	   Let-­‐7	  miRNA.	   Lin28b	  mRNA	   is	   also	  
targeted	  for	  degradation	  by	  Let-­‐7	  miRNA,	  whose	  biogenesis	  is	  in	  turn	  blocked	  by	  Lin28b,	  resulting	  in	  a	  mutually	  
exclusive	  expression	  pattern.	  Arid3a	   is	   thought	   to	  modulate	  BCR	   signaling,	   thereby	  altering	   selection	  of	  newly	  
formed	   B	   cells	   into	   the	   mature	   B-­‐cell	   compartment	   (not	   shown).	   Figure	   taken	   from	   Li,	   Y.S.,	   et	   al.,	   A	  
developmental	  switch	  between	  fetal	  and	  adult	  B	  lymphopoiesis.	  Ann	  N	  Y	  Acad	  Sci,	  2015.	  1362:	  p.	  8-­‐15.	  
Lin28b	   has	   been	   found	   to	   be	   expressed	   by	   pro-­‐B	   cells	   of	   fetal	   origin,	   which	  
consequently	   lack	   Let-­‐7	   miRNA	   expression.	   Progenitor	   B	   cells	   isolated	   from	   adult	  
bone	   marrow	   showed	   the	   complementary	   expression	   pattern	   [188,	   207].	   Forced	  
expression	   of	   Let-­‐7	   miRNA	   in	   fetal	   liver	   derived	   pro-­‐B	   cells	   resulted	   in	   B-­‐2	   B-­‐cell	  
generation	  upon	  transfer	   into	  SCID	  recipient	  mice,	  whereas	  expression	  of	  Lin28b	  in	  
adult	  bone	  marrow	  derived	  pro-­‐B	  cells	  restored	  fetal	  like	  B-­‐cell	  populations	  [207].	  In	  
the	  very	  same	  study,	  the	  authors	  also	  showed	  that	  intact	  BCR	  signaling	  is	  an	  absolute	  
requirement	   for	   B-­‐1	   B-­‐cell	   generation	   from	   Lin28b-­‐expressing	   bone	   marrow	   cells,	  
thereby	   further	   supporting	   the	   idea	   that	   these	   innate-­‐like	   lymphocytes	  depend	  on	  
agonist	  selection.	  The	  transcription	  factor	  Arid3a	  was	  identified	  as	  a	  direct	  target	  of	  
Let-­‐7	  miRNA	  showing	  a	  similar	  expression	  pattern	  as	  Lin28b.	  Moreover,	  Arid3a	  has	  
been	  implicated	  in	  regulating	  BCR	  signaling,	  thereby	  again	  suggesting	  that	  BCR-­‐signal	  
strength	   mediated	   kind	   of	   agonist	   selection	   may	   be	   involved	   in	   regulating	   B-­‐cell	  
population	  selection	  [206,	  209,	  210].	  However,	  Lin28b	   is	  not	  only	  able	  to	  switch	  B-­‐
lymphopoiesis.	   Ectopic	   expression	   of	   Lin28b	   in	   adult	   bone	  marrow	   hematopoietic	  
stem	  and	  progenitor	   cells	  enabled	   them	  to	  mediate	   fetal-­‐like	   reconstitution	  of	  not	  
only	  B-­‐1a	  and	  marginal	  zone	  B	  cells,	  but	  also	  γδ	  T	  cells,	  and	  NKT	  cells	  [188].	  
4.4.2 Differential	   cytokine	   requirements	   during	   fetal	   and	   adult	  
lymphopoiesis	  
Besides	  dependency	  on	  intact	  and	  strong	  signaling	  from	  the	  antigen	  receptor,	  
there	   is	   also	   evidence	   for	   differential	   requirements	   of	   certain	   cytokines	   for	   fetal	  
lymphopoiesis.	   For	   example,	   in	  mice,	   fetal	   B-­‐cell	   development	   is	   known	   to	  be	   less	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dependent	   on	   IL-­‐7	   [211].	   Fetal	   liver	   pro-­‐B	   cells	   of	   gene-­‐deleted	   Stat5-­‐/-­‐	   and	   IL7r-­‐/-­‐	  
embryos	  expressed	  normal	  levels	  of	  Ebf1	  and	  Pax5	  [139,	  176].	  B-­‐1	  B	  lymphopoiesis	  in	  
particular	   has	   also	   been	   shown	   to	   be	   largely	   independent	   of	   IL-­‐7	   [211].	   The	   exact	  
role	   of	   IL-­‐7	   in	   human	   B	   lymphopoiesis	   is	   still	   debated.	   Whereas	   in	   mice,	   in	   the	  
absence	   of	   IL-­‐7,	   both	   T	   and	   B	   lymphopoiesis	   are	   severely	   compromised,	   [212],	   in	  
man,	  individuals	  with	  mutations	  in	  the	  IL7R	  gene	  have	  a	  severe	  T-­‐cell	  deficiency	  yet	  
display	   normal	   numbers	   of	   circulating	   B	   cells	   [213].	   This	   has	   led	   to	   the	   general	  
assumption	   that	   human	   B-­‐cell	   development	   is	   independent	   of	   IL-­‐7.	   However,	   this	  
conclusion	  might	  be	  misleading,	  because	  IL7R	  gene	  mutations	  are	  fatal	  if	  not	  treated	  
with	   bone	  marrow	   transplantation.	   All	   patients	   analyzed	   with	   this	   condition	   have	  
been	   infants	   [214]	   and	   therefore	   their	   B	   cells	   are	   very	   likely	   to	   be	  mostly	   of	   fetal	  
origin.	   In	  a	   fully	  human	  ex	  vivo	  model	  system	  IL-­‐7	   independent	  B-­‐cell	  development	  
can	   only	   be	   accomplished	   using	   umbilical	   cord	   blood	   derived,	   but	   not	   adult	   bone	  
marrow	  derived	  progenitors	  [215].	  The	  IL-­‐7	  responsiveness	  of	  mouse	  adult	  and	  fetal	  
T-­‐cell	  progenitors	  has	  also	  been	   shown	   to	  differ,	  with	   the	   fetal	  ones	  being	   far	   less	  
dependent	   [216].	   In	   addition,	   adult	   DN1	   and	   DN2	   thymocyte	   differentiation	   is	  
inhibited	  by	  IL-­‐7,	  whereas	  fetal	  DN1	  and	  DN2	  thymocytes	  are	  not	  affected	  [217].	  
Thymic-­‐stromal	   lymphopoietin	   (TSLP)	   is	   a	   cytokine	   that	  was	  originally	   cloned	  
from	   a	   thymic	   stromal	   cell	   line	   [218]	   and	   has	   been	   implicated	   to	   mediate	   IL-­‐7	  
independent	   fetal	  B	   lymphopoiesis	   [219,	  220].	  The	  receptor	   for	  TSLP	  shares	   the	   IL-­‐
7Rα	  chain	  with	  the	  IL-­‐7	  receptor,	  but	  uses	  the	  unique	  TSLPR	  chain	  instead	  of	  the	  cγ	  
chain	  for	  signaling	  [221,	  222].	  IL7r-­‐/-­‐	  mice	  lack	  IL-­‐7	  as	  well	  as	  TSLP	  mediated	  signaling	  
and	   show	   a	   10-­‐fold	   more	   severe	   reduction	   in	   B-­‐cell	   numbers	   compared	   to	   IL-­‐7	  
deficient	  mice	  [219,	  220].	  Interestingly,	  the	  B	  lymphopenic	  phenotype	  of	  cγ-­‐/-­‐	  mice	  is	  
exacerbated	   by	   additional	   deficiency	   of	   the	   Tpte2	   gene,	   encoding	   the	   solely	   used	  
TSLPR	   chain	   [223].	   This	   further	   supports	   the	   important	   role	   of	   TSLP	   in	   IL-­‐7	  
independent	   lymphopoiesis.	   The	   responsiveness	   of	   fetal	   derived	  B-­‐cell	   progenitors	  
to	  TSLP,	  which	   is	  not	  measurable	   in	  adult	  pro-­‐B	  cells,	   is	   indicative	  of	  a	  unique	  fetal	  
requirement	   for	  TSLP	   [219,	  220].	  The	   importance	  of	  TSLP	   is	  best	  exemplified	  by	   its	  
transgenic	   expression	   in	   IL-­‐7-­‐/-­‐	   animals.	   Here,	   thymic	   cellularity	   and	   architecture	  
were	   normalized	   [224].	   Besides	   TSLP,	   Flt3L	   has	   been	   implicated	   to	   figure	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prominently	   in	   fetal	   lymphopoiesis.	   Thus,	   Sitnicka	   et	   al.	   revealed	   an	   indispensable	  
role	  of	  Flt3L	  in	  IL-­‐7Rα	  independent	  fetal	  T-­‐lymphopoiesis	  [161].	  Subsequently,	  Jensen	  
et	  al.	  proposed	  that	  Flt3L	  was	  responsible	  for	  sustained	  fetal	  B	  lymphopoiesis	  in	  the	  
absence	   of	   IL-­‐7	   [225].	   In	   summary	   there	   is	   an	   ongoing	   debate	   regarding	   whether	  
TSLP,	  Flt3L,	  or	  both	  cytokines	  participate	  in	  fetal	  lymphopoiesis	  in	  particular.	  
Mice	  are	  born	  after	   a	   gestation	  period	  of	   about	  21	  days	  at	   a	   time	  when	   the	  
cellular	   components	   of	   their	   immune	   system	   are	   only	   beginning	   to	   be	   generated.	  
Therefore,	   the	   fetal	   and	   neonatal	   primary	   lymphoid	   organ	   microenvironments	  
provide	   a	   peculiar	   niche	   matching	   the	   requirements	   for	   the	   rapid	   generation	   of	  
specialized	   lymphocyte	   subsets.	   There	   is	   clearly	   strong	   developmental	   pressure	  
acting	   on	   the	   immune	   system	   to	   rapidly	   establish	   a	   first	   line	   of	   defense	   to	   be	  
functional	   when	   protection	   by	   placentally	   transferred	   maternal	   antibodies	  
disappears	  [226].	  
	  
4.5 Culture	  systems	  
Hematopoiesis	   is	   the	   generic	   name	   for	   the	   coordinated	   differentiation	   of	  
multipotent	  HSCs	  via	  several	  intermediate	  stages	  towards	  a	  mature	  blood	  cell	  type.	  
This	  process	  only	  takes	  place	  in	  certain	  anatomical	  locations	  and	  in	  adult	  mammals	  is	  
localized	   in	   the	   bone	   marrow.	   Lymphocyte	   production	   takes	   place	   mostly	   in	   two	  
anatomical	   locations	   also	   called	   primary	   lymphoid	   organs;	   the	   bone	  marrow	   for	   B	  
cells	   and	   the	   thymus	   for	  T	   cells.	   The	   thymus	   is	   generally	   seeded	  by	  bone	  marrow-­‐
derived	  progenitors	   distinct	   from	  HSC.	   Primary	   lymphoid	  organs	  provide	   a	  defined	  
microenvironment	   for	   lymphocyte	  development.	  This	  microenvironment	  comprises	  
several	   elements	   including	   stromal	   cells,	   the	   proteinaceous	   factors	   they	   express	  
and/or	   secrete	   as	   well	   as	   extracellular	   matrix	   molecules	   with	   which	   stromal	   cells	  
surround	   themselves.	   The	  protein	   factors	   can	  be	  membrane-­‐bound	  or	   soluble	   and	  
stem	   and	   progenitor	   cells	   depend	   on	   these	   for	   their	   survival,	   proliferation,	   or	  
commitment.	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In	   order	   to	   study	   the	   requirements	   or	   general	   features	   of	   hematopoietic	  
development,	   researchers	   depend	   on	   in	   vitro	   culture	   systems	   imitating	   these	  
microenvironments.	   Initial	   studies	   of	   hematopoiesis	   were	   performed	   in	   vivo	   and	  
used	  colony-­‐forming	  unit	   (CFU)-­‐spleen	  assays	  emerging	   in	  the	  spleens	  of	   irradiated	  
recipient	  mice	  upon	  injection	  of	  bone	  marrow	  cell	  suspensions	  as	  measurement	  for	  
HSCs	  and	  their	  pluripotency	  [13].	  However,	  later	  on	  it	  was	  found	  that	  some	  of	  these	  
spleen	   colonies	   were	   only	   transient	   and	   probably	   coming	   from	   hematopoietic	  
progenitors	   and	   not	   real	   HSCs	   [227].	   In	   1966	   Bradley	   and	   Metcalf	   described	   the	  
growth	  of	  mouse	  bone	  marrow	  colonies	   in	  vitro	   in	  soft	  agar	   [228].	  Within	  the	  agar	  
they	  embedded	  feeder	  cells	  derived	  from	  adult	  kidney	  or	  embryos	  that	  provided	  the	  
growth	  factors	  needed	  to	  observe	  growth	  of	  colonies.	  However,	  the	  authors	  already	  
proposed	   that	   “addition	   of	   possible	   humoral	   factors	   to	   the	   culture	   medium	   may	  
provide	   more	   precise	   techniques	   suitable	   for	   the	   examination	   or	   direction	   of	  
differentiative	   trends	   in	   bone	  marrow	   cells”	   [228].	   Down	   to	   the	   present	   day	   CFU	  
assays	  in	  semi-­‐solid	  methylcellulose-­‐based	  medium	  supplemented	  with	  appropriate	  
cytokines	  are	  used	  to	  measure	  the	  frequency	  of	  hematopoietic	  stem	  and	  progenitor	  
cells	   and	   to	   identify	   cytokines	   or	   other	   factors	   that	   influence	   hematopoiesis.	  
Thereby,	   the	  CFU	   is	  classified	  based	  on	  morphologic	  and	  phenotypic	  criteria	  of	   the	  
end-­‐cell	  types	  it	  produced.	  The	  experimentally	  determined	  number	  of	  CFUs	  has	  been	  
shown	   to	   correlate	   positively	   with	   overall	   survival	   after	   transplantation	   of	   the	  
corresponding	  sample	  [229].	  	  
4.5.1 In	  vitro	  B-­‐cell	  cultures	  
For	   B-­‐cell	   development,	   bone	   marrow	   derived	   stromal	   cell	   lines	   have	   been	  
available	   for	   some	   time	  and	  are	   readily	  used	   in	   combination	  with	  a	  defined	   set	  of	  
cytokines	  in	  order	  to	  promote	  B	  lymphopoiesis	  in	  vitro	  [230].	  In	  1982	  such	  an	  in	  vitro	  
co-­‐culture	   system	   for	   the	   propagation	   of	   B	   cells	   was	   established	   by	  Whitlock	   and	  
Witte	   [231].	   In	   these	   so-­‐called	  Whitlock-­‐Witte	   cultures,	   bone	  marrow	   suspensions	  
are	   seeded	   into	   flasks	   and	   after	   some	   time,	   adherent	   cells	   grow	   out	   and	  
subsequently	  serve	  as	  a	  feeder	  layer	  for	  the	  growth	  of	  freshly	  seeded	  B-­‐lymphocyte	  
progenitors.	   Later,	   several	   stromal	   cell	   clones	   supporting	   B	   lymphopoiesis	   and/or	  
myelopoiesis	  were	  established	  and	  extensively	  used.	  The	  use	  of	   stromal	  cell	  based	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systems	   contributed	   decisively	   to	   the	   discovery	   that	   IL-­‐7	   is	   an	   important	   cytokine	  
and	   growth	   factor	   for	   early	   B	   cells	   and	   became	   a	   helpful	   tool	   to	   look	   at	   B-­‐cell	  
colonies	  [232,	  233].	  Whereas	  the	  PA6	  stromal	  cell	  line	  supports	  maintenance	  of	  the	  
earliest	  B-­‐cell	  progenitors	  but	  not	  their	  maturation,	  ST2	  stromal	  cells	  are	  capable	  of	  
supporting	   the	   whole	   process	   of	   B-­‐cell	   differentiation	   [234-­‐236].	   In	   addition,	   S17	  
stromal	   cells	   together	   with	   the	   cytokine	   IL-­‐7	   promote	   B-­‐cell	   growth	   [232,	   237].	  
However,	   these	   stromal	   cells	   also	   support	   myeloid	   as	   well	   as	   erythroid	  
differentiation	   from	   single	   HSCs	   [238].	   The	   NIH-­‐3T3	   fibroblast	   line	   alone	   does	   not	  
support	  proliferation	  of	  bone	  marrow	  derived	  precursors.	  However	  in	  the	  presence	  
of	   additional	   exogenous	   factors,	   B-­‐cell	   differentiation	   can	   be	   supported.	   By	   being	  
able	  to	  add	  defined	  factors,	  a	  degree	  of	  controllability	  on	  the	  system	  is	  achieved.	  
The	  stromal	  cell	   line	  mostly	  used	   in	  recent	  times	   is	  OP9	  [239,	  240].	  OP9	  cells	  
were	  derived	   from	   the	  bone	  marrow	  of	  macrophage	   colony-­‐stimulating	   factor	   (M-­‐
CSF	   or	   CSF-­‐1)	   deficient	   op/op	   mice	   [241].	   In	   the	   absence	   of	   M-­‐CSF,	   B-­‐cell	  
development	  from	  hematopoietic	  progenitors	  is	  much	  more	  efficient	  with	  OP9	  cells	  
because	   macrophage	   growth	   is	   not	   supported;	   macrophage	   growth	   can	   impair	  
lymphocyte	  maintenance	  [242,	  243].	  A	  major	  drawback	  of	  stromal	  cell	  cultures	  is	  the	  
impossibility	   to	   ultimately	   define	   the	   minimal	   signal	   requirements	   for	   B-­‐cell	  
development.	   Additional	   stromal	   cell	   derived	   factors	   as	   well	   as	   their	   relative	  
availability	   cannot	   be	   accurately	   controlled.	   Nevertheless,	   stromal	   cell	   co-­‐cultures	  
helped	   to	   clarify	  many	   important	   issues	   of	   early	   B-­‐cell	   development.	   For	   example	  
firstly	  that	  the	  high	  κ/λ	  light	  chain	  ratio,	  which	  is	  distinctive	  of	  the	  mouse	  peripheral	  
B-­‐cell	  repertoire,	  is	  already	  evident	  in	  the	  antigen-­‐independent	  transition	  from	  pre-­‐B	  
to	   B	   cells	   [244].	   Secondly,	   the	   essential	   role	   of	   Pax5	   in	   suppressing	   alternative	  
lineage	   choices,	   thereby	   committing	   precursors	   to	   the	   B-­‐cell	   lineage	   was	   shown	  
using	  such	  cultures	  [25].	  Thirdly,	  the	  expression	  dynamics	  of	  the	  Rag	  gene	  products	  
during	  rearrangement	  of	  the	  immunoglobulin	  gene	  segments	  were	  investigated	  [83].	  
Moreover	  it	  could	  be	  shown	  that	  mouse	  B	  cells	  could	  undergo	  switch	  recombination	  
even	  when	  the	  heavy	  chain	  locus	  was	  still	  in	  germline	  configuration.	  The	  finding	  that	  
this	   process	   is	   dependent	   on	   the	   end-­‐joining	   repair	   system	   was	   one	   of	   the	  
cornerstones	  in	  subsequently	  identifying	  the	  key	  enzyme	  activation-­‐induced	  cytidine	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deaminase	   (AID)	   [245].	   Despite	   these	   landmark	   discoveries	   and	   in	   order	   to	   better	  
define	  the	  minimal	  requirements	  needed	  for	  long-­‐term	  propagation	  of	  progenitor	  B	  
cells	   in	   vitro,	   we	   developed	   a	   stromal	   cell	   free	   culture	   system	   [manuscript	   in	  
preparation].	  	  
4.5.2 In	  vitro	  T-­‐cell	  cultures	  
Even	   though	   B-­‐cell	   propagation	  was	   for	   a	   long	   time	   successfully	   achieved	   in	  
monolayer	   stromal	  cell	   cultures,	   for	  T	  cells,	  only	  complex	  3D	  culture	  systems	  were	  
applicable	   in	   mimicking	   T-­‐cell	   differentiation	   in	   vitro.	   This	   was	   firstly	   because	   the	  
factor	  determining	  T-­‐cell	  commitment	  at	  the	  expense	  of	  other	  lineage	  fates	  had	  not	  
been	   identified	   and	   secondly	   because	   the	   three-­‐dimensional	   architecture	   of	   the	  
thymus	   had	   been	   shown	   to	   be	   required	   for	   maintaining	   expression	   of	   this	  
commitment	  factor	  even	  in	  thymic	  stromal	  cell	  monolayer	  cultures	  [246].	  Thirdly	  and	  
more	   obviously,	   available	   stromal	   cell	   lines	   seemed	   incapable	   of	   providing	   the	  
appropriate	  signals.	  
Fetal	   thymic	   organ	   cultures	   (FTOC)	   were	   for	   a	   long	   time	   the	   technique	   of	  
choice	   for	   addressing	   T-­‐cell	   development	   in	   vitro	   [247,	   248].	   Even	   though	   rather	  
cumbersome	  to	  set	  up,	  several	  major	  findings	  were	  made	  using	  FTOC.	  Subsequently,	  
reaggregated	   thymic	   organ	   cultures	   (RTOCs),	   where	   thymic	   stromal	   cells	   and	  
potential	   progenitors	   were	   centrifuged	   together,	   efficiently	   supported	   T-­‐cell	  
development	   and	  were	  extensively	  used	   [249].	   Recently,	   the	   group	  of	   Ellen	  Robey	  
has	  applied	  thymus	  slice	  cultures	  to	  study	  T-­‐cell	  development	  in	  situ	  [250].	  The	  latter	  
technique	   has	   the	   advantage	   that	   the	   structural	   integrity	   of	   the	   thymic	  
microenvironment	  with	  medullary	  and	  cortical	  zones	  remains	  intact.	  
In	  2002	   Juan	  Carlos	  Zúñiga-­‐Pflücker	  and	  colleagues	   showed	   for	   the	   first	   time	  
the	   efficient	   and	   long-­‐term	   commitment	   and	   propagation	   of	   T	   cells	   in	   a	   simple	  
stromal	  cell	  monolayer	  system	  [251,	  252].	  Use	  was	  made	  of	  the	  well-­‐established	  OP9	  
stromal	  cell	  line,	  but	  in	  addition,	  since	  the	  Delta-­‐Notch	  system	  had	  been	  identified	  as	  
instructing	   T-­‐cell	   lineage	   choice,	   OP9	   cells	   were	   transduced	  with	   the	   Notch-­‐ligand	  
Delta-­‐like	   1	   (DL1)	   [102,	   104].	   This	   generated	   the	   OP9-­‐DL1	   stromal	   cell	   line,	   which	  
efficiently	   promoted	   the	   generation	   of	   T	   cells	   from	   fetal	   liver	   stem	   cells	   and	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embryonic	   stem	  (ES)	  cells	  and	  has	  been	  extensively	  used	  since	   then.	  However,	   the	  
disadvantage	   of	   co-­‐cultures	   to	   dissect	   the	   detailed	   signaling	   requirements	   for	   the	  
differentiation	  process	   is	   the	  uncontrolled	  delivery	  of	   additional	   signals	  by	   stromal	  
cells.	   Also	   the	   density	   and	   distribution	   of	   DL1	   on	   transduced	   cells	   cannot	   be	  
controlled.	  In	  order	  to	  overcome	  these	  limitations	  we	  developed	  a	  stromal	  cell	  free	  
in	   vitro	   culture	   system	   for	   the	   long-­‐term	  propagation	  of	   fetal	   liver	   and	  adult	   bone	  
marrow	  derived	  pro-­‐T	  cells	  (see	  Figure	  9)	  [253].	  
	  
Figure	  9:	  Schematic	  representation	  of	  the	  stromal	  cell	  free	  culture	  system	  for	  the	  long-­‐term	  propagation	  
of	  fetal	   liver	  and	  adult	  bone	  marrow	  derived	  pro-­‐T	  cells	  [253].	  On	  bacterial	  grade	  tissue	  culture	  plates	  10µg/ml	  
Huf5.4	   anti-­‐human	   IgG-­‐Fc	   antibody	   is	   coated	   in	   PBS.	   After	  washing	   2µg/ml	   Delta-­‐like	   4-­‐human	   IgG1	   Fc	   fusion	  
protein	   is	  bound	  by	  Huf5.4	  and	  consequently	  uniformly	  oriented.	  Hematopoietic	  progenitors	  sorted	  from	  adult	  
bone	  marrow	  or	  fetal	  liver	  tissue	  detect	  the	  Delta-­‐like	  4	  ligand	  with	  their	  Notch	  receptor,	  differentiate	  to	  the	  T-­‐
cell	  lineage	  and	  expand	  long-­‐term	  as	  pro-­‐T	  cells	  resembling	  ex	  vivo	  sorted	  T-­‐cell	  progenitors.	  
The	  extracellular	  domain	  of	  mouse	  Delta-­‐like	  4	  (DL4)	  (amino	  acids	  1-­‐521)	  was	  
fused	   to	   the	   Fc	   part	   of	   human	   IgG1.	   Using	   an	   anti-­‐human	   IgG-­‐Fc	   antibody	  
(hybridoma	  Huf5.4	  –	  generated	   in	  house)	   the	  DL4	   fusion	  protein	  was	  presented	   in	  
the	   correct	   orientation	   to	   be	   detected	   by	   hematopoietic	   progenitor	   cells	   in	   tissue	  
culture	  plates	  [253].	  This	  allows	  for	  the	  long-­‐term	  growth	  of	  functional	  pro-­‐T	  cells	  in	  
vitro.	  
4.5.3 In	   vitro	   culture	   assays	   –	   the	   right	   tool	   to	   address	   in	   vivo	  
hematopoiesis?	  
Regardless	   of	   which	   in	   vitro	   culture	   system	   is	   used	   for	   the	   propagation	   or	  
differentiation	  of	  progenitor	   cells,	   it	   is	   unclear	   to	  which	  extent	   the	   findings	   reflect	  
the	  actual	   in	  vivo	  process.	  The	  addition	  or	  lack	  of	  designated	  cytokines	  or	  adhesion	  
molecules	   in	   in	   vitro	   cultures	  might	   impose	   a	   bias	   for	   the	   outgrowth	   or	   loss	   of	   a	  
certain	   subpopulation.	   Thereby	   the	   cloned	   stromal	   cells	   used	   and	   the	   factors	   they	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produce	  in	  combination	  with	  media	  supplements	  predetermine	  the	  range	  of	  possible	  
outcomes,	  and	  obviously	  excluding	  others.	   It	  might	  be	  an	   illusion	  to	  assume	  one	   is	  
able	  to	  perfectly	  mimic	  the	   in	  vivo	  microenvironment	  by	  providing	  all	   the	  potential	  
growth	  and/or	  differentiation	  stimuli	  that	  make	  an	  endogenous	  hematopoietic	  niche	  
unique.	  Stromal	  cell	  co-­‐culture	  systems	  used	  for	  the	  propagation	  or	  differentiation	  of	  
progenitor	   cells,	   also	   for	  example	   in	   limiting	  dilution	  analyses,	   can	  only	   facilitate	  a	  
certain	   range	  of	   lineage	   fates.	  Thereby	  one	  can	  address	   the	   frequency	  of	  potential	  
progenitors	   with	   a	   certain	   lineage	   potential,	   but	   the	   actual	   contribution	   of	   their	  
potentials	  to	  hematopoiesis	  in	  vivo	  remains	  elusive.	  The	  same	  holds	  true	  for	  colony	  
assays,	   even	   though	   in	   these	   systems	   stromal	   cells	   are	   absent.	   Even	   the	   use	   of	  
uncloned	   (polyclonal)	   bone	   marrow	   derived	   stromal	   cells	   as	   in	   Whitlock-­‐Witte	  
cultures,	  cannot	  reproduce	  the	  spatio-­‐temporal	  patterning	  and	  migration	  activity	  of	  
progenitors,	   which	   go	   through	   different	   niches.	   There,	   the	   composition,	   local	  
availability,	   as	   well	   as	   concentration	   of	   factors	   differ.	   Besides	   fibroblasts,	  
macrophages,	   adipocytes,	   osteoblasts	   and	   osteoclasts	   are	   all	   components	   of	   the	  
bone	  marrow	  stromal	  niche.	  Moreover,	  the	  marrow	  vasculature	  plays	  a	  major	  role	  in	  
hematopoiesis	  [254,	  255].	  In	  summary,	  a	  simple	  cloned	  stromal	  cell	  line	  can	  perhaps	  
never	   reflect	   all	   these	   different	   features.	   Importantly,	   whether	   assays	   should	   be	  
carried	  out	  at	  the	  local	  “physiological”	  low	  (hypoxic)	  oxygen	  concentration	  or	  in	  the	  
standard	  atmospheric	  oxygen	  concentration	  is	  another	  issue.	  
Even	   if	   a	   specific	   combination	   of	   factors	   makes	   lineage	   commitment,	  
differentiation,	  proliferation,	  or	  survival	  of	  a	  cell	  type	  possible	  in	  vitro,	  this	  provides	  
no	  proof	  that	  in	  vivo	  under	  physiological	  conditions	  the	  same	  mechanisms	  function.	  
Nevertheless,	   the	   cultures	   described	   above	   permit	   the	   direct	   comparison	   of	   the	  
lineage	   potentials	   of	   different	   progenitor	   subpopulations.	   Thus,	   “positive”	   and	  
“negative”	   control	   populations	   can	   be	   included	   in	   experiments.	   Importantly,	   to	  
obtain	  large	  numbers	  of	  lymphocyte	  progenitors	  which	  have	  proven	  functionality	  in	  
vivo	  the	  use	  of	  in	  vitro	  expansion	  cultures	  is	  a	  fair	  solution	  [253].	  To	  address	  lineage	  
potentials	   and	   differentiation	   requirements	   the	   stromal	   cell	   based	   or	   the	   colony-­‐
forming	  assays	   are	   a	   suitable	  way	   to	   compare	  different	  populations.	  However	   it	   is	  
totally	  unclear	  whether	  they	  reflect	  what	  is	  actually	  going	  on	  in	  vivo.	  For	  example,	  in	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vitro	   differentiation	   assays	   have	   shown	   that	   the	   earliest	   thymic	   lymphocyte	  
populations	  possess	  robust	  myeloid	  potentials	  besides	  the	  T-­‐cell	  potential	   [41,	  42].	  
However,	   the	   IL-­‐7r	   fate-­‐map	   mouse	   almost	   excluded	   contribution	   of	   ETPs	   to	   the	  
thymic	  myeloid	   lineage	   in	  vivo	   [256].	  Also	  many	  other	  bone	  marrow	  hematopoietic	  
precursors	   such	   as	   HSCs,	  MPPs,	   LMPPs,	   CLPs,	   and	   EPLM	   [1,	   15,	   18,	   21,	   145]	   have	  
been	   shown	   to	   possess	   T-­‐cell	   potential.	   Though,	   the	   T-­‐cell	   fate	   could	   have	   been	  
induced	   artificially	   in	   vitro	   and	  might	   represent	   a	   non-­‐physiological	   differentiation	  
pathway.	  For	  a	  moment	  the	  use	  of	  in	  vivo	  approaches	  such	  as	  transplantation	  assays	  
to	  address	  the	  mechanisms	  of	  hematopoiesis	  might	  seem	  to	  resemble	  more	  closely	  
the	   endogenous	   process.	   However,	   the	   transplantation	   of	   progenitor	   cells	   in	  
myeloablated	  hosts	  induces	  stress-­‐induced	  hematopoiesis,	  which	  might	  be	  still	  very	  
different	  from	  steady-­‐state	  hematopoiesis	  (see	  1.1.3)	  [58].	  
	  
4.6 CD19	  –	  The	  B-­‐cell	  co-­‐receptor	  molecule	  
CD19	   is	   a	   cell-­‐surface	   molecule	   exclusively	   expressed	   by	   B	   cells	   upon	  
commitment.	  For	  that	  reason	  it	  is	  used	  as	  a	  pan-­‐lineage	  marker	  [257].	  CD19	  starts	  to	  
be	   expressed	   early	   on	   during	   B-­‐cell	   development	   as	   a	   direct	   target	   gene	   of	   the	  
transcription	   factor	   Pax5	   [73].	   It	   exerts	   its	   regulatory	   function	   in	   terms	   of	   B-­‐cell	  
activation	  as	  part	  of	  the	  BCR-­‐signaling	  machinery	  [11].	  CD19	  participates	  in	  the	  B-­‐cell	  
co-­‐receptor	  complex	  together	  with	  CD21,	  CD81	  (TAPA-­‐1),	  and	  CD225	  (Leu-­‐13)	  [258-­‐
261].	   It	  mediates	  recruitment	  of	  regulatory	  molecules,	  such	  as	  Vav,	  PLCγ2,	  PI3K,	  or	  
Lyn	   [262-­‐270]	   to	   the	   cell	  membrane	   after	   stimulation.	   Possibly,	   CD19	  brings	   these	  
factors	  in	  close	  proximity	  to	  the	  BCR,	  thereby	  enhancing	  signaling	  activity	  in	  a	  similar	  
manner	  to	  CD4	  and	  CD8	  and	  the	  TCR	  [271,	  272].	  Only	  upon	  terminal	  differentiation	  
into	   antibody-­‐secreting	   plasma	   cells	   CD19	   expression	   is	   abolished	   [257,	   273],	  
whereas	  memory	  B	  cells	  retain	  CD19	  on	  their	  surface.	  Most	  likely,	  the	  shutdown	  of	  
CD19	   expression	   in	   plasma	   cells	   is	   a	   direct	   consequence	   of	   repressed	   Pax5	  
transcription	  [274].	  
The	   two	   extracellular	   immunoglobulin	   (Ig)-­‐	   like	   domains	   of	   CD19	   are	  
connected	   to	   the	   242	   amino	   acid	   long	   cytoplasmic	   domain	   via	   a	   transmembrane	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region	   [275].	   The	   95kDa	   glycoprotein	   belongs	   to	   the	   immunoglobulin	   superfamily	  
[276,	  277].	  The	  nine	  highly	  conserved	  tyrosine	  residues	  of	  the	  intracellular	  part	  are	  
inevitable	   for	   signal	   transduction	   [259,	   260,	   278].	   Figure	   10	   depicts	   a	   schematic	  
drawing	  of	  the	  domain	  structure	  of	  the	  CD19	  protein.	  
	  
Figure	   10:	   Schematic	   representation	   of	   murine	   CD19	   protein	   structure.	   The	   extracellular	   domain	   is	  
composed	   of	   two	   immunoglobulin-­‐like	   domains.	   Intracellularly,	   nine	   highly	   conserved	   tyrosine	   residues	   are	  
unevenly	   distributed	   over	   9	   exons.	   Figure	   taken	   from	   Fujimoto,	  M.,	   et	   al.,	   CD19	   regulates	   Src	   family	   protein	  
tyrosine	  kinase	  activation	  in	  B	  lymphocytes	  through	  processive	  amplification.	  Immunity,	  2000.	  13(1):	  p.	  47-­‐57.	  
In	   the	   early	   nineties,	   the	   group	   of	   Thomas	   Tedder	   generated	   a	   transgenic	  
mouse	   expressing	   the	   human	   CD19	   gene	   [279]	   as	   well	   as	   a	   mouse	   lacking	   CD19	  
[272].	   Robert	   Rickert	   generated	   his	   own	  CD19-­‐deficient	  mouse	  model	  with	   similar	  
results	   [280].	   In	   both	   studies,	   antigen-­‐independent	   B-­‐cell	   development	  was	   found	  
normal,	  whereas	  mature	  recirculating	  B	  cells	  were	  decreased	  [272,	  280].	  Moreover,	  
the	  unconventional	  B-­‐1	  B-­‐cell	  compartment	  was	  lost.	  Transgenic	  expression	  of	  CD19	  
resulted	  in	  a	  dose-­‐dependent	  decline	  in	  mature	  B-­‐cell	  numbers	  [279].	  
4.6.1 CD19-­‐deficient	  mice	  
The	   gene	   encoding	   for	   CD19	  was	   targeted	   by	   homologous	   recombination	   in	  
embryonic	   stem	   cells	   [272].	   The	   resulting	   loss	   of	   CD19	   expression	   in	  mutant	  mice	  
caused	  no	  severe	  differences	  in	  the	  development	  of	  conventional	  B	  cells	  in	  the	  bone	  
marrow.	   However,	   peripheral	   B	   cells	   were	   significantly	   reduced	   in	   numbers,	  
especially	  in	  the	  peritoneal	  cavity	  where	  they	  were	  decreased	  by	  75%.	  More	  detailed	  
analysis	  confirmed	  that	  B-­‐1	  B	  cells,	  the	  prominent	  cell	  type	  in	  the	  peritoneal	  cavity,	  
were	  drastically	  reduced.	  This	  strongly	  indicates	  an	  important	  role	  for	  CD19	  in	  their	  
development	   and/or	  maintenance	   [95,	   272,	   280].	  Marginal	   zone	   B	   cells	  were	   also	  
reduced	   [201].	   The	   remaining	  mature	   B	   cells	   responded	   with	   less	   proliferation	   to	  
mitogenic	   stimulation	   and	   reduced	   serum	   immunoglobulin	   levels	   were	   detected.	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Upon	   sublethal	   irradiation,	   the	   numbers	   of	   auto-­‐reconstituted	   B	   cells	   were	  
decreased	   in	   CD19-­‐/-­‐	   mice.	   This	   was	   first	   evident	   in	   the	   large	   cycling	   pre-­‐BII	   cell	  
compartment	  suggesting	  an	   involvement	  of	  CD19	  in	  preBCR	  signaling	  [281].	  Also	   in	  
mixed	   bone	  marrow	   chimeras,	   CD19-­‐deficient	   early	   B	   cells	   showed	   a	   competitive	  
disadvantage	  compared	  to	  wild	  type	  cells	  [281].	  Bromodeoxyuridine	  (BrdU)	  and	  CFSE	  
labeling	   revealed	   a	   shorter	   lifespan	   of	   CD19-­‐deficient	   cells	   in	   vivo	   [282]	   and	  
concomitant	   overexpression	   of	   Bcl2	   suggested	   an	   involvement	   of	   CD19	   in	   cell	  
survival.	   In	   such	  mice,	   the	  marginal	   zone	   compartment	   was	   partially	   rescued	   and	  
follicular	  B-­‐cell	  numbers	  were	   increased.	  However,	  germinal	  centers	   (GC)	  were	  still	  
not	  formed	  upon	  immunization	  with	  a	  hapten-­‐protein-­‐conjugate,	  which	  implies	  that	  
Bcl2	  cannot	  substitute	  for	  antigen	  induced	  differentiation	  signals	  [282].	  
Generally,	   CD19-­‐deficiency	   severely	   impairs	   BCR-­‐signaling	   capacity	   [283]	  
resulting	   in	   poor	   reactivity	   to	   most	   transmembrane	   signals.	   For	   example,	   the	  
proliferative	  capacity	  in	  response	  to	  lipopolysaccharide	  (LPS)	  stimulation	  or	  surface-­‐
IgM	   crosslinking	   was	   reduced	   compared	   with	   wild	   type	   littermates	   [272].	   The	  
impaired	  response	  of	  CD19-­‐/-­‐	  mice	  against	  the	  T-­‐cell	  independent	  (TI)-­‐2	  antigen	  α(1-­‐
3)-­‐dextran	   can	   be	   attributed	   to	   the	   reduced	   numbers	   of	   B-­‐1	   B	   cells	   in	   these	  mice	  
[280,	  284].	  However,	  since	  CD19-­‐deficient	  mice	  responded	  normally	  to	  immunization	  
with	   the	   TI-­‐2	   antigen	   4-­‐hydroxy-­‐3-­‐nitrophenylacetyl	   (NP)-­‐Ficoll,	   the	   response	   to	  
which	  is	  mediated	  by	  B-­‐2	  B	  cells,	  one	  can	  conclude	  that	  CD19	  is	  not	  necessary	  for	  B-­‐
cell	   activation	   mediated	   by	   TI-­‐2	   antigens	   [280].	   Nevertheless,	   the	   intense	   cross-­‐
linking	  of	  BCR	  by	  NP-­‐Ficoll	  may	  compensate	  for	  the	  lack	  of	  CD19	  in	  these	  conditions.	  
Upon	  immunization	  with	  the	  T-­‐cell	  dependent	  antigen	  dinitrophenyl-­‐keyhole	  limpet	  
hemocyanin	  (DNP-­‐KLH)	  serum-­‐immunoglobulin	  levels	  where	  10%	  reduced	  compared	  
to	  wild	  type	  littermates,	  and	  even	  30%	  upon	  re-­‐challenge	  [272].	  Generally,	  features	  
originating	   in	   a	   GC	   reaction,	   such	   as	   affinity	  maturation,	  memory	   B	   cell	   and	   long-­‐
lived	  plasma	  cell	   generation,	  were	   reduced.	  Total	  numbers	  of	  GCs	  were	  decreased	  
and	  the	  ones	  present	  were	  smaller	  in	  size	  [272,	  280,	  285].	  Resulting	  from	  the	  hypo-­‐
responsive	   nature	   of	   CD19-­‐deficient	   B	   cells,	   their	   selection	   into	   germinal	   center	  
responses	  was	   diminished.	   The	   survival	   of	   existing	  memory	   B	   cells	   is	   also	   entirely	  
dependent	  on	  CD19	  [286].	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4.6.2 Human	  CD19	  transgenic	  mice	  (hCD19tg)	  
In	  human	  CD19	  transgenic	  mice,	  the	  construct	  was	  exclusively	  expressed	  by	  B	  
cells,	   most	   likely	   due	   to	   the	   high	   homology	   between	   the	   murine	   and	   the	   human	  
CD19	  promoter	  [24,	  73].	  These	  mice	  display	  a	  reduction	  of	  mature	  peripheral	  B	  cell	  
numbers.	  However,	  a	  decrease	  is	  first	  detectable	  at	  the	  B220loIgM+	  immature	  B	  cell	  
stage	  in	  the	  bone	  marrow	  [272].	  The	  effect	  is	  gene	  dose-­‐dependent,	  as	  heterozygous	  
mice	  show	  an	  intermediate	  phenotype	  and	  B-­‐cell	  numbers	  change	  with	  varying	  copy	  
numbers	   [279].	   If	   the	   expression	   level	   of	   the	   human	  CD19	   transgene	  matches	   the	  
one	  on	  circulating	  human	  B	  cells,	  one	  can	   rescue	  normal	  B-­‐cell	   function	  as	  well	   as	  
development	  in	  CD19-­‐deficient	  mice	  [287].	  CD19	  diminishes	  the	  activation	  threshold	  
of	  surface	  immunoglobulin,	  thereby	  potentially	  initiating	  clonal	  deletion	  of	  immature	  
IgM+	   B	   cells	   by	   imitating	   a	   BCR	   with	   high	   affinity	   for	   self-­‐antigens	   [11].	   This	  
hypothesis	   is	   substantiated	  by	   the	   similarity	   in	  phenotype	  between	  CD19-­‐deficient	  
mice	  and	  those	  overexpressing	  the	  μ-­‐	  or	  δ-­‐immunoglobulin	  heavy	  chain	  [288,	  289].	  
Here,	  a	  premature	  and	  pronounced	  positive	  signal	  during	  B-­‐cell	  development	  results	  
in	  decreased	  numbers	  of	  peripheral	  mature	  cells.	  
The	   hyper-­‐reactivity	   of	   hCD19tg	   B	   cells	   is	   reflected	   in	   their	   increased	  
proliferative	   response	   to	   LPS	   stimulation	   or	   anti-­‐IgM	   treatment	   [272].	   Also	  
immunization	   with	   a	   T-­‐cell	   dependent	   antigen	   results	   in	   elevated	   serum	  
immunoglobulin	  levels	  despite	  the	  evident	  B-­‐cell	  deficiency	  in	  these	  mice	  [272,	  279].	  
CD19	  deletion	  and	  its	  transgenic	  expression	  suggest	  that	  tight	  control	  of	  CD19	  
levels	   is	   essential	   for	   accurate	   B-­‐cell	   development.	   The	   hypo-­‐responsiveness	   of	  
CD19-­‐deficient	  and	  the	  hyper-­‐responsiveness	  of	  hCD19tg	  cells	   imply	  that	  CD19	   is	  a	  
direct	  regulator	  of	  B-­‐cell	  activation	  thresholds,	  most	   likely	  due	  to	  its	  role	  as	  part	  of	  
the	   co-­‐receptor	   complex.	   The	   loss	   of	   CD19	   could	   potentially	   result	   in	   a	   loss	   of	  
sufficient	   “tonic”	   signaling	   activity,	   resulting	   in	   B	   cells	   failing	   positive	   selection.	   In	  
contrast,	  transgenic	  expression	  of	  elevated	  CD19	  levels	  might	  mimic	  an	  autoreactive	  
BCR,	  thereby	  inducing	  negative	  selection.	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Hematopoietic	   cells	   are	   continuously	   generated	   throughout	   life	   from	  
hematopoietic	   stem	   cells	   (HSC),	   thus	  making	   hematopoiesis	   a	   favorable	   system	   to	  
study	   developmental	   cell	   fate	   decisions.	   The	   main	   factors	   incorporating	  
environmental	  signals	   to	  developing	  hematopoietic	  cells	  are	  cytokines,	  which	  exert	  
their	  function	  either	  in	  a	  permissive	  or	  an	  instructive	  way.	  The	  cytokines	  Flt3-­‐ligand	  
(FL)	   and	   interleukin-­‐7	   (IL7)	   are	   important	   regulators	   of	   B-­‐cell	   development,	   since	  
their	  absence	  leads	  to	  compromised	  commitment	  to	  the	  B-­‐cell	  lineage,	  manifested	  in	  
the	   dramatic	   reduction	   of	   CD135+CD127+Ly6D+CD19-­‐	   progenitors	   and	   the	   loss	   of	  
their	  B-­‐cell	  potential.	  However,	  the	  cytokines'	  precise	  mode	  of	  action	  in	  this	  process	  
has	  been	  a	  subject	  of	  debate.	  In	  the	  present	  study	  we	  assessed	  the	  rescue	  of	  B-­‐cell	  
commitment	   in	   mice	   lacking	   IL7	   while	   at	   the	   same	   time	   over-­‐expressing	   FL.	   Our	  
analysis	   showed	   that	   increased	   in	   vivo	   levels	   of	   FL	   are	   sufficient	   to	   rescue	   B-­‐cell	  
commitment	  in	  the	  absence	  of	  IL7,	  demonstrating	  significant	  expression	  of	  Ebf1	  and	  
Pax5	   and	   restored	  generation	  of	  CD19+	  B-­‐cell	  progenitors.	   Further	  analysis	  of	   IL7-­‐/-­‐	  
mice	   over-­‐expressing	   the	   pro-­‐survival	   gene	   Bcl2,	   as	   well	   as	   IL7tg	   and	   FL-­‐/-­‐	   mice,	  
suggests	  that	  both	  FL	  and	  IL7	  regulate	  B-­‐cell	  commitment	  in	  a	  permissive	  manner;	  FL	  
by	   inducing	   proliferation	   of	   CD135+CD127+Ly6D+CD19-­‐	   progenitors	   and	   IL7	   by	  
providing	  survival	  signals	  to	  these	  progenitors.	  	  
	  
	   	  






Hematopoiesis,	  the	  generation	  of	  all	  blood	  cells	  from	  hematopoietic	  stem	  cells	  
(HSC),	  is	  a	  lifelong	  process	  that	  takes	  place	  in	  the	  adult	  bone	  marrow.	  Over	  the	  last	  
decades,	   accumulating	   evidence	   has	   suggested	   that	   HSC	   give	   rise	   to	   the	   different	  
hematopoietic	   lineages	   through	   the	   generation	   of	   oligo-­‐potent	   progenitors	   with	  
limited	  self-­‐renewal	  capacity	  and	  restricted	  developmental	  potentials.	  The	  activation	  
of	  lineage-­‐specific	  gene-­‐transcription	  programs	  in	  these	  progenitors	  eventually	  leads	  
to	  their	  commitment	  to	  a	  particular	  hematopoietic	   lineage.	  Cytokines	  are	  the	  most	  
prominent	   environmental	   factors	   that	   regulate	   lineage	   commitment	   of	  
hematopoietic	   progenitors	   and	   they	   do	   so	   by	   acting	   either	   in	   an	   instructive	   or	   a	  
permissive	  manner	  [1].	  In	  the	  instructive	  mode	  of	  action	  cytokines	  induce	  a	  signaling	  
cascade	  in	  the	  target	  progenitor	  cell	  that	  leads	  to	  the	  initiation	  of	  a	  lineage-­‐specific	  
gene	   program,	   typically	   through	   up-­‐regulation	   and/or	   activation	   of	   transcription	  
factors,	  eventually	  resulting	   in	  commitment	  to	  a	  particular	   lineage.	   In	  contrast,	   the	  
permissive	  model	   advocates	   that	   commitment	   of	   progenitors	   to	   different	   lineages	  
occurs	  in	  a	  cell-­‐autonomous,	  stochastic	  manner	  and	  the	  cytokine	  acts	  as	  a	  selection	  
rather	  than	  a	  commitment	  factor,	  by	  promoting	  the	  survival	  and/or	  proliferation	  of	  a	  
specific	   lineage	   at	   the	   expense	   of	   other	   lineages	   originating	   from	   the	   same	  
progenitor.	   Elucidating	   the	   precise	   mode	   of	   action	   of	   cytokines	   is	   technically	  
challenging	  and	  therefore	  the	  instructive	  versus	  permissive	  debate	  on	  hematopoietic	  
cytokines	   remains	   open	   [2].	  While	   the	   permissive	  model	   has	   been	   favored	   in	   the	  
past,	   recent	  data	  have	  provided	  solid	  evidence	   for	   the	   instructive	  action	  of	  several	  
important	  cytokines	  such	  as	  M-­‐CSF,	  G-­‐CSF,	  EPO	  and	  Flt3-­‐ligand	  [3-­‐6].	  However,	  our	  
understanding	  of	  how	  cytokines	  regulate	  hematopoiesis	  remains	  elusive,	  as	  different	  
cytokines	  can	  act	  in	  various	  ways	  and	  their	  function	  might	  be	  cell-­‐context	  dependent	  
[7].	   Moreover,	   most	   studies	   to	   date	   have	   addressed	   cytokine	   regulated	   myeloid	  
differentiation	  and	  little	  is	  known	  about	  the	  role	  of	  cytokines	  in	  commitment	  to	  the	  
lymphoid	  lineages.	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Interleukin-­‐7	  (IL7)	  is	  considered	  the	  most	  crucial	  cytokine	  for	  the	  generation	  of	  
B	  cells.	  The	  importance	  of	  IL7	  for	  B-­‐cell	  development	  has	  been	  clearly	  demonstrated	  
by	  the	  dramatic	  defect	  in	  B-­‐cell	  generation	  in	  mice	  lacking	  either	  the	  cytokine	  [8]	  or	  
its	  receptor	  [9].	  Interestingly,	  while	  human	  B-­‐cell	  progenitors	  are	  also	  responsive	  to	  
IL7	   [10],	  disruption	  of	   IL7	  signaling	  caused	  by	  mutations	  seems	  to	  not	  ablate	  B-­‐cell	  
development	  in	  these	  patients	  [11,	  12].	   IL7	  has	  been	  initially	   identified	  as	  a	  growth	  
factor	   for	   B-­‐cell	   progenitors	   [13]	   and	   early	   studies	   demonstrated	   that	   over-­‐
expression	  of	  the	  pro-­‐survival	  gene	  Bcl2	  in	  an	  in	  vivo	  setting	  was	  unable	  to	  rescue	  B-­‐
cell	   development	   in	   the	   absence	   of	   IL7	   signaling,	   therefore	   suggesting	   that	   the	  
cytokine	  acts	  in	  an	  instructive	  manner	  to	  commit	  progenitors	  to	  the	  B-­‐cell	  fate	  [14,	  
15].	   The	   subsequent	   findings	   that	   uncommitted	   Common	   Lymphoid	   Progenitors	  
(CLP)	  from	  IL7-­‐/-­‐	  mice	  lacked	  expression	  of	  the	  transcription	  factor	  Early	  B-­‐cell	  Factor	  
1	  (Ebf1)	  [16]	  and	  that	  Ebf1	  over-­‐expression	  could	  partially	  restore	  B-­‐cell	  generation	  
from	   these	   CLP	   [17],	   led	   to	   the	   hypothesis	   that	   IL7,	   through	   Stat5	   activation,	  
instructs	   commitment	   to	   the	   B-­‐cell	   lineage	   by	   initiating	   Ebf1	   expression	   in	  
uncommitted	  progenitors.	  In	  support	  of	  this	  hypothesis,	  a	  putative	  Stat5	  binding	  site	  
was	   later	   identified	  on	   the	  Ebf1	  promoter	   [18].	  However,	  a	  more	   recent	   study	  has	  
shown	  that	  Bcl2	  can	  rescue	  B-­‐cell	  generation	  in	  a	  Stat5	  conditional	  knock-­‐out	  mouse	  
model	   [19].	   Furthermore,	   it	   has	   been	   demonstrated	   that	   the	   Ebf1-­‐expressing	  
fraction	   of	   CLP	   (Ly6D+	   CLP)	   is	   dramatically	   reduced	   in	   IL7-­‐/-­‐	   mice	   [20],	   therefore	  
providing	  an	  alternative	  possibility	  for	  the	  reduced	  Ebf1	  expression	  observed	  in	  IL7-­‐/-­‐	  
CLP.	   Interestingly,	   this	   Ly6D+CD19-­‐	   progenitor	   stage	   is	   where	   B-­‐cell	   commitment	  
events	  are	  initiated	  at	  the	  molecular	  level	  [21].	  Hence,	  while	  the	  importance	  of	  IL7	  as	  
a	   growth	   factor	   for	   committed	   B-­‐cell	   progenitors	   has	   been	   well	   established,	   it	  
remains	  unclear	  whether	  it	  instructs	  oligo-­‐potent	  progenitors	  to	  commit	  to	  the	  B-­‐cell	  
lineage	  through	  Ebf1	  and	  Pax5	  up-­‐regulation.	  	  
Ftl3-­‐ligand	  (FL),	  the	  only	  known	  ligand	  for	  Flt3	  receptor	  (CD135),	  is	  a	  cytokine	  
important	   for	   the	   generation	  of	  many	  hematopoietic	   lineages	   and	   its	   function	  has	  
gained	  much	   attention	   as	  mutations	   in	   FL	   signaling	   are	   commonly	   found	   in	   Acute	  
Myeloid	  Leukemia	   (AML)	   [22].	  Committed	  B-­‐cell	  progenitors	  do	  not	  express	  CD135	  
since	  expression	  of	  the	  B-­‐cell	  commitment	  factor	  Pax5	  leads	  to	  Flt3	  down-­‐regulation	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[23].	  However,	   early	   studies	  on	  Flt3-­‐/-­‐	   and	  FL-­‐/-­‐	  mice	   showed	  an	   impaired	  ability	  of	  
bone	   marrow	   progenitors	   from	   these	   mice	   to	   reconstitute	   B	   cells	   upon	   in	   vivo	  
transplantation	   [24,	   25],	   while	   subsequent	   experiments	   demonstrated	   that	   FL	   is	  
essential	  for	  maintaining	  normal	  numbers	  of	  uncommitted	  B-­‐cell	  progenitors	  [26].	  	  
We	   have	   recently	   described	   a	   FL-­‐transgenic	   mouse	   model	   (hereafter	   FLtg)	  
expressing	  high	   levels	  of	  FL	   in	  vivo,	  which	  has	  enabled	  us	   to	  suggest	  an	   instructive	  
role	   for	   FL	   in	   early	   stages	   of	   hematopoiesis	   [6].	   By	   breeding	   these	  mice	  with	   IL7-­‐/-­‐	  
mice	   we	   show	   in	   the	   present	   study	   that	   increased	   FL	   levels	   can	   rescue	   B-­‐cell	  
commitment	   in	   CD135+CD127+CD19-­‐	   progenitors	   and	   restore	   the	  numbers	  of	   early	  
CD19+	  B-­‐cell	  progenitors	  in	  the	  absence	  of	  IL7	  signaling,	  suggesting	  a	  permissive	  role	  
for	  IL7	  in	  B-­‐cell	  commitment.	  Further	  analyses	  of	  a	  combination	  of	  mouse	  genotypes	  
over-­‐expressing	   or	   lacking	   FL	   and	   IL7,	   as	   well	   as	   the	   pro-­‐survival	   gene	   Bcl2,	   have	  
enabled	  us	  to	  identify	  a	  permissive	  role	  for	  both	  IL7	  and	  FL	  in	  B-­‐cell	  commitment.	  	  
	  
	   	  




Materials	  and	  Methods	  
	  
Mice	  
For	   breeding	   and	   analysis,	   age-­‐	   and	   sex-­‐matched	  C57BL/6	   FL-­‐/-­‐	   [25],	   FLtg	   [6],	  
IL7-­‐/-­‐	  [8],	  IL7Rα-­‐/-­‐	  [9],	  IL7tg	  [27],	  and	  Bcl2tg	  [28]	  mice	  were	  used	  at	  6–11	  weeks	  of	  age.	  
All	  mice	  were	  bred	   and	  maintained	   in	   our	   animal	   facility	   under	   specific	   pathogen-­‐
free	  conditions.	  Animal	  experiments	  were	  carried	  out	  within	  institutional	  guidelines	  
(authorization	  number	  1888	  from	  cantonal	  veterinarian	  office,	  Basel).	  
	  
Antibodies,	  flow	  cytometry,	  and	  sorting.	  
For	  analysis,	  cells	  were	  flushed	  from	  femurs	  of	  the	  two	  hind	  legs	  of	  mice.	  The	  
procedure	  was	  performed	  in	  PBS	  containing	  0.5%	  BSA	  and	  5mM	  EDTA.	  The	  following	  
antibodies	   were	   used	   for	   flow	   cytometry	   (from	   BD	   Pharmingen,	   eBioscience,	  
BioLegend,	  or	  produced	  in	  house):	  anti-­‐B220	  (RA3-­‐6B2),	  anti-­‐CD117	  (2B8),	  anti-­‐CD19	  
(1D3),	  anti-­‐NK1.1	  (PK136),	  anti-­‐SiglecH	  (551),	  anti-­‐CD11c	  (HL3),	  anti-­‐CD115	  (AFS98),	  
anti-­‐Ly6D	  (49-­‐H4),	  anti-­‐CD127	  (SB/199),	  anti-­‐CD135	  (A2F10),	  anti-­‐Sca1	  (D7),	  anti-­‐IgM	  
(M41),	  anti-­‐CD21	  (7G6),	  anti-­‐CD23	  (B3B4),	  anti-­‐CD4	  (GK1.5),	  anti-­‐CD8	  (53.6.7),	  anti-­‐
TCRβ	   (H57).	   For	   detection	   of	   Ebf1	   and	   cell	   cycle	   analysis,	   cells	   were	   fixed	   and	  
permeabilized	   after	   cell-­‐surface	   staining	   using	   the	   Foxp3	   Fix/Perm	   buffer	   set	  
(eBioscience),	   and	   subsequently	   stained	  with	  PE-­‐conjugated	   anti-­‐Ebf1	   (T26-­‐818)	   or	  
FITC-­‐conjugated	  anti-­‐Ki67	  (B56)	  and	  DAPI,	  according	  to	  the	  supplier’s	  protocol.	  Flow	  
cytometry	   was	   done	   using	   a	   BD	   LSRFortessa	   (BD	   Biosciences)	   and	   data	   were	  
analyzed	   using	   FlowJo	   Software	   (Treestar).	   For	   cell	   sorting,	   a	   FACSAria	   IIu	   (BD	  
Biosciences)	  was	  used	  (>98%	  purity).	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In	  vitro	  limiting	  dilution	  assays	  
Experiments	  have	  been	  performed	  as	  previously	  described	  [6].	  
	  
Quantitative	  real-­‐time	  PCR	  analysis	  
RNA	  extraction	  was	  performed	  using	  TRI	  Reagent®	  (Life	  Technologies)	  followed	  
by	  cDNA	  synthesis	  using	  using	  GoScript™	  Reverse	  Transcriptase	  (Promega).	  Real-­‐time	  
PCR	   was	   performed	   using	   SYBR	   Green	   PCR	  Master	  Mix	   (Applied	   Biosystems).	   The	  
primers	   used	   were:	   Ebf1:	   Ebf1-­‐F:	   5’-­‐CAGGAAACCCACGTGACAT-­‐3’;	   Ebf1-­‐R:	   5’-­‐
CCACGTTGACTGTGGTAGACA-­‐3’,	   Pax5:	   Pax5-­‐F:	   5’ACGCTGACAGGGATGGTG-­‐3’;	   Pax5-­‐
R:	   5’-­‐GGGGAACCTCCAAGAATCAT-­‐3’,	   Foxo1:	   Foxo1-­‐F:	   5’-­‐AGTGGATGGTGAAGAGCGT-­‐
3’,	   Foxo1-­‐R:	   5’-­‐GAAGGGACAGATTGTGGCG-­‐3’,	   Actin:	   Actin-­‐F:	   5’-­‐
CTGTCGAGTCGCGTCCACC-­‐3’,	  Actin-­‐R:	  5’-­‐CGCAGCGATATCGTCATCCA-­‐3’.	  
	  
Statistical	  analysis	  
Statistical	   analysis	   was	   performed	   with	   Prism	   6.0g	   software	   (GraphPad	  
Software,	   Inc.).	   Two-­‐tailed	   unpaired	   Student’s	   t	   tests	   were	   used	   for	   statistical	  
comparisons.	  If	  not	  differently	  indicated,	  data	  are	  presented	  as	  mean	  values	  ±	  SD	  or	  
SEM	  as	  indicated.	  n.s.	  not	  significant	  or	  P	  >	  0.05,	  *P	  ≤	  0.05,	  **P	  ≤	  0.01,	  ***P	  ≤	  0.001,	  
****P	  ≤	  0.0001.	  
	   	  






Increased	  in	  vivo	  levels	  of	  FL	  rescue	  B-­‐cell	  commitment	  in	  IL7-­‐/-­‐	  CD19-­‐	  progenitors	  
	  
We	   have	   previously	   reported	   the	   characterization	   of	   an	   uncommitted	   B-­‐cell	  
progenitor,	   with	   combined	   lymphoid	   and	  myeloid	   potential	   (Early	   Progenitor	   with	  
Lymphoid	   and	   Myeloid	   potential	   –	   EPLM)	   [29].	   Further	   sub-­‐fractionation	   of	   this	  
population	  with	  the	  use	  of	  surface	  markers	  SiglecH,	  CD11c,	  CD115	  and	  Ly6D	  enabled	  
us	   to	   identify	   the	   Ly6D+SiglecH-­‐CD11c-­‐CD115-­‐	   fraction	   of	   EPLM	   (hereafter	   Ly6D+	  
EPLM)	  as	  the	  population	  containing	  most	  of	  the	  B-­‐cell	  potential	  within	  EPLM,	  while	  
being	   devoid	   of	  myeloid	   potential	   (Servera	   et	   al,	   manuscript	   in	   preparation).	   This	  
EPLM	   subpopulation	   is	   identified	   as	   Lin-­‐CD19-­‐CD117intB220intLy6D+CD135+CD127+	  
(Figure	   1A),	   therefore	   partially	   overlapping	   phenotypically	   with	   Ly6D+	   CLP	  
(Supplementary	  Figure	  1)	  and	  pre-­‐pro-­‐B	  cells	  [30,	  31].	  Ly6D+	  EPLM	  numbers	  in	  IL7-­‐/-­‐	  
and	  FL-­‐/-­‐	  mice	  showed	  a	  significant	  decrease	  compared	  to	  WT	  control	  animals;	  7-­‐fold	  
for	   IL7-­‐/-­‐	   and	   13-­‐fold	   for	   FL-­‐/-­‐	   Ly6D+	   EPLM	   (Figure	   1B	   and	   C).	   A	   similar	   dramatic	  
decrease	  was	  observed	  in	  Ly6D+	  CLP	  from	  both	  mutant	  mice	  (Figure	  1B	  and	  C),	  while	  
FL	   deficiency	   also	   affected	   the	   numbers	   of	   Ly6D-­‐	   EPLM	   and	   CLP	   (Supplementary	  
Figure	  2).	  Therefore,	  the	  Ly6D+	  EPLM/CLP	  represents	  the	  earliest	  stage	  in	  the	  B-­‐cell	  
developmental	  pathway	  affected	  by	  the	  absence	  of	  IL7.	  
We	  have	  recently	  generated	  a	  mouse	  model	  expressing	  high	  in	  vivo	  levels	  of	  FL	  
[6].	   Analysis	   of	   the	   progenitor	   compartment	   in	   these	   mice	   showed	   a	   dramatic	  
increase	   in	   the	   numbers	   of	   EPLM	   and	   CLP,	   with	   the	   Ly6D+	   fractions	   of	   these	  
progenitors	  increased	  90-­‐fold	  and	  28-­‐fold	  relative	  to	  WT,	  respectively	  (Figure	  1D	  and	  
E).	  Prompted	  by	  this	  finding	  we	  crossed	  FLtg	  with	  IL7-­‐/-­‐	  mice	  in	  an	  attempt	  to	  assess	  
the	   extent	   to	   which	   increased	   FL	   levels	   could	   potentially	   rescue	   the	   loss	   of	  
Ly6D+CD19-­‐	  progenitors	   in	   IL7-­‐/-­‐	  mice.	  As	  shown	   in	  Figure	  2	   (A	  and	  B),	   in	  vivo	  over-­‐
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expression	  of	  FL	  leads	  to	  a	  significant	  increase	  in	  the	  numbers	  of	  FLtg-­‐IL7-­‐/-­‐	  EPLM	  and	  
CLP,	  which	   reach	   the	   levels	  observed	   in	   FLtg	  mice.	  Crucially,	   a	   full	   rescue	  of	   Ly6D+	  
EPLM	   and	   CLP	   can	   be	   seen	   in	   these	   mice,	   with	   a	   striking	   470-­‐fold	   and	   31-­‐fold	  
increase	  in	  their	  numbers,	  respectively,	  relative	  to	  their	  IL7-­‐/-­‐	  counterparts	  (Figure	  2	  
A	  and	  B).	  Furthermore,	   the	  numbers	  of	   the	  earliest	  committed	  CD19+CD117+	  pro-­‐B	  
cells	  were	  fully	  restored	  in	  FLtg-­‐IL7-­‐/-­‐	  mice,	  showing	  a	  251-­‐fold	  increase	  compared	  to	  
IL7-­‐/-­‐	   mice	   (Figure	   2C,	   Supplementary	   Figure	   3).	   However,	   this	   rescue	   was	   less	  
pronounced	   in	   downstream	   CD19+CD117-­‐IgM-­‐	   and	   CD19+IgM+	   B-­‐cell	   stages	   (Figure	  
2C),	  since	  these	  cells	  require	  IL7	  to	  expand.	  As	  a	  result	  of	  this	  rescue	  in	  bone	  marrow	  
B-­‐cell	   generation,	   numbers	   of	   splenic	   marginal	   zone	   and	   follicular	   B	   cells	   were	  
significantly	   increased	   in	   FLtg-­‐IL7-­‐/-­‐	   mice	   compared	   to	   IL7-­‐/-­‐	   (Figure	   2D).	   T-­‐cell	  
development	   in	   the	   thymus	   of	   Fltg-­‐IL7-­‐/-­‐	   mice	   was	   not	   rescued	   (data	   not	   shown)	  
while	  an	  increase	  in	  peripheral	  T	  cells	  was	  observed	  (Supplementary	  Figure	  4)	  most	  
likely	  due	  to	  the	  increased	  IL2	  levels	  in	  these	  mice	  [32].	  
In	   order	   to	   assess	   whether	   these	   rescued	   FLtg-­‐IL7-­‐/-­‐	   Ly6D+CD19-­‐	   progenitors	  
have	  the	  potential	  to	  give	  rise	  to	  B	  cells	  in	  vitro,	  we	  sorted	  FLtg-­‐IL7-­‐/-­‐	  Ly6D+	  EPLM	  and	  
plated	   them	   on	   OP9	   stromal	   cells	   in	   the	   presence	   of	   IL7,	   in	   limiting	   dilution	  
conditions.	  As	   shown	   in	  Figure	  3A,	  FLtg-­‐IL7-­‐/-­‐	   Ly6D+	  EPLM	  could	  generate	  B	  cells	  at	  
similar	   frequencies	   as	   their	   WT	   and	   FLtg	   counterparts,	   while	   the	   few	   IL7-­‐/-­‐	   Ly6D+	  
EPLM	  we	  were	  able	  to	  isolate	  were	  unable	  to	  do	  so	  (data	  not	  shown).	  This	  indicates	  
that	   increased	   FL	   levels	   restore	   the	   generation	   of	   these	   Ly6D+	   progenitors,	   rather	  
than	  merely	  expanding	  the	  few	  Ly6D+	  EPLM/CLP	  found	  in	  IL7-­‐/-­‐	  mice.	  Moreover,	  real-­‐
time	   quantitative	   PCR	   analysis	   of	   Ly6D+	   EPLM	   from	   FLtg-­‐IL7-­‐/-­‐	   mice	   revealed	  
significant	  expression	  of	  Ebf1,	  Pax5	  and	  Foxo1	  transcription	  factors	  in	  the	  absence	  of	  
IL7	  (Figure	  3B).	  This	  result	  was	  confirmed	  for	  Ebf1	  expression	  at	  the	  protein	  level	  by	  
intracellular	  FACS	  staining.	  As	  shown	  in	  Figure	  3	  C	  and	  D,	  a	  significant	  proportion	  of	  
FLtg-­‐IL7-­‐/-­‐	  Ly6D+	  EPLM	  expressed	  Ebf1	  protein.	  Even	  though	  the	  percentage	  of	  FLtg-­‐
IL7-­‐/-­‐	  Ebf1+Ly6D+	  EPLM	  did	  not	  reach	  WT	  levels,	  it	  was	  similar	  to	  the	  one	  found	  in	  FLtg	  
mice,	   which	   produce	   IL7.	   Therefore,	   Ebf1/Pax5	   expression	   and	   subsequent	  
commitment	  to	  the	  B-­‐cell	  fate	  can	  occur	  without	  active	  IL7	  signaling	  present,	  arguing	  
against	  an	  instructive	  role	  of	  this	  cytokine	  in	  B-­‐cell	  commitment.	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CD127	   (IL7Rα)	   is	   a	   receptor	   subunit	   shared	   between	   IL7	   and	   thymic	   stromal	  
lymphopoietin	  (TSLP),	  a	  cytokine	  able	  to	  rescue	  B-­‐cell	  development	  in	  the	  absence	  of	  
IL7	  when	  present	  at	  high	   levels	   [33].	  Since	  TSLP	   is	  produced	  by	  dendritic	  cells	   [34],	  
which	  are	  dramatically	  expanded	   in	  FLtg	  mice	   [6],	   in	   vivo	   FL	  over-­‐expression	  could	  
lead	   to	   increased	   levels	   of	   TSLP	  which	   in	   turn	  would	   rescue	  B-­‐cell	   development	   in	  
FLtg-­‐IL7-­‐/-­‐	  mice.	  To	  investigate	  this	  possibility	  we	  injected	  IL7-­‐/-­‐	  or	  IL7Rα-­‐/-­‐	  mice	  with	  
FL	   (10	   daily	   injections	   of	   10μg	   each)	   and	   assessed	   the	   rescue	   of	   Ly6D+	   EPLM	   and	  
downstream	  CD19+	  progenitors	   in	   these	  mice.	  As	   shown	   in	  Figure	  3E,	  FL	   injections	  
into	   IL7-­‐/-­‐	   mice	   resulted	   in	   a	   significant	   increase	   in	   total	   EPLM,	   Ly6D+	   EPLM	   and	  
CD19+CD117+	   B-­‐cell	   progenitors,	   comparable	   to	   the	   rescue	   observed	   in	   FLtg-­‐IL7-­‐/-­‐	  
mice.	  FL	  injected	  IL7Rα-­‐/-­‐	  mice	  also	  demonstrated	  a	  significant	  rescue	  of	  Ly6D+	  EPLM	  
and	   CD19+CD117+	   pro-­‐B	   cells,	   indicating	   that	   the	   observed	   rescue	   of	   B-­‐cell	  
commitment	  in	  Fltg-­‐IL7-­‐/-­‐	  mice	  is	  not	  mediated	  through	  the	  action	  of	  TSLP.	  
	  
IL7	  promotes	  survival,	  but	  not	  proliferation,	  of	  Ly6D+CD135+CD127+CD19-­‐	  progenitors	  
	  
Even	  though	  our	  FLtg-­‐IL7-­‐/-­‐	  mouse	  model	  suggests	  that	  IL7	  is	  dispensable	  for	  B-­‐
cell	  commitment,	  the	  dramatic	  decrease	  in	  IL7-­‐/-­‐	  Ly6D+	  EPLM/CLP	  argues	  for	  a	  role	  of	  
IL7	  in	  the	  maintenance	  of	  this	  population	  when	  FL	  levels	  are	  limiting.	  This	  could	  be	  
either	  by	  promoting	  their	  survival	  or	  their	  proliferation.	  To	  investigate	  the	  potential	  
role	  of	  IL7	  as	  a	  survival	  factor	  for	  Ly6D+CD135+CD127+CD19-­‐	  progenitors	  we	  crossed	  
IL7-­‐/-­‐	  mice	  with	  mice	  expressing	  the	  pro-­‐survival	  gene	  Bcl2	  under	  the	  control	  of	  the	  
H2k	  MHC	   Class	   I	   promoter	   [28].	   Analysis	   of	   the	   CD19-­‐	   progenitor	   compartment	   in	  
these	   mice	   showed	   a	   minor	   but	   statistically	   significant	   2.6-­‐fold	   increase	   in	   the	  
numbers	  of	  Ly6D+	  EPLM	  and	  a	  similar	  2.2-­‐fold	  increase	  in	  Ly6D+	  CLP	  (Figure	  4A	  and	  
B).	   Cell	   cycle	   stage	   analysis	   of	   Ly6D+	   EPLM	   of	   these	   mice	   indicated	   that	   Bcl2	  
transgene	   over-­‐expression	   had	   an	   anti-­‐proliferative	   effect	   on	   Ly6D+	   EPLM	  
(Supplementary	  Figure	  5),	  thereby	  compromising	  to	  some	  extent	  the	  rescue	  of	  these	  
progenitors’	  numbers.	  Importantly,	  when	  plated	  on	  OP9	  stromal	  cells	  together	  with	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IL7,	  Bcl2tg-­‐IL7-­‐/-­‐	  Ly6D+	  EPLM	  could	  potently	  give	  rise	  to	  B	  cells	  at	  frequencies	  similar	  
to	   WT	   mice	   (Figure	   4C),	   indicating	   that	   this	   partially	   rescued	   Ly6D+	   population	   is	  
functional	   in	   giving	   rise	   to	   B	   cells.	   Indeed,	   when	   analyzing	   CD19+	   committed	  
progenitors	   in	   the	  bone	  marrow	  we	   could	   see	   a	   significant	   68-­‐fold	   increase	   in	   the	  
earliest	  CD19+CD117+	  pro-­‐B	  cell	  compartment,	  compared	  to	  IL7-­‐/-­‐	  (Figure	  4D).	  Due	  to	  
the	   anti-­‐proliferative	   effect	   of	   Bcl2	   over-­‐expression	   (Supplementary	   Figure	   5	   and	  
[35]),	  as	  well	  as	  the	  requirement	  for	  IL7	  that	  CD19+	  cells	  have	  for	  their	  proliferation,	  
Bcl2tg-­‐IL7-­‐/-­‐	   CD19+CD117+	   numbers	   did	   not	   reach	   WT	   levels,	   while	   downstream	  
CD19+	   immature	   B	   cell	   populations	   showed	   a	   less	   pronounced	   but	   still	   significant	  
rescue	   (Figure	   4D).	   In	   the	  periphery	   of	   these	  mice,	   Bcl2	   over-­‐expression	   increased	  
the	   numbers	   of	   marginal	   zone	   and	   follicular	   B	   cells,	   while	   T-­‐cell	   numbers	   were	  
rescued,	   as	   previously	   reported	   (Supplementary	   Figure	   6)	   [14].	   We	   conclude	   that	  
providing	   an	   extra	   Bcl2-­‐mediated	   survival	   signal	   in	   vivo	   can	   partially	   rescue	   IL7-­‐/-­‐	  
Ly6D+CD19-­‐	  progenitors	  with	  the	  ability	  to	  commit	  to	  the	  B-­‐cell	  pathway	  and	  results	  
in	  a	  significant	  generation	  of	  CD19+	  progenitors;	  therefore	  suggesting	  a	  role	  for	  IL7	  in	  
facilitating	  the	  survival	  of	  Ly6D+CD135+CD127+CD19-­‐	  progenitors.	  
In	   order	   to	   evaluate	   the	   potential	   proliferative	   effect	   of	   IL7	   on	  
Ly6D+CD135+CD127+CD19-­‐	   progenitors,	   we	   analyzed	   a	   mouse	   model	   in	   which	  
expression	  of	  IL7	  is	  driven	  by	  an	  MHC	  Class	  II	  promoter,	  resulting	  in	  increased	  in	  vivo	  
levels	  of	  the	  cytokine	  [36].	  These	  mice	  exhibit	  a	  lymphoproliferative	  phenotype	  with	  
increased	   numbers	   of	   CD19+	   B	   cells	   [27].	   In	   contrast	   to	   bone	  marrow	  CD19+	   cells,	  
Ly6D+	  EPLM	  numbers	  did	  not	  increase	  in	  response	  to	  elevated	  IL7	  (Figure	  5A,	  B	  and	  
C).	  In	  addition,	  the	  cell	  cycle	  profile	  of	  Ly6D+	  EPLM	  remained	  unaltered	  in	  IL7tg	  mice	  
compared	   to	  WT	   (Figure	  5D),	   arguing	  against	  a	  proliferative	  action	  of	   IL7	  on	   these	  
progenitors.	   In	   order	   to	   exclude	   the	   possibility	   that	   a	   proliferative	   signal	   by	   FL	  
present	  in	  these	  mice	  might	  compromise	  the	  effect	  of	  increased	  IL7	  on	  the	  cell	  cycle	  
status	  of	  Ly6D+	  EPLM,	  we	  crossed	  IL7tg	  with	  FL-­‐/-­‐	  mice.	  As	  shown	  in	  Figure	  5E	  and	  F,	  
in	  vivo	  over-­‐expression	  of	  IL7	  did	  not	  result	  in	  a	  significant	  increase	  in	  Ly6D+	  EPLM	  or	  
CLP	   numbers	   in	   the	   absence	   of	   FL.	   In	   contrast,	   a	   3-­‐fold	   increase	   in	   numbers	   of	  
CD19+CD117+	   cells	   was	   observed	   (Figure	   5G),	   which	   is	   in	   agreement	   with	   the	  
proliferative	   effect	   of	   IL7	   on	   CD19+	   B	   cells.	   Ultimately	   this	   resulted	   in	   a	   small	   but	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significant	   increase	   in	  splenic	   follicular	  B	  cells	   (Supplementary	  Figure	  7).	  Moreover,	  
cell	   cycle	   analysis	   of	   IL7tg-­‐FL-­‐/-­‐	   Ly6D+	   EPLM	   showed	   no	   significant	   change	   in	   the	  
cycling	   profile	   of	   these	   cells	   compared	   to	   their	   FL-­‐/-­‐	   counterparts	   (Figure	   5H).	  
Therefore,	   we	   conclude	   that	   while	   IL7	   acts	   as	   a	   proliferative	   factor	   for	   CD19+	  
committed	  B	  cells,	  it	  does	  not	  do	  so	  for	  their	  Ly6D+CD19-­‐	  precursors.	  
	  
FL	  induces	  proliferation	  of	  Ly6D+CD135+CD127+CD19-­‐	  progenitors	  
	  
As	   evident	   in	   Figure	   5H,	   loss	   of	   in	   vivo	   FL	   signaling	   resulted	   in	   a	   significant	  
increase	  in	  the	  percentage	  of	  resting	  Ly6D+	  EPLM	  and	  a	  simultaneous	  decrease	  in	  the	  
percentage	   of	   cycling	   cells,	   consistent	   with	   a	   proliferative	   action	   of	   FL	   on	   Ly6D+	  
EPLM.	   Indeed,	   comparison	  of	   Ly6D+	   EPLM	  numbers	   in	  mice	  either	   lacking	  or	  over-­‐
expressing	  FL	  showed	  a	  14-­‐fold	  reduction	  in	  FL-­‐/-­‐	  Ly6D+	  EPLM	  numbers	  compared	  to	  
WT,	  while	  FLtg	  Ly6D+	  EPLM	  increased	  105-­‐fold	  (Figure	  6A).	  A	  similar	  response	  to	  FL	  
levels	  was	  observed	   in	   Ly6D+	  CLP,	   as	  well	   as	   Ly6D-­‐	   EPLM	  and	  CLP	   (Figure	  6A).	   Cell	  
cycle	  stage	  analysis	  of	  Ly6D+	  EPLM	  from	  these	  mice	  showed	  a	  significant	  increase	  in	  
the	  percentage	  of	  resting	  cells	  and	  a	  decrease	  in	  the	  percentage	  of	  cycling	  cells	  when	  
FL	   signaling	   is	   absent,	   while	   FLtg	   Ly6D+	   EPLM	   showed	   the	   reverse	   (Figure	   6B	   and	  
Supplementary	  Figure	  8).	  Thus,	  our	  data	  indicate	  that	  FL	  promotes	  the	  proliferation	  
of	  Ly6D+CD135+CD127+CD19-­‐	  progenitors.	  
In	   order	   to	   evaluate	   if	   FL	   additionally	   regulates	   the	   survival	   of	  
Ly6D+CD135+CD127+CD19-­‐	   progenitors,	   we	   crossed	   FL-­‐/-­‐	   mice	   with	   Bcl2tg	   mice.	   As	  
shown	  in	  Figure	  6C,	  Bcl2tg-­‐FL-­‐/-­‐	  mice	  showed	  a	  minor	  2-­‐fold	  increase	  in	  Ly6D+	  EPLM	  
numbers	  compared	  to	  their	  FL-­‐/-­‐	  counterparts	  (1.8-­‐fold	  for	  Ly6D+	  CLP).	  Nevertheless,	  
the	  in	  vitro	  B-­‐cell	  potential	  of	  FL-­‐/-­‐	  Ly6D+	  EPLM	  progenitors	  was	  not	  improved	  by	  Bcl2	  
over-­‐expression	   (Figure	   6D).	   Downstream	   CD19+	   progenitors	   also	   demonstrated	   a	  
partial	   but	   significant	   rescue	   (Figure	   6E).	   Our	   analysis	   of	   Bcl2tg-­‐FL-­‐/-­‐	  mice	   suggests	  
that	   the	   reduction	   in	   the	   Ly6D+CD135+CD127+CD19-­‐	   progenitors	   observed	   in	   FL-­‐/-­‐	  
mice	  could	  only	  partially	  be	  explained	  by	  a	  survival	  role	  of	  FL.	  Nevertheless,	  the	  clear	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change	  in	  the	  cycling	  profile	  of	  these	  progenitors	  in	  response	  to	  the	  absence	  or	  the	  
over-­‐abundance	  of	  FL	  in	  vivo,	  as	  well	  as	  the	  inability	  of	  Bcl2	  to	  rescue	  their	  in	  vitro	  B-­‐
cell	  potential,	  points	  towards	  proliferation	  as	  being	  the	  main	  effector	  function	  of	  the	  
cytokine	  at	  this	  developmental	  stage.	  
	  
FL	  does	  not	  instruct	  commitment	  to	  the	  B-­‐cell	  lineage	  
	  
The	  striking	  rescue	  in	  B-­‐cell	  commitment	  observed	  in	  our	  FLtg-­‐IL7-­‐/-­‐	  mice	  could	  
be	  explained	  by	  a	  potential	  instructive	  role	  of	  FL	  when	  present	  at	  high	  levels	  in	  vivo.	  
However,	   as	   shown	   in	   Figure	   3A,	   FLtg	   and	   FLtg-­‐IL7-­‐/-­‐	   Ly6D+	   EPLM	   did	   not	   show	   a	  
higher	   capacity	   in	   generating	   B	   cells	   in	   vitro,	   compared	   to	  WT	   Ly6D+	   EPLM.	  More	  
importantly,	   Ebf1	   and	   Pax5	   expression	   in	   these	   cells	   appeared	   to	   be	   reduced	  
compared	   to	   WT,	   with	   Ebf1	   mRNA	   being	   expressed	   at	   almost	   half	   the	   amount	  
relative	  to	  WT	  and	  Pax5	  even	  less	  (Figure	  3B).	  Intracellular	  staining	  for	  Ebf1	  protein	  
expression	  showed	  that	  the	  percentage	  of	  Ebf1-­‐expressing	  Ly6D+	  EPLM	  was	  reduced	  
in	   FLtg	  mice	   (Figure	   3C	   and	  D).	   Therefore,	   increased	   in	   vivo	   FL	   signaling	   seems	   to	  
result	  in	  a	  decreased	  Ebf1+Ly6D+	  EPLM	  population,	  rather	  than	  a	  down-­‐regulation	  of	  
Ebf1	  gene	  expression.	  We	  extended	  this	  analysis	  to	  FL-­‐/-­‐	  Ly6D+	  EPLM	  and	  found	  that	  
while	   absence	   of	   FL	   in	   vivo	   leads	   to	   a	   reduction	   in	   the	   numbers	   of	   Ly6D+	   EPLM	  
(Figure	  1C),	   it	  does	  not	  significantly	  reduce	  the	  percentage	  of	  Ebf1+	  cells	  within	  the	  
population	   (Figure	   7A	   and	   B),	   consistent	  with	   a	   permissive	   rather	   than	   instructive	  
role	  of	  FL.	  Finally,	  the	  decrease	  in	  the	  Ebf1+	  fraction	  of	  Ly6D+	  EPLM	  upon	  exposure	  to	  
high	   levels	  of	   FL	  was	   reflected	   in	   the	   increased	  ability	  of	   these	  progenitors	   to	  give	  
rise	  to	  T	  cells	  in	  vitro,	  as	  manifested	  by	  the	  high	  frequency	  of	  T-­‐cell	  clone	  generation	  
when	  FLtg	  Ly6D+	  EPLM	  were	  plated	  on	  OP9DL1	  stromal	  cells	   in	  the	  presence	  of	   IL7	  
(Figure	  7C).	  The	  above	  data	  suggest	  that	  FL	  does	  not	  instruct	  commitment	  to	  the	  B-­‐
cell	  lineage	  through	  up-­‐regulation	  of	  Ebf1	  and	  Pax5	  expression.	  
	   	  






Commitment	   to	   the	  B-­‐cell	   lineage	   is	  mediated	  by	   the	  expression	  of	  Ebf1	  and	  
Pax5	   transcription	   factors	   and	   it	   is	   initiated	   prior	   to	   CD19	   expression,	   in	  
CD135+CD127+Ly6D+	  progenitors	  [30,	  31].	  In	  IL7-­‐/-­‐	  mice	  this	  Ly6D+	  CLP	  compartment	  
is	   significantly	   reduced	   [20],	   a	   finding	   that	  we	   confirmed	   in	   the	   present	   study	   for	  
both	  CLP	  and	  EPLM,	  a	  B220int/+	  population	  partly	  overlapping	  with	  CLP	  and	  pre-­‐pro	  B	  
cells	   (Figure	   1B	   and	   C).	   Thus,	   the	   Ly6D+	   CLP/EPLM	   progenitors	   represent	   the	  
developmentally	  earliest	  stage	  in	  the	  B-­‐cell	  pathway	  affected	  by	  the	  absence	  of	  IL7.	  
Moreover,	   IL7	   has	   a	   proliferative	   effect	   on	   committed	   CD19+	   B-­‐cell	   progenitors,	  
therefore	  making	  the	  investigation	  of	  its	  role	  in	  B-­‐cell	  commitment	  challenging	  when	  
using	   CD19+	   cells	   as	   readout.	   Hence,	   we	   assessed	   the	   role	   of	   IL7	   in	   B-­‐cell	  
commitment	   by	   analyzing	   the	   Ly6D+	   CLP/EPLM	   compartment	   in	   different	   mouse	  
models.	   Our	   analysis	   of	   FLtg-­‐IL7-­‐/-­‐	   mice	   showed	   a	   complete	   rescue	   of	   Ly6D+	  
CLP/EPLM	  both	  in	  numbers	  and	  in	  their	  ability	  to	  generate	  B	  cells	  in	  vitro	  (Figures	  2	  
and	   3).	   Furthermore,	   in	   Fltg-­‐IL7-­‐/-­‐	   mice	   Ebf1	   and	   Pax5	   were	   expressed	   at	   similar	  
levels	  to	  FLtg	  mice,	  thereby	  indicating	  that	  IL7	  signaling	  is	  not	  required	  for	  their	  up-­‐
regulation	  at	  the	  Ly6D+CD19-­‐	  stage.	  These	  results	  suggest	  that	  IL7	  is	  not	  acting	  as	  an	  
instructive	  cytokine	   in	  B-­‐cell	  commitment	  by	   initiating	  Ebf1	  and	  Pax5	  expression	  at	  
the	  CD135+CD127+CD19-­‐	   stage,	   as	  previously	  hypothesized	   [16-­‐18],	   but	   rather	   as	   a	  
permissive	  one.	  
While	   early	   studies	   showed	   an	   inability	   of	   Bcl2	   over-­‐expression	   to	   rescue	   B	  
cells	  in	  the	  absence	  of	  IL7	  signaling	  [14,	  15],	  a	  more	  recent	  investigation	  suggested	  a	  
survival	  role	  for	  IL7	  in	  B-­‐cell	  development	  based	  on	  a	  Bcl2-­‐mediated	  rescue	  of	  CD19+	  
progenitors	   in	   conditional	   Stat5-­‐/-­‐	   mice	   [19].	   However,	   all	   previous	   studies	   have	  
focused	  on	  the	  potential	  rescue	  of	  CD19+	  committed	  cells.	  Moreover,	  they	  have	  used	  
IL7Rα-­‐/-­‐	  mice,	  thereby	  excluding	  the	  assessment	  of	  CD19-­‐	  progenitor	  B-­‐cell	  potential	  
upon	  exogenous	  IL7	  addition,	  an	  important	  phenotype	  of	  IL7	  deficiency.	  By	  focusing	  
von	  Muenchow	  et	  al.	   	   	  
	  
57	  
on	   Ly6D+CD19-­‐	   progenitors,	   where	   B-­‐cell	   commitment	   is	   initiated,	   our	   analysis	   of	  
Bcl2tg-­‐IL7-­‐/-­‐	  mice	   showed	   a	  minor	   but	   significant	   rescue	   in	   Ly6D+	   EPLM	   (Figure	   4).	  
Importantly,	   a	   full	   restoration	   of	   their	   ability	   to	   give	   rise	   to	   B	   cells	   in	   culture	  was	  
observed	   (Figure	   4C),	   pointing	   towards	   survival	   as	   a	   main	   role	   for	   IL7	   at	   the	  
CD135+CD127+CD19-­‐	   stage.	   In	   agreement	  with	   the	   aforementioned	   published	   data	  
we	   find	  a	   significant	  but	  not	   complete	   rescue	  of	  CD19+	  progenitors	   in	  Bcl2tg-­‐IL7-­‐/-­‐,	  
which	   can	   be	   explained	   partly	   by	   the	   inability	   of	   Bcl2	   to	   rescue	   the	   proliferative	  
function	   of	   IL7	   and	   partly	   by	   its	   own	   anti-­‐proliferative	   effect	   (Suppl.	   Fig.	   4)	   [35].	  
Interestingly,	  analysis	  of	  IL7tg	  mice,	  expressing	  high	  levels	  of	  IL7	  in	  vivo,	  showed	  that	  
IL7	   indeed	  acts	  as	  a	  proliferative	  factor	  following	  commitment	  to	  the	  B-­‐cell	   lineage	  
and	   expression	   of	   CD19,	   but	   not	   before.	   Even	   in	   the	   absence	   of	   FL,	   when	   Ly6D+	  
CLP/EPLM	   numbers	   were	   compromised,	   excess	   IL7	   was	   unable	   to	   significantly	  
increase	   their	  numbers,	  while	   it	  did	  so	   for	  CD19+	  B-­‐cell	  progenitors	   (Figure	  5).	  This	  
result	   is	   in	   agreement	   with	   our	   proposed	   role	   for	   IL7	   as	   a	   survival	   factor	   for	  
Ly6D+CD19-­‐	   progenitors,	   since	   increased	   in	   vivo	   levels	   of	   a	   survival	   but	   not	  
proliferative	   factor	   would	   not	   result	   in	   increased	   numbers	   of	   progenitors,	   when	  
survival	  is	  not	  already	  compromised.	  Hence,	  we	  propose	  that	  the	  main	  role	  of	  IL7	  at	  
the	  CD135+CD127+CD19-­‐	  stage	   is	  to	  provide	  survival	  signals	  to	  the	  progenitors	  until	  
they	   commit	   to	   the	   B-­‐cell	   lineage	   upon	   Pax5	   and	   CD19	   expression,	   after	   which	   it	  
induces	  their	  proliferation	  (Figure	  7D).	  This	  survival	  role	  becomes	  particularly	  critical	  
when	  FL	  levels	  are	  limiting,	  thereby	  explaining	  the	  reduction	  in	  Ly6D+	  CLP/EPLM	  seen	  
in	  IL7-­‐/-­‐	  mice.	  	  
The	  rescue	  in	  B-­‐cell	  commitment	  without	  active	  IL7	  signaling	  occurs	  when	  FL	  is	  
expressed	  above	  physiological	   levels.	  Even	   though	  a	  minor	   role	   for	  FL	  as	  a	   survival	  
factor	  for	  CD135+CD127+Ly6D+CD19-­‐	  progenitors	  cannot	  be	  excluded,	  the	  main	  effect	  
of	   FL	   on	   these	   progenitors	   seems	   to	   be	   the	   induction	   of	   their	   proliferation,	   as	  
suggested	  by	   their	   expansion	   and	   their	   increased	   cycling	   upon	   FL	   over-­‐expression,	  
with	  the	  reverse	  phenotype	  observed	  upon	  loss	  of	  FL	  signaling	  (Figure	  6).	  Moreover,	  
increased	  FL	  leads	  to	  expansion	  of	  Lin-­‐CD117+Sca1+	  cells	  (LSK)	  [6],	  thereby	  increasing	  
the	  developmental	  input	  into	  the	  CD135+CD127+Ly6D+CD19-­‐	  progenitor	  stage.	  None	  
of	   the	   mouse	   models	   analyzed	   in	   the	   present	   study	   gave	   any	   evidence	   for	   an	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instructive	  role	  of	  FL	  in	  B-­‐cell	  commitment.	  In	  contrast,	  excess	  FL	  seems	  to	  result	  in	  a	  
proportional	   reduction	   of	   the	   Ebf-­‐	   and	   Pax5-­‐expressing	   Ly6D+CD19-­‐	   progenitors	  
(Figures	   3	   and	   7).	   One	   explanation	   for	   this	   reduction	   could	   be	   the	   increased	  
percentage	  of	  cycling	  FLtg	  Ly6D+CD19-­‐	  progenitors,	  resulting	  in	  a	  decreased	  fraction	  
of	   them	   initiating	   the	   B-­‐cell	   developmental	   program.	   Alternatively,	   another	  
environmental	   factor,	   responsible	   for	   initiation	   of	   Ebf1/Pax5	   expression	   and	   B-­‐cell	  
commitment,	   could	   be	   the	   limiting	   factor	   in	   FLtg	   mice,	   thus	   leading	   to	   a	   smaller	  
fraction	  of	   the	  expanded	  Ly6D+CD19-­‐	   compartment	  entering	   the	  B-­‐cell	  pathway,	   in	  
comparison	   to	   WT.	   Notably,	   increased	   FL	   signaling	   does	   not	   increase	   Stat5	  
phosphorylation	   levels	   in	   Ly6D+	   EPLM	   (data	   not	   shown),	   therefore	   excluding	   the	  
possibility	   that	   excess	   FL	   can	   substitute	   a	   potential	   instructive	   function	   of	   IL7	  
through	   aberrant	   Stat5	   activation.	   Our	   conclusion	   is	   that	   in	  WT	  mice	   FL	   is	  mainly	  
responsible	   for	   generating	   enough	   CD135+CD127+Ly6D+CD19-­‐	   progenitors,	   both	   by	  
inducing	  their	  proliferation	  and	  by	  increasing	  their	  developmental	  input	  from	  the	  LSK	  
compartment	  (Figure	  7D)	  [37,	  38].	  As	  a	  result,	  increased	  in	  vivo	  levels	  of	  FL	  lead	  to	  a	  
dramatic	   increase	   in	   numbers	   of	   CD135+CD127+Ly6D+CD19-­‐	   progenitors,	   therefore	  
surpassing	   the	   need	   for	   the	   survival	   role	   of	   IL7	   at	   this	   stage	   and	   resulting	   in	   a	  
significant	  fraction	  of	  them	  committing	  to	  the	  B-­‐cell	  lineage.	  
The	  generation	  of	  B-­‐cell	  progenitors	  observed	  in	  our	  FLtg-­‐IL7-­‐/-­‐	  mouse	  model	  is	  
reminiscent	   of	   the	   apparent	   IL7	   independency	   of	   human	   B	   lymphopoiesis,	   as	  
demonstrated	  by	  the	  relatively	  normal	  numbers	  of	  B	  cells	  in	  patients	  with	  mutations	  
in	  components	  of	   the	   IL7	   signaling	  pathway	   [11,	  12].	   It	   should	  be	  noted,	  however,	  
that	  all	  patients	  with	  such	  mutations	  are	  neonates	  and	  in	  neonatal	  IL7-­‐/-­‐	  mice	  B-­‐cell	  
development	   has	   also	   been	   shown	   to	   take	   place	   [39].	   Therefore,	   the	   apparent	  
difference	  in	  the	  IL7	  dependency	  of	  B-­‐cell	  development	  between	  humans	  and	  mice	  
could	  actually	  reflect	  the	  corresponding	  difference	  between	  fetal/neonatal	  and	  adult	  
lymphopoiesis.	  Our	  data	  showing	   increased	  FL	  signaling	  being	  able	   to	   rescue	  B-­‐cell	  
commitment	   in	   the	   absence	   of	   IL7	   could	   provide	   a	   potential	   explanation	   for	   this	  
apparent	   difference.	   Fetal/neonatal	   CD135+IL7R+CD19-­‐	   progenitors	   might	   be	  
subjected	   to	   higher	   levels	   of	   FL	   by	   their	   microenvironment	   and/or	   show	   higher	  
sensitivity	  to	  FL	  signaling,	  in	  comparison	  to	  adult	  CD135+IL7R+CD19-­‐	  progenitors,	  thus	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making	   the	   survival	   role	   of	   IL7	   redundant.	   In	   support	   of	   this	   hypothesis,	   previous	  
studies	  have	  shown	  that	  even	  though	  fetal	  B-­‐cell	  progenitors	  preferentially	  respond	  
to	  TSLP,	  FL	  signaling	  remains	  an	  absolute	  requirement	  for	  fetal	  B	  lymphopoiesis	  [40,	  
41].	  	  
Whether	   cytokines	   regulate	   differentiation	   to	   different	   blood	   lineages	   in	   an	  
instructive	   or	   a	   permissive	   way	   has	   been	   a	   long	   standing	   debate	   [42,	   43].	   It	   is	  
becoming	  increasingly	  evident	  that	  cell	  fate	  regulation	  by	  cytokines	  is	  quite	  complex,	  
with	   the	   effect	   of	   cytokines	   on	   progenitors	   being	   influenced	   by	   their	   intra-­‐cellular	  
context,	   and	   vice	   versa	   [7].	   Our	   present	   data	   indeed	   suggest	   that	   the	   action	   of	  
cytokines	   can	   be	   cell-­‐context	   dependent.	   Our	   previous	   analysis	   of	   early	  
hematopoiesis	   in	   FLtg	   mice	   indicated	   an	   instructive	   role	   for	   FL	   in	   promoting	  
differentiation	  of	  multi-­‐potent	  progenitors	  towards	  lympho-­‐myeloid	  and	  away	  from	  
erythroid	   fate	   [6].	   In	   the	   present	   study,	   we	   provide	   evidence	   that	   FL	   acts	   in	   a	  
permissive	   manner	   when	   it	   comes	   to	   commitment	   of	   CD135+CD127+CD19-­‐	  
progenitors	   to	   the	   B-­‐cell	   lineage.	   In	   addition,	   we	   show	   that	   while	   IL7	   induces	  
proliferation	  on	  committed	  CD19+	  B-­‐cell	  progenitors,	  it	  does	  not	  do	  so	  on	  IL7R+CD19-­‐	  
progenitors,	   suggesting	   that	   changes	   in	   the	   transcription	   factor	   and	   signaling	  
molecule	   landscape	   upon	   commitment	   to	   the	   B-­‐cell	   lineage	   influence	   the	   effector	  
function	  of	  IL7.	  
The	  Ebf1/Pax5	  up-­‐regulation	  and	  subsequent	  B-­‐cell	  commitment	   in	  FLtg-­‐IL7-­‐/-­‐	  
mice	  that	  we	  show	  herein	  reveals	  that	   IL7	  signaling	  can	  be	  dispensable	  for	  early	  B-­‐
cell	  commitment	  events,	  therefore	  suggesting	  a	  permissive	  role	  for	  IL7.	  This,	  in	  turn,	  
raises	  the	  issue	  of	  the	  potential	  environmental	  regulation	  of	  B-­‐cell	  commitment.	  One	  
possibility	   could	   be	   that	   another	   environmental	   signal	   from	   the	   bone	   marrow	  
microenvironment	   -­‐	   other	   than	   IL7,	   TSLP	   and	   FL	   -­‐	   initiates	   Ebf1	   expression	   in	  
CD135+IL7R+Ly6D+CD19-­‐	   progenitors	   resulting	   in	   subsequent	  Pax5/CD19	   expression	  
and	  B-­‐cell	  commitment.	  Alternatively,	  CD135+IL7R+Ly6D+CD19-­‐	  progenitors	  that	  have	  
not	   been	   instructed	   by	   other	   signal(s)	   to	   develop	   to	   other	   lineages,	   could	   express	  
Ebf1	   in	   a	   cell-­‐autonomous,	   stochastic	   manner,	   with	   a	   fraction	   of	   those	   obtaining	  
sufficient	   Ebf1	   levels	   to	   initiate	   the	  B-­‐cell	   gene	  program	  and	  eventually	   commit	   to	  
the	   B-­‐cell	   lineage.	   The	   intricate	   transcription	   factor	   network	   that	   sustains	   B-­‐cell	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commitment	   through	   a	   series	   of	   positive	   feedback	   regulatory	   loops	   [44]	   provides	  
conceptual	   support	   to	   the	   latter	  hypothesis.	  Further	   investigation	  of	   the	  molecular	  
B-­‐cell	  commitment	  events	  in	  relation	  to	  environmental	  signals	  is	  required	  to	  confirm	  
either	  of	  the	  two	  aforementioned	  hypotheses.	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Figure	   1:	   IL7	   and	   FL	   are	   necessary	   for	   the	   generation	   of	   a	   normal	  
Ly6D+CD135+CD127+CD19-­‐	  compartment.	  (A)	  FACS	  plots	  showing	  the	  gating	  strategy	  
used	   for	   identification	   of	   Ly6D+	   EPLM	   and	   their	   percentage	   of	   CD135	   and	   CD127	  
expression.	  Lineage	  staining:	  SiglecH,	  CD115,	  CD11c,	  NK1.1,	  Gr-­‐1.	  (B)	  Representative	  
FACS	  plots	  of	  EPLM	  (upper	  row)	  and	  CLP	  (lower	  row)	  from	  the	  bone	  marrow	  of	  WT,	  
von	  Muenchow	  et	  al.	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IL7-­‐/-­‐	   and	   FL-­‐/-­‐	   mice.	   (C)	   Absolute	   numbers	   of	   Ly6D+	   EPLM	   (upper	   graph)	   and	   CLP	  
(lower	  graph)	  from	  the	  bone	  marrow	  of	  WT	  (n=7),	  IL7-­‐/-­‐	  (n=5)	  and	  FL-­‐/-­‐	  (n=10)	  mice.	  
(D)	  Representative	  FACS	  plots	  of	  EPLM	  and	  CLP	  from	  WT	  and	  FLtg	  mice.	  (E)	  Absolute	  
numbers	  of	  total	  EPLM	  and	  CLP	  (left	  graphs)	  and	  Ly6D+	  EPLM	  and	  CLP	  from	  WT	  and	  
FLtg	  mice.	  
	  
	   	  




Figure	  2:	  Increased	  in	  vivo	  FL	  levels	  rescue	  B-­‐cell	  generation	  in	  IL7-­‐/-­‐	  mice.	  (A)	  
Representative	   FACS	  plots	  of	   EPLM	   (upper	  panel)	   and	  CLP	   (lower	  panel)	   from	  WT,	  
IL7-­‐/-­‐,	  FLtg	  and	  FLtg-­‐IL7-­‐/-­‐	  mice.	  (B)	  Absolute	  numbers	  of	  EPLM	  (top	  left),	  CLP	  (bottom	  
left),	  Ly6D+	  EPLM	  (top	  right)	  and	  Ly6D+	  CLP	  (bottom	  right)	  from	  the	  mouse	  genotypes	  
indicated	   on	   the	   x-­‐axes.	   For	   each	   mouse	   genotype	   mean	   ±	   SEM	   is	   shown.	   (C)	  
von	  Muenchow	  et	  al.	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Absolute	  numbers	  of	  CD19+CD117+	  (top),	  CD19+CD117-­‐IgM-­‐	  (middle)	  and	  CD19+IgM+	  
(bottom)	  bone	  marrow	  cells	  from	  the	  mice	  indicated	  on	  the	  x-­‐axes.	  For	  each	  mouse	  
genotype	   mean	   ±	   SEM	   is	   shown.	   (D)	   Absolute	   numbers	   of	   CD19+CD21highCD23low	  
marginal	  zone	  (left)	  and	  CD19+CD21+CD23+	  follicular	  (right)	  B	  cells	   in	  the	  spleens	  of	  
WT	  or	  mutant	  mice,	  as	  indicated	  on	  the	  x-­‐axes.	  For	  each	  mouse	  genotype	  mean	  ±	  SD	  
is	  shown.	  
	  
	   	  




Figure	  3:	  Increased	  in	  vivo	  FL	  rescues	  B-­‐cell	  commitment	  in	  the	  absence	  of	  IL7	  
and/or	   TSLP.	   (A)	   In	   vitro	   limiting	   dilution	   analysis	   of	   Ly6D+	   EPLM	   B-­‐cell	   potential.	  
Ly6D+	   EPLM	   were	   sorted	   from	   WT,	   FLtg	   and	   FLtg-­‐IL7-­‐/-­‐	   mice	   and	   plated	   at	   the	  
indicated	  concentrations	  on	  OP9	  stromal	  cells	  together	  with	  IL7.	  One	  representative	  
out	   of	   four	   independent	   experiments	   is	   shown.	   (B)	   Real-­‐time	   quantitative	   PCR	  
analysis	  showing	  expression	  of	  Ebf1,	  Pax5	  and	  Foxo1	  mRNAs	   in	  Ly6D+	  EPLM	  sorted	  
from	  the	  indicated	  mouse	  genotypes.	  Bars	  show	  fold	  expression	  relative	  to	  WT	  (set	  
von	  Muenchow	  et	  al.	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as	   1).	   Error	   bars	   represent	   the	   SEM	   from	   3-­‐6	   independent	   experiments.	   (C)	  
Representative	   FACS	   plots	   showing	   expression	   of	   Ebf1	   protein	   within	   the	   Ly6D+	  
EPLM	  of	   the	   indicated	  mouse	  genotypes.	   (D)	  Percentages	  of	  Ebf1-­‐expressing	  Ly6D+	  
EPLM	  from	  WT	   (n=7),	   IL7-­‐/-­‐	   (n=3),	   FLtg	   (n=11)	  and	  FLtg-­‐IL7-­‐/-­‐	   (n=6)	  mice.	  Bars	   show	  
mean	  ±	  SEM.	  (E)	  EPLM	  (left),	  Ly6D+	  EPLM	  (middle)	  and	  CD19+CD117+	  (right)	  numbers	  
from	  WT,	  IL7-­‐/-­‐,	  FLtg,	  FLtg-­‐IL7-­‐/-­‐	  mice,	  as	  well	  as	  from	  IL7-­‐/-­‐	  and	  IL7Rα-­‐/-­‐	  mice	  injected	  
intra-­‐peritoneally	  with	  10	  daily	  doses	  of	  10	  μg	  FL	  each	  (indicated	  as	  +FL).	  Shown	   is	  
mean	  ±	  SEM.	  
	  
	   	  




Figure	   4:	   Bcl2	   over-­‐expression	   partially	   rescues	   B-­‐cell	   commitment	   in	   IL7-­‐/-­‐	  
mice.	   (A)	   Representative	   FACS	   plots	   of	   EPLM	   (upper	   panel)	   and	   CLP	   (lower	   panel)	  
from	  WT,	   IL7-­‐/-­‐,	   Bcl2tg	   and	   Bcl2tg-­‐IL7-­‐/-­‐	   mice.	   (B)	   Absolute	   numbers	   of	   EPLM	   (top	  
left),	   CLP	   (bottom	   left),	   Ly6D+	   EPLM	   (top	   right)	   and	   Ly6D+	  CLP	   (bottom	   right)	   from	  
WT	  and	  mutant	  mice,	  as	  indicated	  on	  the	  x-­‐axes.	  For	  each	  mouse	  genotype	  mean	  ±	  
von	  Muenchow	  et	  al.	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SEM	   is	   shown.	   (C)	   In	   vitro	   limiting	  dilution	  analysis	  of	   Ly6D+	  EPLM	  B-­‐cell	   potential.	  
Ly6D+	  EPLM	  were	  sorted	  from	  WT,	  IL7-­‐/-­‐,	  Bcl2tg	  and	  Bcl2tg-­‐IL7-­‐/-­‐	  mice	  and	  plated	  at	  
the	   indicated	   concentrations	   on	   OP9	   stromal	   cells	   together	   with	   IL7.	   One	  
representative	   out	   of	   three	   independent	   experiments	   is	   shown.	   (D)	   Absolute	  
numbers	   of	   CD19+CD117+	   (left),	   CD19+CD117-­‐IgM-­‐	   (middle)	   and	   CD19+IgM+	   (right)	  
bone	  marrow	  cells	  from	  WT	  and	  mutant	  mice,	  as	   indicated	  on	  the	  x-­‐axes.	  For	  each	  
mouse	  genotype	  mean	  ±	  SEM	  is	  shown.	  
	  
	   	  




Figure	   5:	   IL7	   does	   not	   induce	   proliferation	   of	   Ly6D+CD135+CD127+CD19-­‐	  
progenitors.	  (A)	  Absolute	  number	  of	  CD19+CD117+	  cells	   in	  the	  bone	  marrow	  of	  WT	  
(n=10),	  IL7-­‐/-­‐	  (n=5)	  and	  IL7tg	  (n=8)	  mice.	  (B)	  Total	  number	  of	  EPLM	  in	  bone	  marrow	  of	  
WT	   (n=14),	   IL7-­‐/-­‐	   (n=7)	   and	   IL7tg	   (n=5)	  mice.	   (C)	   Ly6D+	   EPLM	  numbers	   in	   the	  bone	  
marrow	   of	  WT	   (n=14),	   IL7-­‐/-­‐	   (n=7)	   and	   IL7tg	   (n=5)	   mice.	   (D)	   Cell	   cycle	   analysis	   of	  
Ly6D+	  EPLM	  from	  WT	  (n=5)	  and	  IL7tg	  (n=2)	  mice.	  Graph	  shows	  percentages	  of	  Ly6D+	  
EPLM	  in	  G0	  (Ki67-­‐DAPI-­‐),	  G1	  (Ki67+DAPI-­‐)	  and	  G2/S/M	  (Ki67+DAPI+)	  stages.	  Bars	  in	  A,	  
von	  Muenchow	  et	  al.	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B,	  C	  and	  D	  show	  mean	  ±	  SEM.	  (E)	  Representative	  FACS	  plots	  of	  EPLM	  (upper	  panel)	  
and	  CLP	  (lower	  panel)	  from	  WT,	  FL-­‐/-­‐,	  IL7tg	  and	  IL7tg-­‐FL-­‐/-­‐	  mice.	  (F)	  Absolute	  numbers	  
of	  EPLM	  (top	  left),	  CLP	  (bottom	  left),	  Ly6D+	  EPLM	  (top	  right)	  and	  Ly6D+	  CLP	  (bottom	  
right)	   from	   WT	   and	   mutant	   mice,	   as	   indicated	   on	   the	   x-­‐axes.	   For	   each	   mouse	  
genotype	   mean	   ±	   SEM	   is	   shown.	   (G)	   Absolute	   numbers	   of	   CD19+CD117+	   bone	  
marrow	  cells	  from	  WT	  and	  mutant	  mice,	  as	  indicated	  on	  the	  x-­‐axis.	  For	  each	  mouse	  
genotype	  mean	  ±	  SEM	  is	  shown.	  (H)	  Cell	  cycle	  analysis	  of	  Ly6D+	  EPLM	  from	  WT	  (n=5),	  
FL-­‐/-­‐	  (n=3),	  IL7tg	  (n=2)	  and	  IL7tg-­‐FL-­‐/-­‐	  (n=3)	  mice.	  Graph	  shows	  percentages	  of	  Ly6D+	  
EPLM	  in	  G0	  (Ki67-­‐DAPI-­‐),	  G1	  (Ki67+DAPI-­‐)	  and	  G2/S/M	  (Ki67+DAPI+)	  stages.	  Bars	  show	  
mean	  ±	  SEM.	  
	  
	   	  




Figure	   6:	   FL	   promotes	   proliferation	   but	   not	   survival	   of	  
Ly6D+CD135+CD127+CD19-­‐	  progenitors.	  (A)	  Absolute	  numbers	  of	  EPLM	  (top	  left),	  CLP	  
(bottom	  left),	  Ly6D+	  EPLM	  (top	  right)	  and	  Ly6D+	  CLP	  (bottom	  right)	  from	  WT	  (n=14),	  
FL-­‐/-­‐	   (n=10)	   and	   FLtg	   (n=9)	  mice.	   Bars	   show	  mean	   ±	   SEM.	   (B)	   Cell	   cycle	   analysis	   of	  
Ly6D+	  EPLM	  from	  WT	  (n=5),	  FL-­‐/-­‐	  (n=3)	  and	  FLtg	  (n=9)	  mice.	  Graph	  shows	  percentages	  
of	   Ly6D+	  EPLM	   in	  G0	   (Ki67-­‐DAPI-­‐),	  G1	   (Ki67+DAPI-­‐)	  and	  G2/S/M	  (Ki67+DAPI+)	   stages.	  
Bars	  show	  mean	  ±	  SEM.	  (C)	  Absolute	  numbers	  of	  EPLM	  (top	  left),	  CLP	  (bottom	  left),	  
Ly6D+	  EPLM	  (top	  right)	  and	  Ly6D+	  CLP	  (bottom	  right)	  from	  WT	  and	  mutant	  mice,	  as	  
indicated	  on	  the	  x-­‐axes.	  For	  each	  mouse	  genotype	  mean	  ±	  SEM	  is	  shown.	  (D)	  In	  vitro	  
von	  Muenchow	  et	  al.	   	   	  
	  
75	  
limiting	   dilution	   analysis	   of	   Ly6D+	   EPLM	   B-­‐cell	   potential.	   Ly6D+	   EPLM	  were	   sorted	  
from	  WT,	   FL-­‐/-­‐	   and	   Bcl2tg-­‐FL-­‐/-­‐	  mice	   and	   plated	   at	   the	   indicated	   concentrations	   on	  
OP9	   stromal	   cells	   together	   with	   IL7.	   (E)	   Absolute	   numbers	   of	   CD19+CD117+	   (left),	  
CD19+CD117-­‐IgM-­‐	   (middle)	   and	   CD19+IgM+	   (right)	   bone	  marrow	   cells	   from	  WT	   and	  
mutant	  mice,	  as	   indicated	  on	  the	  x-­‐axes.	  For	  each	  mouse	  genotype	  mean	  ±	  SEM	  is	  
shown.	  
	  
	   	  




Figure	   7:	   FL	   does	   not	   instruct	   Ebf1	   expression	   and	   B-­‐cell	   commitment.	   (A)	  
Representative	   FACS	   plots	   showing	   expression	   of	   Ebf1	   protein	   within	   the	   Ly6D+	  
EPLM	   of	  WT,	   FL-­‐/-­‐	   and	   FLtg	  mice.	   (B)	   Percentages	   of	   Ebf1-­‐expressing	   Ly6D+	   EPLM	  
from	  WT	  (n=7),	  FL-­‐/-­‐	  (n=5)	  and	  FLtg	  (n=12)	  mice.	  Bars	  show	  mean	  ±	  SEM.	  (C)	  In	  vitro	  
limiting	   dilution	   analysis	   of	   Ly6D+	   EPLM	   T-­‐cell	   potential.	   Ly6D+	   EPLM	   were	   sorted	  
from	   WT	   and	   FLtg	   mice	   and	   plated	   at	   the	   indicated	   concentrations	   on	   OP9DL1	  
stromal	  cells	  together	  with	  IL7.	  One	  representative	  of	  four	  independent	  experiments	  
is	   shown.	   (D)	   schematic	   model	   for	   the	   permissive	   role	   of	   IL7	   and	   FL	   acting	   on	  
hematopoietic	  progenitors	  and	  CD19+	  committed	  B-­‐cell	  precursors.	   	  




Supplementary	  Figure	  1:	  Gating	  strategy	  for	  identification	  of	  CLP.	  FACS	  plots	  
showing	   the	   gating	   strategy	   used	   for	   identification	   of	   Ly6D+	   CLP.	   Lineage	   staining:	  
SiglecH,	  CD115,	  CD11c,	  NK1.1,	  Gr-­‐1.	  
	   	  




Supplementary	   Figure	   2:	   Absolute	   numbers	   of	   EPLM	   (A)	   and	   CLP	   (B)	  
progenitors	   in	  WT	   (n=7),	   IL7-­‐/-­‐	   (n=5)	   and	   FL-­‐/-­‐	   (n=10)	   mice.	   EPLM	   were	   stained	   as	  
shown	   in	  Figure	  1A	  and	  CLP	  as	   shown	   in	  Supplementary	  Figure	  1.	   Student’s	   t	   test.	  
***P	  ≤	  0.001.	  Bars	  show	  mean	  ±	  SEM.	  
	   	  




Supplementary	  Figure	  3:	  Rescue	  of	  CD19+	  bone	  marrow	  B-­‐cell	  progenitors	  in	  
FLtg-­‐IL7-­‐/-­‐	   mice.	   Figure	   shows	   representative	   FACS	   plots	   for	   the	   identification	   of	  
CD19+CD117+,	  CD19+CD117-­‐IgM-­‐	  and	  CD19+IgM+	  bone	  marrow	  cells.	   	  




Supplementary	  Figure	  4:	  T	  and	  B	  cells	   in	  the	  spleens	  of	  FLtg-­‐IL7-­‐/-­‐	  and	  single	  
mutant	  mice	   as	   indicated.	   (A)	   Representative	   FACS	   plots	   illustrating	   T	   cells	   in	   the	  
spleens	  of	  WT	  (first	  row),	  IL7-­‐/-­‐	  (second	  row),	  FLtg	  (third	  row),	  and	  FLtg-­‐IL7-­‐/-­‐	  (fourth	  
row)	  mice.	  After	  gating	  on	  living	  lymphocytes	  TCRβ+	  cells	  are	  further	  sub-­‐grouped	  in	  
von	  Muenchow	  et	  al.	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CD4	  and	  CD8	  positive	  T	  cells.	  (B)	  Representative	  FACS	  plots	  illustrating	  B	  cells	  in	  the	  
spleens	  of	  WT	  (first	  row),	  IL7-­‐/-­‐	  (second	  row),	  FLtg	  (third	  row),	  and	  FLtg-­‐IL7-­‐/-­‐	  (fourth	  
row)	  mice.	  After	  gating	  on	  living	  lymphocytes	  CD19+	  cells	  are	  further	  sub-­‐grouped	  in	  
CD21highCD23low	  marginal	   zone	  B	   cells	   and	  CD21+CD23+	   follicular	   B	   cells.	   (C	   and	   D)	  
Absolute	  numbers	  of	   splenic	  CD4+	   (C)	   and	  CD8+	   (D)	   T	   cells,	   stained	  as	   shown	   in	  A,	  
from	  WT	  and	  mutant	  mice	  as	  indicated	  on	  the	  x-­‐axes.	  ***P	  ≤	  0.001,	  ****P	  ≤	  0.0001.	  
Student’s	  t	  test;	  n	  =	  9-­‐15.	  Data	  shown	  above	  are	  mean	  ±	  SD.	  
	   	  




Supplementary	   Figure	   5:	  Anti-­‐proliferative	   effect	   of	   Bcl2	   over-­‐expression	   in	  
vivo.	  (A)	  Cell	  cycle	  analysis	  of	  Ly6D+	  EPLM	  from	  WT	  (n=5),	  Bcl2tg,	  (n=2),	   IL7-­‐/-­‐	   (n=2)	  
and	   Bcl2tg-­‐IL7-­‐/-­‐	   (n=4)	  mice.	   Graph	   shows	   percentages	   of	   Ly6D+	   EPLM	   in	  G0	   (Ki67-­‐
DAPI-­‐),	  G1	  (Ki67+DAPI-­‐)	  and	  G2/S/M	  (Ki67+DAPI+)	  stages.	  *P	  ≤	  0.05,	  **P	  ≤	  0.01,	  ***P	  ≤	  
0.001.	  Student’s	  t	   test.	  Bars	  show	  mean	  ±	  SEM.	  (B)	  Representative	  Ki67/DAPI	  FACS	  
plots	  of	  the	  Ly6D+	  EPLM	  cell	  cycle	  analysis	  collectively	  presented	  in	  A.	   	  




Supplementary	  Figure	  6:	  Bcl2-­‐mediated	  rescue	  of	  splenic	  T	  and	  B	  cells	  in	  the	  
absence	  of	  IL7.	  (A)	  Representative	  FACS	  plots	  illustrating	  T	  cells	  in	  the	  spleens	  of	  WT	  
(first	  row),	  IL7-­‐/-­‐	  (second	  row),	  Bcl2tg	  (third	  row),	  and	  Bcl2tg-­‐IL7-­‐/-­‐	  (fourth	  row)	  mice.	  
After	   gating	  on	   living	   lymphocytes	  TCRβ+	   cells	   are	   further	   sub-­‐grouped	   in	  CD4	  and	  
von	  Muenchow	  et	  al.	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CD8	  positive	  T	  cells.	  (B)	  Representative	  FACS	  plots	  illustrating	  B	  cells	  in	  the	  spleens	  of	  
WT	   (first	   row),	   IL7-­‐/-­‐	   (second	   row),	  Bcl2tg	   (third	   row),	   and	  Bcl2tg-­‐IL7-­‐/-­‐	   (fourth	   row)	  
mice.	   After	   gating	   on	   living	   lymphocytes	   CD19+	   cells	   are	   further	   sub-­‐grouped	   in	  
CD21highCD23low	  marginal	  zone	  B	  cells	  and	  CD21+CD23+	  follicular	  B	  cells.	  (C)	  Absolute	  
numbers	  of	  splenic	  CD4+	  (top)	  and	  CD8+	  (bottom)	  T	  cells,	  stained	  as	  shown	  in	  A,	  from	  
WT	   and	  mutant	  mice	   as	   indicated	   on	   the	   x-­‐axes.	   (D)	   Absolute	   numbers	   of	   splenic	  
marginal	  zone	  (top)	  and	  follicular	  (bottom)	  B	  cells,	  stained	  as	  shown	  in	  B,	  from	  WT	  
and	   mutant	   mice	   as	   indicated	   on	   the	   x-­‐axes.	   **P	   ≤	   0.01,	   ***P	   ≤	   0.001,	   ****P	   ≤	  
0.0001.	  Student’s	  t	  test;	  n	  =	  4-­‐9.	  Data	  shown	  above	  are	  mean	  ±	  SD.	  
	   	  




Supplementary	  Figure	  7:	  Effect	  of	  IL7	  over-­‐expression	  on	  WT	  and	  FL-­‐/-­‐	  splenic	  
T	  and	  B	  cells.	  (A)	  Representative	  FACS	  plots	  illustrating	  T	  cells	  in	  the	  spleens	  of	  WT	  
(first	   row),	   FL-­‐/-­‐	   (second	   row),	   IL7tg	   (third	   row),	   and	   IL7tg-­‐FL-­‐/-­‐	   (fourth	   row)	   mice.	  
After	   gating	  on	   living	   lymphocytes	  TCRβ+	   cells	   are	   further	   sub-­‐grouped	   in	  CD4	  and	  
von	  Muenchow	  et	  al.	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CD8	  positive	  T	  cells.	  (B)	  Representative	  FACS	  plots	  illustrating	  B	  cells	  in	  the	  spleens	  of	  
WT	  (first	  row),	  FL-­‐/-­‐	  (second	  row),	  IL7tg	  (third	  row),	  and	  IL7tg-­‐FL-­‐/-­‐	  (fourth	  row)	  mice.	  
After	   gating	   on	   living	   lymphocytes	   CD19+	   cells	   are	   further	   sub-­‐grouped	   in	  
CD21highCD23low	  marginal	  zone	  B	  cells	  and	  CD21+CD23+	  follicular	  B	  cells.	  (C)	  Absolute	  
numbers	  of	  splenic	  CD4+	  (top)	  and	  CD8+	  (bottom)	  T	  cells,	  stained	  as	  shown	  in	  A,	  from	  
WT	   and	  mutant	  mice	   as	   indicated	   on	   the	   x-­‐axes.	   (D)	   Absolute	   numbers	   of	   splenic	  
marginal	  zone	  (top)	  and	  follicular	  (bottom)	  B	  cells,	  stained	  as	  shown	  in	  B,	  from	  WT	  
and	  mutant	  mice	  as	  indicated	  on	  the	  x-­‐axes.	  ns	  not	  significant	  or	  P	  >	  0.05,	  ****P	  ≤	  
0.0001.	  Student’s	  t	  test;	  n	  =	  3-­‐15.	  Data	  shown	  above	  are	  mean	  ±	  SD.	  
	   	  




Supplementary	  Figure	  8:	  Effect	  of	   in	  vivo	  FL	  levels	  on	  the	  cell	  cycle	  of	  Ly6D+	  
EPLM.	   Representative	   Ki67/DAPI	   FACS	   plots	   of	   the	   Ly6D+	   EPLM	   cell	   cycle	   analysis	  
collectively	  presented	  in	  Figure	  6B.	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A stromal cell free culture system generates mouse
pro-T cells that can reconstitute T-cell compartments
in vivo
Nadine Gehre∗1, Anja Nusser∗1, Lilly von Muenchow∗1,
Roxane Tussiwand2, Corinne Engdahl1, Giuseppina Capoferri1,
Nabil Bosco1, Rhodri Ceredig3 and Antonius G. Rolink1
1 Developmental and Molecular Immunology, Department of Biomedicine, University of Basel,
Basel, Switzerland
2 University of Washington, Department of Pathology and Immunology, St. Louis, USA
3 Department of Biosciences, University of Galway, Galway, Ireland
T-cell lymphopenia following BM transplantation or diseases such as AIDS result in
immunodeficiency. Novel approaches to ameliorate this situation are urgently required.
Herein, we describe a novel stromal cell free culture system in which Lineage−Sca1+c-kit+
BM hematopoietic progenitors very efficiently differentiate into pro-T cells. This culture
system consists of plate-bound Delta-like 4 Notch ligand and the cytokines SCF and IL-7.
The pro-T cells developing in these cultures express CD25, CD117, and partially CD44;
express cytoplasmic CD3ε; and have their TCRβ locus partially D–J rearranged. They could
be expanded for over 3 months and used to reconstitute the T-cell compartments of sub-
lethally irradiated T-cell-deficient CD3ε−/− mice or lethally irradiated WT mice. Pro-T
cells generated in this system could partially correct the T-cell lymphopenia of pre-Tα−/−
mice. However, reconstituted CD3ε−/− mice suffered from a wasting disease that was
prevented by co-injection of purified CD4+ CD25high WT Treg cells. In a T-cell-sufficient
or T-lymphopenic setting, the development of disease was not observed. Thus, this in
vitro culture system represents a powerful tool to generate large numbers of pro-T cells
for transplantation and possibly with clinical applications.
Keywords: BM transplantation  Lymphopenia  Notch ligand Delta-like 4 (DL4)  T-cell
development  Treg cell
 Additional supporting information may be found in the online version of this article at thepublisher’s web-site
Introduction
Like all other cells of the hematopoietic system, T cells are derived
from HSCs. However, unlike all other hematopoietic lineages, T-
cell development occurs only in the thymus. The thymus does not
harbor HSCs and in order to maintain T lymphopoiesis, it must be
constantly colonized by progenitor cells migrating from the BM
Correspondence: Prof. Antonius G. Rolink
e-mail: antonius.rolink@unibas.ch
[1–4]. Transplantation experiments have shown that various BM
progenitors can enter the thymus and generate T cells [5], how-
ever the nature of these progenitors under physiological conditions
is still debated.
Based on the expression of the surface markers CD4 and
CD8, thymopoiesis can be subdivided into four consecutive stages.
Developmentally, the earliest cells express neither CD4 nor CD8
∗These authors contributed equally to this work.
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and are called double-negative (DN) cells. DNs are the precursors
of cells expressing both CD4 and CD8 molecules, called double-
positive (DP) cells. DP cells that survive the positive and negative
selection processes in the thymus will generate single-positive cells
expressing either CD4 or CD8 that leave the thymus to colonize
secondary lymphoid organs.
The DN stages can be further subset using the differential sur-
face expression of CD25, CD44, and CD117. The developmentally
earliest DN1 cells are CD44+CD117+, but do not express CD25.
DN2 cells express all three markers, whereas DN3 cells have lost
CD44 and CD117 [6–8]. Upon productive rearrangement of TCRβ
gene fragments, the pre-TCR is expressed and DN3 cells undergo
proliferative expansion [9, 10] before they enter stage DN4 and
lose expression of CD25. Immature single-positive cells are the
direct descendants of DN4 cells and express CD8 in mice [6–8].
DP cells have CD4 as well as CD8 on their surface and rearrange
the TCRα gene segments. Cells that are able to express a func-
tional αβTCR undergo positive and negative selection [11, 12] to
become single-positive mature T cells.
Besides IL7-IL7R [13, 14] and SCF-cKit [15, 16] signaling,
WNT and Sonic hedgehog [17, 18] are known to be important for
T-cell development. However, Notch signaling has been shown
to be the most crucial one. Conditional inactivation of Notch-1
[19] or one of its ligands, Delta-like 4 (DL4) [8, 20], resulted in
a complete block of T-cell development in the thymus. Several
years ago Zu´niga-Pflu¨cker et al. introduced a stromal cell based
system able to induce T-cell differentiation from fetal-liver-derived
HPCs [21, 22]. They retrovirally transduced OP9 BM stromal cells
to express the Notch ligand DL 1 (OP9-DL1) and heretofore this
system has been the one to be used to understand early stages
of thymocyte development. However, additional signals delivered
by OP9 cells cannot be excluded and the exact amount of DL1
expression and the intensity of Notch signal delivery are hard
to control. Moreover, it is unlikely that pro-T cells derived from
coculture settings will ever be approved for therapeutic purposes.
Therefore, to identify the minimal requirements necessary for T-
cell commitment and differentiation, we developed a stromal cell
free culture system. This culture system consists of plate-bound
DL4, soluble SCF, and IL-7. Under these conditions, BM-derived,
lineage-negative Sca1+ and CD117+ cells (LSKs) differentiate into
DN2–DN3 like cells. These cells can then be transplanted to recon-
stitute the T-cell compartments of both T-cell-sufficient and T-
cell-deficient mice and to improve the T-cell compartments in
T-lymphopenic recipients.
Results
Development of a stromal cell free culture system to
study T-cell differentiation
Stromal cell based culture systems have been useful for ana-
lyzing T-cell development in vitro [21, 23]. However, in our
hands, several points emerged from using this culture system,
the most notable being the heterogeneous response of cloned
Pax-5-deficient pro-B cells during their induction to differentiate
toward the T-cell lineage [24]. A possible reason for this het-
erogeneity was the variability in strength and duration of Notch
signaling. Therefore, to equalize the delivery of Notch signals, we
prepared a soluble DL4-Fc fusion protein [25–27]. This contained
mouse DL4 linked to the Fc-region of human IgG1. However, initial
in vitro experiments of adding DL4-Fc fusion protein to progenitor
cells were not successful. Therefore, we decided to fix the DL4-Fc
fusion protein to the surface of tissue culture plates via an
in-house-generated human IgG1 Fc region-specific mouse mAb
(Huf 5.4). Thus, a solution containing 10 μg/mL of the Huf 5.4
DL4-Fc-capturing mAb was used to coat plastic plates before
addition of soluble DL4-Fc.
Using the OP9-DL1 stromal cell system, we had previously
shown that Pax-5-deficient (Pax-5−/−) pro-B cells differentiated
toward the T-cell lineage upregulated CD117 and downregulated
CD93 [16]. As shown in Figure 1A, these same cells underwent
exactly the same phenotypic changes on plate-bound DL4.
Optimal differentiation was achieved when plates were coated
with 1 μg/mL or more of DL4-Fc.
The initial finding that nonattached DL4-Fc did not induce
the differentiation of Pax-5−/− pro-B cells toward the T-cell
lineage suggested that soluble DL4-Fc might even inhibit T-cell
differentiation. To test this hypothesis, Pax-5−/− pro-B cells were
cultured in plates coated with 2 μg/mL DL4-Fc in the presence
of IL-7 (100 U/mL) and SCF (20 ng/mL) together with various
amounts of soluble DL4-Fc.
As shown in Figure 1B, differentiation could be completely
inhibited by soluble DL4-Fc added at concentrations between 1
and 10 μg/mL. Now that the differentiation of a cloned cell line
toward the T-cell lineage appeared homogeneous and occurred in
a semi-synchronous fashion, gene expression analysis of Pax-5−/−
pro-B cells, cultured 5 days on plate-bound DL4 in presence of
IL-7 and SCF, was carried out. As controls, Pax-5−/− pro-B cells
cultured in the presence of IL-7 and SCF only (no stromal cells)
were used. Table 1A and B summarize the T-cell genes upregu-
lated more than threefold and B-cell genes downregulated more
than threefold. Overall this gene expression analysis revealed 140
genes more than threefold upregulated and 252 genes more than
threefold downregulated. The complete dataset of differentially
expressed genes is summarized in Supporting Information Table 1
as well as in a Geo Dataset under the accession number GSE46191.
These findings strongly support the conclusion that this stromal
cell free culture system efficiently induces the development of
Pax-5−/− pro-B cell clones toward the T-cell lineage and moreover
might well be an ideal system to identify Notch target genes neces-
sary for T-cell development using a clonal population of responder
cells.
Developing T cells from ex vivo isolated progenitors
To further test this stromal cell free culture system, we initiated
cultures with sorted undifferentiated hematopoietic progenitors,
in this case LSK cells, from BM. Fifty thousand mouse BM LSK
cells were sorted and cultured in 1 mL medium supplemented
C© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
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Figure 1. Culturing Pax-5−/− pro-B cells
with SCF and IL-7 modulates CD93 and
CD117 expression. (A, B) Pax-5−/− pro-B cells
were cultured for 5 days (A) on plates coated
with 0.0, 0.1 1, and 10 μg/mL DL4-Fc only, or
(B) on plates coated with 1 μg/mL DL4-Fc in
the presence of SCF; IL-7; and 0.0, 0.1, 1, and
10 μg/mL soluble DL4-Fc. The expression
of CD93 and CD117 was evaluated by flow
cytometry. One representative experiment
of four experiments performed is shown.
Percentages of CD117+/CD93+ cells are indi-
cated.
with 100 U/mL IL-7 and 20 ng/mL SCF in 1 well of a 24-well
plate coated with 1 μg/mL DL4-Fc. After 5–6 days, cells became
confluent and were then re-plated in 2 × 4 mL IL-7- and
SCF-containing medium into 2 wells of a 6-well plate coated with
DL4-Fc. Thereafter, the cells were recultured at 2 × 105/mL into
fresh DL4-Fc-coated plates every 4 days in medium containing the
cytokines.
Phenotypic analysis was performed at various days after onset
of cultures but found not to change significantly over time. Thus,
as shown in Figure 2A–E, a small fraction of cells expressed high
levels of CD44 and low levels of CD25 (4.0% in this example;
4.1% ± 0.8, n = 6; Fig. 2A). Yet, another small fraction expressed
low levels of CD25 and no CD44 (4.0% ± 0.8, n = 6). All
the other cells expressed high levels of CD25 and around 60%
(59.0% ± 1.2, n = 6) of those were also CD44high, whereas the
rest were CD44-negative. Moreover, all cells expressed CD117
whose level of expression correlated with that of CD44 (Fig. 2B).
Furthermore, CD27, Gata3, Notch1, and Bcl 11b were detectable
(Supporting Information Fig. 1). Cytoplasmic staining revealed
that over 85% (87.7% ± 0.4, n = 6) expressed CD3ε (Fig. 2C).
Neither cytoplasmic TCRβ (Fig. 2D) nor cell-surface CD4 or CD8
(data not shown) were detectable in or on these cells. Next, we
analyzed Dβ1−Jβ1 TCR rearrangements (Fig. 2E). As expected,
all seven rearrangements were readily detectable in total ex
vivo isolated thymocytes and no un-rearranged germline band
was detectable (lane 1). In marked contrast, conventionally
cultured Pax-5−/− pro-B cells did not show any rearrangements
but only the germline band (lane 2). In two independently
established pro-T-cell lines cultured with plate-bound DL4-Fc
(lanes 3 and 4), all seven rearrangements were readily detectable
and the germline band was also clearly visible. Based on these
phenotypic and rearrangement analyses, our in vitro propagated
Table 1. T-cell-associated genes upregulated (A) and B-cell-associated genes downregulated (B) in Pax-5-deficient pro-B cells cultured for 5 days
on DL4-Fc-coated plates in the presence of SCF and IL-7
A B
Gene Fold change up Transcript ID Gene Fold change down Transcript ID
CD3γ 187.6 NM 009850 EBF-1 25.5 NM 007897
Granz. A 156.7 NM 010370 VpreB3 23 BC062250
GATA-3 39.4 NM 008091 Lef1 14.9 NM 010703
Granz. B 34.3 NM 013542 VpreB1 12.5 NM 016982
CD7 30.7 NM 009854 VpreB2 9.5 NM 016983
Deltex-1 15.1 NM 008052 IgH 6 AF028616
TCF-7 13.9 NM 009331 BLK 5.2 NM 007549
CD25 9.2 AK168113 IgL 4.7 AF005353
CD27 8.8 NM 001033126 CD93 4.1 NM 010740
TCRγ 8.5 BC034889 CD79B 3.9 NM 008339
CD3δ 6.8 NM 013487 CD79A 3.3 NM 007655
SLP76 6.1 NM 010696
CD117 3.7 NM 021099
TCRβ 3.5 AF012139
Notch-3 3.3 NM 008716
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Figure 2. LSKs differentiate into pro-T cells
when cultured on DL4-Fc-coated plates in the
presence of IL-7 and SCF and can be kept pro-
liferating for long term. LSKs were cultured on
DL4-Fc-coated plates in the presence of IL-7
and SCF for 5 weeks. (A) Flow cytometry plot
of CD44 and CD25 expression. (B) Flow cytom-
etry plot of CD44 and CD117 expression. (C)
Histogram of cytoplasmic CD3ε expression. (D)
Histogram of cytoplasmic TCRβ expression.
(A–D) One representative ofmore than ten indi-
viduals established pro-T-cell lines is shown.
(E) Dβ1–Jβ1 rearrangement analysis of total thy-
mocytes (lane 1), Pax-5-deficient pro-B cells cul-
tured on stromal cells in the presence of IL-7
(lane 2) and LSKs cultured on DL4-Fc-coated
plates in the presence of IL-7 and SCF (lane 3
and 4). TCR rearrangement analysis was per-
formed on five individually established pro-
T-cell lines. The results of two of them are
shown. (F) Proliferation of LSKs cultured on
DL4-Fc-coated plates in the presence of IL-7 and
SCF. One representative of three established
pro-T-cell lines is shown.
pro-T cells seem to closely resemble DN2–DN3 thymocytes
isolated ex vivo.
We also analyzed the long-term proliferative capacity of these
pro-T cells. A cumulative growth curve of one of over ten of such
experiments is shown in Figure 2F. As can be seen, growth was
exponential over the 79 days of this experiment, with cells expand-
ing from 105 to 1024, a 1019-fold increase with an average overall
doubling time of about 1.5 days. This finding indicates that these
pro-T cells have extensive self-renewal capacity in vitro.
The above-described findings were made with LSKs as starting
cells. However, identical results (phenotype and growth proper-
ties) were obtained when CLPs, DN1, or DN2 cells were seeded.
In vivo T-cell reconstitution of T-cell-deficient
recipients by T-cell progenitors
Recently it was shown that pro-T cells propagated on OP9-DL1
stromal cells were able to partly reconstitute the T-cell compart-
ments in vivo [28]. To test whether our pro-T cells generated in a
stromal cell free system could also reconstitute all T-cell compart-
ments in vivo, we performed the following experiment: CD45.1
CD3ε-deficient mice were lightly irradiated (4 Gy) and reconsti-
tuted intravenously with 5 × 106 T-cell progenitors generated
from BM LSKs of CD45.2 mice cultured on plate-bound DL4-Fc in
the presence of SCF and IL-7 for more than 5 weeks. As shown
in Figure 3A, at 3 weeks after transfer, practically all thymocytes
were CD45.2-positive. Moreover, these thymi contained all CD4-
and CD8-defined subpopulations (Fig. 3B) and TCRβ was brightly
expressed on the expected proportions of CD4- and CD8-defined
subsets (Fig. 3C). At this time point, about 10–30 × 106 cells could
be recovered from these thymi. However, the reconstitution of the
thymus was only transient in that by 4–5 weeks DPs had disap-
peared. Careful kinetic analysis of thymus reconstitution revealed
that only very low numbers of donor-derived thymocytes were
present at day 14 and that highest numbers were found at days
21–26. Analysis of the peripheral T-cell compartments 5–6 weeks
post reconstitution revealed a robust reconstitution of both CD4
(2–4 × 106 per spleen) and CD8 (0.5–1.5 × 106 per spleen) T
cells (Fig. 3D). This reconstitution was observed in all mice (over
20 mice analyzed). However, CD4 cells expressing Foxp3 were
practically undetectable (Fig. 3E), indicating an absence of Treg
cells. Likely as a consequence of this, transplanted mice developed
a fatal wasting disease marked by diarrhea and weight loss, 5–6
weeks posttransplantation. Histological analysis of both liver and
colon revealed massive lymphocyte infiltrations in these organs
(Fig. 3F and G).
Previously, we reported that the development of a similar
type of wasting disease could be prevented by co-injection of
mature Treg cells [29]. Likewise, using the pro-T-cell transplan-
tation model described herein, development of wasting disease
could also be prevented by cotransfer of mature Treg cells. Thus,
C© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
936 Nadine Gehre et al. Eur. J. Immunol. 2015. 45: 932–942
Figure 3. T-cell reconstitution of sublethally irradiated
CD45.1 CDε−/− mice by CD45.2 pro-T cell. (A–C) CD45.1
CDε−/− mice were sublethally irradiated, and then 107
CD45.2 pro-T cells were injected. Twenty-four days later,
thymi of these mice were analyzed for expression of (A)
CD45.2 (bold-line histogram) (B) CD4 and CD8 on CD45.2+
cells, and (C) CD4 and TCRβ on CD45.2+ cells by flow cytom-
etry. (D–G) CD45.1 CDε−/− mice were sublethally irradi-
ated and injected with 107 CD45.2 pro-T cells. Forty-five
days later, spleen, liver, and colon were evaluated by flow
cytometry and histology. (D and E) Flow cytometry plots
of spleen (not gated on CD45.2) are shown. (D) CD4 and
CD8 expression (E) CD4 and Foxp3 expression (F and G)
H&E staining of (F) liver and (G) colon sections are shown
with a 200×magnification. One representativemouse of 20
reconstituted mice is shown.
4 Gy-irradiated CD45.1+ CD3ε−/− recipients were reconstituted
with a mixture of 1 × 105 ex vivo sorted CD4+CD25high Treg cells
from C57Bl/6 CD45.1 mice and 5 × 106 CD45.2 B6 T-cell progen-
itors from in vitro cultures. Mice remained healthy and peripheral
blood was analyzed 10 weeks after transfer (Fig. 4A). CD45.1+
CD4+ (Treg-derived) cells (identified as CD45.2-negative, left pop-
ulation) were still present alongside CD45.2+ donor progenitor-
derived cells comprising both CD4+ and CD4− (presumably
CD8+), lymphocytes (right population). Thus, provision of a small
number of Treg cells protected adult mice from the development of
wasting following transplantation of progenitor T cells. In fact, in
the peripheral CD4+ compartment of transplanted mice, not only
progeny of the injected (CD45.1+) Treg cells could be found, but
also Foxp3+ cells from the injected CD45.2+pro-T cells (Fig. 4B).
To test whether these peripheral CD4+ T cells were functional,
mice were immunized with the T-dependent Ag NIP-OVA (NIP is
4-hydroxy-5-iodo-3-nitrophenyl) in CFA. After 14 days, the IgG
anti-NIP Ab titer in CD3ε-deficient mice injected with in vitro
propagated pro-T cells together with Treg cells was practically
indistinguishable from that in immunized normal C57BL/6 mice
(Fig. 4C). In marked contrast, in immunized CD3ε-deficient mice
that had received only Treg cells, the anti-NIP Ab titer was very
low. Thus, CD4+ T cells derived from the in vitro propagated pro-
T cells are functional in that they can help the Ab response to a
classical T-dependent Ag. Moreover, we also addressed the func-
tionality of the CD8 T cells derived from the in vitro propagated
pro-T cells. Therefore, these cells derived from a B6 pro-T cell were
in vitro stimulated with irradiated BALB/c spleen cells. At day 5 of
culture, the capacity of these cells to lyse BALB/c target cells was
tested. As shown in Supporting Information Figure 2, stimulated
pro-T-cell-derived CD8 T cells were as efficient as stimulated CD8
T cells derived from B6 mice in lysing BALB/c targets. Thus, CD8+
T cells derived from the in vitro propagated pro-T cells seem to be
functional.
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Figure 4. Prevention of wasting disease by cotransfer of mature Treg cells. Sublethally irradiated CD45.1 CDε−/− mice were reconstituted with 5 ×
106 CD45.2 pro-T cells and 105 CD45.1+ CD4+ CD25+ T cells. (A) CD4 and CD45.2 expression in peripheral blood was analyzed 70 days after injection
by flow cytometry. (B) CD4 and Foxp3 expression in peripheral blood gated on CD4–CD45.2 cells was analyzed 70 days after injection.(A, B) One
representative of over 20 reconstituted mice is shown. (C) Sublethally irradiated CD45.1 CDε−/- mice were reconstituted with 5 × 106 CD45.2 pro-T
cells and 105 CD45.1+ CD4+ CD25+ T cells and immunized at day 50 with NIP-OVA. IgG anti-NIP titer was determined 10 days after immunization.
Each symbol represents an individual mouse and the horizontal line represents the mean titer. The NIP-OVA immunization was performed twice
with five mice each.
Long-term in vitro propagated pro-T cells can improve
the T-cell compartments in T-lymphopenic mice
Pre-Tα deficient mice are highly T-cell lymphopenic [9, 30]. To
test whether our pro-T cells could correct the T-lymphopenia of
such mice, we transplanted CD45.1+ pro-T cells into sublethally
irradiated CD45.2+ pre-Tα−/− mice. In the LNs 6weeks after trans-
plantation, 15.0 ± 5.3% (n = 6) of lymphoid cells were derived
from the injected CD45.1+ cells and these contained 66.9 ± 2.5%
CD4 and 29.7 ± 1.5% CD8 single-positive cells. Most of these
donor CD45.1+ cells expressed the TCRβ chain and 24.4 ± 5.6%
of the CD4+ cells also expressed Foxp3. A representative FACS
analysis is shown in Figure 5A–D. Comparison of the donor- and
host-derived T-cell compartments revealed that 9.2 ± 3.8% of the
LN cells were donor CD4 and 5.2 ± 1.5% host CD4 cells.
Among LN CD4 T cells from pre-Tα−/− mice, the percentage
of Foxp3-expressing cells is highly increased (around 30% in pre-
Tα−/− mice and 10% in WT mice). Surprisingly, only 13.7 ± 1.7%
of the host CD4 cells expressed Foxp3, indicating a normalization
of this compartment (data not shown). Moreover, 4.0 ± 1.4% of
the LN cells were found to be donor-derived CD8 cells whereas
5.3 ± 0.5% were of host origin. Thus, the transfer of pro-T cells to
pre-Tα−/− mice resulted in at least a twofold increase of peripheral
T-cell numbers. In the spleens, the number of pro-T-cell-derived
CD4 cells was 3.7 × 106 ± 0.5 × 106 (n = 6), whereas that
of CD8 T cells was 0.9 × 106 ± 0.2 × 106 (n = 6). Moreover,
these findings also demonstrate that the inefficient generation of
Treg cells from transplanted pro-T cells observed in CD3ε-deficient
recipients is not due to an intrinsic pro-T-cell defect but rather due
to an environmental effect within recipients.
In vitro propagated pro-T cells can reconstitute all
T-cell compartments of lethally irradiated mice
In men, HSC transplantation is an effective treatment for vari-
ous hematological disorders [31–34]. However, due to prolonged
lymphopenia, T-cell reconstitution and T-cell immunity in these
patients are impaired for prolonged periods of time [32–34].
Therefore, methods that would accelerate T-cell reconstitution
might further improve the utility of HSC transplantation treat-
ment. Here we tested whether our pro-T cells could provide such
a tool. Thus, lethally irradiated CD45.1+ B6 mice were reconsti-
tuted with a mixture of unfractionated BM cells from CD45.1+
CD3ε−/− and pro-T cells from CD45.2+ mice.
FACS analyses of thymi performed 3–4 weeks after reconstitu-
tion (Fig. 6A) showed that virtually all thymocytes were CD45.2+
(Fig. 6A) with the expected CD4- and CD8-defined subpopulations
(Fig. 6B), and TCRβ brightly expressed on the expected propor-
tions of SP thymocytes (Fig. 6C). Analysis of LNs after 6–10 weeks
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Figure 5. Improvement of T-cell compartments by in
vitro propagated pro-T cells. Sublethally irradiated pre-Tα-
deficient mice (CD45.2) were injected with 107 CD45.1 pro-T
cells. LNswere analyzed 30 days after injection by flow cytom-
etry for pro-T (A) CD4 and CD45.1 expression, (B) CD8 and CD4
expression on CD45.1-gated cells, (C) CD4 and TCRβ expres-
sion on CD45.1-gated cells, and (D) CD4 and Foxp3 expression
onCD45.1-gated cells. One representative of ten reconstituted
pre-Tα-deficient mice is shown.
revealed that 12.2 ± 1.8% of lymphoid cells were of donor origin
(n = 8) and 66.2 ± 7.2% of these were CD4-positive and 23.2 ±
5.8% CD8-positive. Moreover, 13.6 ± 4.8% of the donor-derived
CD4 cells expressed Foxp3. Also, small number of donor-derived
γδT cells as well as NK1.1-positive cells were detectable. A repre-
sentative FACS analysis is shown in Figure 6D–H. Thus, our in vitro
propagated pro-T cells can indeed take part in the reconstitution
of the T-cell compartments of lethally irradiated BM-reconstituted
WT mice. Up to now, the latest time point after transfer we ana-
lyzed these mice was 3 months. By this time pro-T-cell-derived
T cells were still readily detectable.
Discussion
Herein we describe a stromal cell free culture method for the
expansion of mouse progenitor T cells for therapeutic purposes.
For this, the Notch ligand DL4 was prepared as a fusion protein
with the Fc fragment of human IgG1 and used to coat tissue culture
plastic plates. To avoid the release of soluble DL4/Fc fusion protein
from the plates that could inhibit T-cell development, the fusion
protein was fixed to the plates using the Huf5.4 mouse anti-human
Fc mAb.
Using sorted BM multipotent LSK progenitors incubated with
IL-7 and SCF, a continuous expansion of cells was seen for up to 6
months. During this time, cells divided every 30 h and retained a
DN2–DN3 phenotype, i.e. cells were CD25+, CD117+, CD44+/−,
CD3ε+, and TCRβ− and had their TCRβ locus partially D–J rear-
ranged. Furthermore, CD27, Gata3, Notch1, and Bcl11b were
expressed. Thus, this culture system allows the generation of very
large numbers of early T-lineage cells and as we have recently
shown [35] is an ideal tool to study the early molecular and epi-
genetic changes accompanying early T-cell development.
The long-term proliferation without changes in phenotype
shows that the DN2–DN3 like cells generated in this in vitro cul-
ture system, unlike the equivalent cells in the in vivo thymus,
possess a very robust self-renewal capacity. Thus, the total pool of
thymocytes is normally replaced every 4 weeks approximately by a
new cohort of BM-derived progenitors recently immigrated to the
thymus [4]. Moreover, transplantation of WT thymus grafts into
SCID or Rag-deficient mice only results in one wave of T-cell pro-
duction; thereafter the thymus gets colonized by host BM-derived
cells [36, 37]. Based on these findings, it was concluded that the
thymus lacks self-renewing progenitors. However, in mice unable
to generate thymus-settling progenitors in their BM, early thymo-
cytes can show self-renewing capacity [38, 39]. As shown herein,
when grown in vitro, early thymocytes can have self-renewing
capacity. However, under physiological conditions, newly immi-
grated BM progenitors seem to be very efficient at replacing the
endogenous early thymocyte progenitors from the niches that pro-
vide the environment for this self-renewal.
Recently, Ikawa et al. [27] also described a stromal cell free
culture system allowing fetal-derived LSKs to differentiate into
pro-T cells and in which pro-T cells differentiated into DP thymo-
cytes upon IL-7 withdrawal. We have also found (data not shown)
that upon IL-7 withdrawal, fetal liver but not adult BM-derived
LSKs differentiated to CD4/CD8-expressing DP cells. Currently we
are trying to identify the genes that could account for this obvi-
ous difference in differentiation capacity between fetal and adult
pro-T cells.
Lymphopenia following BM transplantation or diseases
such as AIDS result in immunodeficiency and a compromised
immune system [32–34, 40, 41]. Novel approaches to ameliorate
this situation are required. Some time ago, Zakrzewski et al.
[28] showed that T-cell reconstitution after allogeneic HSC
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Figure 6. Different T-cell compartments are reconstituted by
in vitro propagated pro-T cells. Lethally irradiated CD45.1 B6
mice were reconstituted with 3 × 106 CD45.1+ CD3ε-deficient
BM cells and 107 CD45.2+ pro-T cells. (A–C) Thymi were ana-
lyzed 25 days after reconstitution by flow cytometry for (A)
CD45.2 expression, (B) CD4 and CD8 expression, and (C) CD4
and TCRβ expression. One representative of ten reconstituted
mice is shown. (D–H) LNs were analyzed 60 days after recon-
stitution by flow cytometry for pro-T (D) CD45.2 expression,
(E) CD4 and CD8 expression, (F) CD4 and TCRβ expression, (G)
CD4 and Foxp3 expression, and (H) TCRγδ and NK1.1 expres-
sion. (E–H) Dot plots were gated on CD45.2+ cells. One repre-
sentative of seven reconstituted mice is shown.
transplantation in mice could be improved by the adoptive
transfer of in vitro generated T-cell progenitors. However, a major
drawback of this study was that progenitor T cells were generated
by coculture on Notch ligand DL1 expressing OP9 stromal cells,
i.e. a method unlikely to be approved for use in patients. Pro-T
cells generated by the stromal cell free culture system described
herein would be more likely approved for therapeutic purposes in
men. Therefore, T-cell reconstitution using pro-T cells generated
in a stromal cell free system is, in our opinion, of great relevance.
Previously we reported that sublethally irradiated T-cell-
deficient mice reconstituted with WT BM cells eventually suf-
fer from a lethal wasting disease due to a paucity of Treg cells
[29]. Disease onset could be prevented by the cotransplantation
of mature Treg cells. Herein we have shown similar results using
transplanted in vitro grown pro-T cells. The inability of injected
pro-T cells to generate Treg cells does not seem to be due to an
intrinsic defect since when they are used to reconstitute T-cell-
proficient mice, about 20% of donor pro-T-cell-derived CD4 cells
expressed Foxp3. Therefore, the inefficiency of the pro-T cells to
generate Treg cells in T-cell-deficient recipient mice is most proba-
bly due to a defective thymus anlage. Medullary thymic epithelial
cells play an important role in the generation of Treg cells [42]
and it is known that the medullary thymic architecture in T-cell-
deficient mice is particularly defective [43, 44], thereby resulting
in poor Treg generation from transplanted in vitro generated pro-T
cells.
In men, various immunodeficiency diseases are caused by the
complete or partial absence of T cells [40, 41, 45] (and references
herein). Therapeutic approaches that would improve the T-cell
compartments in these patients should result in an amelioration
of the disease. That the lymphopenic T-cell compartment of pre-
Tα-deficient mice can be greatly improved by the transfer of in
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vitro derived pro-T cells as described herein suggests that a similar
treatment might be efficacious in patients.
The T-cell compartments of patients receiving hematopoietic
stem cell transplants are frequently abnormal and not functional
[32–34]. That reconstitution of the T-cell compartments in lethally
irradiated WT mice transplanted with BM from donors inca-
pable of generating T cells can in part be rescued by the cotran-
sfer of in vitro derived pro-T cells strongly suggests that such type
of cells would greatly improve the reconstitution of the T-cell com-
partments in patients after HSC transplantation.
Materials and methods
Mice
Female C57BL/6 CD45.1, C57BL/6 CD45.2, BALB/c, and CD3ε−/−
[46] as well as pre-Tα-deficient [9] mice of 5–8 weeks of age were
used. All mice were bred and maintained in our animal facility
under specific pathogen-free conditions. All animal experiments
were carried out within institutional guidelines (authorization
numbers 1886 and 1888 from Kantonales Veterina¨ramt, Basel).
Recombinant DL4-Fc fusion protein
The production and purification of a fusion protein consisting of
the extracellular portion of mouse DL4 (amino acids 1–521) and
the Fc portion of human IgG1 have been described before [47].
mAb against human IgG1 Fc
A mouse monoclonal IgG Ab against the Fc part of human IgG1
(clone Huf5.4) was produced by conventional techniques using
the fusion partner Sp2/0.
Cell lines and cell culture
Pax-5−/− pro-B cells were generated and maintained on OP9 stro-
mal cells in IMDM supplemented with 2% FBS, 5 × 10−5M β-
mercaptoethanol, 1 mM glutamine, 0.03% w/v Primatone (Quest,
Naarden, The Netherlands), 100 U/mL penicillin, and in the pres-
ence of IL-7 (100 U/mL) as previously described [48].
To establish pro-T cells, 48- or 24-well tissue culture plates
from Nunc (Nunc A/S, Roskilde, Denmark) were initially used.
Once established, cells were maintained in 6-well bacterial-grade
plates (Greiner Bio-One, Kremsmu¨nster, Austria), because of their
higher coating capacity. Wells were pre-coated overnight or longer
with 10 μg/mL mAb anti-human IgG1-Fc in PBS (0.25 mL per well
for 48-well plates, 0.5 mL per well for 24-well plates, or 2 mL per
well for 6-well plates) at 4°C. Thereafter, wells were washed twice
with IMDM (see above) and then used for coating with DL4-Fc at
2 μg/mL (or as indicated) in IMDM overnight, washed, and used
for cell culture.
Flow cytometry and cell sorting
FITC-, PE-, allophycocyanin-, or biotin-labeled mAbs specific for
CD3ε, CD4, CD8α, CD25, CD44, CD45.1, CD45.2, CD93, CD117,
Sca-1, TCRβ, TCRγδ, Foxp3, and NK1.1 were either purchased
from BD Biosciences (Franklin Lakes, NJ, USA) or eBiosciences
(San Diego, CA, USA), or purified from hybridoma culture super-
natants. Staining of the cells was performed as described before
[24]. Flow cytometry was performed using a FACS Calibur (BD
Biosciences) and data were analyzed using the Cell Quest Pro
Software (BD Biosciences). For cell sorting, a FACS Aria (BD
Biosciences) was used. Reanalysis of sorted cells revealed >98%
purity in all instances. LSKs were defined and sorted as previously
described [49–51].
Histological analysis
Frozen sections were stained with H&E according to standard
procedures.
PCR analyses of TCRβ gene rearrangements
DNA was isolated from indicated cells and analyzed by PCR for
Dβ1 to Jβ1 rearrangements as described before [51].
Transfers of cultured progenitor cells
Recipient mice were irradiated as indicated and injected with the
pro-T cells intravenously.
NIP-specific IgG responses
Mice were immunized subcutaneously at day 0 with 100 μg NIP-
OVA in a 1:1 CFA emulsion. Serum IgG against NIP was analyzed
at day 14 using ELISA as described in [52].
Gene expression analysis using Affymetrix chip array
For detection of mRNA quantity, an Affymetrix Gene Chip Mouse
Gene 1.0 ST Array was used. Mean RIN (RNA Integrity Number)
values (± SD) were 9.7 ± 0.4. All steps were carried out accord-
ing to the GeneChipWhole Transcript Sense Target Labeling Assay
Manual, Version 4 provided by Affymetrix. Raw data were ana-
lyzed with Agilent GeneSpringGX 9.0 or Partek genomics suite.
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Supporting information table 1: Genes more than 3 fold up- or down-regulated in Pax5 deficient pro-B cells 
cultured for 5 days on plate bound DL4-Fc in the presence SCF and IL-7. As controls, Pax5-/- pro-B cells 




Fold Change Regulation Transcript ID Gene Title 
187,6 up NM_009850 CD3 antigen, gamma (Cd3g), mRNA 
156,7 up NM_010370 Granzyme A (Gzma), mRNA 
70,4 up NM_008220 Haemoglobin, beta adult major chain (Hbb-b1), mRNA 







Platelet derived growth factor receptor, beta polypeptide 
(Pdgfrb), mRNA 
39,4 up NM_008091 GATA binding protein 3 (Gata3), mRNA 
34,3 up NM_013542 Granzyme B (Gzmb), mRNA 
33,5 up NM_008354 Interleukin 12 receptor, beta 2 (Il12rb2), mRNA 
31,1 up NM_011594 Tissue inhibitor of metalloproteinase 2 (Timp2), mRNA 
30,7 up NM_009854 CD7 antigen (Cd7), mRNA 
22,3 up NM_009430 Protease, serine, 2 (Prss2), mRNA 
20,5 up NM_013566 Integrin beta 7 (Itgb7), mRNA 
16,6 up NM_009864 Cadherin 1 (Cdh1), mRNA 
15,1 up NM_008052 Deltex 1 homolog (Drosophila) (Dtx1), mRNA 
15 up NM_029529 Solute carrier family 35, member D3 (Slc35d3), mRNA 
13,9 up NM_009331 Transcription factor 7, T-cell specific (Tcf7), mRNA 







Integrin, alpha E, epithelial-associated (Itgae), transcript 
variant 2, mRNA 
12,6 up NM_177204 RIKEN cDNA D330017J20 gene 
12,5 up NM_009640 Angiopoietin 1 (Angpt1), mRNA 









11,4 up NM_011815 FYN binding protein (Fyb), mRNA 









10,7 up NM_007753 Carboxypeptidase A3, mast cell (Cpa3), mRNA 
10,5 up NM_134133 RIKEN cDNA 2010002N04 gene 






NM_008709 V-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) (Mycn), mRNA 
9,2 up AK168113 interleukin 2 receptor, alpha chain 
9 up XR_031927 peptidase M20 domain containing 2 
8,8 up NM_001033126 CD antigen 27 (Cd27), transcript variant 2, mRNA 
8,7 up NM_001033468 G protein-coupled receptor 114 (Gpr114), mRNA 
8,5 up BC034889 T-cell receptor gamma, variable 1-3 
8,2 up NM_198034 SID1 transmembrane family, member 1 (Sidt1), mRNA 
8 up NM_021334 Integrin alpha X (Itgax), mRNA 







Cytochrome P450, family 1, subfamily b, polypeptide 1 
(Cyp1b1), mRNA 




up ENSMUST00000 111960 
 
--- 
6,8 up NM_013487 CD3 antigen, delta polypeptide 
6,7 up NM_008007 Fibroblast growth factor 3 
6,7 up M18858 --- 
6,5 up NM_011408 Schlafen 2 (Slfn2), mRNA 
6,3 up NM_201639 Desmuslin 
6,1 up NM_008859 Protein kinase C, theta (Prkcq), mRNA 
 6,1 up NM_145149 RAS guanyl releasing protein 4 (Rasgrp4), mRNA 
6,1 up NM_010696 Lymphocyte cytosolic protein 2 (Lcp2), mRNA 






NM_010658 v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian) (Mafb), mRNA 
6 up NM_008036 FBJ osteosarcoma oncogene B (Fosb), mRNA 
6 up NM_013464 Aryl-hydrocarbon receptor (Ahr), mRNA 
5,9 up NM_175414 Tetraspanin 9 (Tspan9), mRNA 
5,9 up NM_010583 IL2-inducible T-cell kinase (Itk), mRNA 
5,5 up NM_008048 Insulin-like growth factor binding protein 7 (Igfbp7), mRNA 
5,5 up NM_009217 Somatostatin receptor 2 (Sstr2), mRNA 







T cell receptor associated transmembrane adaptor 1 (Trat1), 
mRNA 
5,1 up NM_008706 NAD(P)H dehydrogenase, quinone 1 (Nqo1), mRNA 
5 up NM_009928 Procollagen, type XV (Col15a1), mRNA 
5 up NM_007913 Early growth response 1 (Egr1), mRNA 
4,9 up NM_011346 Selectin, lymphocyte (Sell), mRNA 
4,9 up NM_025980 Notch-regulated ankyrin repeat protein (Nrarp), mRNA 
4,9 up NM_001013384 Podocan-like 1 (Podnl1), mRNA 
4,8 up AF491829 Leukocyte-associated Ig-like receptor 1 
4,7 up NM_010220 FK506 binding protein 5 (Fkbp5), mRNA 
4,6 up NM_011673 UDP-glucose ceramide glucosyltransferase (Ugcg), mRNA 
4,6 up NM_008452 Kruppel-like factor 2 (lung) (Klf2), mRNA 








synaptotagmin-like 3 (Sytl3), mRNA 







Phosphatidylinositol 3-kinase, catalytic, beta polypeptide 
(Pik3cb), mRNA 
4,4 up NM_009985 Cathepsin W (Ctsw), mRNA 
4,4 up NM_027979 Chitinase 1 (chitotriosidase) (Chit1), mRNA 





























Glucose-fructose oxidoreductase domain containing 1 
(Gfod1), mRNA 
4,3 up NM_001033780 RIKEN cDNA I830077J02 gene 
4,3 up NM_178743 Solute carrier family 26, member 11 (Slc26a11), mRNA 
4,3 up NM_022032 PERP, TP53 apoptosis effector (Perp), mRNA 
4,2 up NM_133662 Immediate early response 3 (Ier3), mRNA 
4,1 up NM_029983 Src-like-adaptor 2 (Sla2), mRNA 








Choline dehydrogenase (Chdh), mRNA 















Solute carrier family 16 (monocarboxylic acid transporters), 
member 7 (Slc16a7), mRNA 
4 up XR_031416 Similar to ornithine decarboxylase 
 4 up BC141885 --- 
3,9 up NM_025779 Coiled-coil domain containing 109B (Ccdc109b), mRNA 















Rap guanine nucleotide exchange factor (GEF) 2 (Rapgef2), 
mRNA 







Phospholipase A2, group IVA (cytosolic, calcium-dependent) 
(Pla2g4a), mRNA 
3,7 up NM_172637 HECT domain containing 2 (Hectd2), mRNA 
3,7 up NM_009370 Transforming growth factor, beta receptor I (Tgfbr1), mRNA 
3,6 up NM_023543 Chimerin (chimaerin) 2 (Chn2), mRNA 







T-cell receptor beta, joining region /// T-cell receptor beta, 
variable 8.2 
3,5 up NM_009631 Adenosine A3 receptor (Adora3), transcript variant 1, mRNA 
3,5 up NM_010234 FBJ osteosarcoma oncogene (Fos), mRNA 







Ubiquitin associated and SH3 domain containing, A 
(Ubash3a), mRNA 
3,5 up NM_016740 S100 calcium binding protein A11 (calgizzarin) 
3,4 up NM_173014 Acyltransferase like 1A (Aytl1a), mRNA 















Methylenetetrahydrofolate dehydrogenase (NAD+ 
dependent), methenyltetrahydrofolate cyclohydrolase 
(Mthfd2), mRNA 
3,4 up NM_021435 Solute carrier family 35, member B4 (Slc35b4), mRNA 
3,4 up XR_002131 predicted gene, EG639787 
3,4 up XR_034503 similar to Odc1 protein 
3,3 up NM_008719 Neuronal PAS domain protein 2 (Npas2), mRNA 
3,3 up XM_001476259 DENN/MADD domain containing 4A 
3,3 up NM_010575 Integrin alpha 2b (Itga2b), mRNA 







A disintegrin and metallopeptidase domain 19 (meltrin beta) 
(Adam19), mRNA 
3,3 up XM_001476259 DENN/MADD domain containing 4A 
3,3 up NM_053149 Hemogen (Hemgn), mRNA 
3,2 up NM_177420 Phosphoserine aminotransferase 1 (Psat1), mRNA 
3,2 up NM_009916 Chemokine (C-C motif) receptor 4 (Ccr4), mRNA 
3,2 up NM_007656 CD82 antigen (Cd82), mRNA 







Carbamoyl-phosphate synthetase 2, aspartate 
transcarbamylase, and dihydroorotase (Cad), mRNA 







Solute carrier family 25 (mitochondrial carrier, Aralar), 































NM_011256 Phosphatidylinositol transfer protein, membrane-associated 2 (Pitpnm2), mRNA 
3,1 up NM_011777 zyxin (Zyx), mRNA 







Rho GTPase activating protein 6 (Arhgap6), transcript 
variant 1, mRNA 
3 up NM_008685 Nuclear factor, erythroid derived 2 (Nfe2), mRNA 
3 up XM_001476259 DENN/MADD domain containing 4A 
3 up NM_134080 Filamin, beta (Flnb), mRNA 
3 up NM_007633 Cyclin E1 (Ccne1), mRNA 
 
Fold Change Regulation Transcript ID Gene Title 
41,5 down NM_001043228 Deoxynucleotidyltransferase, terminal (Dntt), mRNA 
31,7 down NM_025956 RIKEN cDNA 1700011H14 gene 
28,8 down NM_009263 Secreted phosphoprotein 1 (Spp1), mRNA 
25,5 down NM_007897 Early B-cell factor 1 (Ebf1), mRNA 
23 down BC062250 Pre-B lymphocyte gene 3 (Vpreb3), mRNA 







Receptor (calcitonin) activity modifying protein 3 (Ramp3), 
mRNA 
21,7 down NM_009019 Recombination activating gene 1 (Rag1), mRNA 







Carbohydrate (chondroitin 6/keratan) sulfotransferase 3 
(Chst3), mRNA 
17,8 down NM_029338 RIKEN cDNA 1700027N10 gene 
17,1 down NM_011521 Syndecan 4 (Sdc4), mRNA 
17 down NM_024204 Ankyrin repeat domain 22 (Ankrd22), mRNA 
16,1 down NM_001081227 RIKEN cDNA 6330403A02 gene 
15,9 down NM_133775 Interleukin 33 (Il33), mRNA 
15,3 down NM_001081377 Protocadherin 9 (Pcdh9), mRNA 
14,9 down NM_010703 lymphoid enhancer binding factor 1 (Lef1), mRNA 
14,7 down NM_011580 Thrombospondin 1 (Thbs1), mRNA 














NM_008115 Glial cell line derived neurotrophic factor family receptor alpha 2 (Gfra2), mRNA 
12,5 down NM_016982 pre-B lymphocyte gene 1 (Vpreb1), mRNA 
12,4 down NM_174850 MICAL-like 2 (Micall2), mRNA 
12,4 down NM_001081377 Protocadherin 9 (Pcdh9), mRNA 
12 down NM_024007.3 early B-cell factor 1 (Ebf1), mRNA 
11,7 down NM_008829 Progesterone receptor (Pgr), mRNA 
11,6 down NM_152804 Polo-like kinase 2 (Drosophila) (Plk2), mRNA 
11,3 down NM_007960 Ets variant gene 1 (Etv1), mRNA 
11,2 down NM_175461 RIKEN cDNA C030014K22 gene 







Cholinergic receptor, nicotinic, alpha polypeptide 4 (Chrna4), 
mRNA 







Transient receptor potential cation channel, subfamily C, 
member 6 (Trpc6), mRNA 
10,2 down NM_024124 Histone deacetylase 9 (Hdac9), mRNA 
9,5 down NM_016983 pre-B lymphocyte gene 2 (Vpreb2), mRNA 







NM_001033409 Leucine-rich repeat-containing G protein-coupled receptor 6 (Lgr6), mRNA 
8,7 down NM_001081039 Dedicator of cytokinesis 9 (Dock9), mRNA 
8,5 down NM_001008548 Phosphodiesterase 2A, cGMP-stimulated (Pde2a), mRNA 
8,5 down NM_009917 Chemokine (C-C motif) receptor 5 (Ccr5), mRNA 













Cat eye syndrome chromosome region, candidate 6 homolog 
(human), mRNA 
7,9 down NM_028078 Immunoglobulin superfamily, member 5 (Igsf5), mRNA 






NM_027864 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N- acetylgalactosaminyltransferase 14 (Galnt14), mRNA 
7,4 down NM_183221 FAT tumor suppressor homolog 4 (Drosophila) (Fat4), mRNA 
7,2 down NM_010954 Neural cell adhesion molecule 2 (Ncam2), mRNA 
7,1 down NM_153095 MAS-related GPR, member A1 (Mrgpra1), mRNA 
6,8 down NM_138751 Transmembrane protein 47 (Tmem47), mRNA 
6,7 down NM_008626 Mannose receptor, C type 2 (Mrc2), mRNA 







Potassium large conductance calcium-activated channel, 







Rap guanine nucleotide exchange factor (GEF) 3 (Rapgef3), 
mRNA 
6,6 down NM_011595 Tissue inhibitor of metalloproteinase 3 (Timp3), mRNA 







Regulator of G-protein signalling 7 binding protein (Rgs7bp), 
mRNA 
6,3 down NM_008505 LIM domain only 2 (Lmo2), mRNA 
6,2 down NM_011858 odd Oz/ten-m homolog 4 (Drosophila) (Odz4), mRNA 







Calcium channel, voltage-dependent, N type, alpha 1B 
subunit (Cacna1b), transcript vari 







Ubiquitin-conjugating enzyme E2A, RAD6 homolog (S. 
cerevisiae) (Ube2a), mRNA 
6 down NM_017372 Lysozyme (Lyzs), mRNA 
6 down AF028616 immunoglobulin heavy variable V1-72 







Solute carrier family 9 (sodium/hydrogen exchanger), 
member 2 (Slc9a2), mRNA 







Beta galactoside alpha 2,6 sialyltransferase 1 (St6gal1), 
mRNA 







Amyloid beta (A4) precursor protein-binding, family B, 
member 1 (Apbb1), mRNA 
5,4 down NM_011809 E26 avian leukemia oncogene 2, 3' domain (Ets2), mRNA 
5,4 down NM_027491 Ras-related GTP binding D (Rragd), mRNA 
5,4 down NM_010229 FMS-like tyrosine kinase 3 (Flt3), mRNA 
5,3 down NM_146162 Transmembrane protein 119 (Tmem119), mRNA 







Ral guanine nucleotide dissociation stimulator,-like 1 (Rgl1), 
mRNA 
5,3 down NM_010570 Insulin receptor substrate 1 (Irs1), mRNA 







AB061277 cytidine monophospho-N-acetylneuraminic acid hydroxylase, mRNA 
5,2 down NM_007549 B lymphoid kinase (Blk), mRNA 
5,2 down NM_008320 Interferon regulatory factor 8 (Irf8), mRNA 
5,2 down NM_001102615 Kinesin family member 19A (Kif19a), mRNA 







BTB and CNC homology 2 (Bach2), transcript variant 2, 
mRNA 
5,1 down NM_009904 Calmegin (Clgn), mRNA 
4,9 down NM_009235 SRY-box containing gene 15 (Sox15), mRNA 
4,9 down XM_001480949 Similar to natural killer cell receptor-P1, mRNA 
4,9 down NM_175329 Nur77 downstream gene 2 (Ndg2), mRNA 
4,9 down NM_013674 Interferon regulatory factor 4 (Irf4), mRNA 







ST3 beta-galactoside alpha-2,3-sialyltransferase 6 (St3gal6), 
mRNA 







Calcium/calmodulin-dependent protein kinase II, beta 
(Camk2b), mRNA 
4,6 down NM_007956 Estrogen receptor 1 (alpha) (Esr1), mRNA 
4,6 down NM_010739 Mucin 13, epithelial transmembrane (Muc13), mRNA 















Gap junction membrane channel protein beta 3 (Gjb3), 
mRNA 
4,5 down NM_177192 RIKEN cDNA D030011O10 gene, mRNA 







Endothelial differentiation sphingolipid G-protein-coupled 
receptor 1 (Edg1), mRNA 
4,5 down NM_008548 Mannosidase 1, alpha (Man1a), mRNA 
4,5 down NM_146008 T-complex 11 (mouse) like 2 (Tcp11l2), mRNA 
4,4 down NM_019739 Forkhead box O1 (Foxo1), mRNA 
4,4 down NM_027496 RIKEN cDNA 5730557B15 gene, mRNA 
4,4 down AK082395 RIKEN cDNA 4930486G11 gene, mRNA 
4,4 down NM_207237 Mannosidase, alpha, class 1C, member 1 (Man1c1), mRNA 
4,4 down NM_145133 Traf2 binding protein (T2bp), mRNA 







Solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 7 (Slc7a7), mRNA 
4,4 down NM_011104 Protein kinase C, epsilon (Prkce), mRNA 







A kinase (PRKA) anchor protein (gravin) 12 (Akap12), 
mRNA 




















NM_021415 Calcium channel, voltage-dependent, T type, alpha 1H subunit (Cacna1h), mRNA 






NM_198294 Tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1 (Tanc1), mRNA 
4,2 down NM_172734 Serine/threonine kinase 38 like (Stk38l), mRNA 
4,2 down NM_009330 HNF1 homeobox B (Hnf1b), mRNA 
 4,2 down NM_001005423 Melanoregulin (Mreg), mRNA 
4,1 down NM_007564 Zinc finger protein 36, C3H type-like 1 (Zfp36l1), mRNA 
4,1 down NM_019840 Phosphodiesterase 4B, cAMP specific (Pde4b), mRNA 







ATPase, H+ transporting, lysosomal V0 subunit A1 
(Atp6v0a1), mRNA 
4,1 down BC026950 Kynureninase (L-kynurenine hydrolase), mRNA 
4,1 down NM_153584 cDNA sequence BC031353, mRNA 
4,1 down NM_010740 CD93 antigen (Cd93), mRNA 
4,1 down NM_015786 Histone cluster 1, H1c (Hist1h1c), mRNA 







ATPase, Ca++ transporting, plasma membrane 4 (Atp2b4), 
mRNA 
4 down NM_177303 RIKEN cDNA B430119L13 gene, mRNA 
4 down NM_177645 RIKEN cDNA 1110028C15 gene 
4 down AF329833 GH regulated TBC protein 1 (Grtp1), mRNA 
4 down NM_133791 WW, C2 and coiled-coil domain containing 2 (Wwc2), mRNA 
4 down NM_008606 matrix metallopeptidase 11, mRNA 
4 down NM_172842 lymphocyte transmembrane adaptor 1, mRNA 
4 down NM_027410 RIKEN cDNA 2210010N04 gene 
3,9 down NM_011925 CD97 antigen (Cd97), mRNA 
3,9 down NM_008339 CD79B antigen (Cd79b), mRNA 
3,9 down NM_019949 ubiquitin-conjugating enzyme E2L 6, mRNA 
3,9 down NM_172753 RIKEN cDNA 4732435N03 gene 
3,9 down AK171913 macrophage activation 2 like, mRNA 
3,9 down NM_001079686 Synaptic nuclear envelope 1 (Syne1), mRNA 
3,9 down AY344585 predicted gene, ENSMUSG00000074792 
3,9 down NM_015753 Zinc finger E-box binding homeobox 2 (Zeb2), mRNA 
3,9 down NM_133655 Cd81 antigen (Cd81), mRNA 
3,8 down NM_174851 Interleukin 28 receptor alpha (Il28ra), mRNA 
3,8 down NM_198724 EGF-like domain 7 (Egfl7), mRNA 
3,8 down NM_011175 Legumain (Lgmn), mRNA 
3,8 down NM_138309 Cd99 antigen-like 2 (Cd99l2), mRNA 
3,8 down AY512938 predicted gene, ENSMUSG00000069163 















Protein tyrosine phosphatase, non-receptor type 18 
(Ptpn18), mRNA 
3,7 down NM_177192 RIKEN cDNA D030011O10 gene 
3,7 down NM_019976 Proline/serine-rich coiled-coil 1 (Psrc1), mRNA 















Fumarylacetoacetate hydrolase domain containing 2A 
(Fahd2a), mRNA 















Phosphodiesterase 6D, cGMP-specific, rod, delta (Pde6d), 
mRNA 
3,6 down NM_007420 Adrenergic receptor, beta 2 (Adrb2), mRNA 
3,6 down NM_009367 Transforming growth factor, beta 2 (Tgfb2), mRNA 
3,6 down NM_016764 Peroxiredoxin 4 (Prdx4), mRNA 
3,6 down NM_013739 Docking protein 3 (Dok3), mRNA 
 3,6 down NM_172728 cAMP responsive element binding protein 5 (Creb5), mRNA 







3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase-like 1 
(Hmgcll1), mRNA 
3,5 down BC058790 major facilitator superfamily domain containing 4, mRNA 
3,5 down AF045503 predicted gene, EG434609 







Basic helix-loop-helix domain containing, class B, 8 
(Bhlhb8), mRNA 
3,5 down NM_177768 cDNA sequence BC038156 






NM_011977 Solute carrier family 27 (fatty acid transporter), member 1 (Slc27a1), mRNA 
3,5 down NM_008902 Placental protein 11 related (Pp11r), mRNA 
3,4 down NM_009194 Solute carrier family 12, member 2 (Slc12a2), mRNA 







Ras association (RalGDS/AF-6) domain family 4 (Rassf4), 
mRNA 







Acyl-CoA synthetase short-chain family member 1 (Acss1), 
mRNA 
3,4 down AK156585 RIKEN cDNA 9530009G21 gene 
3,4 down NM_153175 GTPase, IMAP family member 6 (Gimap6), mRNA 
3,4 down NM_133697 RIKEN cDNA 1110003E01 gene 







Neuron-glia-CAM-related cell adhesion molecule (Nrcam), 
mRNA 
3,4 down NM_008099 Germinal center expressed transcript 2 (Gcet2), mRNA 







CD79A antigen (immunoglobulin-associated alpha) (Cd79a), 
mRNA 















Cbp/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 4 (Cited4), mRNA 
3,3 down NM_027401 RIKEN cDNA 1700010C24 gene, mRNA 
3,3 down NM_011074 PFTAIRE protein kinase 1 (Pftk1), mRNA 







KH domain containing, RNA binding, signal transduction 
associated 3 (Khdrbs3), mRNA 







Sodium channel, voltage-gated, type III, alpha (Scn3a), 
mRNA 
3,3 down NM_029870 RIKEN cDNA A930001N09 gene, mRNA 
3,3 down NM_008349 Interleukin 10 receptor, beta (Il10rb), mRNA 
3,3 down NM_026622 RIKEN cDNA 3110057O12 gene, mRNA 
3,3 down NM_172442 Deltex 4 homolog (Drosophila) (Dtx4), mRNA 
3,3 down NM_016773 Nucleobindin 2 (Nucb2), mRNA 
3,3 down NM_015767 Tocopherol (alpha) transfer protein (Ttpa), mRNA 
3,2 down AF057537 immunoglobulin kappa chain variable 1-135, mRNA 
3,2 down NM_011309 S100 calcium binding protein A1, mRNA 















NM_153582 CKLF-like MARVEL transmembrane domain containing 4 (Cmtm4), mRNA 
3,2 down NM_008803 Phosphodiesterase 8A (Pde8a), mRNA 
3,2 down NM_009368 Transforming growth factor, beta 3 (Tgfb3) 
3,2 down NM_145976 cDNA sequence BC027057, mRNA 
3,2 down NM_015749 Transcobalamin 2 (Tcn2), mRNA 















Poly (ADP-ribose) polymerase family, member 1 (Parp1), 
mRNA 
3,2 down AK084447 RIKEN cDNA C330007P06 gene, mRNA 
3,2 down NM_001013390 Sodium channel, type IV, beta (Scn4b), mRNA 
3,2 down NM_010585 Inositol 1,4,5-triphosphate receptor 1 (Itpr1), mRNA 
3,1 down NM_010358 Glutathione S-transferase, mu 1 (Gstm1), mRNA 
3,1 down NM_019969 Pleiomorphic adenoma gene 1 (Plag1), mRNA 







Pleckstrin homology-like domain, family A, member 3 
(Phlda3), mRNA 
3,1 down NM_001039394 RAB43, member RAS oncogene family (Rab43), mRNA 
3,1 down NM_001003955 RAB11 family interacting protein 5 (class I), mRNA 
3,1 down NM_173006 Paraoxonase 3 (Pon3), mRNA 
3,1 down NM_001025250 Vascular endothelial growth factor A (Vegfa), mRNA 







Pyruvate dehydrogenase kinase, isoenzyme 2 (Pdk2), 
mRNA 
3,1 down NM_001001986 RIKEN cDNA 8430427H17 gene 
3,1 down NM_029100 Selenoprotein N, 1 (Sepn1), mRNA 
3,1 down NM_146096 RIKEN cDNA 5730446C15 gene 
3,1 down NM_198642 RIKEN cDNA 5031414D18 gene 
3,1 down NM_175484 Coronin, actin binding protein, 2B (Coro2b), mRNA 







Serine (or cysteine) peptidase inhibitor, clade E, member 2 
(Serpine2), mRNA 
3 down NM_015767 Tocopherol (alpha) transfer protein (Ttpa), mRNA 







Pterin 4 alpha carbinolamine dehydratase/dimerization 








Chaperone, ABC1 activity of bc1 complex like (S. pombe) 
(Cabc1), mRNA 
3 down NM_172731 FYVE, RhoGEF and PH domain containing 5 (Fgd5), mRNA 
3 down NM_027496 RIKEN cDNA 5730557B15 gene 
3 down NM_020332 Progressive ankylosis (Ank), mRNA 
3 down AK173319 Ring finger protein 169, mRNA 
3 down NM_010794 Mannoside acetylglucosaminyltransferase 1 (Mgat1), mRNA 







ELOVL family member 7, elongation of long chain fatty acids 
(yeast) (Elovl7) 

















Supporting Information Figure 1
 
Gata3, Notch1, Bcl11b and CD27 expression by pro-T cells cultured on DL4-Fc 
coated plates in the presence of IL-7 and SCF for more than 5 weeks. (A) 
Semiquantitative RT-PCR analysis. (B) FACS analysis. Gray histogram represents the 
unstained control. 
These experiments were performed with three individually established pro-T cell lines. 
The results obtained with one representative line are shown.  
Supporting Information Figure 2














Cytotoxic activity of pro T cell derived B6 T cells () wild type B6 T cells () and 
Balb/c T cells (▲) stimulated with irradiated Balb/c spleen cells. 3H-thymidine 
labeled Balb/c LPS blast were used as targets. 
Supporting information materials and methods 
 
Semiquantitative RT-PCR 
Total RNA from pro T cells was reverse transcribed and PCR amplified. The 
following primers were used: β-actin, 5’- 
GAAGTCTAGAGCAACATAGCACAGCTTCTC-3’ and 5’- 
GTGGGAATTCGTCAGAAGGACTCCTATGTG-3’, GATA3, 5’-
GTCATCCCTGAGCCACATCT-3’ and 5’-TAGAAGGGGTCGGAGGAACT-3’, 
Notch1, 5’-AACTGCTCCGAGGAGATCAA-3’ and 5’-
ACACAGGTGCCATTGTTGAA-3’, Bcl11b, 5’-TGCCTTCCCATCTATGTTCC-3’ 
and 5’-GAAGAGGAGGAGGAGGAGGA-3’. 
 
Cytotoxic T-cell assay 
Total spleen cells from B6 Rag2 deficient mice at 6 weeks after transplantation of in 
vitro propagated B6 pro T cells were co-cultured at a density of 2.5 x 106/ml with 
irradiated Balb/c spleen cells (2.5 x 106/ml) for 5 days. At day 5 the capacity to lyse 
Balb/c LPS blasts was tested. Normal B6 spleen cells stimulated with irradiated 
Balb/c spleen cells and Balb/c spleen cells co-cultured with irradiated Balb/c spleen 
cells were used as controls. 
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Fetal	   liver	   (FL)	   and	   bone	  marrow	   (BM)	   derived	   pro-­‐B	   cells	   were	   propagated	  
long-­‐term	  in	  stromal	  cell	   free	  cultures	  supplemented	  with	   interleukin-­‐7	  (IL-­‐7),	  stem	  
cell	  factor	  (SCF)	  and	  FLT3	  ligand.	  Within	  a	  week,	  most	  cells	  expressed	  surface	  CD19,	  
CD79a	  and	  CD79b,	  λ5	  and	  VpreB	  antigens	  and	  had	  rearranged	   immunoglobulin	  D-­‐J	  
heavy	   chain	   genes.	   Cells	   efficiently	   differentiated	   into	   IgM+	   B	   cells	   upon	   IL-­‐7	  
withdrawal.	   Both	   FL	   and	   BM	   pro-­‐B	   cells	   reconstituted	   the	   B-­‐cell	   compartments	   of	  
immuno-­‐incompetent	   Rag2-­‐deficient	   mice	   with	   FL	   pro-­‐B	   generating	   follicular,	  
marginal	  zone	  (MZB)	  and	  B-­‐1a	  B	  cells,	  but	  BM	  pro-­‐B	  cells	  mainly	  MZB.	  Reconstituted	  
mice	  generated	  significant	  IgM	  and	  IgG	  antibodies	  to	  a	  type	  II	  T-­‐independent	  antigen	  
with	  FL	  pro-­‐B	  cell	  reconstituted	  mice	  generating	  surprisingly	  high	  IgG1	  titers.	  Finally,	  
we	   show	   for	   the	   first	   time	   that	   in	   vitro	   propagated	   pro-­‐B	   and	   pro-­‐T	   cells	  
reconstituted	   both	   the	   B-­‐	   and	   T-­‐cell	   compartments	   of	   Rag2-­‐deficient	   mice	   and	  
mounted	  a	  T-­‐cell	  dependent	  antibody	  response.	  Thus	  it	  is	  possible	  to	  reconstitute	  a	  
functional	   adaptive	   immune	   system	   with	   in	   vitro	   propagated,	   stromal	   cell	   free,	  
lymphocyte	   progenitors.	   This	   novel	   stromal	   cell	   free	   culture	   system	   facilitates	   our	  
understanding	  of	  B-­‐cell	  development	  and	  might	  be	  applied	  clinically.	  
	  
	   	  






Like	  all	  other	  hematopoietic	  cells,	  B	  cells	  are	  derived	  from	  hematopoietic	  stem	  
cells	   (HSCs).	   In	   mice,	   most	   B-­‐cell	   development	   takes	   place	   in	   the	   FL	   before	   birth	  
whereas	  in	  adults,	  the	  BM	  is	  the	  major	  site.	  The	  various	  stages	  of	  B-­‐cell	  development	  
can	  be	  distinguished	  by	  combinations	  of	   cell	   surface	  and	   intracellular	  markers,	   cell	  
cycle	   profile	   and	   rearrangement	   status	   of	   IgH	   and	   IgL	   chain	   loci	   [1-­‐4].	   B-­‐cell	  
commitment	  is	  determined	  by	  the	  transcription	  factor	  Pax5	  [5-­‐7].	  One	  of	  the	  target	  
genes	  of	  Pax5	  is	  CD19	  [8]	  and	  the	  earliest	  B-­‐cell	  committed	  precursor,	  also	  called	  a	  
pro-­‐B	   cell,	   is	   CD19+	   CD117+	   [1,	   9].	   These	   cells	   have	   their	   IgH	   chains	   in	   D	   –	   J	  
rearranged	   configuration	   [4]	   and	  a	   large	   fraction	   is	   proliferating	   [1].	   Such	   cells	   are	  
absent	  in	  Pax5-­‐deficient	  [10]	  and	  Il7	  or	  Il7R	  gene	  deleted	  mice	  [11,	  12]	  indicating	  the	  
importance	   of	   these	   molecules	   in	   early	   B-­‐cell	   development.	   Also	   the	   receptor	  
tyrosine	   kinases	  CD117	  and	  CD135	  and	   their	   corresponding	   ligands,	   SCF	  and	  Flt3L,	  
play	  an	  important	  role	  in	  early	  B-­‐cell	  development	  [13-­‐17].	  Blocking	  SCF	  binding	  with	  
an	  anti-­‐CD117	  antibody	  inhibits	  pro-­‐B	  cell	  proliferation	  in	  IL-­‐7-­‐containing	  stromal	  cell	  
cultures	  [18]	  and	  CD135	  or	  Flt3L-­‐deficient	  mice	  have	  a	  dramatically	  reduced	  BM	  pro-­‐
B-­‐cell	  compartment	  [19].	  Taken	  together,	  these	  results	  show	  the	  importance	  of	  Pax5	  
and	  cytokine-­‐related	  molecules	  in	  early	  B-­‐cell	  development.	  
Over	  20	  years	  ago,	  we	  showed	  that	  FL-­‐derived	  pro-­‐B	  cells	  could	  be	  grown	  long-­‐
term	  on	  stromal	  cells	  and	  IL-­‐7	  [20].	  Moreover,	  using	  Bcl2	  transgenic	  pro-­‐B	  cells	  IL-­‐7	  
withdrawal	   resulted	   in	   an	   efficient	   differentiation	   into	   surface	   IgM	  positive	   B	   cells	  
[20,	  21].	  However,	  until	  now,	  it	  has	  not	  been	  possible	  to	  grow	  BM-­‐derived	  pro-­‐B	  cells	  
long-­‐term	  using	   stromal	   cell	   based	   culture	   systems.	   In	   the	   present	   report	  we	  now	  
show	  for	  the	  first	   time	  that	   it	   is	  also	  possible	  to	  grow	  BM-­‐derived	  pro-­‐B	  cells	   long-­‐
term,	  with	   and	  even	  without	   stromal	   cell	   support.	  We	  have	  described	  an	  early	   (E)	  
progenitor	   (P)	   with	   lymphoid	   (L)	   and	  myeloid	   (M)	   developmental	   potential,	   called	  
EPLM,	  in	  the	  BM	  [22].	  EPLM	  express	  B220	  and	  CD117	  but	  not	  CD19	  or	  NK1.1.	  When	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cultured	  either	  on	  OP9	  stromal	  cells	  plus	  IL-­‐7	  or	  with	  IL-­‐7,	  SCF	  and	  FLT3L	  but	  without	  
stromal	   cells,	   EPLM	   from	   the	   FL	   or	   BM	   can	   be	   propagated	   long-­‐term	   and	  
differentiate	   into	   CD19+	   pro-­‐B	   cells.	   Moreover,	   upon	   in	   vivo	   transplantation	   into	  
immunodeficient	   Rag2	   gene	   deficient	   hosts,	   these	   pro-­‐B	   cells	   can	   reconstitute	   a	  
functional	   B-­‐cell	   compartment.	   Finally,	   we	   also	   show	   that	   when	   these	   mice	   are	  
reconstituted	   with	   a	   mixture	   of	   in	   vitro	   propagated	   pro-­‐B	   and	   stromal	   cell	   free	  
propagated	   pro-­‐T	   cells	   [23],	   a	   small,	   but	   functional	   adaptive	   immune	   system	   is	  
generated.	  
	   	  






Establishment	  of	  a	  culture	  system	  that	  allows	  the	   long-­‐term	  in	  vitro-­‐propagation	  of	  
BM	  pro-­‐B	  cells	  
	  
More	   than	   20	   years	   ago	   we	   described	   a	   stromal	   cell	   based	   culture	   system	  
permitting	   the	   long-­‐term	   in	   vitro	   growth	   of	   FL-­‐derived	   pro-­‐B	   cells	   [20].	   However,	  
until	   now,	   we	   were	   unable	   to	   grow	   BM	   pro-­‐B	   cells	   long-­‐term.	   More	   recently	   we	  
identified	   a	   B220+CD117+CD19-­‐NK1.1-­‐	   progenitor	   in	   the	   BM	   that	   showed	   a	   strong	  
lymphoid	  and	  myeloid	  developmental	  potential	  and	  that	  we	  called	  EPLM	  [22].	  Now	  
we	   tested	   the	   capacity	   of	   BM-­‐derived	   EPLM	   to	   generate	   long-­‐term	   growing	   pro-­‐B	  
cells.	   Therefore	   B220+CD117+CD19-­‐NK1.1-­‐	   (CD19-­‐)	   cells	   and	   B220+CD117+CD19+	  
NK1.1-­‐	   (CD19+)	   cells	   from	   FL	   or	   BM	   were	   sorted	   (Figure	   1a)	   and	   plated	   on	   OP9	  
stromal	  cells	  plus	  IL-­‐7.	  After	  an	  initial	  culture	  period	  of	  6	  days,	  cells	  were	  harvested	  
every	  3	  -­‐	  4	  days	  and	  re-­‐plated	  on	  fresh	  stromal	  cells	  and	  IL-­‐7.	  As	  shown	  in	  figure	  1b,	  
CD19-­‐	   (EPLM)	   cells	   showed	   continuous	   growth	   with	   doubling	   times	   of	   about	   30	  
hours,	  whereas	  CD19+	  cells	  proliferated	  for	  the	  first	  7	  days	  and	  then	  their	  numbers	  
plateaued.	  In	  order	  to	  test	  whether	  differential	  gene	  expression	  was	  underlying	  this	  
different	   in	   vitro	   expansion	  capacity	  we	  performed	  RNAseq	  on	  CD19+	   cells	  derived	  
from	   CD19-­‐	   EPLM	   grown	   for	   12	   days	   on	   OP9	   plus	   IL-­‐7	   and	   freshly-­‐isolated	  
CD19+CD117+	   cells	   similarly	   grown	   for	   5	   days.	   This	   analysis	   revealed	   that	   only	   83	  
genes,	   none	   of	   which	   were	   B-­‐cell	   related,	   were	   twofold	   or	   more	   differentially	  
expressed	   (summary	   table	   1).	   In	   fact,	   the	   44	   B-­‐cell	   related	   genes	   found	   in	   this	  
analysis	   were	   similarly	   expressed	   (summary	   table	   2	   and	   supplementary	   figure	   1).	  
Gene	  ontology	  analysis	  performed	  on	  the	  83	  genes	  did	  not	  identify	  genes	  that	  might	  
explain	  the	  growth	  difference	  observed.	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Comparison	   of	   the	   growth	   rate	   of	   FL	   and	   BM-­‐derived	   EPLM	  on	  OP9	   stromal	  
cells	  with	  IL-­‐7	  revealed	  that	  FL-­‐derived	  cells	  grew	  marginally	  better	  than	  those	  from	  
the	  BM	  (Figure	  1c).	  Most	  importantly,	  FACS	  analysis	  showed	  that	  over	  95%	  of	  these	  
cultured	  FL	  and	  BM	  EPLM	  gained	   the	  expression	  of	  CD19	   (Figure	  1d).	  Around	  25%	  
BM	   and	   over	   60%	   FL-­‐derived	   cells	   expressed	   CD117	   (Figure	   1d).	   RT-­‐PCR	   analysis	  
revealed	   that	   both	   expressed	   CD79a,	   CD79b,	   Igll1	   (λ5)	   and	   Vpreb1	   and	   both	   had	  
undergone	  DH	   -­‐	   JH	   rearrangements	   (Figure	  1e).	  Thus,	  BM	  and	  FL	  EPLM	  cultured	  on	  
OP9	  plus	  IL-­‐7	  give	  rise	  to	  long-­‐term	  proliferating	  pro-­‐B	  cells.	  
	  
Establishment	   of	   a	   stromal	   cell	   free	   culture	   system	   that	   allows	   the	   long-­‐term	  
propagation	  of	  BM	  and	  FL	  pro-­‐B	  cells	  
	  
FL	   pro-­‐B	   cells	   propagated	   on	   stromal	   cells	   plus	   IL-­‐7	   reconstituted	   the	   B-­‐cell	  
compartment	  of	  immuno-­‐deficient	  mice	  [20,	  24,	  25].	  However,	  it	  is	  unlikely	  that	  pro-­‐
B	   cells	   derived	   from	   co-­‐culture	   settings	   will	   ever	   be	   approved	   for	   therapeutic	  
purposes.	  Therefore,	  we	  developed	  a	  stromal	  cell	   free	  culture	  system	  consisting	  of	  
soluble	  IL-­‐7,	  SCF,	  and	  FLT3L.	  As	  shown	  in	  Figure	  2a	  and	  b,	  EPLM	  derived	  from	  FL	  and	  
BM	  showed	  very	  robust	  growth	  under	  these	  stromal	  cell	  free	  conditions.	  In	  fact,	  the	  
growth	   rate	  of	  BM-­‐derived	  EPLM	  was	   identical	  under	   stromal	   cell	   and	   stromal	   cell	  
free	  conditions	   (Figure	  2a).	  On	   the	  other	  hand	   the	  growth	  of	   FL	  EPLM	  was	   slightly	  
slower	  without	  stromal	  cell	  support	  (Figure	  2b).	  FACS	  analysis	  revealed	  that	  stromal	  
cell	  free	  cultured	  EPLM	  acquired	  CD19	  expression	  and	  around	  35%	  BM	  and	  over	  75%	  
FL-­‐derived	   cells	   expressed	   CD117	   (Figure	   2c	   and	   d).	   Moreover,	   stromal	   cell	   free	  
cultured	   cells	   expressed	   CD79a,	   CD79b,	   Igll1	   (λ5)	   and	   Vpreb1	   and	   had	   their	   IgH	  
chains	   in	   DH-­‐JH	   rearranged	   configuration	   (Figure	   2e).	   Thus,	   both	   BM	   and	   FL	   EPLM	  
cultured	  with	   IL-­‐7,	   SCF	   and	   FLT3L	  without	   stromal	   cells	   also	   give	   rise	   to	   long-­‐term	  
proliferating	  pro-­‐B	  cells.	  
Previously	  we	  showed	  that	  upon	  IL-­‐7	  removal,	   in	  vitro	  propagated	  pro-­‐B	  cells	  
underwent	  massive	  apoptosis	  that	  was	  prevented	  by	  the	  transgenic	  over-­‐expression	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of	   the	   anti-­‐apoptotic	   Bcl2	   gene.	   IL-­‐7	   removal	   from	   cultured	   transgenic	   Bcl2	  
expressing	   pro-­‐B	   cells	   resulted	   in	   a	   large	   fraction	   differentiating	   into	   surface	   IgM	  
positive	  B	  cells	  [21].	  To	  test	  whether	  BM	  EPLM-­‐derived	  pro-­‐B	  cells	  could	  differentiate	  
upon	   IL-­‐7	   withdrawal,	   we	   sorted	   such	   cells	   from	   Bcl2	   transgenic	   mice	   and	  
maintained	   cultures	   either	   on	  OP9	   or	   in	   stromal	   cell	   free	   conditions.	   As	   shown	   in	  
figure	  2f	  (upper	  panels)	  very	  few	  (0.4%	  on	  OP9,	  left	  panel	  and	  1.2%	  stromal	  cell	  free,	  
right	  panel)	   cells	   grown	   in	   the	  presence	  of	   IL-­‐7	  expressed	  a	  μH	   (IgM)	  and	   Igκ	   light	  
chain	  on	  their	  surface.	  However,	  6	  days	  after	  IL-­‐7	  withdrawal,	  26%	  of	  the	  stromal	  cell	  
culture	  derived	  pro-­‐B	  cells	  were	   IgM+,	   Igk+	   (Figure	  2f,	   left	  upper	  panel,	  upper	   right	  
quadrant)	   and	   the	   remaining	   7.1%	   IgM+,	   Igk-­‐	   (upper	   left	   quadrant)	   cells	   being	   Igλ+	  
(data	   not	   shown).	   As	   shown	   in	   figure	   2f	   (lower	   right	   dot	   plot),	   these	   values	  were	  
17.3%	  and	  7.8%	  respectively	  for	  pro-­‐B	  cells	  cultured	  in	  stromal	  cell	  free	  conditions.	  
Thus	   BM	   EPLM-­‐derived	   pro-­‐B	   cells	   propagated	   either	   on	   stromal	   cells	   or	   grown	  
stromal	   cell	   free	   differentiated	   efficiently	   into	   IgM	   positive	   B	   cells	   upon	   IL-­‐7	  
withdrawal.	  
	  
In	  vivo	  reconstitution	  of	  the	  B-­‐cell	  compartments	  by	  pro-­‐B	  cells	  derived	  from	  BM	  or	  FL	  
EPLM	  
	  
To	   test	   the	   capacity	   of	   in	   vitro	   generated	   FL	   or	   BM-­‐derived	   pro-­‐B	   cells	   to	  
reconstitute	  mice,	  107	  EPLM-­‐derived	  pro-­‐B	   from	  FL	  or	  BM	  of	  C57BL/6	  CD45.1	  mice	  
cultured	   on	   OP9	   stroma	   or	   stromal	   cell	   free	   were	   transferred	   into	   sub-­‐lethally	  
irradiated	  CD45.2	  C57BL/6	  Rag2-­‐deficient	  mice.	  Five	  to	  ten	  weeks	  following	  transfer,	  
reconstitution	  was	   assessed	   by	   FACS	   analysis	   of	   spleen	   or	   peritoneal	   cavity	   (PerC)	  
cells.	  As	  shown	  in	  figure	  3a	  for	  FL-­‐derived	  and	  figure	  4a	  for	  BM-­‐derived	  donor	  cells	  
(upper	  row	  dot	  plots),	  CD45.1+	  expression	  was	  restricted	  to	  CD19+	  cells	  and	  all	  CD19+	  
cells	   co-­‐expressed	   IgM	   (second	   row).	   Thus,	   all	   in	   vitro	   propagated	   pro-­‐B	   cells	  
generated	  B	  cells	  but	  no	  other	  lineages.	  Based	  on	  expression	  of	  CD5,	  FL-­‐derived	  pro-­‐
B	  cells	  grown	  either	  on	  stroma	  or	  stromal	  cell	  free,	  gave	  rise	  to	  a	  large	  fraction	  of	  B-­‐
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1a	  B	  cells	  especially	   in	  the	  PerC	  (Figure	  3a	  third	  row	  cytograms).	  As	  expected,	  BM-­‐
derived	   pro-­‐B	   cells	   generated	   few	   CD5	   expressing	   B	   cells	   (Figure	   4a	   third	   row	  
cytograms).	  Spleen	  marginal	  zone	  B	  (MZB)	  and	  follicular	  B	  cells	  (FB)	  were	  identified	  
using	   combined	   CD21	   and	   CD23	   expression	   on	   gated	   CD19+	   cells.	   The	   CD21	   and	  
CD23	  expression	  pattern	  on	  splenic	  B	  cells	  derived	  from	  FL	  pro-­‐B	  cells	  propagated	  on	  
either	  OP9	  stromal	  or	  stromal	  cell	  free	  were	  similar	  (Figure	  3a	  lower	  row	  cytograms).	  
Thus	   40	   –	   60%	  were	   CD21+/CD23+	   FB	   and	   30	   –	   40%	  were	   CD21+/CD23-­‐	  MZB.	   The	  
CD19+/CD21-­‐/CD23-­‐	   cells	   (lower	   left	   quadrant)	  most	   likely	   represent	   B-­‐1	   B	   cells.	   In	  
figure	  3a	  a	  representative	  immunohistochemical	  picture	  of	  a	  spleen	  section	  of	  such	  a	  
reconstituted	   mouse	   is	   shown.	   Thus	   like	   in	   wild	   type	   mice	   B-­‐cell	   follicles	   were	  
formed	   with	   IgMhigh	   (green)	   IgDlow	   (blue)	   MZB	   cells	   surrounding	   metallophilic	  
macrophages	  (red)	  and	  IgM+IgDhigh	  FB	  inside.	  Mice	  reconstituted	  with	  BM	  pro-­‐B	  cells	  
cultured	  by	  the	  two	  methods	  also	  showed	  no	  obvious	  differences	  in	  CD21	  and	  CD23	  
expression	   (Figure	   4a	   lower	   row	   cytograms).	   However,	   in	   marked	   contrast	   to	   FL-­‐
derived	  pro-­‐B	  cells,	  more	  than	  70%	  of	  BM	  pro-­‐B	  cell-­‐derived	  B	  cells	  were	  MZB	  and	  
only	  15	  –	  20%	  were	  FB	  (Figure	  4a	  lower	  row	  cytograms).	  
Spleens	  of	  mice	  reconstituted	  with	  FL-­‐derived	  pro-­‐B	  cells	  contained	  around	  5	  x	  
106	  B	  cells	  with	  no	  difference	  between	  cells	  cultured	  with	  or	  without	  stroma	  (figure	  
4b).	  In	  contrast,	  spleens	  of	  mice	  reconstituted	  with	  BM-­‐derived	  pro-­‐B	  cells	  contained	  
only	   0.5	   x	   106	   B	   cells	   irrespective	   of	   whether	   they	   had	   been	   propagated	   with	   or	  
without	   stroma.	   Thus	   FL-­‐derived	   pro-­‐B	   cells	   seem	   to	   be	   much	   more	   efficient	   at	  
reconstitution	  than	  BM-­‐derived	  cells.	  To	  test	  this	  latter	  conclusion	  more	  stringently,	  
we	   performed	   a	   competitive	   reconstitution	   experiment.	   Sub-­‐lethally	   irradiated	  
CD45.2	  C57BL/6	  Rag2-­‐deficient	  mice	  were	  reconstituted	  with	  a	  1:1	  mixture	  of	  5	  x	  106	  
CD45.2	  FL-­‐derived	  and	  CD45.1	  BM-­‐derived	  pro-­‐B	  cells.	  After	  8	  weeks,	  FACS	  analysis	  
of	  one	  representative	  mouse	  showed	  (Figure	  4c)	  that	  44%	  of	  total	  splenocytes	  were	  
CD19+	   and	   of	   these	   97.5%	   (42.9/44)	   were	   FL	   and	   only	   2.5%	   (1.1/4.4)	   were	   BM-­‐
derived.	   Thus	   FL-­‐derived	   pro-­‐B	   cells	   are	   superior	   to	   BM-­‐derived	   ones	   also	   in	  
competitive	   transplantation	   settings.	   Similar	   results	   were	   obtained	   in	   more	   than	  
three	   independent	   experiments.	   Taken	   together,	   the	   difference	   in	  MZB	   to	   FB-­‐cell	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ratio	   between	   FL	   and	   BM-­‐derived	   pro-­‐B	   cell-­‐reconstituted	  mice	   is	   most	   likely	   the	  
consequence	  of	  the	  different	  efficiency	  of	  B-­‐cell	  reconstitution.	  
Some	   time	  ago	   it	  was	   shown	   that	   adult	  HSC	   could	  be	   functionally	   converted	  
into	  FL	  HSC	  upon	  enforced	  expression	  of	  the	  Lin28B	  gene	  [26].	  More	  recently	  it	  was	  
also	   shown	   that	  Lin28B	   expressing	  BM-­‐derived	  pro-­‐B	   cells	   gained	  properties	  of	   FL-­‐
derived	   ones	   [27,	   28].	   To	   test	  whether	   Lin28B	   expression	   could	   also	   influence	   the	  
reconstitution	   efficiency,	   we	   introduced	   a	   MigR1	   retrovirus	   encoding	   Lin28B	   into	  
BM-­‐derived	  pro-­‐B	  cells.	  Then	  5	  x	  106	  Lin28B	  transduced	  and	  5	  x	  106	  non-­‐transduced	  
BM-­‐derived	   pro-­‐B	   cells	   were	   co-­‐transferred	   into	   sub-­‐lethally	   irradiated	   Rag2-­‐
deficient	  recipients.	  Representative	  FACS	  blots	  of	  spleens	  of	  such	  mice	  are	  shown	  in	  
supplementary	   figure	   2.	   Only	   2%	   CD19+	   cells	   were	   found	   and	   about	   half	   of	   these	  
expressed	   Lin28B	   (GFP).	   Thus	   the	   overall	   reconstitution	   was	   very	   poor	   and	   the	  
expression	  of	  Lin28B	  did	  not	   improve	   the	   in	  vivo	  B-­‐cell	   generating	  capacity	  of	  BM-­‐
derived	   pro-­‐B	   cells.	   However,	   practically	   all	   CD19+	   cells	   were	   IgM+	   and	   over	   80%	  
Lin28B+	   cells	   expressed	   CD5,	   thereby	   resembling	   B-­‐1	   B	   cells.	   Thus	  with	   respect	   to	  
CD5	  expression,	  we	  also	  found	  that	  Lin28B	  over-­‐expression	  was	  able	  to	  convert	  BM	  
pro-­‐B	  cells	  to	  ones	  phenotypically	  resembling	  FL	  cells.	  
	  
BM	  or	  FL	  pro-­‐B	  cell	  reconstituted	  Rag2-­‐deficient	  mice	  mount	  antibody	  response	  to	  a	  
T-­‐cell	  independent	  type	  2	  antigen	  
	  
To	  test	  whether	  the	  B-­‐cell	  compartments	  of	  Rag2-­‐deficient	  reconstituted	  mice	  
were	   functional,	   8	   weeks	   after	   cell	   transfer	   they	   were	   immunized	   with	   the	   T-­‐cell	  
independent	   antigen	   NIP-­‐Ficoll.	   Serum	   anti-­‐NIP	   titers	   were	   determined	   one	   week	  
before	  and	   two	  weeks	  after	   immunization.	  All	   reconstituted	  mice	  mounted	  a	  good	  
IgM	  anti-­‐NIP	  response	  with	  IgM	  titers	  comparable	  to	  those	  in	   immunized	  wild	  type	  
C57BL/6	  mice	   (Figure	  5a).	  On	   the	  other	  hand,	  mice	   reconstituted	  with	  BM-­‐derived	  
pro-­‐B	   cells	   showed	   a	   rather	   low,	   but	   still	   significant,	   IgG	   anti-­‐NIP	   response	   (Figure	  
5b).	  However,	  the	  IgG	  anti-­‐NIP	  response	  induced	  in	  mice	  reconstituted	  with	  FL	  pro-­‐B	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cells	  was	  as	  high	  or	  even	  higher	  than	  in	  wild	  type	  C57BL/6	  mice	  (Figure	  5b).	  Thus	  the	  
pro-­‐B	  cell	  reconstituted	  B-­‐cell	  compartments	  were	  functional.	  	  
The	   surprisingly	   high	   IgG	   anti-­‐NIP	   titers	   in	   FL	   pro-­‐B	   reconstituted	   mice	  
prompted	  us	  to	  determine	  their	  isotypes.	  As	  shown	  in	  figure	  5c,	  the	  IgG2A	  and	  IgG2B	  
anti-­‐NIP	   titers	  were	   low	  and	  comparable	   to	   those	   in	   immunized	  wild	   type	  C57BL/6	  
mice,	   whereas	   IgG1	   and	   IgG3	   titers	  were	   considerably	   higher.	   Although	   high	   IgG3	  
titers	   are	   observed	   in	   other	   T-­‐cell	   independent	   responses,	   switching	   to	   IgG1	   was	  
thought	  to	  be	  a	  highly	  T-­‐cell	  dependent	  phenomenon	  since	  it	  requires	  IL-­‐4	  [29-­‐31].	  In	  
addition	   to	   T	   cells,	   IL-­‐4	   was	   also	   reported	   to	   be	   produced	   by	  mast	   cells	   [32,	   33],	  
basophils	   [34],	   eosinophils	   [35]	   and	   group	   2	   innate	   lymphoid	   cells	   (ILC2)	   [36].	   The	  
generation	   of	   ILCs	   is	   largely	   dependent	   on	   IL-­‐7	   and	   consequently	   Rag2/common	  
gamma	  chain	  (Rag2cγ)	  double-­‐deficient	  mice	  are	  practically	  devoid	  of	   ILCs	  [37,	  38].	  
Therefore,	   we	   reconstituted	   Rag2	   and	   Rag2cγ	   double-­‐deficient	   mice	   with	   107	   FL-­‐
derived	  pro-­‐B	  cells	  and	  analyzed	  immune	  responses	  as	  described	  above.	  Results	  are	  
summarized	   in	  Figure	  6a-­‐d.	  Both	  Rag2	  and	  Rag2cγ	  double-­‐deficient	  mice	  showed	  a	  
very	  significant	  IgM	  and	  IgG	  anti-­‐NIP	  response	  (Figure	  6a	  and	  b),	  similar	  and/or	  even	  
higher	   than	   wild	   type	   C57BL/6	  mice.	  Moreover,	   both	   types	   of	   reconstituted	  mice	  
showed	  a	  very	  strong	   IgG1	  and	   IgG3	  anti-­‐NIP	   response	   (Figure	  6c	  and	  d).	  Thus	   the	  
IgG	  class	  switching	  observed	  in	  immunized	  reconstituted	  mice	  does	  not	  seem	  to	  be	  
regulated	  by	  ILCs.	  
	  
Reconstitution	   of	   the	   adaptive	   immune	   system	   in	   Rag2-­‐deficient	   mice	   by	   in	   vitro-­‐
propagated	  pro-­‐B	  cells	  and	  pro-­‐T	  cells	  
	  
Recently,	  we	  described	  a	  new	  stromal	  cell	  free	  culture	  system	  that	  allows	  the	  
long-­‐term	   propagation	   of	   pro-­‐T	   cells	   and	   showed	   that	   they	   could	   be	   used	   to	  
reconstitute	   the	   T-­‐cell	   compartment	   of	   T-­‐cell	   deficient	   mice	   [23].	   However,	   the	  
thymus	  of	  these	  reconstituted	  mice	  was	  rather	  poor	  at	  generating	  regulatory	  T	  cells	  
(Tregs)	   and	   mice	   developed	   a	   wasting	   disease	   preventable	   by	   the	   co-­‐transfer	   of	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mature	  Treg	  cells.	  We	  have	  since	  observed	  that	  co-­‐transfer	  of	  pro-­‐T	  cells	  and	  pro-­‐T	  
cells	   transduced	   with	   a	   retrovirus	   encoding	   Foxp3-­‐IRES-­‐GFP	   could	   overcome	   the	  
need	  of	  co-­‐transferring	  mature	  Tregs.	  Therefore,	  we	  tested	  whether	  the	  transfer	  of	  
in	  vitro	  propagated	  pro-­‐B	  cells	  together	  with	  a	  mixture	  of	  non-­‐transduced	  and	  Foxp3	  
transduced	  pro-­‐T	  cells	  (ratio	  4:1)	  could	  lead	  to	  the	  formation	  of	  an	  adaptive	  immune	  
system	   in	   Rag2-­‐deficient	  mice.	   In	   initial	   experiments,	   where	   pro-­‐B	   and	   pro-­‐T	   cells	  
were	  injected	  simultaneously,	  resulted	  in	  T	  but	  no	  B-­‐cell	  reconstitution	  (not	  shown).	  
We	   therefore	   performed	   sequential	   cell	   transfers.	   Sub-­‐lethally	   irradiated	   C57BL/6	  
Rag2-­‐deficient	  mice	  were	   first	   reconstituted	  with	   107	   FL-­‐derived	   pro-­‐B	   cells	   and	   4	  
weeks	   later	   injected	  with	  107	  pro-­‐T	  cells	  of	  which	  2.5	  x	  106	  were	  Foxp3+.	  Six	  weeks	  
after	   pro-­‐T	   cell	   transfer	   FACS	   analysis	   on	   peripheral	   blood	   revealed	   a	   significant	   B	  
and	   T-­‐cell	   reconstitution	   (data	   not	   shown).	   Because	   FL	   pro-­‐B	   cells	   partially	  
reconstituted	  the	  B-­‐cell	  compartment	  of	  B-­‐cell	  deficient,	  T-­‐cell	  proficient,	  µMt	  mice	  
(Supplementary	   Figure	   3a)	   and	   mounted	   a	   T-­‐cell	   dependent	   immune	   response	  
(Supplementary	   Figure	   3b	   and	   c)	  we	   tested	  whether	   the	   established	   B	   and	   T	   cells	  
were	  functional	  and	  could	  cooperate.	  Reconstituted	  mice	  were	  therefore	  immunized	  
with	  the	  T-­‐cell	  dependent	  antigen	  NIP-­‐OVA.	  Rag2-­‐deficient	  mice	  that	  only	  received	  
pro-­‐B	  cells	  were	  used	  as	  controls.	  The	  anti-­‐NIP	  titers	  were	  determined	  in	  sera	  taken	  
one	   week	   before	   and	   two	   weeks	   after	   immunization.	   No	   IgM	   or	   IgG	   anti-­‐NIP	  
response	   was	   observed	   in	   Rag2-­‐deficient	  mice	   reconstituted	   with	   pro-­‐B	   cells	   only	  
(Figure	  7a).	   In	  marked	  contrast,	  mice	  reconstituted	  with	  both	  pro-­‐B	  and	  pro-­‐T	  cells	  
mounted	   a	   strong	   IgM	   and	   relatively	   weak,	   but	   significant,	   IgG	   anti-­‐NIP	   response	  
(Figure	  7a).	  Thus	  the	  reconstituted	  adaptive	  immune	  system	  was	  functional.	  
To	   test	   the	   extent	   of	   reconstitution,	   mice	   were	   subjected	   to	   detailed	   FACS	  
analysis	  at	  10	  –	  14	  weeks	  after	  pro-­‐T	  cell-­‐transfer.	  A	  representative	  FACS	  staining	  of	  
the	  spleen	  of	  one	  of	  these	  mice	  is	  shown	  in	  figure	  7b.	  Splenocytes	  comprised	  10%	  B	  
cells,	  10%	  CD8	  T	  cells	  and	  20%	  CD4	  T	  cells.	  Moreover,	  around	  10%	  of	  the	  CD4	  T	  cells	  
expressed	  GFP	  indicating	  they	  were	  Tregs.	  To	  quantitate	  reconstitution,	  cell	  numbers	  
in	  the	  spleens	  of	  7	  individual	  mice	  14	  weeks	  after	  pro-­‐T	  cell	  transfer	  were	  assessed	  
and	  are	  shown	  in	  figure	  7c.	  Thus	  around	  3.5	  x	  106	  CD19+	  IgM+	  B	  cells,	  1	  x	  106	  CD8	  T	  
cells	   and	   3	   x	   106	   CD4	   T	   cells	   were	   found.	   Of	   the	   CD4	   T	   cells	   0.5	   x	   106	   were	   GFP	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positive	   indicating	   that	   they	  were	   derived	   from	   the	   Foxp3	   transduced	   pro-­‐T	   cells.	  
Thus	   the	   transfer	   of	   in	   vitro	   propagated	   pro-­‐B	   and	   pro-­‐T	   cells	   into	   Rag2-­‐deficient	  
mice	  resulted	  into	  reconstitution	  of	  a	  small,	  but	  functionally	  active,	  adaptive	  immune	  
compartment.	  
	   	  






Culture	  methods	  allowing	  the	  long-­‐term	  propagation	  of	  FL-­‐derived	  pro-­‐B	  cells	  
have	   been	   available	   for	   more	   than	   20	   years	   [20].	   However,	   to	   the	   best	   of	   our	  
knowledge,	   it	  has	  not	  yet	  been	  possible	  to	  grow	  BM-­‐derived	  pro-­‐B	  cells	   long-­‐term.	  
To	   our	   knowledge,	   this	   is	   the	   first	   report	   describing	   the	   long-­‐term	   in	   vitro	  
propagation	  of	  BM-­‐derived	  pro-­‐B	  cells	  and	  how	  these	  can	  be	  used	  to	  reconstitute	  a	  
functional	  immune	  system	  in	  immunodeficient	  recipient	  mice.	  Pro-­‐B	  cells	  from	  Pax5-­‐
/-­‐	  mice	  were	  previously	   shown	   to	  have	  multi-­‐lineage	  developmental	  potential	   [39].	  
We	   identified	   an	   equivalent	   B220+CD117+CD19-­‐NK1.1-­‐	   cell	   with	   lymphoid	   and	  
myeloid	  developmental	  potential	  in	  the	  BM	  of	  wild	  type	  mice,	  which	  we	  called	  EPLM	  
[22].	   Herein	  we	   show	   that	   BM-­‐derived	   EPLM	  when	   cultured	   on	   OP9	   stromal	   cells	  
plus	   IL-­‐7	   differentiated	   into	   pro-­‐B	   cells	   phenotypically	   expressing	   CD19,	   CD79a,	  
CD79b,	   Igll1	   and	  Vpreb1	   and	   genotypically	   having	   their	  DH-­‐JH	   genes	   rearranged.	   In	  
contrast	  to	  freshly	  isolated	  CD19+CD117+	  pro-­‐B	  cells,	  those	  derived	  from	  EPLM	  could	  
be	  cultured	   long-­‐term	   in	  vitro.	  Gene	  expression	  profiling	  did	  not	   reveal	  an	  obvious	  
explanation	   for	   this	   difference	   in	   growth	   capacity.	   One	   possibility	   is	   that	   this	   is	  
regulated	  via	  RNA	  modification	  or	  at	  the	  translational	  level	  [40-­‐42].	  
Up	  to	  now,	  the	  long-­‐term	  growth	  of	  pro-­‐B	  cells	  required	  co-­‐culture	  on	  stromal	  
cells,	  yet	   the	  specific	   role	  of	   stromal	  cells	   in	   this	  culture	  system	  was	  unknown.	  For	  
mouse	  B-­‐cell	  development,	  IL-­‐7	  and	  its	  receptor	  components	  play	  a	  crucial	  role	  [11,	  
12,	   43],	   best	   illustrated	   by	   the	   finding	   that	   mice	   deficient	   for	   IL-­‐7	   or	   its	   receptor	  
components	   are	  practically	   devoid	  of	   pro-­‐B	   cells.	   Additionally,	   pro-­‐B	   cell	   growth	   is	  
inhibited	  by	  an	  anti-­‐CD117	  antibody	   that	  blocks	   ligand	   (SCF)	  binding	   [18]	  and	  mice	  
deficient	   for	  FLT3L	  or	   its	   receptor	  have	  a	  strongly	   reduced	  pro-­‐B-­‐cell	   compartment	  
[15,	  16,	  19].	   Taken	   together,	   these	   results	   suggest	   that	   IL-­‐7,	   SCF,	   and	  FLT3L	  play	  a	  
crucial	  role	  in	  early	  B-­‐cell	  development.	  Indeed,	  we	  now	  show	  that	  EPLMs	  efficiently	  
grow	  and	  differentiate	   into	  pro-­‐B	  cells	  when	  cultured	   in	  the	  combined	  presence	  of	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IL-­‐7,	  SCF	  and	  FLT3L	  without	  contact	  with	  stromal	  cells.	  Thus	  pro-­‐B-­‐cell	  development	  
and	  proliferation	  is	  not	  absolutely	  dependent	  on	  stromal	  cells	  and	  indirectly	  suggests	  
that	   SCF	   and	   FLT3L	   can	   substitute	   for	   stromal	   cells.	   Moreover,	   we	   showed	   that	  
following	  withdrawal	   of	   IL-­‐7	   from	  both	   stromal	   cell	   and	   stromal	   cell	   free	   cultures,	  
propagated	   pro-­‐B	   cells	   efficiently	   differentiated	   into	   IgM+	   B	   cells.	   This	   finding	  
strongly	  supports	  our	  previous	  conclusion	  that	   IL-­‐7	  mediated	  proliferation	  of	  pro-­‐B	  
cells	   blocks	   their	   differentiation	   [44].	   Previously	   it	   was	   shown	   that	   pro-­‐B	   cells	  
maintained	  on	  stromal	  cells	  plus	   IL-­‐7	  could	   reconstitute	   the	  B-­‐cell	   compartment	  of	  
immunodeficient	  mice	   [20].	  Here	  we	  confirm	  and	  extend	  these	  findings.	  Thus	  both	  
FL	  and	  BM	  EPLM-­‐derived	  pro-­‐B	  cells	  propagated	  either	  on	  stromal	  cells	  or	   stromal	  
cell	  free	  could	  give	  rise	  to	  a	  significant	  B-­‐cell	  compartment	  upon	  transfer	  into	  Rag2-­‐
deficient	  mice.	  However,	  FL-­‐derived	  pro-­‐B	  cells	  were	  about	  40	  fold	  more	  efficient	  at	  
B-­‐cell	  reconstitution	  than	  their	  BM-­‐derived	  partners.	  	  
Recently	   it	  was	   shown	   that	   upon	   introduction	   of	   the	   Lin28B	   gene	   BM	   pro-­‐B	  
cells	  gained	  characteristics	  of	  FL-­‐derived	  pro-­‐B	  cells	  [27].	  Indeed,	  as	  we	  show	  herein,	  
in	   vitro	   propagated	  BM-­‐derived	  pro-­‐B	   cells	   transduced	  with	   the	  Lin28B	   gene	   could	  
generate	  CD5	  positive	  B	  cells	  in	  vivo.	  However,	  expression	  of	  the	  Lin28B	  gene	  did	  not	  
improve	  the	  in	  vivo-­‐reconstitution	  capacity	  of	  BM	  pro-­‐B	  cells.	  	  
Previously,	  a	   relative	  enlargement	  of	   the	  MZB	  compartment	  was	  observed	   in	  
mice	   with	   reduced	   B	   lymphopoiesis	   [45-­‐49]	   and	   it	   was	   hypothesized	   that	   in	   B-­‐
lymphopenic	   mice,	   newly-­‐formed	   B	   cells	   first	   fill	   up	   the	   MZB	   compartment.	   The	  
preferred	   reconstitution	  of	   the	  MZB	   compartment	   could	  be	  due	   to	   the	   specialized	  
environment	  within	  the	  splenic	  marginal	  zone.	  Additionally,	  the	  specificity	  of	  the	  BCR	  
might	   play	   a	   role	   in	   that	   only	   those	   B	   cells	  with	   a	   certain	   specificity	   home	   to	   the	  
marginal	  zone	  and	  once	  there,	  expand	  by	  proliferation	  [50].	  
When	   immunized	   with	   the	   T-­‐cell	   independent	   antigen	   NIP-­‐Ficoll,	   all	  
reconstituted	   mice	   mounted	   an	   anti-­‐NIP	   response	   indicating	   their	   B-­‐cell	  
compartments	  were	  functional.	  Mice	  reconstituted	  with	  BM-­‐derived	  pro-­‐B	  cells	  had	  
a	  slightly	   lower	  IgM	  anti-­‐NIP	  titer	  than	  wild	  type	  mice	  and	  showed	  a	  significant	  IgG	  
anti-­‐NIP	   response.	   However,	   this	   response	   was	   at	   least	   10	   fold	   lower	   than	   that	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observed	   in	  wild	   type	  mice.	   Thus	  BM	  pro-­‐B	   cell	   derived	  B	   cells	   are	   functional;	   the	  
lower	  anti-­‐NIP	  titer	  is	  most	  likely	  due	  to	  the	  relatively	  poor	  reconstitution	  capacity	  of	  
these	  pro-­‐B	  cells.	  In	  marked	  contrast,	  Rag2-­‐deficient	  mice	  reconstituted	  with	  FL	  pro-­‐
B	  cells	  mounted	  an	  IgM	  and	  IgG	  anti-­‐NIP	  response	  that	  was	  identical	  or	  even	  higher	  
than	   that	   observed	   in	   wild	   type	   mice.	   This	   finding	   might	   suggest	   that	   B	   cells	  
generated	   from	   fetal	   progenitors	   are	   the	   main	   anti-­‐NIP	   responders	   in	   a	   primary	  
immunization.	  In	  C57BL/6	  mice,	  the	  primary	  anti-­‐NIP	  antibodies	  are	  characterized	  by	  
the	  very	  high	  usage	  of	  λ1	  light	  chains	  [51].	  Similar	  dominance	  of	  λ1	  over	  κ	  light	  chain	  
was	   observed	   in	   the	   anti-­‐NIP	   response	   of	   pro-­‐B	   cell	   reconstituted	  mice	   (data	   not	  
shown).	  This	  finding	  might	  indicate	  that	  the	  B-­‐cell	  repertoires	  that	  mount	  an	  anti-­‐NIP	  
response	   in	   the	   pro-­‐B	   cell	   reconstituted	  mice	   are	   identical	   to	   those	   responding	   in	  
wild	  type	  mice.	  	  
A	   rather	   surprising	   finding	  were	   the	   high	   IgG1	   anti-­‐NIP	   titers	   observed	   in	   FL	  
pro-­‐B	   cell	   reconstituted	  mice.	   Since	   the	   class	   switch	   to	   IgG1	   is	   thought	   to	   be	   IL-­‐4-­‐
dependent	  and	  reconstituted	  mice	  were	  devoid	  of	  T	  cells,	  the	  question	  arose	  which	  
cell	   type	   was	   responsible	   for	   IL-­‐4	   production	   [29-­‐31].	   Given	   that	   pro-­‐B	   cell	  
reconstituted	   Rag2cγ	   double-­‐deficient	  mice,	  which	   are	   deficient	   in	   ILCs,	  were	   also	  
able	  to	  mount	  such	  a	  high	  IgG1	  response	  makes	  it	  rather	  unlikely	  that	  ILCs	  were	  the	  
source	   of	   IL-­‐4	   [37,	   38].	   This	   further	   suggests	   that	   mast	   cells,	   basophils	   and/or	  
eosinophils,	  which	   are	   also	   able	   to	   produce	   IL-­‐4	   [32-­‐35],	  might	   be	   involved	   in	   this	  
class	   switching.	   FL	   pro-­‐B	   cells	   were	   also	   able	   to	   reconstitute	   a	   functional	   B-­‐cell	  
compartment	  in	  T-­‐cell	  contatining,	  B-­‐cell	  deficient	  μMt	  mice	  (Supplementary	  Figure	  
3).	   This	   result	   might	   seem	   surprising	   given	   that	   the	   T-­‐cell	   compartments	   in	   these	  
mice	  may	  not	  be	  tolerant	  to	  mature	  B	  cells.	  	  
Recently	  we	   showed	   that	   pro-­‐T	   cells	   propagated	   in	   vitro	   under	   stromal	   free	  
conditions	  were	  able	  to	  reconstitute	  the	  T-­‐cell	  compartments	  of	  T-­‐cell	  deficient	  mice	  
[23].	  Here	  we	  show	  that	  the	  combined	  transfer	  of	  stromal	  cell	  free	  propagated	  pro-­‐B	  
and	   pro-­‐T	   cells	   into	   Rag2-­‐deficient	   mice	   results	   in	   the	   generation	   of	   a	   functional	  
adaptive	   immune	   repertoire	   capable	   of	   mounting	   a	   T-­‐cell	   dependent	   antibody	  
response.	   However,	   it	   should	   be	   noted	   that	   the	   pro-­‐T	   cell	   transfer	   has	   to	   be	  
performed	   2-­‐3	   weeks	   after	   the	   pro-­‐B	   cell	   reconstitution.	   When	   both	   populations	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were	   transferred	   together,	  mice	  showed	  a	  good	  T-­‐cell	  but	  no	  B-­‐cell	   reconstitution.	  
This	   finding	   might	   suggest	   that	   under	   such	   combined	   transfer	   conditions	   T	   cells	  
develop	  that	  are	  not	  tolerant	  to	  B	  cells	  and	  therefore	  eliminate	  them.	  
Overall	  the	  findings	  described	  here	  show	  that	  progenitor	   lymphocytes	  can	  be	  
readily	  propagated	  under	  stromal	  free	  conditions	  in	  vitro	  and	  that	  these	  cells	  can	  be	  
used	   to	   reconstitute	   mice	   with	   mature	   functional	   lymphocytes.	   Based	   on	   these	  
results	  the	  establishment	  of	  stromal	  cell	  free	  culture	  systems	  for	  human	  lymphocyte	  
progenitors	   might	   be	   of	   great	   interest	   since	   unlike	   stromal	   cell	   propagated	  
lymphocyte	  progenitors,	  stromal	  cell	  free	  propagated	  cells	  could	  be	  potentially	  used	  
for	  therapeutic	  purposes	  in	  patients	  with	  B	  and/or	  T-­‐cell	  deficiencies.	  
	   	  




Materials	  and	  Methods	  
	  
Mice	  
Female	  C57BL/6	  CD45.1	  and	  CD45.2,	  C57BL/6	  Rag2-­‐deficient	  [52],	  and	  C57BL/6	  
Bcl2	   transgenic	   mice	   [53]	   with	   5–8	   weeks	   of	   age	   were	   used.	   The	   appearance	   of	  
vaginal	   plugs	   was	   counted	   as	   day	   0	   of	   gestation	   and	   embryos	   were	   taken	   at	   day	  
E17.5.	   All	   mice	   were	   bred	   and	   maintained	   in	   our	   animal	   facility	   under	   specific	  
pathogen	  free	  conditions.	  Animal	  experiments	  were	  carried	  out	  within	   institutional	  
guidelines	   (authorization	   numbers	   1886	   and	   1888	   from	   Kantonales	   Veterinäramt,	  
Basel).	  
	  
Cell	  lines,	  cell	  culture,	  and	  supplements	  
The	   OP9	   stromal	   cell	   line	   [54]	   was	   cultured	   as	   a	   monolayer	   in	   IMDM	  
supplemented	  with	  2%	  FBS,	  5	  ×	  10−5	  M	  β-­‐mercaptoethanol,	  1	  mM	  glutamine,	  0.03%	  
w/v	  Primatone	  (Quest,	  Naarden,	  The	  Netherlands),	  and	  100	  U/mL	  penicillin.	  For	  pro-­‐
B	  cell	  culture,	  CD117+B220+CD19-­‐NK1.1-­‐	  cells	  were	  sorted	  from	  the	  FL	  or	  the	  femoral	  
BM	  of	  adult	  mice	  and	  cultured	  at	  104/ml	   in	  supplemented	  IMDM	  either	  on	  a	  semi-­‐
confluent	  layer	  of	  30	  Gy	  γ-­‐irradiated	  OP9	  stromal	  cells	  in	  the	  presence	  of	  100U/ml	  IL-­‐
7,	   or	   without	   stromal	   cell	   support	   but	   in	   the	   presence	   of	   100U/ml	   IL-­‐7,	   50ng/ml	  
FLT3L,	  and	  100ng/ml	  SCF.	   IL-­‐7	  was	  derived	   from	  culture	   supernatant	  of	   J558L	  cells	  
transfected	   with	   murine	   IL-­‐7	   cDNA.	   Polyhistidin-­‐tagged	   SCF	   was	   purified	   from	  
transfected	  Rosetta	  pLacI	  bacteria	  using	  Ni-­‐NTA-­‐agarose	  beads	  (Qiagen,	  Venlo,	  NL).	  
A	   vector	   expressing	   a	   human	   FLT3L-­‐Fc	   fusion	   protein	   was	   expressed	   in	   Chinese	  
hamster	   ovary	   cells.	   The	   supernatant	   was	   passed	   over	   a	   protein	   A-­‐Sepharose	   (GE	  
Healthcare,	  Chalfont	  St.	  Giles,	  GB)	  column	  in	  order	  to	  purify	  the	  protein.	  Pro-­‐T	  cells	  
were	  cultured	  as	  previously	  described	  [23].	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Antibodies,	  flow	  cytometry,	  and	  sorting	  
FITC-­‐,	  PE-­‐,	  allophycocyanin-­‐,	  or	  biotin-­‐labeled	  mAbs	  specific	   for	  CD117,	  B220,	  
CD19,	  NK1.1,	  IgM,	  Igκ,	  CD5,	  CD45.1,	  CD21,	  CD23,	  CD4,	  CD8α,	  and	  TCRβ	  were	  either	  
purchased	  from	  BD	  Biosciences	  (Franklin	  Lakes,	  NJ,	  USA)	  or	  eBiosciences	  (San	  Diego,	  
CA,	   USA),	   or	   purified	   from	   hybridoma	   culture	   supernatants	   according	   to	   standard	  
procedures.	   Staining	   of	   the	   cells	   was	   performed	   as	   described	   before	   [55].	   Flow	  
cytometry	  was	  done	  using	  a	  FACS	  Calibur	  (BD	  Biosciences)	  and	  data	  were	  analyzed	  
using	   the	   CellQuest	   Pro	   (BD	   Biosciences)	   or	   FlowJo	   Software	   (Treestar).	   For	   cell	  
sorting,	  a	  FACSAria	  IIu	  (BD	  Biosciences)	  was	  used	  (>98%	  purity).	  
	  
Transfer	  of	  cultured	  progenitor	  cells	  
Recipient	  mice	  were	  γ-­‐irradiated	  using	  a	  Cobalt	  source	  (Gammacell	  40,	  Atomic	  
Energy	  of	  Canada,	  Ltd)	  4	  hours	  prior	  to	  reconstitution.	  The	  indicated	  number	  of	  pro-­‐
B	  or	  pro-­‐T	  cells	  was	  then	  injected	  into	  the	  tail	  vein.	  
	  
Immunohistochemical	  analysis	  	  
To	   analyze	   pro-­‐B-­‐cell	   derived	   B-­‐cell	   localization	   in	   the	   spleen,	   the	   5µm	   snap	  
frozen	  and	  acetone-­‐fixed	  sections	  were	  incubated	  with	  FITC-­‐labelled	  anti-­‐IgM	  (clone	  
M41,	  self-­‐made),	  APC-­‐labelled	  anti-­‐IgD	  (clone	  1.19	  self-­‐made),	  and	  biotinylated	  anti-­‐
MOMA-­‐1	   (Vector,	   Burlingame,	   CA),	   which	   was	   revealed	   with	   PE-­‐conjugated	  
streptavidin	   (SouthernBiotech,	  Birmingham,	  AL).	   Confocal	  microscopy	   images	  were	  
taken	  with	  a	   LSM	  510	  Meta	   (Zeiss,	  Oberkochen,	  D)	   and	  analyzed	  using	   the	   ImageJ	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NIP-­‐specific	  antibody	  responses	  
Reconstituted	  mice	  were	   immunized	  subcutaneously	  with	  100μg	  NIP-­‐Ficoll	  or	  
NIP-­‐OVA	  in	  a	  1:1	  CFA	  emulsion.	  Serum	  IgM	  and	  IgG	  against	  NIP	  was	  analyzed	  at	  day	  
14	  using	  ELISA	  as	  described	  in	  [56].	  
	  
PCR	  analyses	  
The	   PCR	   conditions	   for	   amplifying	   DHJH	   rearrangements	   were	   described	  
elsewhere	   [4,	   6,	   57].	   The	   primers	   used	  were	   DH	   5´-­‐TTCAAAGCACAATGCCTGGCT-­‐3´	  
and	   JH3	   5´-­‐GTCTAGATTCTCACAAGAGTCCGATAGACCCTGG-­‐3´.	   Oligonucleotide	  
primers	   used	   for	   CD79a	   verification	   from	   pro-­‐B	   cDNA	   were	   5´-­‐
TGTTTGGGTCCCGGATGCCA-­‐3´	  and	  5´-­‐CACGCGGAGGTAAGTACCACA-­‐3´,	  for	  CD79b	  5´-­‐
TCTTCTCAGGTGAGCCGGTA-­‐3´	   and	   5´-­‐	   TATGGTTGGCGCTGTCACAT-­‐3´,	   for	   Igll1	   5´-­‐	  
AGTAGGACAGACTCTGGGCA-­‐3´	   and	   5´-­‐	   GGCTGACCTAGGATTGTGAGC-­‐3´,	   for	   Vpreb1	  
5´-­‐CTCCGGGTCCAAAGATACGAC-­‐3´	   and	   5´-­‐GCTCATAGCAACACCGCAGAA-­‐3´,	   and	   for	  




Statistical	   analysis	   was	   performed	   with	   Prism	   6.0g	   software	   (GraphPad	  
Software,	   Inc.).	   Two-­‐tailed	   unpaired	   Student	   t	   tests	   were	   used	   for	   statistical	  
comparisons.	  If	  not	  differently	  indicated,	  data	  are	  presented	  as	  mean	  values	  ±	  SEM	  
from	  three	  independent	  experiments	  (n.s.	  not	  significant	  or	  P	  >	  0.05,	  *	  or	  +	  P	  ≤	  0.05,	  
**	  or	  ++	  P	  ≤	  0.01,	  ***	  or	  +++	  P	  ≤	  0.001,	  ****	  P	  ≤	  0.0001).	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Summary	  table	  1	  
Differentially	  (Up	  and	  Down	  regulated)	  expressed	  genes	  identified	  from	  edgeR	  
analysis	   (FDR,	   adjusted	   p-­‐value < 0.05,	   fold	   change > 2)	   in	   sorted	   pro-­‐B	  maintained	  
on	  OP9	  plus	  IL-­‐7	  (n=3)	  versus	  pro-­‐B	  cells	  derived	  from	  sorted	  EPLM	  (n=3)	  cultured	  in	  
the	  same	  way.	  
Up-­‐regulated	  genes	  
ENTREZID	   SYMBOL	  
Fold	  
change	   FDR	  
69169	   Faim3	   6.22	   9.56E-­‐11	  
19699	   Reln	   4.76	   0.0001	  
677296	   Fcrl6	   4.64	   2.99E-­‐18	  
14368	   Fzd6	   4.52	   4.68E-­‐07	  
17199	   Mc1r	   4.39	   9.36E-­‐16	  
77717	   6030408B16Rik	   4.3	   4.59E-­‐10	  
12290	   Cacna1e	   4.19	   3.18E-­‐06	  
270893	   Tmem132e	   3.78	   3.13E-­‐14	  
12797	   Cnn1	   3.68	   7.54E-­‐09	  
214791	   Sertad4	   3.14	   6.97E-­‐05	  
217071	   Gm525	   2.99	   0.0007	  
22152	   Tubb3	   2.9	   2.34E-­‐20	  
72630	   Hspa12b	   2.85	   2.22E-­‐07	  
15019	   H2-­‐Q8	   2.82	   0.0037	  
110557	   H2-­‐Q6	   2.8	   0.004	  
211949	   Spsb4	   2.73	   2.22E-­‐05	  
94352	   Loxl2	   2.69	   5.34E-­‐06	  
14012	   Mpzl2	   2.67	   4.90E-­‐21	  
102371	   Myzap	   2.63	   0.0023	  
20497	   Slc12a3	   2.49	   1.87E-­‐07	  
278795	   Lrrc10b	   2.42	   0.0005	  
216881	   Wscd1	   2.42	   0.0003	  
12522	   Cd83	   2.4	   0.0236	  
56198	   Heyl	   2.4	   3.56E-­‐12	  
382077	   Ccdc33	   2.36	   2.26E-­‐05	  
20562	   Slit1	   2.36	   4.28E-­‐11	  
12931	   Crlf1	   2.34	   6.21E-­‐17	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  Muenchow	  et	  al.	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641361	   Pinlyp	   2.32	   5.05E-­‐05	  
26380	   Esrrb	   2.31	   0.0388	  
109272	   Mybpc1	   2.31	   7.35E-­‐05	  
67937	   Tmem59l	   2.27	   5.57E-­‐14	  
13421	   Dnase1l3	   2.27	   0.0011	  
12293	   Cacna2d1	   2.23	   6.97E-­‐05	  
13390	   Dlx1	   2.22	   7.99E-­‐07	  
12740	   Cldn4	   2.21	   0.0035	  
209195	   Clic6	   2.2	   0.0001	  
276829	   Smtnl2	   2.18	   9.36E-­‐16	  
16493	   Kcna5	   2.16	   0.0002	  
11941	   Atp2b2	   2.15	   0.0209	  
74050	   4921525O09Rik	   2.15	   0.0173	  
104174	   Gldc	   2.14	   9.00E-­‐15	  
386750	   Slitrk3	   2.13	   0.0025	  
11433	   Acp5	   2.08	   0.0016	  
22092	   Rsph1	   2.08	   8.77E-­‐05	  
12578	   Cdkn2a	   2.07	   0.0038	  
15375	   Foxa1	   2.07	   0.02	  
16528	   Kcnk4	   2.06	   0.0045	  
654812	   Angptl7	   2.06	   0.0054	  
64011	   Nrgn	   2.04	   0.0022	  
170757	   Eltd1	   2.04	   0.0099	  
15016	   H2-­‐Q5	   2.04	   0.0173	  
14786	   Grb7	   2.03	   9.48E-­‐10	  
235633	   Als2cl	   2	   0.0005	  
	   	   	   	  
	   	   	   	  Down-­‐regulated	  genes	  
ENTREZID	   SYMBOL	  
Fold	  
Change	   FDR	  
381310	   6330403A02Rik	   -­‐7.8	   1.62E-­‐07	  
20202	   S100a9	   -­‐3.97	   0.0013	  
226610	   Fam78b	   -­‐3.86	   8.25E-­‐07	  
12772	   Ccr2	   -­‐3.73	   2.39E-­‐06	  
20201	   S100a8	   -­‐3.63	   2.48E-­‐05	  
68713	   Ifitm1	   -­‐3.55	   0.0013	  
214968	   Sema6d	   -­‐3.51	   0.0055	  
12655	   Chil3	   -­‐3.41	   4.26E-­‐05	  
667034	   Pnp2	   -­‐3.26	   0.0066	  
241633	   Atp8b4	   -­‐3.21	   2.93E-­‐14	  
17523	   Mpo	   -­‐2.97	   0.0001	  
11801	   Cd5l	   -­‐2.72	   0.011	  
72310	   Nkg7	   -­‐2.62	   4.89E-­‐08	  
70602	   5730488B01Rik	   -­‐2.61	   9.08E-­‐07	  
von	  Muenchow	  et	  al.	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20305	   Ccl6	   -­‐2.53	   4.86E-­‐06	  
52024	   Ankrd22	   -­‐2.51	   0.0055	  
13733	   Emr1	   -­‐2.44	   0.0002	  
17105	   Lyz2	   -­‐2.43	   0.0008	  
12978	   Csf1r	   -­‐2.37	   0.0051	  
11639	   Ak4	   -­‐2.37	   0.0001	  
26368	   Ceacam9	   -­‐2.31	   0.0045	  
17476	   Mpeg1	   -­‐2.25	   0.0184	  
17381	   Mmp12	   -­‐2.22	   0.0055	  
13386	   Dlk1	   -­‐2.21	   0.0033	  
54373	   Prss16	   -­‐2.09	   0.0055	  
14728	   Lilrb4	   -­‐2.08	   0.0037	  
14425	   Galnt3	   -­‐2.08	   1.31E-­‐06	  
330671	   B4galnt4	   -­‐2.08	   0.0141	  
18022	   Nfe2	   -­‐2.05	   0.001	  
17474	   Clec4d	   -­‐2	   0.0007	  
	  
Summary	  table	  2	  
Gene	  expression	   level	   (log2	  FPKM)	  of	  44	  B-­‐cell	   related	  genes	   in	   sorted	  pro-­‐B	  
maintained	  on	  OP9	  plus	   IL-­‐7	   (n=3)	  and	  pro-­‐B	  cells	  derived	   from	  sorted	  EPLM	  (n=3)	  
cultured	  in	  the	  same	  way.	  
ENTREZID	   SYMBOL	   ProB.1	   ProB.2	   ProB.3	   EPLM.1	   EPLM.2	   EPLM.3	  
108655	   Foxp1	   12.17	   12.19	   12.19	   12.13	   12.15	   12.22	  
12043	   Bcl2	   8.40	   8.53	   8.54	   9.43	   9.32	   9.29	  
12145	   Cxcr5	   13.15	   13.15	   13.26	   12.81	   12.66	   12.61	  
12445	   Ccnd3	   15.96	   15.93	   15.84	   16.07	   16.03	   16.01	  
12478	   Cd19	   15.00	   14.95	   15.03	   14.80	   14.88	   14.95	  
12483	   Cd22	   11.68	   11.57	   11.44	   11.31	   11.42	   11.62	  
12484	   Cd24a	   16.72	   16.87	   16.79	   17.03	   17.12	   17.09	  
12494	   Cd38	   10.80	   10.86	   10.66	   9.95	   10.04	   10.57	  
12505	   Cd44	   11.70	   12.07	   11.82	   11.76	   11.86	   12.02	  
12515	   Cd69	   10.65	   10.62	   10.75	   10.89	   11.01	   11.16	  
12517	   Cd72	   13.13	   13.10	   13.06	   12.76	   12.93	   12.81	  
12518	   Cd79a	   15.65	   15.61	   15.62	   15.53	   15.48	   15.46	  
12520	   Cd81	   14.62	   14.87	   14.57	   14.37	   14.33	   14.52	  
13591	   Ebf1	   13.75	   13.86	   13.80	   13.74	   13.71	   13.73	  
14678	   Gnai2	   15.23	   15.24	   15.15	   15.15	   15.12	   15.13	  
15184	   Hdac5	   11.77	   11.67	   11.55	   11.59	   11.64	   11.64	  
15985	   Cd79b	   15.69	   15.61	   15.67	   15.55	   15.60	   15.66	  
16136	   Igll1	   17.04	   17.04	   17.14	   17.09	   17.06	   17.06	  
16197	   Il7r	   11.56	   11.73	   11.72	   11.42	   11.71	   11.70	  
von	  Muenchow	  et	  al.	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16364	   Irf4	   12.37	   12.43	   12.39	   11.85	   11.92	   11.89	  
16842	   Lef1	   13.93	   13.78	   13.90	   13.86	   13.80	   13.80	  
17060	   Blnk	   14.34	   14.27	   14.38	   14.43	   14.46	   14.42	  
17068	   Ly6d	   13.60	   13.18	   13.25	   13.26	   13.34	   13.44	  
17210	   Mcl1	   13.43	   13.45	   13.48	   13.27	   13.39	   13.48	  
17869	   Myc	   13.64	   13.48	   13.55	   13.76	   13.78	   13.75	  
18507	   Pax5	   14.11	   14.04	   13.96	   14.08	   14.04	   14.04	  
18707	   Pik3cd	   13.96	   13.90	   13.94	   13.93	   13.93	   13.92	  
18751	   Prkcb	   12.84	   12.89	   12.95	   12.91	   12.94	   12.99	  
18753	   Prkcd	   12.78	   12.84	   12.79	   12.82	   12.91	   12.90	  
18985	   Pou2af1	   15.55	   15.57	   15.52	   15.38	   15.41	   15.43	  
19265	   Ptprcap	   15.54	   15.36	   15.30	   15.40	   15.38	   15.35	  
19373	   Rag1	   11.92	   11.65	   11.89	   12.14	   12.13	   12.28	  
19374	   Rag2	   10.39	   10.40	   10.51	   11.03	   11.03	   10.93	  
20677	   Sox4	   13.50	   13.43	   13.24	   13.19	   13.19	   13.21	  
20877	   Aurkb	   13.46	   13.47	   13.43	   13.56	   13.59	   13.58	  
20963	   Syk	   13.71	   13.67	   13.67	   13.67	   13.69	   13.72	  
20969	   Sdc1	   12.18	   12.54	   12.11	   11.92	   12.04	   12.20	  
21423	   Tcf3	   14.72	   14.54	   14.49	   14.51	   14.47	   14.49	  
21673	   Dntt	   14.80	   14.79	   15.07	   15.20	   15.04	   14.98	  
22362	   Vpreb1	   16.55	   16.61	   16.64	   16.57	   16.52	   16.44	  
22778	   Ikzf1	   13.30	   13.35	   13.31	   13.17	   13.21	   13.24	  
240754	   Lax1	   11.67	   11.69	   11.82	   11.31	   11.30	   11.48	  
56458	   Foxo1	   12.38	   12.31	   12.34	   12.26	   12.24	   12.31	  
72049	   Tnfrsf13c	   11.83	   11.91	   11.80	   11.46	   11.51	   11.55	  
	  
	   	  




Figure	   1:	   Establishment	   of	   EPLM	   derived	   long-­‐term	   proliferating	   pro-­‐B	   cell	  
lines	  from	  BM	  and	  FL.	  (a)	  CD19	  and	  NK1.1	  expression	  by	  B220+CD117+	  C57BL/6	  BM	  
cells.	   (b)	   Growth	   of	   sorted	   BM-­‐derived	   CD19+B220+CD117+NK1.1-­‐	   cells	   and	   CD19-­‐
B220+CD117+NK1.1-­‐	  cells	  on	  OP9	  stromal	  cells	  plus	  IL-­‐7.	  (c)	  Comparison	  of	  the	  growth	  
of	  FL	  and	  BM-­‐derived	  CD19-­‐B220+CD117+NK1.1-­‐	  cells	  on	  OP9	  stromal	  cells	  plus	  IL-­‐7.	  
(d)	   B220,	   CD19	   and	   CD117	   expression	   by	   FL	   and	   BM-­‐derived	   CD19-­‐
B220+CD117+NK1.1-­‐	  cells	  cultured	  for	  12	  days	  on	  OP9	  stromal	  cells	  plus	  IL-­‐7.	  (e)	  RT-­‐
PCR	   expression	   analysis	   of	   Cd79a,	   Cd79b,	   Igll1,	   Vpreb1,	   and	   Actb	   by	   FL	   and	   BM-­‐
derived	  CD19-­‐B220+CD117+NK1.1-­‐	  cells	  cultured	  for	  12	  days	  on	  OP9	  stromal	  cells	  plus	  
IL-­‐7	  and	  DH-­‐JH	  rearrangement	  analysis	  of	  the	  same	  cells.	   	  




Figure	   2:	   Establishment	   of	   EPLM-­‐derived	   long-­‐term	   proliferating	   pro-­‐B	   cell	  
lines	  from	  BM	  and	  FL	  under	  stromal	  cell	  free	  conditions.	  (a)	  Growth	  of	  BM-­‐derived	  
CD19-­‐B220+CD117+NK1.1-­‐	  cells	  on	  OP9	  stromal	  cells	  plus	  IL-­‐7	  or	  in	  the	  presence	  of	  IL-­‐
7,	   SCF	   and	   FLT3L	   in	   absence	   of	   stromal	   cells.	   (b)	   Growth	   of	   FL-­‐derived	   CD19-­‐
B220+CD117+NK1.1-­‐	  cells	  on	  OP9	  stromal	  cells	  plus	  IL-­‐7	  or	  in	  the	  presence	  of	  IL-­‐7,	  SCF	  
and	  FLT3L	  in	  absence	  of	  stromal	  cells.	  (c)	  B220,	  CD19	  and	  CD117	  expression	  by	  BM-­‐
von	  Muenchow	  et	  al.	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derived	   CD19-­‐B220+CD117+NK1.1-­‐	   cells	   cultured	   on	   OP9	   stromal	   cells	   plus	   IL-­‐7	   or	  
cultured	   in	   the	   presence	   of	   IL-­‐7,	   SCF	   and	   FLT3L	   in	   absence	   of	   stromal	   cells	   for	   14	  
days.	  (d)	  B220,	  CD19	  and	  CD117	  expression	  by	  FL-­‐derived	  CD19-­‐B220+CD117+NK1.1-­‐	  
cells	  cultured	  on	  OP9	  stromal	  cells	  plus	  IL-­‐7	  or	  cultured	  in	  the	  presence	  of	  IL-­‐7,	  SCF	  
and	  FLT3L	  in	  absence	  of	  stromal	  cells	  for	  14	  days.	  (e)	  RT-­‐PCR	  expression	  analysis	  of	  
Cd79a,	   Cd79b,	   Igll1,	   Vpreb1	   and	   Actb	   by	   FL	   and	   BM-­‐derived	   CD19-­‐
B220+CD117+NK1.1-­‐	  cells	  cultured	  for	  14	  days	  in	  the	  presence	  of	  IL-­‐7,	  SCF	  and	  FLT3L	  
and	  the	  absence	  of	  stromal	  cells	  and	  DH-­‐JH	  rearrangement	  analysis	  of	  the	  same	  cells.	  
(f)	   µH	   and	   Igκ	   expression	   by	   BM-­‐derived	   CD19-­‐B220+CD117+NK1.1-­‐	   cells	   from	   Bcl2	  
transgenic	  mice	  cultured	  on	  OP9	  stromal	  cells	  plus	  IL-­‐7	  or	  cultured	  in	  the	  presence	  of	  
IL-­‐7,	  SCF	  and	  FLT3L	  (upper	  dot	  blots)	  and	  by	  the	  same	  cells	  cultured	  for	  3	  weeks	  as	  
described	  above	  and	  then	  for	  6	  days	  in	  plain	  medium.	  
	   	  




Figure	   3:	   Reconstitution	   of	   sub-­‐lethally	   irradiated	   CD45.2	   C57BL/6	   Rag2-­‐
deficient	  mice	  with	  CD45.1	   FL-­‐derived	  pro-­‐B	   cells	   propagated	  on	   stromal	   cells	   or	  
stromal	  cell	  free.	  (a)	  CD45.1,	  CD19,	  IgM	  and	  CD5	  expression	  on	  spleen	  cells	  and	  PerC	  
cells	  from	  CD45.2	  C57BL/6	  Rag2-­‐deficient	  mice	  8	  weeks	  after	  transfer	  of	  FL-­‐derived	  
pro-­‐B	   cells	   in	   vitro	   propagated	   on	   OP9	   stromal	   cells	   (left	   panel	   of	   dot	   blots)	   or	  
stromal	  cell	  free	  (right	  panel	  of	  dot	  plots).	  Also	  CD21	  and	  CD23	  expression	  on	  CD19	  
von	  Muenchow	  et	  al.	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gated	   spleen	   cells	   are	   shown.	   (b)	   Representative	   picture	   of	   a	   staining	   for	   IgM	  
(green),	   IgD	   (blue),	   and	  metallophilic	  macrophages	   (MOMA-­‐1	   in	   red)	   in	   spleens	   of	  
C57BL/6	  Rag2-­‐deficient	  mice	  8	  weeks	  after	  transfer	  of	  FL-­‐derived	  pro-­‐B	  cells	  in	  vitro-­‐
propagated	  on	  OP9	  stromal	  cells	  in	  the	  presence	  of	  IL-­‐7.	  
	   	  




Figure	   4:	   Reconstitution	   of	   sub-­‐lethally	   irradiated	   CD45.2	   C57BL/6	   Rag2-­‐
deficient	  mice	  with	  CD45.1	  BM-­‐derived	  pro-­‐B	  cells	  propagated	  on	  stromal	  cells	  or	  
stromal	  cell	  free.	  (a)	  CD45.1,	  CD19,	  IgM	  and	  CD5	  expression	  on	  spleen	  cells	  and	  PerC	  
cells	  from	  CD45.2	  C57BL/6	  Rag2-­‐deficient	  mice	  8	  weeks	  after	  transfer	  of	  BM-­‐derived	  
pro-­‐B	   cells	   in	   vitro	   propagated	   on	   OP9	   stromal	   cells	   (left	   panel	   of	   dot	   blots)	   or	  
stromal	  cell	  free	  (right	  panel	  of	  dot	  plots).	  Also	  CD21	  and	  CD23	  expression	  on	  CD19	  
gated	  spleen	  cells	  are	  shown.	  (b)	  Absolute	  numbers	  of	  CD19+	  IgM+	  cells	  found	  in	  the	  
spleens	   of	   Rag2-­‐deficient	   mice	   reconstituted	   with	   FL	   pro-­‐B	   propagated	   on	   OP9	  
stromal	   cells	   (n	   =	   15),	   FL	   pro-­‐B	   propagated	   stromal	   cell	   free	   (n	   =	   13),	   BM	   pro-­‐B	  
von	  Muenchow	  et	  al.	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propagated	  on	  OP9	  stromal	  cells	  (n	  =	  14),	  BM	  pro-­‐B	  propagated	  stromal	  cell	  free	  (n	  =	  
7).	  Mice	  were	  analyzed	  8	  –	  12	  weeks	  after	  pro-­‐B	  cell	  transfer.	  Student’s	  t	  test.	  Data	  
shown	  above	  are	  mean	  ±	  SEM.	  ns:	  not	  significant	  or	  P>	  0.05,	  **P	  ≤	  0.01	  and	  ****P	  ≤	  
0.0001.	   (c)	   CD19,	   IgM,	   and	   CD45.1	   expression	   from	  a	   spleen	   of	   a	   CD45.2	   C57BL/6	  
Rag2-­‐deficient	  mouse	  8	  weeks	  after	  transfer	  of	  5	  x	  106	  CD45.2	  FL-­‐derived	  pro-­‐B	  cells	  
and	  5	  x	  106	  CD45.1	  BM-­‐derived	  pro-­‐B	  cells.	  Both	  pro-­‐B	  cells	  were	  propagated	  stromal	  
cell	  free.	  
	   	  




Figure	   5:	   Anti-­‐NIP	   response	   of	   C57BL/6	   Rag2-­‐deficient	   mice	   reconstituted	  
with	  BM	  or	   FL	  pro-­‐B	   cells	  propagated	  either	  on	   stromal	   cells	  or	   stromal	   cell	   free	  
and	  immunized	  with	  NIP-­‐Ficoll	  at	  8	  weeks	  after	  cell	  transfer.	  Normal	  C57BL/6	  wild	  
type	  mice	  were	  used	  as	  controls	  and	  statistical	  significance	  compared	  to	  wild	  type	  is	  
indicated	  below	  after	  immunization.	  Titers	  were	  defined	  as	  the	  serum	  dilutions	  that	  
gave	   2	   times	   background	   OD	   values	   in	   the	   ELISA.	   Titers	   were	   determined	   in	   sera	  
taken	   1	   week	   before	   immunization	   (a	   and	   b	   open	   symbols)	   and	   2	   weeks	   after	  
immunization	  (a	  and	  b	  closed	  symbols)	  (a)	  IgM	  anti-­‐NIP	  titers.	  (b)	  IgG	  anti-­‐NIP	  titers.	  
(c)	   Anti-­‐NIP	   IgG	   subclass	   titers	   in	   the	   serum	  of	  mice	   reconstituted	  with	   FL-­‐derived	  
pro-­‐B	  cells	  and	  wild	  type	  mice.	  ns:	  not	  significant	  or	  P	  >	  0.05,	  *	  or	  +	  P	  ≤	  0.05,	  **	  or	  ++	  
P	  ≤	  0.01,	  ***	  or	  +++	  P	  ≤	  0.001,	  ****P	  ≤	  0.0001.	  *	  represents	  significance	  compared	  
to	  pre-­‐bleed.	  +	  represents	  significance	  compared	  to	  titer	  of	  wild	  type	  mice.	  Student’s	  
t	  test.	  n	  =	  5-­‐8.	  Data	  shown	  above	  are	  mean	  ±	  SEM.	  
	   	  




Figure	   6:	   Anti-­‐NIP	   response	   of	   C57BL/6	  wild	   type	  mice,	   Rag2-­‐deficient	   and	  
Rag2cγ	   double-­‐deficient	   mice	   reconstituted	   with	   FL	   pro-­‐B	   cells	   propagated	   on	  
stromal	  cells	  and	  immunized	  with	  NIP-­‐Ficoll	  8	  weeks	  after	  cell	  transfer.	  Titers	  were	  
defined	  as	  the	  serum	  dilutions	  that	  gave	  2	  times	  background	  OD	  values	  in	  the	  ELISA.	  
Titers	  were	   determined	   in	   sera	   taken	   1	  week	   before	   immunization	   (a	   and	   b	   open	  
symbols)	  and	  2	  weeks	  after	  immunization	  (a	  and	  b	  closed	  symbols)	  (a)	  IgM	  anti-­‐NIP	  
titers.	   (b)	   IgG	   anti-­‐NIP	   titers.	   (c)	   IgG1	   anti-­‐NIP	   titers.	   Sera	   from	   C57BL/6	   mice	  
immunized	  with	  NIP-­‐Ficoll	  or	  NIP-­‐OVA	  were	  used	  as	  positive	  controls.	  (d)	  IgG3	  anti-­‐
NIP	  titers.	  Sera	  from	  C57BL/6	  mice	  immunized	  with	  NIP-­‐Ficoll	  or	  NIP-­‐	  OVA	  were	  used	  
as	   positive	   controls.	   ns:	   not	   significant	   or	   P	   >	   0.05,	   *P	   ≤	   0.05,	   **P	   ≤	   0.01,	   ***P	   ≤	  
0.001,	  ****P	  ≤	  0.0001.	  Student’s	  t	  test.	  n	  =	  5-­‐8.	  Data	  shown	  above	  are	  mean	  ±	  SEM.	  
	   	  




Figure	   7:	   Reconstitution	   of	   C57BL/6	   Rag2-­‐deficient	   mice	   with	   in	   vitro	  
propagated	   pro-­‐B	   plus	   pro-­‐T	   cells.	   (a)	   IgM	   and	   IgG	   anti	   NIP	   response	   of	   C57BL/6	  
Rag2-­‐deficient	  mice	  reconstituted	  with	  pro-­‐B	  cells	  or	  pro-­‐B	  cells	  and	  pro-­‐T	  cells	  and	  
immunized	  with	  NIP-­‐OVA	  11	  weeks	  after	  pro-­‐B	  cell	  transfer	  (7	  weeks	  after	  pro-­‐T	  cell	  
transfer).	  Anti-­‐NIP	   titer	  was	  determined	  2	  weeks	   after	   immunization.	   Sera	   taken	  1	  
week	  before	  immunization	  were	  used	  as	  negative	  controls.	  (b)	  IgM,	  CD19,	  CD4,	  CD8,	  
TCRβ,	  and	  GFP	  expression	  by	  splenic	  cells	  derived	  from	  C57BL/6	  Rag2-­‐deficient	  mice	  
reconstituted	  with	  pro-­‐B	  cells	  and	  pro-­‐T	  cells.	  Analysis	  was	  performed	  12	  weeks	  after	  
pro-­‐T	  cell	  transfer.	  (c)	  Absolute	  numbers	  of	  CD4,	  CD4-­‐GFP	  and	  CD8	  T	  cells	  and	  CD19+	  
IgM+	  B	  cells	   found	   in	  the	  spleen	  of	  C57BL/6	  Rag2-­‐deficient	  mice	  reconstituted	  with	  
pro-­‐B	   and	   pro-­‐T	   cells.	   Analysis	   was	   performed	   at	   10-­‐14	   weeks	   after	   pro-­‐T	   cell	  
transfer.	  *P	  ≤	  0.05,	  **P	  ≤	  0.01,	  ***P	  ≤	  0.001,	  ****P	  ≤	  0.0001.	  Student’s	  t	  test.	  n	  =	  7-­‐
9.	  Data	  shown	  above	  are	  mean	  ±	  SEM.	   	  




Supplementary	  figure	  1:	  B-­‐cell	  related	  genes	  are	  equally	  expressed.	  Heatmap	  
illustrating	  gene	  expression	  level	  of	  B-­‐cell	  related	  genes	  (log2	  FPKM)	  in	  sorted	  pro-­‐B	  
maintained	  on	  OP9	  plus	  IL-­‐7	  (n=3)	  versus	  pro-­‐B	  cells	  derived	  from	  sorted	  EPLM	  (n=3)	  
cultured	  in	  the	  same	  way.	   	  




Supplementary	   Figure	   2:	   In	   vitro-­‐propagated	   BM-­‐derived	   pro-­‐B	   cells	  
transduced	  with	  the	  Lin28B	  gene	  could	  generate	  CD5	  positive	  B	  cells	  in	  vivo.	  CD19	  
and	  GFP	  expression	  and	  IgM,	  GFP	  and	  CD5	  expression	  on	  CD19-­‐gated	  cells	  recovered	  
from	  C57BL/6	  Rag2-­‐deficient	  mice	  reconstituted	  with	  5	  x	  106	  BM-­‐derived	  pro-­‐B	  cells	  
and	   5	   x	   106	   BM-­‐derived	   Lin28B-­‐IRES-­‐GFP	   transduced	   pro-­‐B	   cells.	   Analysis	   was	  
performed	  8	  weeks	  after	   cell	   transfer.	   This	  has	  been	  observed	   in	  more	   than	   three	  
independent	  experiments.	  
	  
	   	  




Supplementary	   Figure	   3:	   Reconstitution	   of	   the	   B-­‐cell	   compartment	   in	   µMt	  
mice	  with	  FL-­‐derived	  pro-­‐B	  cells.	  (a)	  CD19	  and	  IgM	  expression	  by	  µMT	  spleen	  cells	  8	  
weeks	   after	   transfer	   of	   FL-­‐derived	   pro-­‐B	   cells.	   (b)	   IgM	   anti-­‐NIP	   titer	   of	   µMT	  mice	  
immunized	  with	  NIP-­‐OVA	  at	  8-­‐10	  weeks	  after	  pro-­‐B	  cell	  transfer.	  Anti-­‐NIP	  titers	  were	  
determined	  in	  the	  sera	  taken	  2	  weeks	  after	  immunization.	  Sera	  taken	  1	  week	  before	  
immunization	   were	   used	   as	   negative	   controls.	   Sera	   from	   wild	   type	   C57BL/6	   mice	  
immunized	  with	  NIP-­‐OVA	  were	  used	  as	  positive	  controls.	  (c)	  IgG	  anti-­‐NIP	  titer	  of	  μMT	  
mice	  immunized	  with	  NIP-­‐OVA	  at	  8-­‐10	  weeks	  after	  pro-­‐B	  cell	  transfer.	  Anti-­‐NIP	  titers	  
were	  determined	  in	  the	  sera	  taken	  2	  weeks	  after	   immunization.	  Sera	  taken	  1	  week	  
before	   immunization	  were	  used	  as	  negative	  controls.	   Sera	   from	  wild	   type	  C57BL/6	  
mice	  immunized	  with	  NIP-­‐OVA	  were	  used	  as	  positive	  controls.	  *P	  ≤	  0.05,	  **P	  ≤	  0.01.	  




	   	  




Supplemental	  Materials	  and	  Methods	  
	  
Mice	  
Female	  C57BL/6	  µMT	  mice	  [1]	  with	  5–8	  weeks	  of	  age	  were	  used.	  All	  mice	  were	  
bred	  and	  maintained	   in	  our	  animal	  facility	  under	  specific	  pathogen	  free	  conditions.	  
Animal	   experiments	  were	   carried	   out	  within	   institutional	   guidelines	   (authorization	  
numbers	  1886	  and	  1888	  from	  Kantonales	  Veterinäramt,	  Basel).	  
	  
Plasmids	  
Complete	  murine	  Lin28b	  cDNA	  amplified	  from	  mouse	  FL	  cDNA	  was	  cloned	  into	  
the	  MigR1	  retroviral	  expression	  vector.	  MigR1	  was	  a	  gift	  from	  Warren	  Pear	  (Addgene	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a  b  s  t  r  a  c  t
CD19  plays  a  crucial  role  in  mature  B cell development  as  best  exempliﬁed  by  the  ﬁnding  that  CD19
deﬁcient  mice  have  severely  reduced  mature  B  cell  compartments  (Engel  et al., 1995;  Rickert  et al.,
1995).  In the present  study  we show  that the  transition  into  the  mature  B cell compartments  is heavily
dependent  on  the correct  amount  of CD19  expression.  Thus,  Nup-98–HoxB4  immortalized  hematopoietic
stem  cells  (HSCs)  over-expressing  CD19  show  upon  transplantation  an  impaired  pro/pre  B to  immature
B cell  transition  in  the  bone  marrow,  whereas  Nup-98–HoxB4  HSCs  expressing  a shRNA  that  down-up98–HoxB4
 cell development
election
modulates  CD19  expression  show  upon  transplantation  a  strongly  reduced  mature  B cell  compartment.
Overall  our  ﬁndings  indicate  that  too  high  CD19  expression  might  result  into  too  strong  BCR signaling  in
the  bone  marrow  and therefore  causing  negative  selection.  Too  low  CD19  expression  might  result  into
too little  BCR  signaling  and  thereby  preventing  the  B  cells  to  enter  the  mature  pool  (absence  of  positive
selection).
©  2014  Elsevier  B.V.  All  rights  reserved.. Introduction
Early stages of B cell development take place in the bone marrow
BM), whereas ﬁnal maturation takes place in the spleen. In order to
et selected into the long-lived mature compartment B cells have
o pass several crucial selection steps. Signal strength delivered
rom the B cell receptor (BCR) seems to be a key determination fac-
or. This is best exempliﬁed by the large number of BCR signaling
utants which show a developmental arrest [1]. Among the differ-
nt modulators of BCR signaling, CD19 is known as positive regula-
or. Together with CD21, CD81, and CD225 it builds the co-receptor
f the BCR [2,3]. CD19 has been shown to lower the threshold for B
ell activation and decreases the amount of anti-IgM that is needed
o induce DNA synthesis [4]. Upon ligation the conserved tyro-
ine residues of the cytoplasmic domain become phosphorylated
nd serve as binding sites for SH2 domains of regulatory proteins,
uch as PI3K and Lyn, thereby acting on BCR signaling [5,6]. How-
ver, also ligand-independent “tonic” signaling activity has been
escribed for CD19, which is possibly involved in generating a basal
Abbreviations: BCR, B cell receptor; FoB, follicular B cell; HSC, Hematopoietic
tem cell; Ig, Immunoglobulin; MZB, marginal zone B cell; OV.EX. CD19, over-
xpression of murine CD19; shCD19 shRNA, directed against murine CD19 mRNA.
∗ Corresponding author. Tel.: +41 61 267 16 31; fax: +41 61 695 30 70.
E-mail address: antonius.rolink@unibas.ch (A.G. Rolink).
ttp://dx.doi.org/10.1016/j.imlet.2014.01.011
165-2478/© 2014 Elsevier B.V. All rights reserved.signaling level essential for positive selection [7,8]. CD19 is a 95 kDa
transmembrane protein which is ﬁrst detectable on the surface of
DH–JH rearranged proB cells and remains expressed until terminal
differentiation into memory B cells. However, antibody secreting
plasma cells are CD19 negative [9,10]. CD19 deﬁcient mice have
been described previously [11,12]. In these mice early stages of B
cell development do not seem to be affected. However, they have
reduced numbers of mature B cells suggesting that the transition
from immature to mature B cells is impaired. Also mice over-
expressing human CD19 have been generated [13]. The earliest
stages of B cell development were not affected. However, beginning
with IgM+ immature cells in the bone marrow total numbers were
reduced. Taken together these ﬁndings strongly suggest that CD19
plays a crucial role in the transition of immature to mature B cells.
In the present study we analyzed this phenomenon in more
detail. In order to do this, we employed the recently described
method of immortalizing multipotent hematopoietic cells with a
retrovirus encoding a Nup98–HoxB4 fusion protein [14]. It was
shown that upon injection into irradiated recipients these cells are
able to give rise to all hematopoietic lineages [14]. We  introduced in
these cells a retrovirus encoding CD19 and a retrovirus containing
a shRNA directed against CD19. Our in vivo ﬁndings with these cells
show that early stages of B cell development are independent of the
CD19 expression level, whereas only those immature B cells that
express amounts of CD19 comparable to non-transduced B cells can
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. Materials and methods
.1. Mice
RAG-2 deﬁcient mice were ﬁrst described by Shinkai et al. and
D3 deﬁcient mice by Malissen et al. [15,16]. Animals were bred
nder pathogen-free conditions at the Center for Biomedicine at the
niversity of Basel. Experiments were carried out within institu-
ional guidelines with the permission of national or local authorities
permission numbers 1886 and 1888).
.2. Generation of Nup98–HoxB4 transduced multipotent
ematopoietic progenitor cells from CD3−/− mice
In order to “immortalize” hematopoietic progenitor cells of
D3−/− mice using the Nup98–HoxB4 construct we employed a
ethod, that was ﬁrst described by Sauvageau et al., and then
urther improved by Ruedl et al. [14,16,17]. In short, bone mar-
ow of mice, treated with 5-Fluorouracil (5-FU), was transduced
ith the pMYc-IP vector containing a Nup98–HoxB4 fusion protein.
fter selection for transduced cells using the puromycin-resistance
1 g/ml), cells were kept in culture by addition of 3% (v/v) IL-6
upernatant and 100 ng/ml stem cell factor (SCF).
.3. Cell lines and cell culture
The CD19 positive Abelson virus-transformed preB cell line
0E1 was grown in IMDM supplemented with 5 × 10−5 M ˇ-
ercaptoethanol, 1 mM glutamine, 0.03% (w/v) Primatone (Quest;
aarden, NL), 100 U/ml penicillin, 100 g/ml streptomycin and
% (v/v) fetal bovine serum [18]. Once established, Nup98–HoxB4
ransduced hematopoietic progenitor cells were maintained in the
ame IMDM,  additionally supplemented with 3% (v/v) IL-6 super-
atant and 100 ng/ml SCF.
.4. Plasmids
Complete murine CD19 cDNA was cloned into the
MigR1-IRES-GFP expression vector. To decrease CD19 pro-
ein levels a shRNA (5′-CTCGAGAAGGTATATTGCTGTTGACAGT
AGCGCTCTGAGAAGCTGGCTTGGTATTAGTGAAGCCACAGATGTAA
ACCAAGCCAGCTTCTCAGAATGCCTACTGCCTCGGAATTC-3′) tar-
eting the beginning of exon 2 of murine CD19 mRNA was
ntroduced into the MSCV-LTRmiR30-PIG (LMP) vector. The pMYc-
UP98–HOXB4-IP retroviral vector was a kind gift from Christiane
uedl and Klaus Karjalainen. Its preparation was described before
14].
.5. Transfection of phoenix-eco cells, retroviral transduction and
orting
Phoenix-eco cells were seeded in a 6-well plate at a density of
 × 105 cells/well one day before transfection [19]. Medium was
emoved and transfection conducted using FuGENE HD (Promega;
itchburg, WI)  according to the manufacturer’s protocol. Two  days
fter transfection virus supernatant was collected and used imme-
iately or stored at −80 ◦C. For transduction 106 target cells were
esuspended in virus supernatant and spun 3 h at 1157 rcf and 33 ◦C.
uccessfully transduced cells were sorted using a FACSAria (BD
iosciences; Franklin Lakes, NJ) to >98% purity..6. Transplantation
Mice were sublethally irradiated (4 Gy). For reconstitution
0 × 106 cells were injected intravenously. At around 5 weeks aftery Letters 160 (2014) 113–119
transfer, mice were sacriﬁced and organ cell suspensions were pre-
pared by mechanical disruption. Bone marrow was aspirated from
the femur.
2.7. Antibodies and ﬂow cytometry
Anti-CD19-PE (6D5) was purchased from BioLegend (San Diego,
CA). Anti-B220-PE (RA3-6B2), anti-CD23-PE (B3B4), anti-CD19-
PECy7 (1D3) and anti-Ter119-PE (TER-119) were purchased from
BD Bioscience (Franklin Lakes, NJ). Anti-B220 (RA3 6B2), anti-IgM
(M41) and anti-CD21 (7G6) were puriﬁed from hybridoma culture
supernatants on protein G-Sepharose columns (Pharmacia) as rec-
ommended by the supplier. Puriﬁed monoclonal antibodies were
conjugated with Alexa647 according to standard protocols. Stain-
ing of cells was performed as previously described [20]. Propidium
iodide (Sigma–Aldrich; St. Louis, MO)  was  used at 0.5 g/ml. Flow
cytometry was  performed using a FACSCalibur (BD Biosciences)
and data were analyzed using the FlowJo (Tree Star; Ashland, OR)
software.
3. Results
3.1. Generation of retroviruses encoding murine CD19 and
containing shRNA directed against CD19
To analyze the effect of the CD19 “dose” on various B subpop-
ulations, plasmids containing either complete murine CD19 cDNA
or a shRNA directed against CD19 mRNA were generated. In both
the sequence of interest was linked to a GFP cassette via an IRES
sequence. In this way  a broad spectrum of CD19 protein expres-
sion could be covered and easily monitored by GFP expression
levels. Functionality of the various retroviruses was  tested in vitro
through transduction of the CD19+ Abelson virus-transformed preB
cell line 40E1 [18]. Non-transduced cells expressed identical levels
of CD19 compared to the ones infected with the empty pMigR1
vector. In marked contrast, shRNA transduced GFP positive cells
expressed about an order of magnitude less CD19 on the surface
than non-transduced controls. On the other hand, GFP positive cells
transduced with CD19 encoding retrovirus expressed about a 10
fold higher level of CD19 than non-transduced cells (Fig. 1A).
3.2. Generation of multipotent progenitors expressing CD19 or
containing shRNA for down-modulation of CD19 expression
Recently it was shown that BM cells with hematopoietic
stem cell properties (hereafter called HSCs) can be immortalized
by expression of a Nup98–HoxB4 fusion protein [14]. Here we
employed these cells in order to analyze the effect of over and/or
under expression of CD19 on B cell development. Therefore, HSCs
from CD3 deﬁcient mice were generated [16]. In brief, BM cells
were collected from 5-Fluorouracil treated mice and cultured for 3
days in medium containing IL-6 and SCF. Thereafter, the cells were
infected with a retrovirus encoding a Nup98–HoxB4 fusion protein
and containing a puromycin resistance cassette. By day 3 of cul-
ture puromycin was added (1 g/ml). After 3 days of culture with
puromycin cells were harvested and infected with retroviruses con-
taining the empty pMigR1-IRES-GFP expression vector, the CD19
encoding pMigR1-IRES-GFP expression vector and the MSCV-LMP
vector containing the CD19 shRNA and GFP. After 4 days of recul-
ture GFP expressing cells were FACS sorted and further propagated.
As shown in Fig. 1B all transduced HSCs expressed robust levels of
GFP. Moreover, HSCs transduced with the CD19 encoding pMigR1-
IRES-GFP expression vector expressed homogenous levels of CD19
on their surface (Fig. 1B).
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Fig. 1. In vitro testing of the various retroviral constructs. (A) Left histograms: CD19 expression on non-transduced 40E1 cells (gray histogram), CD19 expression on shCD19






























transduced 40E1 cells (gray histograms), GFP expression by shCD19 transduced 40
broken line histogram). (B) GFP and CD19 expression by Nup98–HoxB4 HSCs from
ncoding retrovirus (middle dot plot) and OV.EX. CD19 encoding retrovirus (right d
.3. Decreased CD19 expression does not inﬂuence bone marrow
 cell development, whereas increased CD19 expression inhibits
he formation of IgM+ bone marrow cells
In order to test the potential inﬂuence of increased or decreased
D19 expression on B cell development in the BM,  the various trans-
uced HSCs were intravenously injected into sublethally irradiated
6 RAG-2 deﬁcient mice [15]. We  used B6 CD3 deﬁcient HSCs,
ince we showed previously that RAG deﬁcient mice reconstituted
ith wild type HSCs develop a fatal “syngeneic graft versus host
isease” due to an impaired regulatory T cell development [21].
At around 5 weeks after transfer B cell development in these
ice was analyzed. In the BM of all 3 groups over 90% of the cells
xpressed GFP indicating a very robust reconstitution (data not
hown). CD19 expression analysis on B220 positive cells revealed
hat expression was practically identical to wild type cells on those
erived from pMigR1 transduced HSCs (Fig. 2A and B). However,
220+ cells derived from CD19 shRNA transduced HSCs expressed
bout 4 fold less CD19 whereas those derived from CD19 over-
xpressing HSCs expressed about 4 fold more CD19 than wild type
ells (Fig. 2A and B). The percentage of B220+ IgM− cells found in the
M of pMigR1 and shCD19 transduced HSCs was  practically iden-
ical, whereas this percentage was slightly lower in the group that
eceived the CD19 over-expressing HSCs (Fig. 2C). Moreover, also
he percentage of B220+ IgM+ cells found in the groups transplanted
ith pMiR1 and shCD19 HSCs was practically identical (Fig. 2D).
owever, in the mice that received the CD19 over-expressing HSCs
he percentage of B220+ IgM+ cells was found to be 3–4 fold lower
Fig. 2D), indicating that too high expression of CD19 inhibits the
ransition from pro/pre to immature B cells in the BM.  We  alsols (solid line histogram) and GFP expression by OV.EX. CD19 transduced 40E1 cells
 deﬁcient mice transduced with pMigR1 (control) retrovirus (left dot plot) shCD19
t).
determined GFP expression levels by the various B cell subpopula-
tions in the BM and used Ter119 positive cells as controls. As shown
in Fig. 2E, Ter119+ cells (gray histogram), pro/pre B cells (dotted his-
togram) and immature B cells (solid line histogram) obtained from
the BM of recipients of shCD19 transduced HSCs, all expressed the
same level of GFP and thus strengthen the conclusion that down-
modulation of CD19 does not inﬂuence B cell development in the
BM.  However, BM immature B (solid line histogram) cells from
mice that received CD19 over-expressing HSCs seemed to express
lower amounts of GFP than pro/pre B (dotted line histogram) and
Ter119+ cells (gray histogram) (Fig. 2-F). This ﬁnding strengthens
the conclusion that CD19 over-expression inhibits the transition
from pro/pre to immature B cells in the BM.
3.4. CD19 over-expression and CD19 down-modulation severely
reduce the splenic B cell compartments
In the spleens of the mice reconstituted with the 3 differently
transduced HSCs over 70% of the cells expressed GFP indicating that
our HSCs also gave a very robust peripheral reconstitution (data
not shown). In marked contrast to the BM, CD19 expression by
B220+ splenic cells derived from CD19 over-expressing HSCs was
practically identical to CD19 expression by wild type B cells (gray
histogram) (Fig. 3-A and B). Moreover, also the majority (over 60%)
of B220+ splenic cells derived from the shCD19 HSCs expressed
CD19 levels comparable to their wild type controls and only 40%
expressed lower levels of CD19 (Fig. 3A and B). The latter cells
presumably represent immature (transitional) B cells. Likely as a
consequence of the counter selection of CD19 over- and under-
expressing cells, IgM+ IgD+ B cell numbers found in the spleen of
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Fig. 2. B cell development in the BM of sublethally irradiated B6 RAG-2 deﬁcient mice at 5 weeks after reconstitution with Nup98–HoxB4 HSCs transduced pMiR1 (control),
shCD19 and OV.EX. CD19 expressing retroviruses. (A) CD19 expression on B220+ BM cells derived from mice that received: left histogram pMigR1 transduced HSCs (gray
histogram WT  control and solid line histogram pMigR1 derived), middle histogram shCD19 transduced HSCs (gray histogram WT control, solid line histogram shCD19 HSCs)
and  right histogram OV.EX. CD19 HSCs (gray histogram WT control, solid line histogram OV.EX.CD19 HSCs). (B) Mean ﬂuorescence index (MFI) of CD19 expression on B220+
BM cells derived from the recipients of the various transduced HSCs. The MFI  of wild type controls is deﬁned as 1. N = 5– 6. (C) Percentage of B220+ IgM− cells in the BM of
the  recipients that received the various HSCs. (D) Percentage of B220+ IgM+ cells in the BM of the recipients that received the various HSCs. (E) GFP expression by Ter119+







ihCD19  HSCs. Upper histogram and dot plot show the gating strategy. (F) GFP exp
ine  histogram) and B220+ IgM+ BM cells (solid line histogram) derived from recipie
trategy.ice reconstituted with shCD19 HSCs and CD19 over-expressing
SCs were severely reduced in comparison to those that received
MigR1 transduced control HSCs (Fig. 3C). The observed reduction
n B cells affected the follicular (FoB) and marginal zone B (MZB)n by Ter119+ erythrocyte precursors (gray histogram), B220+ IgM− cells (broken
ansplanted with OV.EX. CD19 HSCs. Upper histogram and dot plot show the gatingcell compartments in a similar way  (Fig. 3D and E). Moreover, MZB
and follicular B cells found in the spleens of mice reconstituted with
shCD19 HSCs or CD19 over-expressing HSCs expressed similar lev-
els of CD19 than the corresponding cells derived from wild type
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Fig. 3. Splenic B cell compartments of sublethally irradiated B6 RAG-2 deﬁcient mice at 5 weeks after reconstitution with Nup98–HoxB4 HSCs transduced with pMiR1
(control), shCD19 and OV.EX. CD19 expressing retroviruses. (A) CD19 expression on B220+ spleen cells derived from mice that received: left histogram pMigR1 transduced
HSCs  (gray histogram WT control and solid line histogram pMigR1 derived), middle histogram shCD19 transduced HSCs (gray histogram wild type control, solid line histogram
shCD19 HSCs) and right histogram OV.EX. CD19 HSCs (gray histogram WT control, solid line histogram OV.EX. CD19 HSCs). (B) Mean ﬂuorescence index (MFI) of CD19 on
B220+ splenocytes derived from the recipients of the various transduced HSCs. The MFI  of wild type controls is deﬁned as 1. N = 5–6. (C) Total number of IgM+ IgD+ splenic B
cells  found in the recipients of the various transduced HSCs. (D) The total number of follicular B cells (FoB) is deﬁned as CD21intermediate CD23high found in the spleen of the
recipients of the various transduced HSCs. (E) The total number of marginal zone B cells (MZB) is deﬁned as CD21high CD23low found in the spleen of the recipients of the










che  spleens of recipients reconstituted with shCD19 transduced HSCs (upper histog
eft  hand histograms: CD19 expression by MZB  cells and follicular B cells (gray hi
istograms: GFP expression of MZB  cells (gray histograms), follicular B cells (solid l
gray histogram) mice (Fig. 3F). Furthermore, GFP expression lev-
ls were found to be strongly down-modulated in MZB  and in 70%
f the follicular B cells derived from shCD19 HSCs (Fig. 3D) and in
ll mature B cells derived from CD19 over-expressing HSCs (Fig. 3E)
n comparison to non-B cells derived from the same HSCs (Fig. 3F).
hus, only B cells that express CD19 levels similar to wild type B
ells were selected into mature B cell compartments. and recipients reconstituted with CD19 over-expressing HSCs (lower histograms).
ms represent CD19 expression on corresponding WT control B cells). Right hand
stogram) and non B cells (broken line histogram).
4. Discussion
CD19 is known to be a speciﬁc co-receptor of the BCR, but
its exact mode of action is not yet completely understood. Co-
ligation of CD19 and IgM was  shown to lower the threshold for
B cell activation and proliferation in response to IgM cross-linking
[4]. Therefore, CD19 is thought to act as a response regulator of
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sig. 4. Schematic representation of B cell development and the stages in which 
evelopmental process.
CR signaling. Additionally, CD19 has also been implicated in a
CR-independent tonic signaling activity via the CD19/Lyn/Vav
utonomous ampliﬁcation loop [7,22]. The very important role of
D19 in B cell development was best revealed by the generation
f a CD19 deﬁcient mouse [11,12]. In these mice early stages of B
ell development are non-altered however, mature B cell compart-
ents are severely reduced [11,12].
In the present study we analyzed if B cell development is also
nﬂuenced by lower or higher amounts of CD19 expression. In
rder to do so we employed the recently by Ruedl et al.  developed
up-98–HoxB4 immortalized HSC system [14]. These cells can be
asily propagated in vitro and very efﬁciently can give rise to all
ematopoietic lineages upon in vivo transplantation [14]. Moreover
enes can be relatively easy introduced in these HSCs by retroviral
nfection [this manuscript and unpublished data]. However, the
etroviral transduction efﬁciency is only around 5% as determined
y GFP expressing retroviral vectors [unpublished observation]. An
dvantage of this low efﬁciency is that most likely only a single
etroviral copy will be integrated per cell. Moreover, the expres-
ion of the introduced gene rather broad and can vary by two
rders of magnitude as determined by FACS (Fig. 1B). Furthermore,
he expression level of the gene of interest correlates very well
ith IRES GFP expression (Fig. 1B) i.e. low GFP expression–low
xpression of the gene of interest and high GFP expression–high
xpression of the gene of interest. Therefore the Nup-98–HoxB4
SCs form to our opinion a unique experimental system to address
he over-expression and silencing of genes in a quantitative way.
Here we used this system to analyze the effect of CD19 over-
xpression and CD19 silencing on B cell development. With respect
o CD19 over-expression we observed an inhibition of B cell devel-
pment already at the transition of pro/pre B to immature B cells
n the BM.  Thus, only the cells that expressed CD19 comparable to
ild type cells were able to enter the immature pool. This ﬁnd-
ng suggests that CD19 over-expression results into strong BCR
ignaling leading to deletion and/or receptor editing [23,24]. Our
nding that the pro/pre B cell compartment in the BM of the
ice that received CD19 over-expressing HSCs was  already sig-
iﬁcantly reduced (Fig. 2C) might indicate that immature B cells
ver-expressing CD19 cannot or only poorly be rescued by receptor
diting.
CD19 silencing does not seem to inﬂuence B cell development
n the BM.  However, CD19 silencing results in severely impaired
ature B cell formation. Therefore, CD19 down-modulation
nhibits the migration of immature B cells from the BM into the
pleen and/or due to too little BCR signaling might prevent the
ositive selection of splenic transitional B cells into the mature
ompartments. Currently we favor the second explanation and the
nding that a signiﬁcant fraction of CD21+ CD23+ cells express rel-
tively high levels of GFP and could be transitional B cells might
upport this hypothesis. However, deﬁnite experimental proof forover-expression and CD19 under-expression can result in an impairment of this
this is still missing. In Fig. 4 a schematic view of how CD19 over-
expression and silencing can inﬂuence B cell development is shown.
Taken together the data presented here show that not only the
mere expression of CD19 determines efﬁcient B cell development,
but that also the amount of CD19 expression plays a critical role in
this developmental process. Therefore, under physiological condi-
tions the regulation of CD19 expression is a crucial process. Since
it was shown that CD19 expression is under control of the tran-
scription factor Pax5, it might well be Pax5 activity regulates CD19
expression [25].
Finally, our ﬁndings that deregulated CD19 expression impairs
B cell development might suggest that B cell deﬁciencies in patients
could also be due to deregulated CD19 expression. The ﬁnding by
van Zelm et al., that null-mutations in the CD19 gene lead to an
antibody-deﬁciency syndrome in humans, supports this hypothesis
[26].
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In	  man,	  hematopoiesis	   generates	  approximately	  1011	   to	  1012	  new	  blood	  cells	  
daily	   in	   a	   healthy	   adult	   person	   [290].	   Between	   HSCs	   and	   mature	   blood	   cells,	  
progenitors	  undergo	  proliferation	  and	  progressive	  loss	  of	  developmental	  potentials.	  
The	   process	   is	   governed	   by	   the	   combined	   use	   of	   soluble	   and	   membrane-­‐bound	  
factors.	  Thereby	  a	  stable	  gene	  expression	  profile	  is	  established	  in	  progenitors,	  which	  
ultimately	   generates	   the	  unique	  phenotype	  of	   differentiated	   cells.	   The	   cells	   of	   the	  
adaptive	   immune	   system	   undergo	   substantial	   somatic	   rearrangements	   of	   gene	  
segments	   encoding	   their	   specific	   antigen-­‐recognizing	   receptors.	   Thereby,	   double-­‐
strand	   breaks	   are	   introduced	   in	   the	   DNA,	   parts	   are	   excised,	   and	   eventually	   the	  
ligated	  positions	  are	  complemented	  with	  non-­‐templated	  nucleotide	   insertions.	  The	  
enormous	  variety	  of	  receptor	  specificities	  emerging	  from	  the	  random	  recombination	  
of	   gene	   segments	   can	   obviously	   generate	   cells	   recognizing	   self-­‐structures.	  
Sophisticated	   selection	   processes	   together	   with	   peripheral	   tolerance	   mechanisms	  
ensure	  that	  the	  immune	  system	  fends	  off	  only	  foreign	  structures	  and	  intruders	  and	  is	  
tolerant	   to	   self.	   At	   the	   same	   time	   a	   sufficient	   number	   of	   lymphocytes	   bearing	  
differing	   antigen	   specific	   receptors	   needs	   to	   be	   maintained	   in	   order	   to	   ensure	  
adequate	  protection.	  Despite	   the	   incredible	  number	  of	  differentiation,	  maturation,	  
recombination,	   selection,	   and	   proliferation	   events	   occurring	   every	   day	   in	   the	  
hematopoietic	   system,	   there	  are	   relatively	   few	  mistakes	  made,	  at	   least	   if	   failure	   is	  
defined	  as	  its	  translation	  into	  an	  observable	  phenotype	  or	  disease	  setting.	  However,	  
due	  to	  its	  complexity	  the	  process	  needs	  tight	  control	  mechanisms.	  In	  our	  laboratory	  
we	   try	   to	   understand	   the	   molecular	   and	   cellular	   mechanisms	   and	   requirements	  
guiding	  mouse	  lymphocyte	  development.	  
About	  a	  decade	  ago,	  our	  laboratory	  identified	  a	  new	  bone	  marrow	  progenitor	  
cell	  population	  with	   lymphoid	  and	  myeloid	  potential.	  We	  called	  this	  cell	   the	  EPLM.	  
Now	  we	  have	   found	   subpopulations	  within	  EPLM	  and	   that	   the	  multipotentiality	  of	  
this	  population	   is	   reflected	   in	  a	  Ly6D+	  subpopulation,	  which	   is	   likely	   to	  contain	   the	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direct	   progenitor	   of	   CD19+	   committed	   pre-­‐BI	   B	   cells.	   IL-­‐7	   deficient	   mice	   display	   a	  
severe	  B-­‐cell	   defect	   and	   in	   these	  mutant	  mice,	   the	   Ly6D+	   subpopulation	   is	   absent.	  
We	   observed	   a	   complete	   rescue	   of	   early	   B-­‐cell	   populations	   in	   these	   mice	   when	  
excess	   Flt3L	   was	   provided.	   It	   is	   known	   that	   fetal	   B-­‐cell	   development	   is	   less	  
dependent	   on	   IL-­‐7	   [211]	   than	   that	   of	   adults	   and	   that	   the	   Flt3L	   cytokine	   is	   able	   to	  
drive	  IL-­‐7-­‐independent	  B	  lymphopoiesis	  [225].	  Therefore	  excess	  Flt3L	  might	  mediate	  
fetal-­‐like	  hematopoiesis	   in	  the	  absence	  of	  IL-­‐7.	  The	  fact	  that	  commitment	  to	  the	  B-­‐
cell	  lineage	  is	  possible	  without	  the	  assistance	  of	  IL-­‐7	  is	  in	  contrast	  to	  reports	  claiming	  
that	  IL-­‐7	  is	  a	  non-­‐redundant	  cytokine	  [2].	  We	  could	  also	  show	  that	  besides	  Flt3L,	  Bcl2	  
rescued	   to	   some	   extent	   the	   B-­‐cell	   defect	   of	   IL-­‐7-­‐deficient	   mice.	   Initial	   reports	  
describing	   this	  phenomenon	  might	  have	  missed	   the	  effect	  due	   to	   the	  omitted	   IL-­‐7	  
mediated	  proliferation	  [133,	  134].	  However,	  the	  recently	  described	  rescue	  of	  Stat5-­‐
deficient	  pro-­‐B	   cells	  by	   transgenic	  Bcl2	  expression	  agrees	  with	  our	  data	   [139].	   The	  
different	  mutant	   and	   transgenic	  mice	  we	  generated	   reveal	   that	   IL-­‐7	   acts	   as	   a	   pro-­‐
survival	   factor	  before	  commitment	  to	  the	  B-­‐cell	   lineage	  and	  following	  commitment	  
as	   a	   proliferative	   factor.	   In	   contrast,	   IL-­‐7	   is	   not	   an	   absolute	   requirement	   for	   B-­‐cell	  
commitment.	   Therefore	   we	   propose	   that	   no	   instructive	   signal	   is	   necessary	   for	  
commitment	   of	   progenitor	   cells	   to	   the	  B-­‐cell	   lineage.	   The	  B-­‐cell	   fate	  might	   be	   the	  
“default”	   course	   that	   is	   adopted	   if	   no	   other	   lineage	   option	   is	   assigned	   by	  
commitment	   signals	   for	   example	   via	   Notch1	   [104].	   Thereby,	   in	   IL-­‐7KO	   x	   Flt3L	  
transgenic	  mice,	   the	   immense	  number	  of	   lymphoid	  progenitor	   cells	   is	   sufficient	   to	  
generate	  detectable	  numbers	  of	  committed	  B	  cells.	  
We	   also	   developed	   in	   vitro	   cell	   culture	   systems	   for	   the	   long-­‐term	   growth	   of	  
functional	  mouse	  progenitor	  T	  as	  well	  as	  B	  lymphocytes.	  We	  were	  able	  to	  overcome	  
the	  need	  for	  supporting	  stromal	  cell	  layers	  by	  adding	  soluble	  or	  plate-­‐bound	  factors,	  
which	   we	   think	   are	   indispensable	   for	   the	   propagation	   of	   early	   lymphocyte	  
progenitors.	   In	   this	  way	  we	  circumvent	  co-­‐culture	  systems	  where	   the	  strength	  and	  
duration	   of	   signal	   delivery	   is	   difficult	   to	   control.	  We	   already	   used	   the	   stromal	   cell	  
free	  pro-­‐T	  cell	   culture	  system	  successfully	  and	  could	  show	  that	   the	   transition	   from	  
DN3	  to	  DP	  thymocytes	  is	  strictly	  dependent	  on	  Delta-­‐like	  4	  induced	  Notch	  signaling	  
[291].	  Thereby	  we	  could	  confirm	  previously	  generated	  results,	  which	  were	  obtained	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in	  a	  stromal	  cell	  based	  culture	  system	  [292].	  Moreover	  using	  stromal	  cell	  free	  grown	  
pro-­‐T	  cells,	  we	  were	  able	  to	   investigate	  the	  epigenetic	  profile	  of	  early	  mouse	  T-­‐cell	  
development	   without	   contamination	   of	   transcripts	   from	   stromal	   cells	   [293].	   This	  
system	   mimics	   the	   bone	   marrow	   or	   thymus	   environment,	   respectively,	   in	   a	   way	  
making	   the	   co-­‐culture	  with	   stromal	   cells	   redundant.	   The	   successful	   propagation	  of	  
progenitor	   cells	  without	   stromal	   cell	   support	   promotes	   the	   concept	   that	   lymphoid	  
development	  is	  not	  strictly	  dependent	  on	  stromal	  cells.	  It	  all	  depends	  on	  the	  factors	  
provided	   by	   the	   stromal	   cells	   and	   not	   on	   close	   proximity	   to	   the	   stromal	   cell	   body	  
itself.	   One	   further	   indication	   for	   this	   is	   the	   presence	   of	   all	   normal	   stages	   of	   B-­‐cell	  
development	   in	   the	   secondary	   lymphoid	  organs	  of	   IL-­‐7	   transgenic	  mice	   [294].	   This	  
suggests	   that	  when	   IL-­‐7	   is	   readily	   available	   and	   no	   longer	   a	   limiting	   factor	   for	   the	  
expansion	  of	  progenitor	  B	  cells,	  B-­‐cell	  development	  can	  happen	  everywhere.	  
We	  aim	  to	  use	  these	  stromal	  cell	  free	  culture	  systems	  in	  the	  future	  to	  address	  
the	  requirements	  for	  human	  lymphocyte	  development	  as	  well	  as	  to	  expand	  human	  
T-­‐	   and	   B-­‐cell	   progenitors.	   Potentially,	   these	   cells	   could	   be	   used	   to	   treat	  
lymphocytopenias	   caused	   for	   example	   by	   HIV	   infection	   or	   after	   chemo-­‐	   or	  
radiotherapy.	   Since	   these	   progenitors	   would	   originate	   from	   expansion	   cultures	  
without	  stromal	  cell	  support,	  they	  are	  much	  more	  likely	  to	  be	  approved	  for	  human	  
therapy.	   However,	   first	   attempts	   using	   CD34+	   cord	   blood	   derived	   progenitor	   cells	  
were	   not	   successful.	   The	   differential	   growth	   capacities	   of	   human	   and	   mouse	  
lymphocyte	  precursors	  might	  be	  attributed	  to	  the	  different	  life	  spans	  of	  mouse	  and	  
man.	  In	  mice,	  development	  as	  well	  as	  aging	  is	  faster	  compared	  to	  the	  human	  system.	  
For	  example	  the	  temporal	  maturation	  of	  the	  MZB	  cells	  in	  humans	  is	  only	  completed	  
after	  1-­‐2	  years,	  whereas	  in	  rodents	  it	  takes	  only	  2-­‐3	  weeks	  [295].	  Also	  the	  turnover	  
rate	  of	  naïve	  T	  cells	   is	  much	  faster	   in	  mice	  than	  in	  man	  [296].	   It	  might	  also	  be	  true	  
that	   hematopoietic	   progenitor	   cells	   from	   humans	   grow	   much	   slower	   in	   tissue	  
culture.	   Also	   in	   a	   recent	   publication	   by	   Kraus	   et	   al.	   the	   authors	   had	   to	   pass	   the	  
human	   progenitor	   cells	   through	   different	   cytokine	   cocktails	   to	   get	   them	   to	  
proliferate	  and	  to	  differentiate	  [297].	  
The	  striking	  difference	  in	  reconstitution	  capacity	  of	  bone	  marrow	  versus	  fetal	  
liver	  derived	  pro-­‐B	   cells,	   irrespective	  of	  whether	   they	  were	  grown	  with	  or	  without	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stromal	   cell	   support,	   is	   still	   an	   unresolved	   phenomenon.	   Only	   few	   differentially	  
expressed	  genes	  have	  been	   identified	   that	   characterize	   fetal	   versus	  bone	  marrow-­‐
derived	   precursors.	   One	   gene	   product	   we	   found	   differentially	   expressed	   amongst	  
fetal	  liver	  and	  bone	  marrow	  derived	  pro-­‐B	  as	  well	  as	  pro-­‐T	  cells	  was	  the	  transcription	  
factor	  Sox13.	  Sox13	  is	  a	  very	  interesting	  gene,	  because	  there	  are	  some	  clues	  that	  link	  
it	   to	   fetal	   hematopoiesis.	   Sox13	   has	   been	   shown	   to	   mediate	   the	   αβ-­‐γδ	   lineage	  
decision	   in	   the	   thymus	   [298]	   and	   γδ	   T	   cells	   are	   one	   of	   the	   innate-­‐like	   lymphocyte	  
subsets	  generated	  in	  distinct	  waves	  mainly	  during	  embryogenesis.	  When	  Sox13	  was	  
first	   cloned	   and	   it’s	   expression	   tracked	   in	   the	   mouse	   embryo	   it	   was	   found	   to	   be	  
expressed	  in	  the	  arterial	  walls	  of	  E13.5	  embryos	  [299].	  From	  E11.5	  onward	  the	  AGM	  
region,	   in	   particular	   the	   ventral	   wall	   of	   the	   dorsal	   aorta,	   is	   the	   first	   site	   where	  
definitive	   HSCs	   autonomously	   arise	   [300].	   Therefore	   a	   closer	   investigation	   of	   the	  
AGM	  region	  for	  Sox13	  expression	  might	  be	  worthwhile,	  even	  though	  Sox13	  remains	  
expressed	  in	  arterial	  walls	  even	  after	  birth	  indicating	  a	  more	  general	  requirement	  for	  
Sox13	   in	   angiogenesis	   [299].	   Unfortunately,	   a	   later	   study	   investigating	   the	  
spatiotemporal	   expression	   pattern	   of	   Sox13	   protein	   during	   mouse	   embryonic	  
development	  did	  not	  describe	  expression	   in	   the	   arteriovascular	   system	   [301].	  Also	  
early	   fetal	   thymocytes	   expressed	  high	   levels	   of	   Sox13	   and	   it	  was	   also	   found	   to	   be	  
expressed	  in	  a	  day	  18	  thymocyte	  cell	  line	  [299].	  
More	   recently,	   Sox13	   has	   been	   implicated	   in	   fine-­‐tuning	   of	   the	   Wnt/Tcf	  
pathway	  by	  directly	  interacting	  with	  the	  transcription	  factor	  Hhex	  (hematopoietically	  
expressed	   homeobox)	   in	   the	   early	   embryo	   [302].	   Hhex,	   in	   turn,	   is	   an	   important	  
modulator	   of	   the	   earliest	   stages	   of	   definitive	   hematopoiesis	   [303].	   Hhex	   itself	   has	  
already	  been	  shown	  to	  be	  a	  downstream	  target	  of	  Sox17,	  which	  is	  a	  close	  relative	  of	  
Sox13	  and	  an	  important	  regulator	  of	  fetal	  liver	  derived	  HSCs	  [173,	  304].	  In	  addition	  
to	   that,	   Hhex	   determined	   cKit	   expression	   in	   an	   immature	   T-­‐cell	   leukemia	   mouse	  
model	   [305].	   In	   line	   with	   this	   observation,	   ectopic	   expression	   of	   Sox13	   in	   bone	  
marrow	  derived	  pro-­‐B	  cells	  results	  in	  increased	  expression	  of	  cKit	  in	  vitro.	  Yet	  in	  vivo	  
reconstitution	   capability	   was	   still	   poor	   (unpublished	   observation).	   Nevertheless,	   it	  
might	  be	  interesting	  to	  investigate	  a	  potential	  downstream	  effect	  of	  Sox13,	  acting	  on	  
cKit	  expression	  via	  Hhex.	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At	   least	   in	  our	  hands,	  none	  of	  the	  genes	  we	  found	  differentially	  expressed	   in	  
fetal	   liver	   and	   bone	   marrow	   derived	   precursors	   could	   confer	   the	   quantitative	  
reconstitution	  competence	  of	  fetal	  liver	  derived	  pro-­‐B	  cells	  if	  they	  were	  expressed	  in	  
bone	  marrow	  derived	  pro-­‐B	  cells.	  For	   instance,	  when	  we	  transduced	  bone	  marrow	  
derived	  pro-­‐B	   cells	  with	   Lin28b	  we	  did	  not	   see	   increased	   reconstitution.	  However,	  
the	   B-­‐1	   B	   cell	   compartment	   was	   overly	   represented	   suggesting	   therefore,	   that	  
Lin28b	   expression	   in	   bone	   marrow	   derived	   pro-­‐B	   cells	   conferred	   on	   them	   some	  
qualities	   of	   fetal	   progenitors.	   It	   might	   well	   be	   that	   the	   superior	   reconstitution	  
capacity	   of	   fetal	   liver	   derived	   pro-­‐B	   cells,	   as	   well	   as	   their	   biased	   lineage	   fate,	   are	  
consequences	   of	   independent	   transcriptional	   programs.	   Clearly	   the	   exceptional	  
features	  of	  fetal	  liver	  derived	  progenitors	  are	  the	  consequence	  of	  a	  complex	  network	  
of	  exclusively	  expressed	  or	  regulated	  factors,	  which	  largely	  remain	  to	  be	  elucidated.	  
Our	   stromal	   cell	   free	   cell	   culture	   systems	   for	  progenitor	  B	  and	  T	   cells	   are	  an	  
ideal	   tool	   to	   closely	   investigate	   the	   cues	  mediating	   the	  divergent	   features	  of	   adult	  
bone	  marrow	  and	  fetal	  liver	  derived	  lymphocyte	  development.	  Next	  we	  are	  planning	  
to	   analyze	   the	   VH	   repertoires	   of	   fetal	   liver	   and	   bone	  marrow-­‐derived	   progenitors.	  
Due	  to	  the	  absence	  of	  Dntt	  gene	  expression,	  encoding	  for	  the	  TdT	  enzyme,	  fetal	  liver	  
derived	  lymphocytes	   lack	  non-­‐germline	  nucleotide	  additions	  at	  the	  DH-­‐JH	  and	  VH-­‐DH	  
junctions	  of	  the	  IgH	  chain	  [196,	  306-­‐308].	  This	  strongly	  restricts	  CDR3	  diversity	  and	  
consequently	   the	  B-­‐cell	   repertoire.	   It	   is	  possible,	   that	   the	  divergent	   repertoire	   in	  B	  
cells	   is	   one	   of	   the	   main	   determinants	   instructing	   a	   different	   developmental	   fate	  
characteristic	   of	   fetal	   progenitors.	   An	   indication	   for	   this	   is	   the	   elegant	   experiment	  
performed	  by	  Lam	  et	  al.,	  where	  they	  showed	  that	  replacing	  an	  “adult”	  with	  a	  “fetal”	  
BCR	  conferred	  fetal	  properties	  to	  adult	  cells	  [202].	  This	  supports	  our	  finding	  that	  the	  
fetal	  and	  adult	  properties	  of	  progenitors	  are	  cell	  intrinsic.	  
Besides	   the	   above	   experiments,	   we	   also	   successfully	   employed	   the	   culture	  
system	  recently	  developed	  by	  Ruedl	  et	  al.	  [3].	  Bone	  marrow	  cells	  with	  hematopoietic	  
stem	   cell	   properties	   can	   be	   immortalized	   by	   expression	   of	   a	   Nup98-­‐HoxB4	   fusion	  
protein.	   Under	   appropriate	   culture	   conditions,	   they	   can	   be	   expanded	   and	   readily	  
manipulated	   in	   vitro.	   At	   the	   same	   time	   they	   retain	   complete	   hematopoietic	  
reconstitution	   capability	   upon	   injection	   into	  myelo-­‐ablated	   recipient	   mice.	   Indeed	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we	  used	  these	  stem	  cells	  to	  address	  the	  effect	  of	  varying	  CD19	  expression	  levels	  on	  
the	  development	  of	  B	  cells	  [309].	  The	  CD19	  molecule	  is	  part	  of	  the	  BCR	  co-­‐receptor	  
complex	  and	   is	  CD19	  known	   to	  act	  as	  a	  positive	   regulator	  of	  BCR	  signaling	  activity	  
[11].	  From	  several	  mutants	  affecting	  BCR	  signaling	  it	  is	  known	  that	  B	  cells	  depend	  on	  
a	  certain	  signal	  strength	  range	  for	  developmental	  progression	  into	  the	  mature	  B-­‐cell	  
compartment	  [4,	  100,	  310-­‐312].	  This	  is	  a	  possible	  explanation	  for	  the	  developmental	  
block	  observed	  when	  either	  higher	  or	  lower	  than	  normal	  CD19	  levels	  were	  expressed	  
[309].	  These	  might	  mimic	  an	  autoreactive	  or	  not	   fully	   functional	  BCR,	   respectively,	  
resulting	   in	   failure	   of	   positive	   selection.	   That	   CD19	   is	   able	   to	   modulate	   the	  
responsiveness	   of	   cells	   to	   mitogenic	   stimuli	   has	   already	   been	   shown	   in	   CD19	  
transgenic	  and	  CD19	  deficient	  mice	  [272,	  279].	  Wild	  type	  B-­‐1	  B	  cells	  express	  around	  
50%	  more	   CD19	  molecules	   on	   their	   cell	   surface	   compared	   to	   B-­‐2	   B	   cells	   [95]	   and	  
their	  development	  depends	  on	   the	  amount	  of	  CD19.	  This	   is	  best	   illustrated	  by	   the	  
dramatic	   loss	   of	   B-­‐1	   B	   cells	   in	   CD19-­‐deficient	  mice	   and	   their	   increase	   in	   hCD19tg	  
mice	  [95,	  272,	  280].	  In	  our	  system,	  we	  could	  not	  specifically	  address	  the	  role	  of	  CD19	  
in	  B-­‐1	  B-­‐cell	  development	  because	  the	  establishment	  of	  Nup98-­‐HoxB4	  HSCs	  was	  so	  
far	   only	   successful	   from	   adult	   bone	   marrow	   derived	   cells	   and	   B-­‐1	   B	   cells	   are	  
generated	   most	   efficiently	   from	   fetal	   progenitors	   [206].	   In	   its	   role	   as	   response	  
regulator	  of	  BCR-­‐mediated	  signals	   [285]	  aberrant	  expression	  of	  CD19	  can	   influence	  
B-­‐1	   B-­‐cell	   generation	   [272,	   279,	   280].	   This	   is	   in	   accordance	   with	   other	   mutations	  
affecting	  BCR	  signaling,	  which	  have	  the	  same	  effect	  [96,	  313-­‐317].	  A	  similar	  kind	  of	  
positive	  selection	  acts	   in	  the	  splenic	  MZB-­‐FoB	  lineage	  decision	  [201,	  318].	  With	  the	  
Nup98-­‐HoxB4	  HSC	  reconstitution	  system	  we	  observed	  that	  the	  reduced	  B-­‐cell	  output	  
caused	   by	   aberrant	   CD19	   expression	   preferentially	   generated	  MZB	   [309].	   This	   has	  
also	  been	  observed	  in	  other	  B	  lymphopenic	  mice	  [201,	  211,	  295,	  319]	  and	  even	  when	  
we	  reconstituted	  Rag2-­‐deficient	  mice	  with	  bone	  marrow	  derived	  pro-­‐B	  cells	  or	  µMt	  
mice	   with	   fetal	   liver	   derived	   pro-­‐B	   cells.	   By	   generating	   MZB	   the	   most	   rapidly	  
responding	  B-­‐cell	  population	  located	  at	  the	  interface	  with	  the	  environment	  becomes	  
established	  first.	  This	  might	  reflect	  the	  evolutionary	  pressure	  acting	  on	  the	  immune	  
system	   to	   provide	   a	   first-­‐line	   of	   defense	   even	   if	   the	   slower	   T-­‐cell	   dependent	  
immunity	   is	   not	   fully	   established.	   This	   is	   in	   contrast	   to	   what	   is	   happening	   during	  
ontogeny.	   In	  mice,	   the	  marginal	   zone	   is	   only	   fully	   established	   two	   to	   three	  weeks	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after	   birth	   [320].	   In	   this	   special	   neonatal	   setting,	   maternal	   antibodies	   as	   well	   as	  
fetally	   generated	   B-­‐1	   B	   cells	   serve	   as	   an	   immediate	   line	   of	   defense	   prior	   to	   the	  
emergence	   of	   a	   functional	   T-­‐cell	   dependent	   immune	   system.	   The	   differential	  
appearance	   of	   MZB	   versus	   FoB	   cell	   compartments	   has	   implications	   for	   neonatal	  
vaccinology	  in	  man.	  
Mutations	  in	  the	  CD19	  gene	  were	  also	  associated	  with	  an	  antibody-­‐deficiency	  
syndrome	   in	   humans	   [321-­‐323].	   The	   disruption	   of	   the	   CD19	   complex	   caused	  
impaired	  BCR	  signaling	  and	   thereby	   impaired	  humoral	   immune	   responses.	   Since	   in	  
more	   than	   90%	   of	   patients	   diagnosed	   with	   primary	   immunodeficiencies	   no	  
associated	   genetic	   defect	   has	   yet	   been	   found	   it	   might	   be	   worth	   comparing	   CD19	  
levels	   expressed	   by	   the	   remaining	   B	   cells.	   It	   is	   very	   likely	   that	   complex	   genetic	  
networks	  and	  not	  a	  single	  gene	  mutation	  are	  responsible	  for	  disease	  manifestations.	  
When	  these	  genetic	  defects	  impair	  CD19	  expression,	  this	  might	  cause	  the	  disease.	  
	  
In	  summary,	  the	  results	  presented	  in	  this	  thesis	  show:	  
1. We	   could	   identify	   the	   direct	   progenitor	   of	   committed	   CD19+	   B	   cells	  
within	  the	  EPLM	  Ly6D+	  subpopulation.	  
2. We	  showed	  that	  IL-­‐7	  is	  not	  absolutely	  required	  for	  commitment	  to	  the	  
B-­‐cell	  lineage	  and	  most	  likely	  acts	  as	  a	  permissive	  factor.	  
3. We	  developed	   stromal	   cell	   free	   in	   vitro	   culture	   systems	   for	   the	   long-­‐
term	   propagation	   of	   functional	   bone	   marrow	   and	   fetal	   liver	   derived	  
progenitor	  T	  and	  B	  cells.	  
4. We	   could	   show	   the	   importance	   of	   fine-­‐tuning	   CD19	   expression	   levels	  
on	  B-­‐cell	  selection.	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